Bioceres Crop Solutions (BIOX) 20-F 29 Oct 21 2021 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2021shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-38405
Entity Registrant Name	Bioceres Crop Solutions Corp.
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	Ocampo 210 bis, Predio CCT, Rosario
Entity Address, City or Town	Province of Santa Fe
Entity Address, Country	AR
Entity Common Stock, Shares Outstanding	41,104,087
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Central Index Key	0001769484
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Business Contact
Document Information [Line Items]
Contact Personnel Name	Gloria Montaron
Entity Address, Address Line One	Ocampo 210 bis, Predio CCT, Rosario
Entity Address, City or Town	Province of Santa Fe
Entity Address, Country	AR
City Area Code	54
Local Phone Number	341-4861122
Contact Personnel Email Address	gloria.montaron@biocerescrops.com
Ordinary Shares, par value US$0.0001 per share
Document Information [Line Items]
Title of 12(b) Security	Ordinary Shares, par value US$0.0001 per share
Trading Symbol	BIOX
Security Exchange Name	NASDAQ

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 36,046,113	$ 42,522,861	$ 3,450,873
Other financial assets	11,161,398	13,436,393	4,683,508
Trade receivables	88,784,172	73,546,633	59,236,377
Other receivables	11,153,705	4,770,672	1,981,829
Income and minimum presumed income taxes recoverable	990,881	112,220	1,263,795
Inventories	61,037,551	29,338,548	27,322,003
Biological assets	2,315,838	965,728	270,579
Total current assets	211,489,658	164,693,055	98,208,964
NON-CURRENT ASSETS
Other financial assets	1,097,462	322,703	376,413
Trade receivables	135,739
Other receivables	2,543,142	1,703,573	1,560,310
Income and minimum presumed income taxes recoverable	12,589	6,029	1,184
Deferred tax assets	3,278,370	2,693,195	3,743,709
Investments in joint ventures and associates	30,657,173	24,652,792	25,321,028
Property, plant and equipment	47,954,596	41,515,106	43,834,548
Intangible assets	67,342,362	35,333,464	39,616,426
Goodwill	28,751,206	25,526,855	29,804,715
Right of use asset	1,327,660	1,114,597
Total non-current assets	183,100,299	132,868,314	144,258,333
Total assets	394,589,957	297,561,369	242,467,297
CURRENT LIABILITIES
Trade and other payables	72,091,408	57,289,862	40,578,494
Borrowings	76,785,857	63,721,735	66,477,209
Employee benefits and social security	4,680,078	4,510,592	5,357,218
Deferred revenue and advances from customers	6,277,313	2,865,437	1,074,463
Income tax payable	7,452,891	1,556,715	142,028
Government grants		1,270	2,110
Consideration for acquisition			2,826,611
Lease liabilities	750,308	665,098
Total current liabilities	168,037,855	130,610,709	116,458,133
NON-CURRENT LIABILITIES
Borrowings	47,988,468	41,226,610	37,079,521
Employee benefits and social security		534,038
Government grants	784	2,335	8,098
Joint ventures and associates	1,278,250	1,548,829	1,970,903
Deferred tax liabilities	25,699,495	16,858,125	21,101,871
Provisions	449,847	417,396	439,740
Consideration for acquisition	11,790,533	452,654	452,654
Private warrants		1,686,643	2,861,511
Convertible notes	48,664,012	43,029,834
Lease liabilities	390,409	444,714
Total non-current liabilities	136,261,798	106,201,178	63,914,298
Total liabilities	304,299,653	236,811,887	180,372,431
EQUITY
Equity attributable to owners of the parent	67,743,242	46,179,395	47,301,863
Non-controlling interests	22,547,062	14,570,087	14,793,003
Total equity	90,290,304	60,749,482	62,094,866
Total equity and liabilities	$ 394,589,957	$ 297,561,369	$ 242,467,297

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Revenues from contracts with customers		$ 206,697,620	$ 172,350,699	$ 160,308,979
Government grants		2,302	24,732	16,372
Initial recognition and changes in the fair value of biological assets		2,826,255	716,741	279,945
Total		209,526,177	173,092,172	160,605,296
Cost of sales		(118,641,803)	(93,575,588)	(86,964,881)
Research and development expenses		(5,617,655)	(4,195,270)	(3,689,391)
Selling, general and administrative expenses		(47,601,901)	(38,345,028)	(39,243,800)
Share of profit or loss of joint ventures and associates		997,429	2,477,193	1,012,486
Other income or expenses, net		(279,359)	(307,499)	365,900
Operating profit		38,382,888	39,145,980	32,085,610
Finance costs		(21,240,236)	(20,880,526)	(23,414,834)
Other financial results		(6,612,104)	(11,822,116)	(18,043,383)
Profit (loss) before income tax		10,530,548	6,443,338	(9,372,607)
Income tax		(14,351,170)	(2,206,710)	(6,986,284)
(Loss) profit for the year		$ (3,820,622)	$ 4,236,628	$ (16,358,891)
(Loss) Profit per share
Basic (loss) profit attributable to ordinary equity holders of the parent	[1]	$ (0.1752)	$ 0.0930	$ (0.6027)
Diluted (loss) profit attributable to ordinary equity holders of the parent		$ (0.1752)	$ 0.0922	$ (0.6027)
Weighted average number of shares
Basic	[1]	39,218,632	36,120,447	30,478,390
Diluted		39,218,632	36,416,988	30,478,390
(Loss) profit for the year		$ (3,820,622)	$ 4,236,628	$ (16,358,891)
Other comprehensive income (loss)		10,051,318	(9,682,116)	3,904,365
Items that may be subsequently reclassified to profit and loss		12,733,775	(13,603,205)	5,251,488
Exchange differences on translation of foreign operations from joint ventures		2,657,567	(3,494,761)	11,337
Exchange differences on translation of foreign operations		10,076,208	(10,108,444)	5,240,151
Items that will not be subsequently reclassified to loss and profit		(2,682,457)	3,921,089	(1,347,123)
Revaluation of property, plant and equipment, net of tax, of joint ventures and associates	[2]	(413,618)	521,406	94,009
Revaluation of property, plant and equipment, net of tax	[3]	(2,268,839)	3,399,683	(1,441,132)
Total comprehensive profit (loss)		6,230,696	(5,445,488)	(12,454,526)
(Loss) profit for the period attributable to:
Equity holders of the parent		(6,870,163)	3,359,175	(18,369,045)
Non-controlling interests		3,049,541	877,453	2,010,154
Result for the year		(3,820,622)	4,236,628	(16,358,891)
Total comprehensive (loss) profit attributable to:
Equity holders of the parent		1,559,264	(5,222,572)	(14,333,037)
Non-controlling interests		4,671,432	(222,916)	1,878,511
Total comprehensive profit (loss)		$ 6,230,696	$ (5,445,488)	$ (12,454,526)
[1]	For the years ended June 30, 2021 and 2019 diluted EPS was the same as basic EPS as the effect of potential ordinary shares would be antidilutive.
[2]	The tax effect of the revaluation of property, plant and equipment of joint ventures and associates was ($222,717), ($173,802) and ($47,005) for the years ended June 30, 2021, 2020 and 2019, respectively.
[3]	The tax effect of the revaluation of property, plant and equipment was ($1,389,643), ($1,133,230) and $480,378 for the years ended June 30, 2021, 2020 and 2019, respectively.

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Income tax relating to changes in revaluation surplus included in other comprehensive income for Joint Venture and Associates	$ (222,717)	$ (173,802)	$ (47,005)
Income tax relating to changes in revaluation surplus included in other comprehensive income	$ (1,389,643)	$ (1,133,230)	$ 480,378

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)	Equity / (deficit) attributable to owners of the parent	Issued capital	Share premium	Own Shares Trade Premium	Stock options and share based incentives	Convertible instruments	Cost of own shares held	Retained deficit	Foreign currency translation reserve	Revaluation of PP&E and effect of tax rate change	Non-controlling Interests	Total
Beginning balance at Jun. 30, 2018	$ 13,713,484	$ 2,810	$ 68,023,449		$ 102,827			$ (26,149,583)	$ (36,612,070)	$ 8,346,051	$ 19,420,172	$ 33,133,656
Adjustment of opening balance for the application of IAS 29	19,560,024							22,546,341		(2,986,317)	7,797,295	27,357,319
Parent company investment (Note 11)	(14,558,347)		(14,558,347)									(14,558,347)
Reverse Stock Options	(102,827)				(102,827)							(102,827)
Reverse recapitalization	21,906,182	329	21,905,853									21,906,182
Capitalization of warrants	(3,432,723)		(3,432,723)									(3,432,723)
Shares issued - Rizobacter call option	21,440,126	474	21,439,652								(14,302,975)	7,137,151
Contribution Semya	3,108,981		3,108,981									3,108,981
Profit (loss) of the year	(18,369,045)							(18,369,045)			2,010,154	(16,358,891)
Other comprehensive (loss) / income	4,036,008								5,132,487	(1,096,479)	(131,643)	3,904,365
Ending balance at Jun. 30, 2019	47,301,863	3,613	96,486,865					(21,972,287)	(31,479,583)	4,263,255	14,793,003	62,094,866
Stock options and share based incentives	3,428,029				3,428,029							3,428,029
Convertible notes	702,981					$ 702,981						702,981
Purchase of own shares	(30,906)						$ (30,906)					(30,906)
Profit (loss) of the year	3,359,175							3,359,175			877,453	4,236,628
Other comprehensive (loss) / income	(8,581,747)								(11,718,618)	3,136,871	(1,100,369)	(9,682,116)
Ending balance at Jun. 30, 2020	46,179,395	3,613	96,486,865		3,428,029	702,981	(30,906)	(18,613,112)	(43,198,201)	7,400,126	14,570,087	60,749,482
Capitalization of warrants	6,849,468	260	7,765,410	$ (916,202)								6,849,468
Shares issued	15,000,000	188	14,999,812									15,000,000
Stock options and share based incentives	1,655,135	97	1,410,299		244,739							1,655,135
Purchase of own shares	(3,500,020)						(3,500,020)					(3,500,020)
Non-controlling interest for business combination											3,305,543	3,305,543
Profit (loss) of the year	(6,870,163)							(6,870,163)			3,049,541	(3,820,622)
Other comprehensive (loss) / income	8,429,427								10,575,393	(2,145,966)	1,621,891	10,051,318
Ending balance at Jun. 30, 2021	$ 67,743,242	$ 4,158	$ 120,662,386	$ (916,202)	$ 3,672,768	$ 702,981	$ (3,530,926)	$ (25,483,275)	$ (32,622,808)	$ 5,254,160	$ 22,547,062	$ 90,290,304

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
OPERATING ACTIVITIES
(Loss) profit for the year	$ (3,820,622)	$ 4,236,628	$ (16,358,891)
Adjustments to reconcile profit to net cash flows
Income tax	14,351,170	2,206,710	6,986,284
Finance results	27,852,340	32,702,642	41,458,217
Depreciation of property, plant and equipment	3,048,539	2,010,136	2,450,256
Amortization of intangible assets	2,388,982	2,149,534	2,376,919
Depreciation of leased assets	827,320	573,897
Transactional expenses	2,022,918		4,535,247
Share-based incentive and stock options	1,655,135	3,428,029	(102,827)
Share of profit or loss of joint ventures and associates	(997,429)	(2,477,193)	(1,012,486)
Loss of control of subsidiaries			(10,591)
Provisions for contingencies	158,818	200,525	(246,832)
Allowance for impairment of trade debtors	560,931	1,499,298	686,985
Allowance for obsolescence	579,832	977,817	564,873
Initial recognition and changes in the fair value of biological assets	(2,826,255)	(716,741)	(279,945)
Gain or loss on sale of equipment and intangible assets	733,042	297,289	91,762
Working capital adjustments
Trade receivables	1,986,982	(21,740,661)	41,486,766
Other receivables	(8,330,278)	(4,864,670)	5,768,475
Income and minimum presumed income taxes	5,814,425	1,207,046	2,777,956
Inventories and biological assets	(34,503,283)	(5,305,792)	(8,638,798)
Trade and other payables	(5,831,743)	8,267,538	(33,696,040)
Employee benefits and social security	(693,125)	(477,872)	931,365
Deferred revenue and advances from customers	2,412,315	843,981	66,158
Income and minimum presumed income taxes payable	(1,837,775)		(1,705,481)
Government grants	(2,821)	(6,603)	(23,019)
Interest collected	2,979,889	1,027,132
Inflation effects on working capital adjustments	(14,735,250)	(16,720,191)	(18,411,540)
Net cash flows (used in)/ generated by operating activities	(6,205,943)	9,318,479	29,694,813
INVESTMENT ACTIVITIES
Proceeds from sale of property, plant and equipment	309,810	51,151	317,953
Investment in joint ventures and associates	(101,883)		(129,340)
Net cash received from business combination	355,804
Proceeds from financial assets	9,324,335	5,041
Investment in financial assets	(4,275,099)	(3,357,407)
Purchase of property, plant and equipment	(2,805,825)	(1,646,697)	(2,044,102)
Capitalized development expenditures	(3,906,630)	(1,263,730)	(682,530)
Purchases of intangible assets	(7,210,630)	(1,591,749)	(722,833)
Net cash flows used in investing activities	(8,310,118)	(7,803,391)	(3,260,852)
FINANCING ACTIVITIES
Proceeds from borrowings	143,499,367	135,348,502	88,693,632
Repayment of borrowings, financed payments and interest payments	(126,023,777)	(101,317,621)	(111,084,915)
(Decrease) increase in bank overdrafts and other short-term borrowings	(3,442,491)	(2,331,974)	(4,968,813)
Other financial proceeds or payments, net	(1,415,034)	2,298,360	(854,731)
Reverse Recapitalization			1,268,633
Leased assets payments	(728,964)	(433,947)
Warrants tender offer payments	(1,030,952)
Purchase of own shares	(3,500,020)	(30,906)
Net cash flows generated by (used in) financing activities	7,358,129	33,532,414	(26,946,194)
Net (decrease) increase in cash and cash equivalents	(7,157,932)	35,047,502	(512,233)
Inflation effects on cash and cash equivalents	(5,584,156)	(552,459)	1,681,113
Cash and cash equivalents as of beginning of the year	42,522,861	3,450,873	2,215,103
Effect of exchange rate changes on cash and equivalents	6,265,340	4,576,945	66,890
Cash and cash equivalents as of the end of the year	$ 36,046,113	$ 42,522,861	$ 3,450,873

GENERAL INFORMATION

GENERAL INFORMATION	12 Months Ended
	Jun. 30, 2021
GENERAL INFORMATION
GENERAL INFORMATION	1. GENERAL INFORMATION Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Group has a unique biotech platform with high impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Bioceres is a global company with an extensive geographic footprint. The Group's agricultural inputs are marketed across more than 30 countries, mainly in Argentina, Brazil, United States, Europe and South Africa. Introductory note On March 14, 2019, Union Acquisition Corp. (“Union” or “UAC”), whose name changed to Bioceres Crop Solutions Corp., consummated a merger pursuant to a share exchange agreement, dated as of November 8, 2018 (as amended, the “Exchange Agreement”), by and among UAC and Bioceres, Inc., a company incorporated under the laws of Delaware, which converted into Bioceres LLC pursuant to the Reorganization (as defined below) on February 28, 2019. Prior to the consummation of the merger on March 14, 2019, the following steps took place among Bioceres, Inc. and certain of its affiliates (collectively the “Reorganization”). On February 13, 2019, Bioceres, Inc. formed a new subsidiary, BCS Holding Inc. ("BCS Holding"), and contributed all of its crop business net assets to BCS Holding in exchange for 100% of the equity interests in BCS Holding. On February 28, 2019, Bioceres, Inc. converted into Bioceres LLC, and on March 1, 2019, Bioceres S.A., a company organized under the laws of Argentina and our ultimate parent company (the "Parent") contributed all of its equity interest in Bioceres Semillas S.A. ("Bioceres Semillas") to Bioceres LLC in exchange for additional equity interests. In addition, concurrently with the consummation of the business combination on March 14, 2019, the Rizobacter Call Option (as defined below) was exercised, pursuant to which the total indirect ownership of BCS Holding in Rizobacter increased to 80.00% of all outstanding stock of Rizobacter. On October 22,2018, Parent, RASA Holding LLC, a Delaware limited liability company and a wholly owned subsidiary of Bioceres, Inc., now a wholly-owned subsidiary of BCS Holding (“RASA Holding”), and certain Rizobacter's sellers (the “Grantors”) entered into an amended and restated option agreement (as may be amended from time to time, the “Rizobacter Call Option Agreement”), pursuant to which the Parent, RASA Holding or any of their nominated affiliates (including BCS Holding and its subsidiaries, collectively the "Beneficiaries") would have the option (the “Rizobacter Call Option”) to purchase from the Grantors all of their 11,916,000 shares of common stock of Rizobacter Argentina S.A., an Argentine corporation and a subsidiary of RASA Holding (“Rizobacter”), representing 29.99% of all outstanding common stock of Rizobacter. Consideration for the Rizobacter Call Option was in cash and in the form of UAC shares. As a result of the business combination and the other transactions contemplated by the Exchange Agreement, as well as the Reorganization and exercise of the Rizobacter Call Option, Union became the holding company of BCS Holding, its subsidiaries and Bioceres Semillas. Upon the consummation of the merger, Union changed its name to Bioceres Crop Solutions Corp. Unless the context otherwise requires, "we," "us," "our,", “Bioceres”, "BIOX," and "Bioceres Crop Solutions" will refer to Bioceres Crop Solutions Corp. and its subsidiaries.

ACCOUNTING STANDARDS AND BASIS

ACCOUNTING STANDARDS AND BASIS OF PREPARATION	12 Months Ended
	Jun. 30, 2021
ACCOUNTING STANDARDS AND BASIS OF PREPARATION
ACCOUNTING STANDARDS AND BASIS OF PREPARATION	2. ACCOUNTING STANDARDS AND BASIS OF PREPARATION Statement of compliance with IFRS as issued by IASB The Consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by International Accounting Standard Board (“IASB”) following the accounting policies as set forth and summarized in Note 4. All IFRS issued by the IASB, effective at the time of preparing these Consolidated financial statements have been applied. Authorization for the issue of the Consolidated financial statements These Consolidated financial statements of the Group as of and for the years ended June 30, 2021, 2020 and 2019 have been authorized by the Board of Directors of Bioceres Crop Solutions on September 30, 2021. Basis of measurement The consolidated financial statements of the Group have been prepared using: ● Going concern basis of accounting, considering the conclusion of the assessment made by the Group’s Management about the ability of the Group and its subsidiaries to continue as a going concern, in accordance with the requirements of paragraph 25 of IAS 1, “Presentation of Financial Statements”. ● Accrual basis of accounting (except for cash flows information). Under this basis of accounting, the effects of transactions and other events are recognized as they occur, even when there are no cash flows. Functional currency and presentation currency a) Functional currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic market in which the entity operates (i.e., “the functional currency”). The Group has applied IAS 29 for its subsidiaries in Argentina. IAS 29 “Financial reporting in hyperinflationary economies” requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy, whether these are based on the historical cost method or the current cost method, be stated in terms of the measuring unit current at the closing date of the reporting period. For such purpose, the inflation produced since the acquisition date or the revaluation date, as applicable, must be computed in non-monetary items. The standard details a series of factors to be considered for concluding whether an economy is hyperinflationary, including, but not limited to, a cumulative inflation rate over a three-year period that approaches or exceeds 100%. Inflation accumulated in three years, as of June 30, 2018, was over 100%. It was for this reason that, in accordance with IAS 29, the Argentine economy had to be considered as hyperinflationary since July 1, 2018. In an inflationary period, any entity that maintains an excess of monetary assets over monetary liabilities, will lose purchasing power, and any entity that maintains an excess of monetary liabilities over monetary assets, will gain purchasing power, provided that such items are not subject to an adjustment mechanism. Briefly, the restatement mechanism of IAS 29 establishes that monetary assets and liabilities will not be restated because they are already expressed in a current unit of measurement at the end of the reporting period. Assets and liabilities subject to adjustments based on specific agreements, will be adjusted according to those agreements. Non-monetary items measured at their current values at the end of the reporting period, such as the net realizable value or others, do not need to be restated. The remaining non-monetary assets and liabilities will be restated according to a general price index. The loss or gain for the net monetary position will be included in the net result of the reporting period, revealing this information in a separate line item. The inflation adjustment to the initial balances was calculated by means of a conversion factor derived from the Argentine price indexes published by the National Institute of Statistics. The index as of June 30, 2021, 2020 and 2019 was 483.6049, 321.9738 and 225.5730, respectively. The comparative figures in these consolidated financial statements presented in a stable currency are not adjusted for subsequent changes in the price levels or exchange rates. Presentation currency The consolidated financial statements of the Group are presented in US dollars. Foreign currency Transactions entered into by Group entities in a currency other than their functional currency are recorded at the relevant exchange rates as of the date upon which such transactions occur. Foreign currency monetary assets and liabilities are translated at the prevailing exchanges rates as of the final day of each reporting period. Exchange differences arising on the retranslation of unsettled monetary assets and liabilities are recognized immediately in profit or loss, except for foreign currency borrowings qualifying as a hedge of a net investment in a foreign operation for which exchange differences are recognized in other comprehensive income and accumulated in the foreign exchange reserve along with the exchange differences arising on the retranslation of the foreign operation. Upon the disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to such operation up to the date of disposal are transferred to the Consolidated statement of profit or loss and other comprehensive income as part of the profit or loss taking place upon such disposal. Subsidiaries Where the Group holds a controlling interest in an entity, such entity is classified as a subsidiary. The Group exercises control over such an entity if all three of the following elements are present: (i) the Group has the power to direct or cause the direction of the management and policies of the entity; (ii) the Group is exposed to the variable returns of such entity; and (iii) the Group has power to affect the variability of such returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control. De-facto control exists in situations where the Group has the practical ability to direct the relevant activities of an entity without holding the majority of the voting rights. In determining whether de facto control exists, the Group considers all relevant facts and circumstances, including: - The relative share of the Group’s voting rights with respect both the size and dispersion of other parties who hold voting rights; - Substantive potential voting rights held by the Group and by other parties; - Other contractual arrangements; and - Historic patterns in voting attendance. The subsidiaries of the Group, all of which have been included in the consolidated financial statements of the Group, are as follows: The Group holds a majority share of the voting rights in all its subsidiaries. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ incorporation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ and principal ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ place of ​ ​ ​ % Equity interest ​ Name Principal activities business Ref 06/30/2021 06/30/2020 ​ 06/30/2019 ​ RASA Holding, LLC Investment in subsidiaries United States a 100.00 % 100.00 % 100.00 % Rizobacter Argentina S.A. Microbiology Business Argentina a 80.00 % 80.00 % 80.00 % Rizobacter do Brasil Ltda. Selling of agricultural inputs Brazil b 79.99 % 79.99 % 79.99 % Rizobacter del Paraguay S.A. Selling of agricultural inputs Paraguay b 79.92 % 79.92 % 79.92 % Rizobacter Uruguay Selling of agricultural inputs Uruguay b 80.00 % 80.00 % 80.00 % Rizobacter South Africa Selling of agricultural inputs South Africa b 76.00 % 76.00 % 76.00 % Comer. Agrop. Rizobacter de Bolivia S.A. Selling of agricultural inputs Bolivia b 79.96 % 79.96 % 79.96 % Rizobacter USA, LLC Selling of agricultural inputs United States b 80.00 % 80.00 % 80.00 % Rizobacter India Private Ltd. Selling of agricultural inputs India b — ​ 80.00 % 80.00 % Rizobacter Colombia SAS Selling of agricultural inputs Colombia b 80.00 % 80.00 % 80.00 % Rizobacter France SAS ​ Research and development ​ France ​ b ​ 80.00 % 80.00 % 80.00 % Bioceres Crops S.A. ​ Research and development ​ Argentina ​ b c ​ 90.00 % 90.00 % 90.00 % BCS Holding LLC ​ Investment in subsidiaries ​ United States ​ a ​ 100.00 % 100.00 % 100.00 % Bioceres Semillas S.A.U. ​ Production and commercialization of seeds ​ Argentina ​ a ​ 100.00 % 100.00 % 100.00 % Verdeca LLC ​ Research and development ​ United States ​ d ​ 100.00 % 50.00 % 50.00 % Insumos Agroquímicos S.A. ​ Selling of agricultural inputs ​ Argentina ​ e ​ 50.1 % — ​ — ​ ​ a) b) c) d) On November 12, 2020 we acquired from Arcadia Biosciences Inc (“Arcadia”) the remaining 50 % ownership interest in Verdeca LLC (“Verdeca”). See Note 6. e) On April 9, 2021 we acquired a controlling interest in Insumos Agroquímicos S.A. (“Insuagro”). See Note 6. Special purpose and structured entities (“SPE”) A structured entity is an entity that has been designed so that voting or similar rights are not the dominant factor in deciding who controls the entity and the relevant activities are directed by means of contractual arrangements. In this cases, we consider the purpose and design of the SPE, including a consideration of the risks the SPE was expected to be exposed to, the risks it was designed to pass on to the parties involved with the SPE and whether we are exposed to some or all of those risks or potential returns. One then considers which activities have a significant impact on the SPE’s returns and determines which parties have an ability to direct each of those activities. The Group controls an SPE when is exposed, or has rights, to variable returns from its involvement with the SPE and has the ability to affect those returns through its power over the SPE.

NEW STANDARDS, AMENDMENTS AND I

NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB	12 Months Ended
	Jun. 30, 2021
NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB
NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB	3. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB New standards and interpretations adopted by the Group The following new standards became applicable for the current reporting period and adopted by the Group. These amendments did not have a material impact on the Group. Amendments to IFRS 16 - Covid-19-related Rent Concessions As a result of the COVID-19 pandemic, rent concessions have been granted to lessees. Such concessions might take a variety of forms, including payment holidays and deferral of lease payments. In May 2020, the IASB made an amendment to IFRS 16 Leases which provides lessees with an option to treat qualifying rent concessions in the same way as they would if they were not lease modifications. In many cases, this will result in accounting for the concessions as variable lease payments in the period in which they are granted. Entities applying the practical expedients must disclose this fact, whether the expedient has been applied to all qualifying rent concessions or, if not, information about the nature of the contracts to which it has been applied, as well as the amount recognized in profit or loss arising from the rent concessions. On issuance, the practical expedient was limited to rent concessions for which any reduction in lease payments affects only payments originally due on or before 30 June 2021. Since lessors continue to grant COVID-19-related rent concessions to lessees and since the effects of the COVID-19 pandemic are ongoing and significant, in March 2021 was decided to extend the time period over which the practical expedient is available for use. The amendments are effective for financial years beginning on or after January 1, 2020. Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 - Interest Rate Benchmark Reform (Phase 2) The Phase 2 amendments, Interest Rate Benchmark Reform—Phase 2, address issues that might affect financial reporting during the reform of an interest rate benchmark, including the effects of changes to contractual cash flows or hedging relationships arising from the replacement of an interest rate benchmark with an alternative benchmark rate (replacement issues). In 2019, the Board issued its initial amendments in Phase 1 of the project. The amendments are related to changes in the basis for determining contractual cash flows of financial assets, financial liabilities and lease liabilities; hedge accounting; and disclosures. They apply only to changes required by the interest rate benchmark reform to financial instruments and hedging relationships. The amendments are effective for financial years beginning on or after January 1, 2020. Earlier application is permitted. New standards and interpretations not yet adopted by the Group Amendments to IAS 1 - Classification of liabilities as current or non-current – Deferral of effective date The amendment defers by one year the effective date of Classification of Liabilities as Current or Non-current, which amends IAS 1 Presentation of Financial Statements. Classification of Liabilities as Current or Non-current was issued in January 2020, effective for annual reporting periods beginning on or after January 1, 2022. However, in response to the covid-19 pandemic, the effective date was deferred by one year to provide companies with more time to implement any classification changes resulting from those amendments. Classification of Liabilities as Current or Non-current is now effective for annual reporting periods beginning on or after January 1, 2023. Earlier application of the amendments continues to be permitted. These amendments are not expected to have material impact on the Group. IFRS 17 Insurance Contracts IFRS 17 was issued in May 2017 as replacement for IFRS 4 Insurance Contracts. It requires a current measurement model where estimates are re-measured in each reporting period. Contracts are measured using the building blocks of i) discounted probability-weighted cash flows, ii) an explicit risk adjustment, and (iii) a contractual service margin (CSM) representing the unearned profit of the contract which is recognized as revenue over the coverage period. The standard allows a choice between recognizing changes in discount rates either in the statement of profit or loss or directly in other comprehensive income. The choice is likely to reflect how insurers account for their financial assets under IFRS 9. An optional, simplified premium allocation approach is permitted for the liability for the remaining coverage for short duration contracts, which are often written by non-life insurers. There is a modification of the general measurement model called the 'variable fee approach' for certain contracts written by life insurers where policyholders share in the returns from underlying items. When applying the variable fee approach, the entity's share of the fair value changes of the underlying items is included in the CSM. The results of insurers using this model are therefore likely to be less volatile than under the general model. The new rules will affect the financial statements and key performance indicators of all entities that issue insurance contracts or investment contracts with discretionary participation features. The new rule is effective for financial years beginning on or after January 1, 2023. The new rule is not expected to have material impact on the Group. Amendments to IFRS 17 These amendments aimed at helping companies implement IFRS 17 and making it easier for them to explain their financial performance. The fundamental principles introduced when the Board first issued IFRS 17 in May 2017 remain unaffected. The amendments, which respond to feedback from stakeholders, are designed to: reduce costs by simplifying some requirements in the Standard; make financial performance easier to explain; and ease transition by deferring the effective date of the Standard to 2023 and by providing additional relief to reduce the effort required when applying IFRS 17 for the first time. These amendments are not expected to have material impact on the Group. Annual Improvements to IFRS Standards 2018–2020 The following improvements were finalized in May 2020: ● ● ● ● The new standard is effective for financial years beginning on or after January 1, 2022. These amendments are not expected to have material impact on the Group. Amendments to IAS 16 - Property, Plant and Equipment: Proceeds before intended use The amendment to IAS 16 Property, Plant and Equipment (PP&E) prohibits an entity from deducting from the cost of an item of PP&E any proceeds received from selling items produced while the entity is preparing the asset for its intended use. It also clarifies that an entity is 'testing whether the asset is functioning properly' when it assesses the technical and physical performance of the asset. The financial performance of the asset is not relevant to this assessment. Entities must disclose separately the amounts of proceeds and costs relating to items produced that are not an output of the entity's ordinary activities. The amendments are effective for annual periods beginning on or after January 1, 2022. These amendments are not expected to have material impact on the Group. Amendments to IFRS 3 - Reference to the Conceptual Framework Minor amendments were made to IFRS 3 Business Combinations to update the references to the Conceptual Framework for Financial Reporting and add an exception for the recognition of liabilities and contingent liabilities within the scope of IAS 37 Provisions, Contingent Liabilities and Contingent Assets and Interpretation 21 Levies. The amendments also confirm that contingent assets should not be recognized at the acquisition date. The amendments are effective for financial years beginning on or after January 1, 2022. These amendments are not expected to have material impact on the Group. Amendments to IAS 37 - Onerous Contracts - Cost of Fulfilling a Contract The amendment to IAS 37 clarifies that the direct costs of fulfilling a contract include both the incremental costs of fulfilling the contract and an allocation of other costs directly related to fulfilling contracts. Before recognizing a separate provision for an onerous contract, the entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract. The amendments are effective for financial years beginning on or after January 1, 2022. These amendments are not expected to have material impact on the Group. Amendments to IAS 12- Deferred Tax related to Assets and Liabilities arising from a Single Transaction The IASB has amended IAS 12, 'Income taxes', to require companies to recognize deferred tax on particular transactions that, on initial recognition, give rise to equal amounts of taxable and deductible temporary differences. IAS 12 was amended to include an additional condition where the initial recognition exemption is not applied. According to the amended guidance, a temporary difference that arises on initial recognition of an asset or liability is not subject to the initial recognition exemption if that transaction gave rise to equal amounts of taxable and deductible temporary differences. The amendments are effective for financial years beginning on or after January 1, 2023. These amendments are not expected to have material impact on the Group. Amendments to IAS 8-Definition of Accounting Estimates These amendments help entities to distinguish between accounting policies and accounting estimates making a distinction between how an entity should present and disclose different types of accounting changes in its financial statements. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty” The amendments are effective for annual periods beginning on or after January 1, 2023 and changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted. These amendments are not expected to have material impact on the Group. Amendments to IAS 1 and IFRS Practice Statement 2- Disclosure of Accounting Policies An entity is now required to disclose its material accounting policy information instead of its significant accounting policies. The amendments clarify that accounting policy information may be material because of its nature, even if the related amounts are immaterial. The amendments are applied prospectively and are effective for annual periods beginning on or after January 1, 2023. Earlier application is permitted. These amendments are not expected to have material impact on the Group.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 4.1. Cash and cash equivalents For the purposes of the statements of financial position and statements of cash flows, cash and cash equivalents include cash on hand and in banks and short-term highly liquid investments. Investments can be readily convertible to known amounts of cash and they are subject to insignificant risk of changes in value. In the consolidated statements of financial position, bank overdrafts are included in borrowings within current liabilities. 4.2. Financial assets The Group measures its financial assets at initial recognition at fair value. The Group classifies its financial assets as financial assets measured at amortized cost (using the effective interest method) on the basis of both: - The Group’s business model for managing the financial assets; and - The contractual cash flows characteristics of the financial asset. The Group has not irrevocably designated a financial asset as measured at fair value through profit or loss to eliminate or significantly reduce a measurement or recognition inconsistency. Financial assets at fair value through profit or loss are measured at fair value through profit and loss due to the business model used in their negotiation and/or the contractual characteristics of their cash flows. Estimates The Group makes estimates of uncollectability of its recorded receivables. Management analyzes trade account receivables in accordance with conventional criteria, adjusting the amount through a charge of an allowance for bad debts upon recognition of the inability of third parties to afford their financial obligations to the Group. Management specifically analyzes the accounts receivable, the historical bad debts, solvency of customers, current economic trends and the changes to the payment conditions of customers to assess the adequate allowance for bad debts. Offsetting of financial assets with financial liabilities Financial assets and liabilities are offset and presented for their net amount in the statements of financial position only when the Group has the right, legally enforceable, to compensate the recognized amounts and has the intention to liquidate for the net amount or to settle the asset and cancel the liability simultaneously. 4.3. Inventories Inventories are recognized at cost initially and subsequently at the lower of cost and net realizable value. Cost comprises all costs of purchase and conversion as well as other costs incurred in bringing the inventories to their present location and condition. Weighted average cost is used to determine the cost of ordinarily interchangeable items. Estimates The Group assesses the recoverability of inventories considering their sale price, whether the inventories are damaged and whether they have become obsolete in whole or in part. Net realizable value is the sale price estimated to be attained in the ordinary course of business, less costs of completion and other selling expenses. The Group sets up an allowance for obsolescence or slow-moving inventories in relation to finished and in-process products. The allowance for obsolescence or slow-moving inventories is recognized for finished products and in-process products based on an analysis by Management of the aging of inventory stocks. 4.4. Biological assets Within current assets, growing crops are included as biological assets, from the moment of sowing until the moment of harvest (approximately 5 to 7 months depending on the crop). At harvest time the biological assets are transformed into agricultural products, including seed varieties for resale, and incorporated into the inventory. Costs are capitalized as biological assets if, and only if, (a) it is probable that future economic benefits will flow to the entity, and (b) the cost can be measured reliably. The Group capitalizes costs such as: planting, harvesting, weeding, seedlings, irrigation, agrochemicals, fertilizers and a systematic allocation of fixed and variable production overheads that are directly attributable to the management of biological assets, among others. Biological assets, both at initial recognition and at each subsequent reporting date, are measured at fair value less costs to sell, except where fair value cannot be reliably measured. Cost approximates fair value when little biological transformation has taken place since the costs were originally incurred or the impact of biological transformation on price is not expected to be material. Gains and losses that arise from measuring biological assets at fair value less costs to sell and measuring agricultural produce at the point of harvest at fair value less costs to sell are recognized in the statement of income in the period in which they arise in the line item “Initial recognition and changes in fair value of biological assets”. From the harvest time, agricultural products are valued at net realizable value because there is a market asset, and the risk of non-sale is non-significant. Generally, the estimation of the fair value of biological assets is based on models or inputs that are not observable in the market and the use of unobservable inputs is significant to the overall valuation of the assets. Unobservable inputs are determined based on the best information available. Key assumptions include future market prices, estimated yields at the point of harvest, estimated production cycle, future cash flows, future costs of harvesting and other costs, and estimated discount rate. Market prices are generally determined by reference to observable data in the principal market for the agricultural produce. Harvesting costs and other costs are estimated based on historical and statistical data. Yields are estimated based on several factors, including the location of the farmland and soil type, environmental conditions, infrastructure and other restrictions and growth at the time of measurement. Yields are subject to a high degree of uncertainty and may be affected by several factors out of the Group’s control including but not limited to extreme or unusual weather conditions, plagues and other crop diseases, among other factors. 4.5. Business combinations The Group applies the acquisition method to account for business combinations. The acquisition cost is measured as the aggregate of the consideration transferred for the acquisition of a subsidiary, which is measured at fair value at the acquisition date, and the amount of any non-controlling interest in such subsidiary. The Group recognizes any non-controlling interest in a subsidiary at the non-controlling interest’s proportionate share of the recognized amounts of subsidiary’s identifiable net assets. The acquisition related costs are expensed as incurred. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. The contingent consideration is classified as an asset or liability that is a financial instrument under IFRS 9 is measured at fair value through profit or loss. Goodwill is initially measured at cost, which is the excess of the aggregate of the consideration transferred and the amount of the non-controlling interest and any previous interest carried over the net identifiable assets acquired, and liabilities assumed. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For impairment testing, goodwill acquired in a business combination is, as of the acquisition date, allocated to each of the cash-generating units of the Group that is expected to benefit from the synergies of the combination, without considering whether other assets or liabilities of the subsidiary are allocated to those units. Any impairment in the carrying value is recognized in the consolidated statement of comprehensive income. In the case of acquisitions in stages, prior to the write-off of the previously held equity interest in the subsidiary, said interest is re-measured at fair value as of the date of acquisition of control over the subsidiary. The result of the re-measurement at fair value is recognized in profit or loss. When a seller in a business combination has contractually agreed to indemnify the Group for the result of a contingency or uncertainty related to the entirety or a portion of an asset or liability, the Group recognizes an indemnification asset. The indemnification asset is measured on the same basis as the indemnification item. At the end of each period, the Group measures the indemnification assets recognized at the acquisition date on the same basis as the indemnified liability, subject to any contractual limitation on the amount and, for an indemnification asset that is not periodically measured at fair value, based on Management’s assessment of the recoverability of the indemnification asset. The Group derecognizes the indemnification asset when it collects or sells it, or when it loses the right over it. 4.6. Business combination under common control Common control of business combination is excluded from the scope of IFRS 3. There is no other specific guidance on this topic elsewhere in IFRS. Therefore, management needs to use judgement to develop an accounting policy that provides relevant and reliable information in accordance with IAS 8. Management accounting police choice for business combination under common control is “Predecessor value method”. A Predecessor value method involves accounting for the assets and liabilities of the acquired business using existing carrying values. Differences between the carrying value and the amount payable should be accounted as an equity contribution. 4.7. Impairment of non-financial assets (excluding inventories and deferred tax assets) Impairment tests on goodwill and intangible assets not yet available for use are undertaken annually at the end of the reporting period. Other non-financial assets are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to sell), the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the smallest group of assets to which it belongs for which there are separately identifiable cash flows (its Cash Generating Unit or CGU). Goodwill is allocated on initial recognition to each of the Group’s CGUs that are expected to benefit from a business combination that gives rise to the goodwill. Impairment charges are included in profit or loss, except to the extent they reverse gains previously recognized in other comprehensive income. An impairment loss recognized for goodwill is not reversed. Estimate Impairment testing of goodwill and intangible assets not yet available for use requires the use of significant assumptions for the estimation of future cash flows and the determination of discount rates. The significant assumptions and the determination of discount rates for the impairment testing of goodwill are further explained in Note 7.9. 4.8. Joint arrangements An associate is an entity over which the Group exerts significant influence. Significant influence is the power to participate in financial and operating policy decision-making at such entity, but it does not involve control or joint control over those policies. The Group is a party to a joint arrangement when there is a contractual arrangement that confers joint control over the relevant activities of the arrangement to the Group and at least one other party. Joint control is assessed under the same principles as control over subsidiaries. The Group classifies its interests in joint arrangements as either: - Joint ventures : where the group has rights to only the net assets of the joint arrangement. - Joint operations : where the group has both the rights to the assets and obligations for the liabilities of the joint arrangement. In assessing the classification of interests in joint arrangements, the Group considers: - The structure of the joint arrangement; - The legal form of joint arrangements structured through a separate vehicle; - The contractual terms of the joint arrangement agreement; and - Any other facts and circumstances (including any other contractual arrangements). The Group accounts for its interests in joint ventures using the equity method, where the Group’s share of post-acquisition profits and losses and other comprehensive income is recognized in the Consolidated statement of profit and loss and other comprehensive income. Losses in excess of the Group’s investment in the joint venture are recognized only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the joint venture. Profits and losses arising on transactions between the Group and its joint ventures are recognized only to the extent of unrelated investors’ interests in the joint venture. The Group’s share in a joint venture’s profits and losses resulting from a transaction is eliminated against the carrying amount of investment in the joint venture through the line “share of profit (or loss) of joint ventures” in the Consolidated statements of profit or loss and other comprehensive income. Any premium paid for an investment in a joint venture above the fair value of the Group’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the investment in the joint venture. Where there is objective evidence that the investment in a joint venture has been impaired, the carrying amount of the investment is tested for impairment in the same way as other non-financial assets. When the Group loses significant influence in an associate or joint control over a joint venture, it measures and recognizes any investment held at fair value. Any difference between the carrying amount of the associate or joint venture when losing significant influence or joint control and the fair value of the held investment and sale revenue are recognized in profit or loss. The Group accounts for its interests in joint operations by recognizing its share of assets, liabilities, revenues and expenses in accordance with its contractually conferred rights and obligations. For all joint arrangements structured in separate vehicles the Group must assess the substance of the joint arrangement in determining whether it is classified as a joint venture or joint operation. This assessment requires the Group to consider whether it has rights to the joint arrangement’s net assets (in which case it is classified as a joint venture), or rights to and obligations for specific assets, liabilities, expenses, and revenues (in which case it is classified as a joint operation). Upon consideration of the factors mentioned above, the Group has determined that all of its joint arrangements except the operation with Espartina S.A. (see below) are structured through separate vehicles only give it rights to the net assets and are therefore classified as joint ventures (Note 13). Rizobacter entered into an agreement with Espartina S.A. ("Espartina") to share its business of producing grain crops. The joint operation is classified as a joint agreement as established in IFRS 11, while the parties are entitled to the assets and obligations over the related liabilities. Rizobacter recognizes as a joint operator, in relation to its participation, assets, liabilities, income and expenses. The production obtained is distributed according to the contributions made by each party. See Note 7.6. Estimates There is considerable uncertainty regarding Management’s estimates of the Group’s ability to recover the carrying amounts of the investments in joint ventures, since such estimates depend on the joint ventures’ ability to generate sufficient funds to complete the development projects, the future outcome of the project deregulation process and the amounts and timing of the cash flows from projects, among other future events. Management assesses whether there are impairment indicators and, if any, it performs a recoverability analysis. Management estimates of the recoverability of these investments represent the best estimate based on available evidence, the existing facts and circumstances, using reasonable and provable assumptions in the cash flow projections. Therefore, the consolidated financial statements do not include adjustments that would be required if the Group were unable to recover the carrying amount of the above-mentioned assets by generating sufficient economic benefits in the future. When the Group acquired control of Rizobacter, it also acquired the joint control of Synertech. Therefore, the investment in Synertech was added at the time of initial recognition of the acquisition at fair value. The determination of the fair value of Synertech at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of higher revenue from sales of micro-granulated fertilizers. 4.9. Property, plant and equipment Property, plant and equipment items are initially recognized at cost. In addition to the purchase price, cost also includes costs directly attributable to such property, plant and equipment items. There are no unavoidable costs with respect to dismantling and removing items. The cost of property, plant and equipment items acquired in a business combination is their fair value at the acquisition date. Depreciation is calculated using the straight-line method to allocate the property, plant or equipment items’ cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows: Research instruments: 3 to 10 years Office equipment: 5 to 10 years Vehicles: 5 years Computer equipment and software: 3 years Fixture and fittings: 10 years Machinery and equipment: 5 to 10 years Buildings: 50 years Useful lives and depreciation methods are reviewed every year as required by IAS 16. Assets under items Land and Buildings, are accounted for at fair value arising from the last revaluation performed, applying the revaluation model indicated by IAS 16. Revaluations are performed on a regular basis, when there are signs that the book value differs significantly from that to be determined using the fair value at the end of the reporting year. To obtain fair values, the existence of an active market is considered for the assets in their current status. For those assets for which an active market in their current status exists, the fair values were determined based on their market values. For the remaining cases, the market values of comparable new assets are analyzed, applying a discount based on the status and wear of each asset and considering the characteristics of each of the revalued assets (for example, improvements made, maintenance status, level of productivity, use, etc. Estimates The Group carries certain classes of property, plant and equipment under the revaluation model under IAS 16. The revaluation model requires that the Group carry property, plant and equipment at revalued amounts, being fair value at the date of revaluation less any subsequent accumulated depreciation and any subsequent accumulated impairment losses. IAS 16 requires that the Group carry out these revaluations with sufficient regularity so that the carrying amounts of its property, plant and equipment do not differ materially from that which would be determined using fair value at the end of a reporting period. The determination of fair value at the date of revaluation requires judgments, estimates and assumptions based on market conditions prevailing at the time of any such revaluation. Changes to any of the Group’s judgments, estimates or assumptions or to the market conditions subsequent to a revaluation will result in changes to the fair value of property, plant and equipment. The Group prepares the corresponding revaluations on a regular basis taking into account the work of independent appraisers. The Group uses different valuation techniques depending on the class of property being valued. Generally, the Group determines the fair value of its industrial buildings and warehouses based on a depreciated replacement cost approach. The Group determines the fair value of its land based on active market prices adjusted, if necessary, for differences in the nature, location or condition of the specific asset. If this information is not available, the Group may use alternative valuation methods, such as recent prices in less active markets. Property valuation is a significant area of estimation uncertainty. Fair values are prepared regularly by Management, taking into account independent valuations. The determination of fair value for the different classes of property, plant and equipment is sensitive to the selection of various significant assumptions and estimates. Changes in those significant assumptions and estimates could materially affect the determination of the revalued amounts of property, plant and equipment. The Group utilizes historical experience, market information and other internal information to determine and/or review the appropriate revalued amounts. The following are the most significant assumptions used in the preparation of the revalued amounts for its classes of property, plant and equipment: a) Land: The Group generally uses the market price of a square meter of land for the same or similar location as the most significant assumption to determine the revalued amount. The Group typically uses comparable land sales in the same location to assess appropriateness of the value of its land. A 10% increase or decrease in the market price of land could have an impact of $ 0.3 million on the revalued amount of its land. b) Industrial buildings and warehouses: The Group generally determines the construction cost of a new asset and then the Group adjusts it for normal wear and tear. Construction prices may include, but are not limited to, construction materials, labor costs, installation and assembly costs, site preparation, professional fees and applicable taxes. Construction costs may differ significantly from year to year and are subject to macroeconomic changes in the economy where the Group operates, such as the impact of inflation and foreign exchange rates. The construction cost of its industrial buildings and warehouses is determined on a US dollar per constructed square meter basis, while the construction cost of its mills, facilities and grain storage facilities is determined by reference to their total capacity measured in tons milled or stored, respectively. A 5% increase or decrease in the construction costs or the estimate of normal wear and tear relating to such assets could have an impact of $ 1.5 million on their revalued amounts. Increases in the carrying amounts arising on revaluation of land and buildings are recognized, net of tax, in other comprehensive income and accumulated in reserves in shareholders’ equity. To the extent that the increase reverses a decrease previously recognized in profit or loss, the increase is first recognized in profit or loss. Decreases that reverse previous increases of the same asset are first recognized in other comprehensive income to the extent of the remaining surplus attributable to the asset; all other decreases are charged to profit or loss. 4.10. Leased assets Until June 30, 2019 the Group classified its leases at the inception as finance or operating leases. Leases were classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases were classified as operating leases and charged to the statements of income in a straight-line basis over the period of the lease. Finance leases were capitalized at the lease’s inception at the lower of the fair value of the leased property and the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, were included as “Borrowings”. As of the effectiveness of IFRS 16, the Group began applying it and recognized the cumulative initial effect as an adjustment to the opening equity at the date of initial application. The comparative information was not restated. On adoption of IFRS 16, the Group recognized lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under the principles of IAS 17 Leases. In applying IFRS 16 for the first time, the Group has used the following practical expedients permitted by the standard: (i) the use of a single discount rate to a portfolio of leases with reasonably similar characteristics, (ii) reliance on previous assessments on whether leases are onerous, (iii) the accounting for operating leases with a remaining lease term of less than 12 months, as at July 1, 2019, as short-term leases, (iv) the exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application, and (v) the use of hindsight in determining the lease term, where the contract contains options to extend or terminate the lease. 4.11. Intangible assets a) Externally acquired intangible assets Externally acquired intangible assets are initially recognized at acquisition date fair value (which is considered as their cost). After initial recognition, those assets are measured at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired from third parties have an estimated useful life as follows (in years): Software: 3 years Trademarks and patents: 5 years Certification ISO Standards: 3 years Useful lives and amortization methods are reviewed every year as required by IAS 38. Estimates The Group acquired certain intangible assets from Arcadia (Note 6). To value those intangible assets, valuation techniques generally accepted in the market were applied, based mainly on the revenue approach (such as excess earnings, relief from royalty, and with or without), considering the characteristics of the assets to be valued and available information to estimate their acquisition date fair value. Application of these valuation techniques requires the use of several assumptions related to future cash flows and the discount rate. b) Internally generated intangible assets (development costs) Expenditure on internally developed products is capitalized if it can be demonstrated that: - It is technically feasible to develop the product for it to be sold; - Adequate resources are available to complete the development; - There is an intention to complete and sell the product; - The Group is able to sell the product; - Sale of the product will generate future economic benefits; and - Expenditure on the project can be measured reliably. Development expenditure not satisfying the above criteria and expenditure on the research phase of internal projects are recognized in the consolidated statement of profit or loss and other comprehensive income as incurred (Note 8.3). Capitalized development costs are amortized using the straight-line method over the periods the Group expects to benefit from selling the products developed (Note 7.8). Useful lives and amortization methods are reviewed every year as required by IAS 38. The research and development process can be divided into several discrete steps or phases, which generally begin with discovery, validation and development and end with regulatory approval and commercial launch. The process for developing seed traits is relatively similar for both GM and non-GM traits. However, the two differ significantly in later phases of development. For example, obtaining regulatory approval for GM seeds is a far more comprehensive and lengthy process than for non-GM seeds. Although breeding programs and industrial biotechnology solutions may have shorter or simpler phases than those described below, the Group has used the industry consensus for seed-trait development phases to characterize its technology portfolios, which is generally divided into the following six phases: i) Discovery: The first phase in the technology development process is the discovery or identification of candidate genes or genetic systems, metabolites, or microorganisms potentially capable of enhancing specified plant characteristics or enabling an agro-industrial biotech solution. ii) Proof of concept: Upon successful validation of the technologies in model systems ( in vitro in vivo iii) Early development: In this phase, field tests commenced in the proof of concept phase are expanded to evaluate various permutations of a technology in multiple geographies and growing cycles, as well as other characteristics in order to optimize the technology’s performance in the targeted organisms. The goal of the early development phase is to identify the best mode of use of a technology to define its performance concept. iv) Advanced development and deregulation: In this phase, extensive field tests are used to demonstrate the effectiveness of the technology for its intended purpose. In the case of GM traits, the process of obtaining regulatory approvals from government authorities is also initiated during this phase, and tests are performed to evaluate the potential environmental impact of modified plants. For solutions involving microbial fermentation, industrial-scale runs are conducted. v) Pre-launch: This phase involves finalizing the regulatory approval process and preparing for the launch and commercialization of the technology. The range of activities in this phase includes seed increases, pre-commercial production, and product and solution testing with selected customers. Usually, a more detailed marketing strategy and preparation of marketing materials occur during this phase. vi) Product launch: In general, this phase, which is the last milestone of the research and development process, is carried out by the Group, the joint ventures and/or the Group’s technology licensees. When technology is commercialized through the joint ventures or technology licensees, a successful product launch will trigger royalty payments to the Group, which are generally calculated as a percentage of the net sales realized by the technology and captured upon commercialization. Demonstrability of technical feasibility generally occurs when the project reaches the “advanced development and deregulation” phase because at this stage success is considered to be probable. c) Intangible assets acquired in a business combination Intangible assets acquired in a business combination and recognized separately from goodwill are initially recognized at acquisition date fair value (which is considered as their cost). After initial recognition, those assets are measured at cost less accumulated amortization and accumulated impairment losses in the same manner as intangible assets acquired separately. Intangible assets acquired in a business combination have an estimated useful life as follows (in years): Product registration: 5 years Customer loyalty: 14 - 26 years Estimates The Group acquired certain intangible assets from Rizobacter and Insuagro in the business combinations. To value those intangible assets, valuation techniques generally accepted in the market were applied, based mainly on the revenue approach (such as excess earnings, relief from royalty, and with or without), considering the characteristics of the assets to be valued and available information to estimate their acquisition date fair value. Application of these valuation techniques requires the use of several assumptions related to future cash flows and the discount rate. 4.12. Financial liabilities The Group measures its financial liabilities at initial recognition at fair value. The Group classifies all its financial liabilities as financial liabilities measured at amortized cost (using the effective interest rate method), except for Private warrants that were measured at fair value. Private warrants did not reach the fixed-for-fixed' condition and were classified as a financial liability and valued at its fair value applying a simulation model of the share price trajectory under the hypothesis of geometric Brownian motion. See Note 7.16. In the case of the private warrants designated as a whole at fair value through profit or loss, the amount

CRITICAL ACCOUNTING JUDGMENTS A

CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES	12 Months Ended
	Jun. 30, 2021
CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES
CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES	5. CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES The Group makes certain estimates and assumptions regarding the future. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below. Critical estimates - Estimate of the trade receivables impairment provision (Note 4.2). - Estimate of the inventory obsolescence allowance (Note 4.3). - Capitalization and impairment testing of development costs (Notes 4.7). - Impairment of goodwill (Notes 4.7). - Recoverability of investments in joint ventures (Note 4.8) - Fair value of land and buildings (Note 4.9 ). - Identification and fair value of identifiable intangible assets arising in acquisitions (Note 4.11 y 4.7). - Share-based payments (Notes 4.22). - Recognition and recoverability of deferred tax assets and credit for minimum presumed income tax (Note 9). - Classification of the Convertible Notes as compound instruments and determination of fair value of the liability component from the initial carrying amount (Note 4.14).

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Jun. 30, 2021
ACQUISITIONS
ACQUISITIONS	6. ACQUISITIONS Bioceres Crops S.A. In June 2019, we signed a share purchase agreement (SPA) with Bioceres S.A. for the 50% of ownership in Bioceres Crops. Consideration of the SPA will be in installments equivalent to the 50% of the royalties that Bioceres Crops Solutions will accrue from Bioceres Crops, up to a total amount of $0.7 million (Note 4.6). Bioceres Crops S.A. (“Bioceres Crops”, previously Semya S.A.) was a company owned 50% by Bioceres S.A. and 50% by Rizobacter Argentina S.A. It was created as a new proposal for the research, development and commercialization of biological products with high technological value: Bioceres Crops' strength consists in the joint and integrated development of biotechnological events, germplasm, biofertilizers and biopesticides to achieve a true synergy in seed treatment. These technologies will increase crop productivity, reduce environmental impact and increase efficiency in the use of resources. Bioceres Crops’ R&D was being developed by Rizobacter and Bioceres who signed, jointly, a Service Agreement in December 2014. When Group Bioceres acquired control over Rizobacter, it also acquired control over Bioceres Crops. As required by paragraph 42 of IFRS 3, the Group re-measured the fair value of its previous equity interest in Bioceres Crops at the acquisition date. The determination of fair value of Bioceres Crops at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of revenue from the launch of seed treatment packs. As a result, Integrated seed products have been recorded as intangibles assets. The purpose of those projects is to develop high value-added biological products for the treatment of soybean and wheat seeds, and generate biotechnological, germplasm and bio-inoculants synergies. Verdeca and other intangibles assets On November 12, 2020 we acquired from Arcadia the remaining ownership interest in Verdeca, a joint agreement formed by Bioceres and Arcadia in 2012 to develop second generation biotechnologies for soybean and to globally commercialize the HB4 Soy technology. As part of the transaction, Bioceres has gained full access to and control of Verdeca´s vetted soybean library of gene-edited materials used to develop new quality and productivity traits for this crop, as well as exclusive rights to all Arcadia technologies that are applicable to soybean and in-licensing rights to Arcadia’s safflower and wheat traits and the related brands. The complementary portfolio of materials being licensed includes wheat varieties that produce flour with 65% less gluten, ten times the dietary fiber content of conventional wheat flours, and oxidative stability, which extends the shelf life of whole flours and food products produced with these flours. In addition, these flours produce breads and other foods that are substantially equivalent in taste and all other aspects to conventional wheat. In consideration for the acquisition of the above-mentioned rights and assets, Bioceres paid Arcadia at the closing of the transaction $5 million in cash and $15 million in equity consisting of 1,875,000 Bioceres common shares. Bioceres has relied on the exemption from the registration requirements of the Securities Act of 1933 under Section 4(a)(2) thereof, for a transaction by an issuer not involving any public offering. Bioceres will also pay Arcadia $2 million subject to Verdeca obtaining Chinese import clearance for HB4 Soy or achieving penetration of this technology in a minimum number of planted hectares. These payments do not include $1 million due to Arcadia post-closing as a reimbursement of costs associated with the transaction. Following the transaction Bioceres agreed with Arcadia to make royalty payments equivalent to 6% of the net HB4 Soy technology revenues realized by Verdeca and capped at a maximum $10 million aggregate amount of royalty payments and a royalty payment equivalent to 25% of the net wheat technology revenues resulting from the in-licensed materials. Moolec Science Ltd On March 16, 2021, we acquired a 6% ownership interest, represented by 2,919,715 ordinary shares, in Moolec Science Ltd. (“Moolec”), a United Kingdom Molecular Farming company pursuing a hybrid concept between plant and cell-based technologies for the production of animal-free food solutions. Insuagro On April 9, 2021, as part of the reorganization process of our crop protection business segment, we acquired a controlling interest in Insuagro, an Argentine public company. The interest acquired is represented by a total of 11,022,000 shares, distributed as follows: (i) 2,749,390 ordinary, registered shares of AR$ 0.10 nominal value each and five votes per share, denominated Class A; and (ii) 8,272,610 ordinary, registered shares of Pesos 0.10 nominal value each and one vote per share, denominated Class B, jointly representing 50.1% of equity interest and 55.05% of voting interest. At closing, two directors (of three total members) resigned to the board and were replaced by two directors of Bioceres. Acquiring control over Insuagro, we also acquired control over two SPEs, Insuagro VI and Insuagro VII. These SPEs are financial trust on public offering, whose underlying assets are trade receivables from Insuagro (trade receivables securitization). Insuagro is the administrator of the receivables, acts as the collection agent and has agreed to replace bad accounts receivable. Certificates of Participation issued by each SPEs are owned by Insuagro. The consideration for the acquisition was $0.282 per share, totaling an amount of $3.1 million (the “Fixed Price”). At closing, we paid $0.2 million, and the rest is payable in three installment due August 31, 2022, 2023 and 2024 for an amount of $0.9 million, $0.9 million and $1.2 million, respectively. The amount payable will accrue an interest annual rate of 5.5%. Furthermore, the Fixed Price may be increased up to 3.5x Adjusted EBITDA (as defined in the share exchange agreement) per share to be measured in each annual reporting period. Fair value of the consideration of payment ​ ​ ​ ​ Cash payment 200,000 Financed payment 2,625,335 Contingent payment 951,622 Total consideration 3,776,957 ​ The consideration of payment was measured at fair value, which was calculated as the sum of the acquisition‑date fair values of the assets transferred, and the liabilities incurred. The fair values measured were based on discounting future cash flow using market discount rates. The difference between fair value and nominal value of consideration will be recognized as finance cost over the period the consideration will be paid. Assets acquired, liabilities assumed, and non-controlling interest recognized. ​ ​ ​ ​ Net assets incorporated Cash and cash equivalents 555,804 Other financial assets 2,024,367 Trade receivables 17,536,888 Other receivables 419,877 Income and minimum presumed income taxes recoverable 117,229 Inventory 5,603,068 Deferred tax assets 106,952 Property, plant and equipment 1,662,516 Intangible assets 264,847 Trade and other payables (17,311,906) Borrowings (5,928,748) Employee benefits and social security (201,472) Deferred revenues and advances from customers (301,017) ​ ​ ​ ​ ​ ​ Revaluation of existing assets ​ ​ ​ Property, plant and equipment 289,529 Intangible assets 2,659,050 Deferred tax (884,574) ​ ​ ​ Total net assets identified 6,612,410 ​ ​ ​ Non-controlling interest (3,305,543) ​ ​ ​ Goodwill 470,090 ​ ​ ​ Total consideration 3,776,957 ​ Goodwill is not expected to be deductible for tax purposes. Non-controlling interest was measured at the present ownership instruments’ proportionate share in the recognized amounts of the acquiree’s identifiable net assets. The amounts of revenue and profit or loss of the acquiree since the acquisition date included in the consolidated statement of comprehensive income for year ended June 30, 2021, were $7.6 million and ($0.2) million, respectively. The revenue and profit or loss of the combined entity for year ended June 30, 2021 as though the acquisition date for the business combination had been as of the beginning of the annual reporting period amount to $233.3 million and ($4.6) million, respectively.

INFORMATION ABOUT COMPONENTS OF

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	12 Months Ended
	Jun. 30, 2021
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	7. INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION 7.1. Cash and cash equivalents ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Cash at bank and on hand ​ 28,327,569 ​ 20,176,452 ​ 3,450,873 Money market funds ​ 7,718,544 ​ 22,346,409 ​ — ​ 36,046,113 42,522,861 3,450,873 ​ 7.2. Other financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ Restricted short-term deposits 425,976 4,390,458 ​ 4,327,275 US Treasury bills ​ 7,885,937 ​ 7,768,410 ​ — Others mutual funds ​ — ​ — ​ 347,718 Other investments 2,849,485 1,277,525 ​ 8,515 ​ 11,161,398 13,436,393 ​ 4,683,508 ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Non-current Shares of Bioceres S.A. 355,251 321,705 374,685 Other investments 742,211 998 1,728 ​ 1,097,462 322,703 376,413 ​ Variations in the allowance for uncollectible trade receivables are reported in Note 7.18. The book value is reasonably approximate to the fair value given its short-term nature. The book value is reasonably approximate to the fair value given its short-term nature. 7.3. Trade receivables ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Trade debtors ​ 87,709,287 ​ 53,047,035 ​ 48,910,484 Allowance for impairment of trade debtors (5,858,503) (3,886,832) (3,360,224) Shareholders and other related parties (Note 17) — 1,090,004 467,743 Allowance for impairment of shareholders and other related parties (Note 17) — (768) (75,596) Allowance for credit notes to be issued (2,987,398) (2,285,197) (800,606) Trade debtors - Parent company (Note 17) — — 440,268 Trade debtors - Joint ventures and associates (Note 17) 221,048 120,992 2,369 Deferred checks 9,699,738 25,461,399 13,651,939 ​ 88,784,172 73,546,633 59,236,377 Non-current ​ ​ ​ ​ ​ ​ Trade debtors ​ 135,739 ​ — ​ — ​ ​ 135,739 ​ — ​ — ​ The book value is reasonably approximate to the fair value given its short-term nature. 7.4. Other receivables ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current Taxes 6,048,533 2,205,342 584,641 Other receivables - Other related parties (Note 17) 1,547 2,102 10,971 Other receivables - Parents companies and related parties to Parents (Note 17) 770,549 102,069 — Other receivables - Joint ventures and associates (Note 17) 2,219,863 1,562,340 250,783 Prepayments to suppliers 1,646,614 379,914 496,001 Prepayments to suppliers - Shareholders and other related parties (Note 17) 132,625 81,737 — Reimbursements over exports 10,547 29,077 366,594 Prepaid expenses and other receivables 1,021 128,650 213,597 Loans receivable 230,000 230,000 — Miscellaneous 92,406 49,441 59,242 ​ 11,153,705 4,770,672 1,981,829 ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Non-current Taxes 862,771 328,701 681,168 Reimbursements over exports 1,680,371 1,293,958 878,470 Miscellaneous — 80,914 672 ​ 2,543,142 1,703,573 1,560,310 ​ The book value is reasonably approximate to the fair value given its short-term nature. 7.5. Inventories ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Agrochemicals 1,161,025 356,489 22,137 Seeds and grains 22,389,400 1,300,998 207,519 Resale products ​ 20,207,496 ​ 13,486,668 ​ 13,894,018 Manufactured products ​ 10,902,683 ​ 8,079,553 ​ 8,370,583 Goods in transit 1,169,303 1,292,239 751,737 Supplies 6,320,594 5,930,471 4,482,827 Allowance for obsolescence (1,112,950) (1,107,870) (406,818) ​ 61,037,551 29,338,548 27,322,003 ​ The roll-forward of allowance for obsolescence is in Note 7.18. Inventories recognized as an expense during the years ended June 30, 2021, 2020 and 2019 amounted to $102,369,869 , $86,179,252 and $80,424,450, respectively. Those expenses were included in cost of sales. 7.6. Biological assets HB4 ® Program Bioceres’ HB4 Program is an identity-preserved production system for growing drought-tolerant soy and wheat. It has multiple objectives, which include expanding Bioceres’ seed inventories, allowing growers to field test Bioceres’ HB4 technology, providing fields for product demonstrations and validating the products’ regional positioning. HB4 seed varieties produced through the program will be commercialized as an integrated product. The seed treatment process to produce the integrated seed product utilizes customized microbial solutions for seed nutrition and protection, including biological fungicides. For HB4 Soy, inoculants are also integrated, including last generation microbiological formulations that ensures greater microorganism survival over the seed, greater nodular dry mass, and better biological fixation of nitrogen. In addition to providing the integrated seed solution for planting, the HB4 program comprises Bioceres’ next-generation crop nutrition and protection technologies for growing both crops. The HB4 program also includes digital apps that give growers access to satellite-based images and data for monitoring crop health, soil conditions and weather, information that helps optimize crop yields. On top of generating extensive and detailed datasets from each grower’s HB4 production fields that are monitored via these digital apps, Bioceres is applying and leveraging data science and blockchain technology to other areas of agriculture’s value chain, such as crop storage, logistics and processing, in order to guarantee HB4 identity and complete farm-to-fork traceability. The identity-preserved HB4 Program utilizes service contracts with growers who are committed to preserving the identity of the HB4 crop under a full-seed production offtake agreement, which includes best environmental farming practices, such as no-till agriculture. Under these agreements, Bioceres contributes the intergated seed solution and the other aforementioned goods (“Contributed goods”) to growers for a pre-agreed price (based on prevailing market prices), which are deduced from the service fees to paid to growers at the time of harvest for the seed multiplication services provided. As part of the transaction described in Note 6, Bioceres acquired full ownership of the HB4 soy inventory. HB4 program for HB4 Soy had been produced jointly with Arcadia in Verdeca. For the year ended June 30, 2021, the Contributed goods for HB4 Program amounted to $8.3 million with weighted average gross margin of approximately 43% across almost 80,000 total hectares. Joint operation with Espartina S.A. On September 1, 2020, Rizobacter Argentina S.A., a subsidiary of the Company, entered into an agreement with Espartina S.A. ("Espartina") to share its business of producing grain crops. The joint operation is classified as a joint agreement as established in IFRS 11, while the parties are entitled to the assets and obligations over the related liabilities. Rizobacter Argentina S.A. recognizes as a joint operator, in relation to its participation, assets, liabilities, income and expenses. The production obtained is distributed according to the contributions made by each party. The in-kind contributions made during the period amount to $0.7 million. Each party decides the means of commercialization and the destination of the grains produced. Under the agreement, Rizobacter provides inputs and money necessary for producing the grains and according to the established participation percentages. For its participation, Espartina contributes all cultivation practices in fields, inputs not provided by Rizobacter, and all administrative expenses related to production. Changes in Biological assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean Corn Wheat Barley HB4 Soy HB4 Wheat Total Beginning of the year 105,101 271,754 45,639 34,050 — 509,184 965,728 Initial recognition and changes in the fair value of biological assets 981,551 250,443 284,903 35,847 741,799 531,712 2,826,255 Costs incurred during the year 252,504 417,586 241,610 37,115 17,716,018 7,053,929 25,718,762 Exchange differences (113,718) (153,795) (65,797) (16,876) (2,823,643) (1,153,734) (4,327,563) Decrease due to harvest (1,171,276) (758,342) (484,044) (87,065) (15,634,174) (4,732,443) (22,867,344) Year ended June 30, 2021 54,162 27,646 22,311 3,071 — 2,208,648 2,315,838 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean Corn Wheat Barley HB4 Wheat Total Beginning of the year 237,723 32,856 — — — 270,579 Initial recognition and changes in the fair value of biological assets 198,932 252,056 202,543 63,210 — 716,741 Decrease due to harvest (447,132) (252,372) (227,303) (59,626) — (986,433) Cost incurred during the year 284,951 314,950 87,615 38,033 509,184 1,234,733 Exchange differences (169,373) (75,736) (17,216) (7,567) — (269,892) Year ended June 30, 2020 105,101 271,754 45,639 34,050 509,184 965,728 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean Corn Wheat Barley Total Beginning of the year — — — — — Initial recognition and changes in the fair value of biological assets 241,707 38,238 — — 279,945 Decrease due to harvest (288,791) (45,687) — — (334,478) Cost incurred during the year 339,088 47,986 — — 387,074 Exchange differences (54,281) (7,681) — — (61,962) Year ended June 30, 2019 237,723 32,856 — — 270,579 ​ As of June 30, 2021, the impact of a 20% increase (decrease) in estimated yields, with all other variables held constant, would result in an increase (decrease) in the fair value of our planting of $0.4 million. 7.7. Property, plant and equipment Property, plant and equipment as of June 30, 2021, 2020 and 2019, included the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Gross carrying amount 63,974,402 54,527,392 57,059,972 Accumulated depreciation (16,019,806) (13,012,286) (13,225,424) Net carrying amount 47,954,596 41,515,106 43,834,548 ​ 1. Net carrying amount for each class of assets is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net carrying ​ Net carrying ​ Net carrying ​ ​ amount ​ amount ​ amount Class 06/30/2021 06/30/2020 06/30/2019 Office equipment ​ 288,920 ​ 188,280 ​ 213,437 Vehicles ​ 1,835,634 ​ 1,149,455 ​ 1,785,701 Equipment and computer software 67,105 32,448 123,472 Fixtures and fittings 2,967,431 3,679,075 4,737,396 Machinery and equipment 5,125,728 5,449,233 6,336,691 Land and buildings 35,674,513 29,746,076 29,969,237 Buildings in progress 1,995,265 1,270,539 668,614 Total 47,954,596 41,515,106 43,834,548 ​ 2. Gross carrying amount as of June 30, 2021 is as follows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ ​ ​ Additions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ ​ ​ from ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ ​ ​ beginning ​ ​ ​ business ​ ​ ​ ​ ​ currency ​ ​ ​ As of the Class of year Additions combination Transfers Disposals translation Revaluation end of year Office equipment ​ 579,882 ​ 66,331 ​ 5,491 ​ — ​ (5,622) ​ 116,743 ​ — ​ 762,825 Vehicles ​ 2,977,542 ​ 987,101 ​ 466,024 ​ — ​ (1,045,656) ​ 127,206 ​ — ​ 3,512,217 Equipment and computer software ​ 465,679 ​ 66,263 ​ 13,952 ​ — ​ — ​ 46,232 ​ — ​ 592,126 Fixtures and fittings 5,480,431 50,976 — 85,490 — 21,046 — 5,637,943 Machinery and equipment 9,054,701 604,307 — — (10,240) 339,043 — 9,987,811 Land and buildings 34,698,618 — 1,466,578 2,517,158 — 4,022,972 (1,219,111) 41,486,215 Buildings in progress 1,270,539 1,030,847 — (438,492) — 132,371 — 1,995,265 Total 54,527,392 2,805,825 1,952,045 2,164,156 (1,061,518) 4,805,613 (1,219,111) 63,974,402 ​ Reclassifications corresponds to transfers to leased assets from finance leases assets. ​ 3. Accumulated depreciation as of June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of the ​ ​ ​ ​ ​ Foreign ​ ​ ​ Accumulated ​ ​ beginning of ​ ​ ​ ​ ​ currency ​ ​ ​ as of the end Class year Disposals Of the year translation Revaluation of year Office equipment 391,602 (3,265) 45,174 40,394 — 473,905 Vehicles 1,828,087 (974,102) 689,273 133,325 — 1,676,583 Equipment and computer software 433,231 — 50,949 40,841 — 525,021 Fixtures and fittings 1,801,356 — 683,537 185,619 — 2,670,512 Machinery and equipment 3,605,468 (10,239) 898,522 368,332 — 4,862,083 Land and buildings 4,952,542 — 681,084 517,991 (339,915) 5,811,702 Total 13,012,286 (987,606) 3,048,539 1,286,502 (339,915) 16,019,806 ​ 4. Gross carrying amount as of June 30, 2020 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ As of the ​ ​ ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ ​ ​ beginning ​ ​ ​ ​ ​ ​ ​ currency ​ ​ ​ As of the Class of year Additions Reclassifications Disposals translation Revaluation end of year Office equipment ​ 629,119 ​ 42,658 ​ — ​ — ​ (91,895) ​ — ​ 579,882 Vehicles ​ 3,604,537 ​ 248,800 ​ (264,069) ​ (139,369) ​ (472,357) ​ — ​ 2,977,542 Equipment and computer software ​ 955,657 ​ 27,961 ​ (375,242) ​ — ​ (142,697) ​ — ​ 465,679 Fixtures and fittings ​ 6,438,430 ​ 14,985 ​ 20,801 ​ — ​ (993,785) ​ — ​ 5,480,431 Machinery and equipment 10,233,501 556,693 (598,561) — (1,136,932) — 9,054,701 Land and buildings 34,530,114 3,261 36,487 — (4,772,065) 4,900,821 34,698,618 Buildings in progress 668,614 752,339 (57,288) — (93,126) — 1,270,539 Total 57,059,972 1,646,697 (1,237,872) (139,369) (7,702,857) 4,900,821 54,527,392 ​ 5. Accumulated depreciation as of June 30, 2020 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of the ​ ​ ​ ​ ​ Foreign ​ ​ ​ Accumulated ​ ​ beginning of ​ Disposals/ ​ ​ ​ currency ​ ​ ​ as of the end of Class year Reclassifications Of the year translation Revaluation year Office equipment ​ 415,682 ​ — ​ 35,879 ​ (59,959) ​ — ​ 391,602 Vehicles ​ 1,818,836 ​ (173,482) ​ 426,623 ​ (243,890) ​ — ​ 1,828,087 Equipment and computer software ​ 832,185 ​ (307,816) ​ 28,170 ​ (119,308) ​ — ​ 433,231 Fixtures and fittings ​ 1,701,034 ​ — ​ 338,092 ​ (237,770) ​ — ​ 1,801,356 Machinery and equipment 3,896,810 (279,322) 553,399 (565,419) — 3,605,468 Land and buildings 4,560,877 — 627,973 (604,216) 367,908 4,952,542 Total 13,225,424 (760,620) 2,010,136 (1,830,562) 367,908 13,012,286 ​ 6. Gross carrying amount as of June 30, 2019 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of opening ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ net book ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ amount for ​ ​ ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ ​ ​ beginning ​ application ​ ​ ​ ​ ​ ​ ​ currency ​ ​ ​ As of the Class of year of IAS 29 Additions Transfers Disposals translation Revaluation end of year Office equipment ​ 243,948 ​ 333,904 ​ 30,621 ​ — ​ (8,493) ​ 29,139 ​ — ​ 629,119 Vehicles ​ 1,660,294 ​ 1,054,631 ​ 1,093,749 ​ — ​ (297,269) ​ 93,132 ​ — ​ 3,604,537 Equipment and computer software ​ 419,638 ​ 416,274 ​ 75,152 ​ — ​ (1,685) ​ 46,278 ​ — ​ 955,657 Fixtures and fittings ​ 3,826,665 ​ 1,909,115 ​ 7,518 ​ 213,333 ​ — ​ 481,799 ​ — ​ 6,438,430 Machinery and equipment 5,404,029 3,976,720 98,034 7,863 (31,407) 778,262 — 10,233,501 Land and buildings 33,026,981 1,438,728 125,930 — — 1,994,906 (2,056,431) 34,530,114 Buildings in progress 182,839 75,405 613,098 (221,196) — 18,468 — 668,614 Total 44,764,394 9,204,777 2,044,102 — (338,854) 3,441,984 (2,056,431) 57,059,972 ​ 7. Accumulated depreciation as of June 30, 2019 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ ​ ​ Adjustments of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ opening net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of the ​ book amount ​ ​ ​ ​ ​ Foreign ​ ​ ​ Accumulated ​ ​ beginning of ​ for application ​ ​ ​ Of the ​ currency ​ ​ ​ as of the end of Class year of IAS 29 Disposals year translation Revaluation year Office equipment ​ 49,129 ​ 309,339 ​ (4,007) ​ 39,997 ​ 21,224 ​ — ​ 415,682 Vehicles ​ 560,691 ​ 750,195 ​ (205,618) ​ 621,974 ​ 91,594 ​ — ​ 1,818,836 Equipment and computer software ​ 207,402 ​ 486,143 ​ (769) ​ 99,350 ​ 40,059 ​ — ​ 832,185 Fixtures and fittings 318,582 ​ 912,404 ​ — ​ 397,989 ​ 72,059 ​ — ​ 1,701,034 Machinery and equipment 937,736 2,121,816 (16,807) 673,784 ​ 180,281 — 3,896,810 Land and buildings 2,513,708 1,343,500 — 617,162 ​ 221,428 (134,921) 4,560,877 Total 4,587,248 5,923,397 (227,201) 2,450,256 ​ 626,645 (134,921) 13,225,424 ​ The depreciation charge is included in Notes 8.3 and 8.4.The Group has no commitments to purchase property, plant and equipment items. A detail of restricted assets is provided in Note 20. Revaluation of property, plant and equipment At a minimum, the Group updates their assessment of the fair value of its land and buildings at the end of each reporting year (after the revaluation policy was adopted), taking into account the most recent independent valuations and market data. Valuations were performed at June 30, 2021. Management determined the property, plant and equipment’s value within a range of reasonable fair value estimates. All resulting fair value estimates for properties are included in level 3. The following are the carrying amounts that would have been recognized if land and building were stated at cost. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Value at cost Class of property 06/30/2021 06/30/2020 06/30/2019 Land and buildings 17,937,729 12,549,876 14,330,892 ​ 7.8. Intangible assets Intangible assets as of June 30, 2021, 2020 and 2019 included the following ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Gross carrying amount 78,019,203 42,832,837 45,848,737 Accumulated amortization (10,676,841) (7,499,373) (6,232,311) Net carrying amount 67,342,362 35,333,464 39,616,426 ​ Net carrying amount of each class of intangible assets is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net carrying ​ Net carrying ​ Net carrying ​ ​ amount ​ amount ​ amount Class 06/30/2021 06/30/2020 06/30/2019 Seed and integrated products HB4 soy and breeding program 27,611,142 7,345,923 6,120,336 Integrated seed products 2,558,220 2,296,955 2,627,946 Crop nutrition ​ ​ ​ Microbiological products 3,996,657 2,503,631 2,208,117 Other intangible assets ​ ​ Trademarks and patents 6,923,256 6,374,782 8,063,648 Software 1,849,041 686,965 994,723 Customer loyalty 19,404,046 16,125,208 19,601,656 RG/RS/OX Wheat ​ 5,000,000 ​ — ​ — Total 67,342,362 35,333,464 39,616,426 ​ 1. Gross carrying amount as of June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ ​ ​ Additions ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ ​ ​ from ​ ​ ​ Foreign ​ ​ ​ ​ beginning of ​ ​ ​ business ​ Transfers / ​ currency ​ As of the Class year Additions combination Disposals translation end of year Seed and integrated products ​ ​ ​ ​ ​ ​ HB4 soy and breeding program (1) ​ 7,345,923 ​ 20,471,002 ​ — ​ (205,783) ​ — ​ 27,611,142 Integrated seed products ​ 2,296,955 ​ — ​ — ​ — ​ 261,265 ​ 2,558,220 Crop nutrition Microbiological products 3,867,593 1,791,008 — (51,716) 430,795 6,037,680 Other intangible assets Trademarks and patents 8,432,746 4,834 499,329 — 887,262 9,824,171 Software 2,088,929 2,205,796 — (711,441) 201,309 3,784,593 Customer loyalty 18,800,691 — 2,424,568 — 1,978,138 23,203,397 GLA/ARA safflower (Note 6) — 2,931,699 — (2,931,699) — — RG/RS/OX Wheat (Note 6) — 5,000,000 — — — 5,000,000 Total 42,832,837 32,404,339 2,923,897 (3,900,639) 3,758,769 78,019,203 ​ (1) Of the total additions, $18.4 million are associated with Arcadia’s transaction mentioned in Note 6. ​ 2. Accumulated amortization as of June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ beginning of ​ ​ ​ Transfers / ​ Foreign currency ​ as of the end Class year Of the year Disposals translation of year Crop nutrition ​ ​ ​ ​ ​ Microbiological products ​ 1,363,962 ​ 523,992 ​ — ​ 153,069 ​ 2,041,023 Other intangible assets ​ ​ ​ ​ ​ Trademarks and patents 2,057,964 626,420 — 216,531 2,900,915 Software 1,401,964 396,207 — 137,381 1,935,552 Customer loyalty 2,675,483 842,363 — 281,505 3,799,351 Total 7,499,373 2,388,982 — 788,486 10,676,841 ​ 3. Gross carrying amount as of June 30, 2020 is as follows: ​ op ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ beginning of ​ ​ ​ ​ ​ currency ​ As of the Class year Additions Disposals translation end of year Seed and integrated products ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HB4 soy and breeding program ​ 6,120,336 ​ 1,225,587 ​ — ​ — ​ 7,345,923 Integrated seed products ​ 2,627,946 ​ 38,143 ​ — ​ (369,134) ​ 2,296,955 Crop nutrition ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Microbiological products 3,267,200 1,358,315 (286,496) (471,426) 3,867,593 Other intangible assets ​ ​ ​ ​ ​ Trademarks and patents 9,810,822 — — (1,378,076) 8,432,746 Software 2,149,340 233,434 — (293,845) 2,088,929 Customer loyalty 21,873,093 — — (3,072,402) 18,800,691 Total 45,848,737 2,855,479 (286,496) (5,584,883) 42,832,837 ​ 4. Accumulated amortization as of June 30, 2020 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ ​ ​ ​ ​ Foreign ​ Accumulated ​ ​ beginning of ​ ​ ​ ​ ​ currency ​ as of the end of Class year Of the period Disposals translation year Crop nutrition ​ ​ ​ ​ ​ Microbiological products ​ 1,059,083 ​ 471,135 ​ (17,495) ​ (148,761) ​ 1,363,962 Other intangible assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trademarks and patents ​ 1,747,174 ​ 556,206 ​ — ​ (245,416) ​ 2,057,964 Software 1,154,617 399,090 — (151,743) 1,401,964 Customer loyalty 2,271,437 723,103 — (319,057) 2,675,483 Total 6,232,311 2,149,534 (17,495) (864,977) 7,499,373 ​ 5. Gross carrying amount as of June 30, 2019 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of opening ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ net book ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ amount for ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ beginning of ​ application ​ ​ ​ ​ ​ currency ​ As of the Class year of IAS 29 Additions Disposals translation end of year Seed and integrated products ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean HB4 ​ 4,927,853 ​ — ​ 1,192,483 ​ — ​ — ​ 6,120,336 Integrated seed products ​ — ​ — ​ 2,627,946 ​ — ​ — ​ 2,627,946 Crop nutrition ​ ​ ​ ​ ​ ​ Microbiology products 2,505,864 841,753 41,485 (318,949) 197,047 3,267,200 Other intangible assets Trademarks and patents 6,278,706 2,986,739 — — 545,377 9,810,822 Software 1,444,603 438,703 200,600 (40,359) 105,793 2,149,340 Customer loyalty 13,998,289 6,658,894 — — 1,215,910 21,873,093 Total 29,155,315 10,926,089 4,062,514 (359,308) 2,064,127 45,848,737 ​ 6. Accumulated amortization as of June 30, 2019, is as follows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of opening ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ net book ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ amount for ​ ​ ​ ​ ​ Foreign ​ Accumulated ​ ​ beginning of ​ application ​ ​ ​ ​ ​ currency ​ as of the end of Class year of IAS 29 Disposals Of the year translation year Crop nutrition ​ ​ ​ ​ ​ Microbiology products 383,380 ​ 202,791 ​ (20,887) ​ 459,287 ​ 34,512 ​ 1,059,083 Other intangible assets ​ ​ ​ ​ ​ Trademarks and patents 704,024 ​ 334,919 ​ — ​ 647,101 ​ 61,130 ​ 1,747,174 Software 495,293 227,264 (40,359) 429,258 43,161 1,154,617 Customer loyalty 915,273 435,389 — 841,273 79,502 2,271,437 Total 2,497,970 1,200,363 (61,246) 2,376,919 218,305 6,232,311 ​ The depreciation charge is included in Notes 8.3 and 8.4. There are no intangibles assets whose use has been restricted or which have been delivered as a guarantee. The Group has not assumed any commitments to acquire new intangibles. Estimates There is an inherent material uncertainty related to Management’s estimation of the ability of the Group to recover the carrying amounts of internally generated intangible assets related to biotechnology projects because it is dependent upon Group`s ability to raise sufficient funds to complete the projects development, the future outcome of the regulatory process, and the timing and amount of the future cash flows generated by the projects, among other future events. Management’s estimations about the demonstrability of the recognition criteria for these assets and the subsequent recoverability represent the best estimate that can be made based on all the available evidence, existing facts and circumstances and using reasonable and supportable assumptions in cash flow projections. Therefore, the Consolidated financial statements do not include any adjustments that would result if the Group were unable to recover the carrying amount of the above-mentioned assets through the generation of enough future economic benefits. 7.9. Goodwill ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Rizobacter Argentina S.A. 22,277,336 20,094,633 23,484,761 Bioceres Crops S.A. 6,003,780 5,432,222 6,319,954 Insumos Agroquímicos S.A. ​ 470,090 ​ — ​ — ​ 28,751,206 25,526,855 29,804,715 ​ The Group is required to test whether goodwill has suffered any impairment on an annual basis. The recoverable amount is determined based on value in use calculations. The use of this method requires the estimation of future cash flows and the determination of a discount rate in order to calculate the present value of the cash flows. Rizobacter CGU. This CGU is composed of all revenues collected through Rizobacter from the production and sale of proprietary and third-party products, both in the domestic and international markets. Additionally, Rizobacter generates revenue from the formulation, fragmentation and resale of third-party products. Among the main groups of products are i) microbiological products (bio-inductors/inoculants, biological fertilizers and bio-controllers); ii) crop and seed protection (treatments, adjuvants, baits, stored grains and seed treatment); and iii) crop nutrition (fertilizers). Packs are generally a combination of a microbiological product (bio-inductors/inoculants) with a crop and seed protection product (treatments). Bioceres Crops CGU. This CGU is composed of the expected revenues from the commercialization of intensive R&D products that previously were allocated on the equity participation. Insuagro CGU. This CGU is composed of all revenues collected through Insuagro from the production and sale of proprietary and third-party products, both in the domestic markets. Management has made the estimates considering the cash flow projections projected by the management and third-party valuation reports on the assets, intangible assets and liabilities assumed. The key assumptions utilized are the following: ​ Key assumption Management’s approach Discount rate ​ The discount rate used ranges was 15.55% for Rizobacter and Bioceres Crops and 22% for Insuagro. The weighted average cost of capital ("WACC") rate has been estimated based on the market capital structure. For the cost of debt, the indebtedness cost of the CGUs was used. For the cost of equity, the discount rate is estimated based on the Capital Asset Pricing Model (CAPM). The value assigned is consistent with external sources of information. Budgeted market share of joint ventures and other customers ​ The projected revenue from the products and services of the CGUs has been estimated by the management based on market penetration data for comparable products and technologies and on future expectations of foreseen economic and market conditions. The value assigned is consistent with external sources of information. Budgeted product prices ​ The prices estimated in the revenue projections are based on current and projected market prices for the products and services of the CGUs The value assigned is consistent with external sources of information. Growth rate used to extrapolate future cash flow projections to terminal period ​ The growth rate used to extrapolate the future cash flow projections to terminal period is 2%. The value assigned is consistent with external sources of information. ​ Management believes that any reasonably possible change in any of these key assumptions would not cause the aggregate carrying amount of the CGU to exceed its recoverable amount. The variations in goodwill occurred during the years, besides the addition of Insuagro CGU, correspond to translation differences. There have been no goodwill impairment indicators. 7.10. Trade and other payables ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Trade creditors 51,389,515 37,139,351 30,489,072 Shareholders and other related parties (Note 17) 52,864 1,031,710 1,796,932 Trade creditors - Parent company (Note 17) 193,718 2,210,308 1,568,036 Trade creditors - Joint ventures and associates (Note 17) 17,669,027 14,409,853 4,805,149 Taxes 2,556,945 2,163,552 1,475,410 Miscellaneous 229,339 335,088 443,895 ​ 72,091,408 57,289,862 40,578,494 ​ The book value is reasonably approximate to the fair value given its short-term nature. 7.11. Borrowings ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Bank overdrafts 32,838 73,362 — Bank borrowings 33,684,287 47,646,912 52,274,611 Corporate bonds 24,742,752 12,611,940 8,416,768 Trust debt securities 3,470,448 — — Net loans payables-Parents companies and related parties to Parents (Note 17) 3,578,921 3,389,521 5,399,883 Subordinated loan ​ 11,276,611 ​ — ​ — Finance lease — — 385,947 ​ 76,785,857 63,721,735 66,477,209 Non-current ​ ​ ​ Subordinated loan ​ — ​ 10,364,045 ​ — Bank borrowings 4,161,827 3,497,671 16,239,743 Corporate bonds 37,826,641 18,364,894 8,018,884 Net loans payables-Parents companies and related parties to Parents (Note 17) 6,000,000 9,000,000 12,358,024 Finance lease — — 462,870 ​ 47,988,468 41,226,610 37,079,521 ​ The carrying value of some borrowings as of June 30, 2021, 2020 and 2019 are measured at amortized cost differ from their fair value. The following fair values measured are based on discounted cash flows (Level 3) due to the use of unobservable inputs, including own credit risk. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 ​ 06/30/2020 ​ 06/30/2019 ​ ​ Amortized ​ ​ ​ Amortized ​ ​ ​ Amortized ​ ​ ​ cost Fair value cost Fair value cost Fair value Current ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bank borrowings 33,684,287 32,770,615 47,646,912 43,046,111 52,274,611 52,088,002 Corporate bonds 24,742,752 24,085,087 12,611,940 11,997,981 8,416,768 7,632,806 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-current Bank borrowings 4,161,827 3,864,666 3,497,671 3,072,395 16,239,743 14,274.55 Corporate bonds 37,826,641 32,656,097 18,364,894 16,135,876 8,018,884 6,972,332 ​ Net loans payables-Parents companies and related parties to Parents As of June 30, 2019 financial assets (other receivables from the controlling entities (“Parents”) and related parties to Parents) and liabilities (loans payable to Parents companies) were offset and the net amount was reported in the Statement of Financial Position where the Company currently had a right to offset the recognized amounts, and there was an intention to settle on a net basis or realize the asset and settle the liability simultaneously. As of June 30, 2021 and 2020, there was no offsets of financial assets and liabilities of the Parents. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross amounts set off Net amounts presented ​ ​ ​ ​ in the Statement of ​ in the Statement of Parents companies and related parties to Parents ​ Gross amounts ​ Financial Position ​ Financial Position Current other receivables 15,827,847 (15,827,847) — Total current assets 15,827,847 (15,827,847) — Current borrowings (21,227,730) 15,827,847 (5,399,883) Total current liabilities (21,227,730) 15,827,847 (5,399,883) Non-current borrowings ​ (12,358,024) ​ — ​ (12,358,024) Total non-current liabilities ​ (12,358,024) ​ — ​ (12,358,024) ​ Corporate bonds a) Issuance of public corporate bonds (principal market) We have a global program of corporate bonds (“CB”) in the Argentine principal market for the issuance of Series of CB through public offering up to an amount of $80 million or the equivalent in other currencies. As of June 30, 2021 we have $22.6 million of public corporate public outstanding. b) Issuance of private corporate bonds On April 4, 2019, the Group issued class I of guaranteed negotiable obligations, not convertible into shares, for a total nominal value of $16 million due on April 5, 2021. As of the date of issuance of These financial statements, we have already paid the last installment of the private bonds. The commitments assumed by the Group have been released . Syndicated loan In 2017, Rizobacter consummated a $45 million syndicated loan with Banco de Galicia y Buenos Aires S.A. as administrator, together with Banco Santander Río S.A., Banco BBVA Francés S.A., Banco Ciudad de Buenos Aires, Banco Provincia de Córdoba S.A., Banco Hipotecario S.A. and Banco Mariva S.A. acting as lenders. As of June 30, 2021, we have already paid the last installment of the Syndicated loan. The commitments assumed by the Group have been released. 7.12. Employee benefits and social security ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Salaries, accrued incentives, vacations and social security 2,341,351 2,960,542 3,044,965 Key management personnel (Note 17) 2,338,727 1,550,050 2,312,253

INFORMATION ABOUT COMPONENTS _2

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	12 Months Ended
	Jun. 30, 2021
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	8. INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 8.1. Revenue from contracts with customers ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Sale of goods and services 204,674,072 170,574,909 159,198,516 Royalties 2,023,548 1,775,790 1,110,463 ​ 206,697,620 172,350,699 160,308,979 ​ Transactions of sales of goods and services with joint ventures and with shareholders and other related parties are reported in Note 17. 8.2. Cost of sales ​ ​ ​ ​ ​ ​ ​ ​ Item 06/30/2021 06/30/2020 06/30/2019 Inventories as of the beginning of the year 29,338,548 27,322,003 19,366,001 Adjustment of opening net book amount for the application of IAS 29 — — 4,273,416 Business combination ​ 5,611,918 ​ — ​ — Purchases of the year 112,084,246 88,195,797 88,380,452 Production costs 11,169,890 10,998,165 11,558,513 Foreign currency translation (509,874) (3,601,829) (9,291,498) Subtotal 157,694,728 122,914,136 114,286,884 Inventories as of the end of the year (*) (39,052,925) (29,338,548) (27,322,003) Cost of sales 118,641,803 93,575,588 86,964,881 ​ (*) Net of agricultural products from HB4 program. 8.3. R&D classified by nature ​ ​ ​ ​ ​ ​ ​ ​ ​ Research Research Research ​ ​ and ​ and ​ and ​ development development development ​ expenses expenses expenses Item 06/30/2021 06/30/2020 06/30/2019 Amortization of intangible assets 1,138,720 1,027,340 1,106,390 Import and export expenses 5,220 17,303 16,360 Depreciation of property, plant and equipment 454,575 97,171 220,849 Freight and haulage ​ 2,335 ​ — ​ — Employee benefits and social securities 1,430,277 787,931 541,025 Maintenance 54,551 59,219 56,395 Energy and fuel 44,518 52,614 52,919 Supplies and materials 1,401,869 871,930 1,175,184 Mobility and travel 29,783 70,138 48,308 Professional fees and outsourced services 235,443 94,286 69,110 Professional fees related parties ​ 691,723 ​ 821,809 ​ 378,273 Office supplies 5,170 9,801 3,796 Information technology expenses ​ 14,531 ​ — ​ — Insurance 24,439 5,353 8,593 Depreciation of leased assets ​ 23,286 ​ 7,079 ​ — Impairment of R&D projects ​ 51,716 ​ 269,001 ​ — Miscellaneous 9,499 4,295 12,189 Total 5,617,655 4,195,270 3,689,391 ​ 8.4. Expenses classified by nature and function ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Selling, general ​ ​ ​ ​ ​ and ​ ​ ​ ​ ​ ​ administrative ​ Total Item ​ Production costs ​ expenses ​ 06/30/2021 Amortization of intangible assets — 1,250,262 1,250,262 Analysis and storage 23,417 123,168 146,585 Commissions and royalties 971,932 996,636 1,968,568 Import and export expenses 70,783 720,888 791,671 Depreciation of property, plant and equipment 1,274,206 1,319,758 2,593,964 Depreciation of leased assets 159,325 644,709 804,034 Impairment of receivables — 560,931 560,931 Freight and haulage 488,683 3,894,696 4,383,379 Employee benefits and social securities 4,974,759 14,979,262 19,954,021 Maintenance 632,406 586,614 1,219,020 Energy and fuel 336,812 52,710 389,522 Supplies and materials 516,431 203,250 719,681 Mobility and travel 11,225 940,619 951,844 Publicity and advertising — 2,518,286 2,518,286 Contingencies — 158,818 158,818 Share-based incentives — 1,655,135 1,655,135 Professional fees and outsourced services 787,462 7,668,043 8,455,505 Professional fees related parties — 157,714 157,714 Office supplies 217,146 463,790 680,936 Insurance 79,272 993,738 1,073,010 Information technology expenses 441 1,347,374 1,347,815 Obsolescence 579,832 — 579,832 Taxes 44,228 6,001,292 6,045,520 Miscellaneous 1,530 364,208 365,738 Total 11,169,890 47,601,901 58,771,791 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Selling, ​ ​ ​ general and ​ ​ ​ Production administrative ​ Total Item ​ costs expenses ​ 06/30/2020 Amortization of intangible assets — 1,122,194 1,122,194 Analysis and storage 46,620 23,851 70,471 Commissions and royalties 1,268,670 553,518 1,822,188 Import and export expenses 190,226 1,321,256 1,511,482 Depreciation of property, plant and equipment 1,170,624 742,341 1,912,965 Depreciation of leased assets 248,948 317,870 566,818 Impairment of receivables — 1,499,298 1,499,298 Freight and haulage 541,019 3,458,525 3,999,544 Employee benefits and social securities 4,744,240 12,505,277 17,249,517 Maintenance 400,162 530,758 930,920 Energy and fuel ​ 397,253 ​ 111,141 ​ 508,394 Supplies and materials ​ 321,962 ​ 260,126 ​ 582,088 Mobility and travel 12,980 1,358,857 1,371,837 Publicity and advertising — 1,718,572 1,718,572 Contingencies — 200,525 200,525 Share-based incentives — 3,428,029 3,428,029 Professional fees and outsourced services 575,566 2,752,852 3,328,418 Professional fees related parties — 32,816 32,816 Office supplies 2,093 356,906 358,999 Insurance 64,019 295,206 359,225 Information technology expenses ​ — ​ 917,230 ​ 917,230 Obsolescence 977,817 — 977,817 Taxes 28,724 4,656,318 4,685,042 Miscellaneous 7,242 181,562 188,804 Total 10,998,165 38,345,028 49,343,193 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Selling, ​ ​ ​ general and ​ ​ ​ Production administrative ​ Total Item ​ costs expenses ​ 06/30/2019 Amortization of intangible assets — 1,270,529 1,270,529 Analysis and storage 5,811 905 6,716 Commissions and royalties 751,972 489,301 1,241,273 Bank expenses and commissions — 30,784 30,784 Import and export expenses 95,111 1,396,636 1,491,747 Depreciation of property, plant and equipment 1,164,810 1,064,597 2,229,407 Impairment of receivables — 686,985 686,985 Freight and haulage 1,433,867 2,662,715 4,096,582 Employee benefits and social securities 5,313,211 12,969,653 18,282,864 Maintenance 501,699 532,648 1,034,347 Energy and fuel 568,848 195,449 764,297 Supplies and materials 275,378 214,513 489,891 Mobility and travel 12,097 1,306,067 1,318,164 Publicity and advertising — 1,709,552 1,709,552 Contingencies — 67,417 67,417 Professional fees and outsourced services 681,790 7,346,607 8,028,397 Professional fees related parties — 401,005 401,005 Office supplies 31,394 352,167 383,561 Insurance 105,302 802,352 907,654 Information technology expenses ​ — ​ 709,539 ​ 709,539 Obsolescence 564,873 — 564,873 Taxes 37,388 4,821,136 4,858,524 Miscellaneous 14,962 213,243 228,205 Total 11,558,513 39,243,800 50,802,313 ​ 8.5. Finance results ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial costs 06/30/2021 06/30/2020 06/30/2019 Interest expenses with the Parents (Note 17) (1,219,776) ​ (1,861,774) ​ (1,386,288) Interest expenses (17,702,770) ​ (17,535,324) ​ (20,450,254) Financial commissions (2,317,690) ​ (1,483,428) ​ (1,578,292) ​ (21,240,236) ​ (20,880,526) ​ (23,414,834) ​ ​ ​ ​ ​ ​ ​ Other financial results ​ ​ ​ Exchange differences generated by assets 22,161,855 ​ 30,194,601 ​ 48,355,784 Exchange differences generated by liabilities (35,541,048) ​ (50,815,215) ​ (66,200,973) Changes in fair value of financial assets or liabilities and other financial results (5,057,589) ​ (418,186) ​ (540,589) Gain from cancellation of purchase option ​ — ​ — ​ 6,582,849 Share-based payment cost of listing shares ​ — ​ — ​ (20,893,789) Net gain of inflation effect on monetary items ​ 11,824,678 ​ 9,216,684 ​ 14,653,335 ​ ​ (6,612,104) ​ (11,822,116) ​ (18,043,383) ​ ​ ​ ​ ​ ​ ​ Total net financial results (27,852,340) ​ (32,702,642) ​ (41,458,217) ​ Profit from translation effects on Argentine Peso denominated loans held by Rizobacter accounted in Other comprehensive income or loss amounted to $6.7 million, $3.6 million, and $1.2 million in the years ended June 30, 2021, 2020 and 2019, respectively.

TAXATION

TAXATION	12 Months Ended
	Jun. 30, 2021
TAXATION
TAXATION	9. TAXATION Tax reform in Argentina In December 2019, the Argentine Government promulgated Law 27,541. It provided that the tax rate reduction established by Law 27,430 (reduction of the income tax rate from 35% to 30% for fiscal periods beginning from January 1, 2018 until December 31, 2019, and 25% for fiscal periods beginning on or after January 1, 2020, inclusive) be suspended until the fiscal years beginning on or after January 1, 2021. Thus, the tax rate of 30% was maintained. Law 27,541 also provided that, for the first and second financial years starting on or after 1 January 2019, one-sixth of the inflation adjustment (provided by Law 27.420) will be computed in the fiscal year of the adjustment calculation and the remaining five-sixths in equal parts in the five tax periods immediately following. In June 2021, the Argentine Government approved a corporate income tax reform replacing the 30% fixed rate in force with a progressive tax rate. Depending on the amount of a corporation’s accumulated net taxable income, the reform could result in an increase or decrease in the corporate income tax rate. Under the progressive corporate income tax, a 25% tax rate will apply on net taxable income for accumulated net taxable income up to AR$5 million. For accumulated net taxable income from AR$5 million to AR$50 million, the progressive scale will apply a 30% tax rate. Finally, for accumulated net taxable income exceeding AR$50 million the progressive scale will apply a 35% tax rate. The reform also extends the 7% withholding tax on dividends for tax years beginning 1 January 2021 and thereafter. Given inflation that is expected in 2021, the Group has determined the income tax considering the application of the inflation adjustment for income tax in Argentina. The balances of income tax and minimum presumed income tax recoverable and payable are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current assets Income tax 990,881 112,220 1,263,795 ​ 990,881 112,220 1,263,795 Non-current assets Income tax 10,105 2,653 — Minimum presumed income tax 2,484 3,376 1,184 ​ 12,589 6,029 1,184 ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Liabilities Income tax 7,452,891 1,556,715 142,028 ​ 7,452,891 1,556,715 142,028 ​ The roll forward of deferred tax assets and liabilities as of June 30, 2021, 2020 and 2019 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets 06/30/2021 06/30/2020 06/30/2019 Tax Loss-Carry Forward ​ 3,226,305 ​ 2,362,657 ​ 2,663,813 Changes in fair value of financial assets or liabilities ​ 89,574 ​ 41,183 ​ 32,062 Trade receivables ​ 609,913 ​ 1,068,054 ​ 374,425 Royalties ​ 485,426 ​ 245,140 ​ — Right-of-use leased asset ​ — ​ 5,424 ​ — Government grants ​ — ​ — ​ 2,649 Others ​ 1,552,370 ​ 813,294 ​ 670,760 Total deferred tax assets ​ 5,963,588 ​ 4,535,752 ​ 3,743,709 ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities ​ 06/30/2021 06/30/2020 06/30/2019 Intangible assets ​ (10,624,621) ​ (6,839,112) ​ (9,458,239) Property, plant and equipment depreciation (12,632,296) (9,365,882) ​ (9,618,648) Borrowings — (7,930) ​ (13,170) Inflation tax adjustment ​ (2,682,172) ​ (2,032,078) ​ (1,706,092) Allowances ​ (78,076) ​ (209,490) ​ (152,159) Inventories ​ (1,821,524) ​ (237,258) ​ (153,563) Biological assets ​ (229,296) ​ — ​ — Government grants ​ (3,179) ​ (3,939) ​ — Others financial assets ​ (276,800) ​ — ​ — Right-of-use leased asset ​ (32,651) ​ — ​ — Others (4,098) (4,993) ​ — Total deferred tax liabilities (28,384,713) (18,700,682) ​ (21,101,871) ​ ​ ​ ​ ​ ​ ​ Net deferred tax (22,421,125) (14,164,930) ​ (17,358,162) ​ The roll forward of deferred tax assets and liabilities as of June 30, 2021, 2020 and 2019 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ from ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income ​ deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ Additions for ​ tax ​ tax ​ Charge ​ Conversion ​ Balance Deferred tax assets ​ 06/30/2020 ​ business combination ​ provision ​ liabilities ​ to OCI ​ difference ​ 06/30/2021 Tax Loss-Carry Forward 2,362,657 — 982,329 — — (118,681) 3,226,305 Changes in fair value of financial assets or liabilities 41,183 — 51,037 — — (2,646) 89,574 Trade receivables 1,068,054 — 138,438 — — (596,579) 609,913 Royalties 245,140 — 214,493 — — 25,793 485,426 Right-of-use leased asset 5,424 — (38,793) 32,651 — 718 — Others 813,294 370,556 (427,433) — — 795,953 1,552,370 Total deferred tax assets 4,535,752 370,556 920,071 32,651 — 104,558 5,963,588 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ Additions ​ Income ​ from ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ for business ​ tax ​ deferred tax ​ Charge to ​ Conversion ​ Balance Deferred tax liabilities ​ 06/30/2020 ​ combination ​ provision ​ assets ​ OCI ​ difference ​ 06/30/2021 Intangible assets (6,839,112) (882,434) (2,188,663) — — (714,412) (10,624,621) Property, plant and equipment depreciation (9,365,882) (537,922) (357,614) — (1,388,022) (982,856) (12,632,296) Borrowings (7,930) — 8,797 — — (867) — Inflation tax adjustment (2,032,078) 73,755 (527,654) — — (196,195) (2,682,172) Allowances (209,490) 201,969 (46,622) — — (23,933) (78,076) Inventories (237,258) (3,546) (1,561,687) — — (19,033) (1,821,524) Biological assets — — (229,296) — — — (229,296) Government grants (3,939) — 1,174 — — (414) (3,179) Others financial assets — — (277,841) — — 1,041 (276,800) Right-of-use leased asset — — — (32,651) — — (32,651) Others (4,993) — 1,423 — — (528) (4,098) Total deferred tax liabilities (18,700,682) (1,148,178) (5,177,983) (32,651) (1,388,022) (1,937,197) (28,384,713) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax (14,164,930) (777,622) (4,257,912) — (1,388,022) (1,832,639) (22,421,125) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ from ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income ​ deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ tax ​ tax ​ Charge ​ Conversion ​ Balance Deferred tax assets 06/30/2019 provision liabilities to OCI difference 06/30/2020 Tax Loss-Carry Forward 2,663,813 (133,346) — — (167,810) 2,362,657 Changes in fair value of financial assets or liabilities 32,062 20,222 — — (11,101) 41,183 Trade receivables 374,425 764,707 — — (71,078) 1,068,054 Goverment grants 2,649 (6,216) 3,939 — (372) — Royalties ​ — ​ 245,140 ​ — ​ — ​ — ​ 245,140 Right-of-use leased asset ​ — ​ 5,676 ​ — ​ — ​ (252) ​ 5,424 Others 670,760 263,407 — — (120,873) 813,294 Total deferred tax assets 3,743,709 1,159,590 3,939 — (371,486) 4,535,752 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ from ​ ​ ​ ​ ​ ​ Income deferred ​ ​ ​ ​ ​ ​ ​ Balance tax ​ tax Charge ​ Conversion ​ Balance Deferred tax liabilities 06/30/2019 provision assets to OCI difference 06/30/2020 Intangible assets (9,458,239) 1,469,311 — — 1,149,816 (6,839,112) Property, plant and equipment depreciation (9,618,648) 45,028 — (1,133,228) 1,340,966 (9,365,882) Borrowings (13,170) 3,548 — — 1,692 (7,930) Inflation tax adjustment (1,706,092) (589,811) — — 263,825 (2,032,078) Allowances ​ (152,159) ​ (84,515) ​ — ​ — ​ 27,184 ​ (209,490) Inventories ​ (153,563) ​ (110,152) ​ — ​ — ​ 26,457 ​ (237,258) Goverment grants ​ — ​ — ​ (3,939) ​ — ​ — ​ (3,939) Others — (4,993) — — — (4,993) Total deferred tax liabilities (21,101,871) 728,416 (3,939) (1,133,228) 2,809,940 (18,700,682) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax (17,358,162) 1,888,006 — (1,133,228) 2,438,454 (14,164,930) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition ​ ​ ​ from ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of control ​ Income ​ deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ of Semya ​ tax ​ tax ​ Charge ​ Conversion ​ Balance Deferred tax assets 06/30/2018 S.A. provision liabilities to OCI difference 06/30/2019 Tax Loss-Carry Forward 3,638,269 113,289 (1,306,198) — — 218,453 2,663,813 Changes in fair value of financial assets or liabilities 35,944 25,868 (33,200) — — 3,450 32,062 Trade receivables 462,756 — (114,765) — — 26,434 374,425 Allowances 370,930 — (555,679) 152,159 — 32,590 — Inventories 710,391 — (119,316) 153,563 — (744,638) — Intangible assets 15,098 (482,387) (22,467) 476,174 — 13,582 — Goverment grants 9,360 — (7,262) — — 551 2,649 Others 359,073 — 290,552 — — 21,135 670,760 Total deferred tax assets 5,601,821 (343,230) (1,868,335) 781,896 — (428,443) 3,743,709 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ Adquisition ​ from ​ ​ ​ ​ ​ ​ of control Income deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance of Semya ​ tax tax ​ Charge ​ Conversion ​ Balance Deferred tax liabilities 06/30/2018 S.A. provision assets to OCI difference 06/30/2019 Intangible assets (5,071,808) — (937,962) (476,174) — (2,972,295) (9,458,239) Property, plant and equipment depreciation (8,497,756) — (335,077) — 576,453 (1,362,268) (9,618,648) Borrowings (19,372) — 7,342 — — (1,140) (13,170) Contingencies (2,709) — 2,869 — — (160) — Inflation tax adjustment — — (1,706,092) — — — (1,706,092) Allowances ​ — ​ — ​ — ​ (152,159) ​ — ​ — ​ (152,159) Inventories ​ — ​ — ​ — ​ (153,563) ​ — ​ — ​ (153,563) Others (297) — 314 — — (17) — Total deferred tax liabilities (13,591,942) — (2,968,606) (781,896) 576,453 (4,335,880) (21,101,871) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax ​ (7,990,121) ​ (343,230) ​ (4,836,941) ​ — ​ 576,453 ​ (4,764,323) ​ (17,358,162) ​ The following table provides a reconciliation of the statutory tax rate to the effective tax rate. As the operations of the Group’s Argentine subsidiaries are the most significant source of profit or loss before tax, the following reconciliation has been prepared using the Argentine statutory tax rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Loss before income tax-rate 0% (17,127,991) (205,022) ​ (21,669,882) Earnings before income tax-rate 21% ​ (2,046,392) ​ 828,074 ​ 1,264 Earnings before income tax-rate 30% ​ 29,704,931 ​ 5,820,286 ​ 12,296,011 Earnings (Loss) before income tax-rate ​ 10,530,548 ​ 6,443,338 ​ (9,372,607) Income tax expense by applying tax rate to profit (loss) before tax (8,481,737) (1,919,981) ​ (3,689,069) Share of profit or loss of subsidiaries, joint ventures and associates 274,877 847,512 ​ (44,721) Stock options charge (58,248) (298,222) ​ 78,681 Rate change adjustment (1,780,962) (144,660) ​ (54,735) Non-deductible expenses (365,350) (84,128) ​ (254,201) Untaxed gains ​ 557,911 ​ — ​ — Representation expenses — (36,691) ​ (136,614) Foreign investment coverage 390,170 551,968 ​ 233,634 Tax provision adjustments ​ 476,890 ​ 307,944 ​ — Tax inflation adjustment ​ (2,182,988) ​ (1,174,964) ​ (941,734) Result of inflation effect on monetary items and other finance results ​ (3,181,733) ​ (255,488) ​ (2,177,525) Income tax expenses (14,351,170) (2,206,710) ​ (6,986,284) ​ The Group did not recognize deferred income tax liabilities of $2,497,033, $1,052,022 and $44,721, as of June 30, 2021, 2020 and 2019, respectively, related to their investments in foreign subsidiaries, associates and joint ventures. In addition, the withholdings and/or similar taxes paid at source may be creditable against the Group’s potential final tax liability. Principal statutory taxes rates in the countries where the Group operates for all of the years presented are: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax rate Tax jurisdiction 2021 2020 2019 Argentina 25% - 35 % 30 % 30 % Cayman Island 0 % 0 % 0 % Paraguay ​ 10 % 10 % 10 % Uruguay ​ 25 % 25 % 25 % France ​ 28 % 28 % 28 % Brazil ​ 34 % 34 % 34 % United State of America 21 % 21 % 21 % ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current tax expense (10,093,258) (4,094,716) (2,149,343) Deferred tax (4,257,912) 1,888,006 (4,836,941) Total (14,351,170) (2,206,710) (6,986,284) ​ The charge for income tax charged directly to profit or loss and the amount and expiry date of carry forward tax losses as of June 30, 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fiscal year Tax-Loss Carry forward Tax-Loss Carry forward Prescription Tax jurisdiction 2017 186,545 55,261 2022 Argentina 2018 168,888 49,976 2023 Argentina 2019 206,082 51,520 2024 Argentina 2019 4,258,576 894,301 2039 United States of America 2020 ​ 1,094,530 ​ 273,633 ​ 2025 ​ Argentina 2020 2,845,571 597,570 2040 United States of America 2021 2,961,583 826,643 2026 Argentina 2021 2,161,267 453,866 2041 United States of America Total 13,883,042 3,202,770 ​ The amount of tax losses for the fiscal year ended on June 30, 2021 is an estimate of the amount to be presented in the tax return. The amount and expiry date of unused tax credits of Argentina minimum presumed income tax as of June 30, 2020 is as follows: ​ ​ ​ ​ ​ ​ Fiscal year Amount Prescription 2014 474 2024 2015 1,003 2025 2016 1,007 2026 Total 2,484 ​ Estimates There is an inherent material uncertainty related to Management’s estimation of the ability of the Group to use the deferred tax assets (both carryforward of unused tax losses and deductible temporary differences) and the credit of minimum presumed income tax because their future utilization depends on the generation of enough future taxable income by the entities within the Group during the periods in which those temporary differences are deductible or when the unused tax losses can be used. Based on the projections of future taxable income for the periods in which the deferred tax assets are deductible, the Group’s management estimates that, except for the part of deferred tax asset that were unrecognized, it is probable that the entities within the Group can utilize those deferred tax assets, which depends, among other factors, on the success of the current projects of agricultural biotechnology, the future market price of commodities and the market share of the entities within the Group. The estimates of Management about the demonstrability of the recognition criteria for these deferred tax assets and their subsequent recoverability represent the best estimate that can be made based on all the available evidence, existing facts and circumstances and the use of reasonable and supportable assumptions in the projections of future taxable income. Therefore, the Consolidated financial statements do not include adjustments that could result if the entities within the Group would not be able to recover the deferred tax assets through the generation of enough future taxable income.

EARNING PER SHARE

EARNING PER SHARE	12 Months Ended
	Jun. 30, 2021
EARNING PER SHARE
EARNING PER SHARE	10. EARNING PER SHARE ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Numerator (Loss) profit for the year (basic EPS) (6,870,163) ​ 3,359,175 ​ (18,369,045) (Loss) profit for the year (diluted EPS) (6,870,163) ​ 3,359,175 ​ (18,369,045) Denominator Weighted average number of shares (basic EPS) 39,218,632 ​ 36,120,447 ​ 30,478,390 Weighted average number of shares (diluted EPS) 39,218,632 ​ 36,416,988 ​ 30,478,390 ​ ​ ​ ​ ​ ​ ​ Basic (loss) gain attributable to ordinary equity holders of the parent ​ (0.1752) ​ 0.0930 ​ (0.6027) Diluted (loss) gain attributable to ordinary equity holders of the parent (0.1752) ​ 0.0922 ​ (0.6027) ​ The 27,116,174 shares issued to Bioceres LLC on March 14, 2019, in exchange for its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas, together with the 119,443 shared issued to exercise the Bioceres Semillas’ tag along and the 862,500 shares received by Bioceres LLC from the original founders of Union Acquisition Corp., were considered retrospectively in the EPS calculations. The denominators used in the EPS calculation assume those events have occurred at the beginning of the earliest period presented. Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares. The Group has three categories of dilutive potential shares, warrants, share-based incentives, and Convertible notes. For the year ended June 30, 2021 and 2019 diluted EPS was the same as basic EPS as the effect of potential ordinary shares would be antidilutive. Warrants outstanding were not included in the diluted EPS calculations for the years ended June 30, 2020 because the average market price of ordinary shares during the periods did not exceed the exercise price of the warrants. However, on August 24, 2020, the Company completed an offer to exchange any and all of its 24,200,000 outstanding warrants and consistently issued 2,601,954 shares in exchange for the warrants tendered. See Note 7.16. Convertible notes outstanding were not included in the diluted EPS calculations for the year ended June 30, 2020 because its interest (net of tax and other changes in income or expense) per ordinary share obtainable on conversion exceeds basic earnings per share. The stock options were included in the diluted EPS calculation for the year ended June 30, 2020 only for the tranches in which the average market price of ordinary shares during the periods was higher than the assumed proceeds per option. See Note 19.

INFORMATION ABOUT COMPONENTS _3

INFORMATION ABOUT COMPONENTS OF EQUITY	12 Months Ended
	Jun. 30, 2021
INFORMATION ABOUT COMPONENTS OF EQUITY
INFORMATION ABOUT COMPONENTS OF EQUITY	11. INFORMATION ABOUT COMPONENTS OF EQUITY Reverse recapitalization The merger mentioned in Note 1, was reflected as a reverse recapitalization (capital transaction) equivalent to the issuance of shares by the private company (Bioceres) for the net monetary assets of the public shell company (Union). The difference in the fair value of equity instruments retained by UAC’s former shareholders (shares and public warrants) over the value of the net monetary assets incorporated represents a service for listing the shares and it should be accounted as a shared based payment in accordance to IFRS 2. The cost of the service was recognized as an expense in the line “Share based payment cost of listing shares” for an amount of $20.9 million. On February 27, 2019, Union held an Extraordinary General Meeting of Shareholders, whereby holders voted in favor of the merger with Bioceres and converted 11,500,000 rights into 1,150,000 Union shares. In connection with this vote, the holders of 11,376,836 ordinary shares of UAC exercised their right to redeem their shares and collected a total amount of $117,005,196. Net process from the trust account was incorporated to the Group for a total amount of $1,083,840. The fair value of the shares retained by UAC former shareholders was calculated based on the UAC share price as of the day of the transaction ($5.35). Immediately following the merger, the Rizobacter Call Option was exercised. For the tranche of 9.99% (that was previously accounted as financial liability) consideration of the payment was in $1,265,000 in cash and in the form of UAC shares, pursuant to which 1,334,047 ordinary shares were issued. The difference between the fair value of the consideration paid and the financial liability was recognized in financial results as “Gain for cancellation of purchase option”. For the tranche of an additional 20%, consideration of the payment was in the form of UAC shares, pursuant to which 3,402,688 ordinary shares were issued. The adjustment in the non-controlling interest was recorded as an equity transaction. After the Rizobacter Call Option was exercised, the total indirect ownership of BCS Holding in Rizobacter increased to 80.00% of all outstanding stock of Rizobacter. The Group has recognized the contribution of assets and liabilities made by the shareholders (Parent company investment), until the merger was consummated, as a share premium. Capital issued The 27,116,174 shares issued to Bioceres LLC in exchange of its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas, together with the 119,443 shares issued to exercise the Bioceres Semillas’ tag-along and the 862,500 shares received by Bioceres LLC from the original founders of Union, were considered retrospectively in issued capital based on the assumption of those events have occurred at the beginning of the earliest period presented. On August 24, 2020, as consequence of the warrants tender offer, we issued 2,601,954 shares in exchange for the warrants tendered. See Note 7.16 On November 12, 2020, we issued 1,875,000 shares in exchange for the acquisition of assets from Arcadia. See Note 6. In the last quarter of the fiscal year 2021, we issued 971,072 shares in reference to the share-based incentives. See Note 19. As of June 30, 2021, we have repurchased 464,455 of our own shares and, (i) 100,000,000 ordinary shares ($0.0001 par value) authorized, (ii) 41,104,087 ordinary shares issued and outstanding outstanding Holders of the ordinary shares are entitled to one vote for each ordinary share. Convertible notes Convertibles notes were classified as compound instruments, a non-derivative financial instrument that contains both a liability and an equity component. The equity consideration was included in the "Convertible instruments" column. See Note 7.17 Non-controlling interests The subsidiary whose non-controlling interest is significant as of June 30, 2021, 2020 and 2019 is: ​ ​ ​ ​ ​ ​ ​ ​ ​ Name 06/30/2021 06/30/2020 06/30/2019 ​ Rizobacter Argentina S.A. ​ 20 % 20 % 20 % Insumos Agroquimicos S.A. ​ 49.9 % — ​ — ​ ​ Below is a detail of the summarized financial information of Rizobacter and Insuagro, prepared in accordance with IFRS, and modified due to fair value adjustments at the acquisition date and differences in accounting policies. The information is presented prior to eliminations between that subsidiary and other Group companies. Rizobacter ​ ​ ​ ​ ​ ​ ​ ​ Summary financial statements: 06/30/2021 06/30/2020 06/30/2019 Current assets 175,827,504 148,256,827 115,546,951 Non-current assets 59,868,513 49,843,457 47,418,450 Total assets 235,696,017 198,100,284 162,965,401 ​ ​ ​ ​ ​ ​ ​ Current liabilities 119,966,445 129,838,941 100,590,919 Non-current liabilities 57,480,984 32,935,399 34,788,705 Total liabilities 177,447,429 162,774,340 135,379,624 ​ ​ ​ ​ ​ ​ ​ Equity attributable to controlling interest 58,246,057 35,324,227 27,584,666 Equity attributable to non-controlling interest 2,531 1,717 1,111 Total equity 58,248,588 35,325,944 27,585,777 ​ ​ ​ ​ ​ ​ ​ Total liabilities and equity 235,696,017 198,100,284 162,965,401 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Summary statements of comprehensive income or loss 06/30/2021 06/30/2021 06/30/2019 Revenues 189,749,478 ​ 162,404,866 ​ 156,741,933 Initial recognition and changes in the fair value of biological assets 1,552,746 ​ 716,741 ​ — Cost of sales ​ (106,636,141) ​ (86,533,561) ​ (85,287,771) Gross margin 84,666,083 ​ 76,588,046 ​ 71,454,162 ​ ​ ​ ​ ​ ​ ​ Research and development expenses (3,208,904) ​ (2,689,468) ​ (2,367,727) Selling, general and administrative expenses (37,500,952) ​ (36,103,289) ​ (31,316,843) Share of profit or loss of joint ventures and associates 481,442 ​ 1,960,549 ​ 1,071,297 Other income 507,246 ​ (380,871) ​ 286,626 Operating profit 44,944,915 ​ 39,374,967 ​ 39,127,515 ​ ​ ​ ​ ​ ​ ​ Financial results (11,032,748) ​ (30,014,131) ​ (24,650,359) Profit before taxes 33,912,167 ​ 9,360,836 ​ 14,477,156 ​ ​ ​ ​ ​ ​ ​ Income tax expense (14,141,515) ​ (3,830,106) ​ (7,729,300) Result for the year 19,770,652 ​ 5,530,730 ​ 6,747,856 ​ ​ ​ ​ ​ ​ ​ Exchange differences on translation of foreign operations 1,704,590 ​ 1,281,974 ​ 17,197 Revaluation of property, plant and equipment, net of tax (2,682,457) ​ 3,921,091 ​ (1,347,124) Total comprehensive result 18,792,785 ​ 10,733,795 ​ 5,417,929 ​ There were no dividends paid to Rizobacter non-controlling interest (NCI) in the years ended June 30, 2021, 2020 and 2019. Insuagro ​ ​ ​ ​ Summary statements of comprehensive income or loss (1) ​ ​ 06/30/2021 Revenues 7,600,041 Cost of sales (5,886,326) Gross margin 1,713,715 ​ ​ ​ Selling, general and administrative expenses (1,065,147) Other income or expenses, net 18,305 Operating profit 666,873 ​ ​ ​ Financial results (961,635) Loss before tax (294,762) Income tax 127,876 Loss for the period (166,886) ​ ​ ​ Exchange differences on translation of foreign operations 180,519 Total comprehensive result 13,633 ​ (1) Results from 9th April 2021, the date of the acquisition of Insuagro. See note 6.

CASH FLOW INFORMATION

CASH FLOW INFORMATION	12 Months Ended
	Jun. 30, 2021
CASH FLOW INFORMATION
CASH FLOW INFORMATION	12. CASH FLOW INFORMATION Significant non-cash transactions related to investing and financing activities are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Investment activities ​ ​ ​ ​ ​ ​ Settlement of liability with loan to joint venture (1) ​ — ​ — ​ 6,964,101 Net assets acquisition by business combination (2) (Note 6) ​ 6,612,410 ​ — ​ — Settlement of receivables through PPE contribution ​ 2,164,156 ​ — ​ — Investment in-kind in other related parties (Note 17) 714,359 ​ 476,292 ​ 463,511 Arcadia asset acquisition financed by debt (Note 6) ​ 7,637,972 ​ — ​ — Arcadia asset acquisition through issuance of capital (Note 6) ​ 15,000,000 ​ — ​ — Non-monetary contributions in joint ventures and associates (Note 13) ​ 2,931,699 ​ 250,000 ​ 94,355 ​ 35,060,596 ​ 726,292 ​ 7,521,967 ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Financing activities Purchase option paid by a parent loan — — (1,265,000) Consideration for acquisition ​ (2,625,335) ​ — ​ — Parent company investment — — (14,558,347) Capitalization of financial debt — — 13,720,000 Reverse recapitalization — — (3,688,963) Net assets incorporated of Semya (3) ​ — ​ — ​ 7,369,168 Acquisition of control of Semya — — (3,684,585) ​ (2,625,335) — (2,107,727) ​ (1) (2) ​ ​ ​ ​ Balance sheet as of March 31, 2021 Total Current assets Cash and equivalents 555,804 Other current assets 24,981,656 Non-current assets Deferred tax 106,952 Other financial assets 719,772 Intangibles 2,923,897 Property, plant and equipment 1,952,045 Total assets 31,240,126 ​ ​ ​ Current liabilities Trade payables and other payables 17,814,395 Borrowings 5,749,928 Deferred tax 884,574 Non-current liabilities Borrowings 178,820 Total liabilities 24,627,717 ​ ​ ​ Total equity 6,612,409 ​ (3) As a result of the Share purchase agreement between Bioceres Crop Solutions and Bioceres S.A. (see Note 6), the Group incorporated the following assets and liabilities: ​ ​ ​ ​ Balance sheet as of May 31, 2019 Total Current assets 67,924 Non-current assets Tax credits 253,655 Intangibles 2,147,199 Goodwill 5,836,268 Total assets 8,305,046 ​ ​ ​ Current liabilities Trade payables 273,442 Borrowings 114,568 Non-current liabilities Deferred tax 547,868 Total liabilities 935,878 ​ ​ ​ Total equity 7,369,168 ​ Disclosure of changes in liabilities arising from financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing activities ​ ​ Consideration Convertible ​ ​ ​ Borrowings ​ for acquisitions ​ notes ​ Total As of June 30, 2018 91,017,133 22,874,609 — 113,891,742 Proceeds from borrowings 88,693,632 — — 88,693,632 Decrease bank overdraft and other short-term borrowings (4,968,813) — — (4,968,813) Payments (83,777,814) (7,140,000) — (90,917,814) Capitalization of financial debt — (13,720,000) — (13,720,000) Interest payment (20,167,101) — — (20,167,101) Exchange differences and currency translation differences 32,759,693 1,264,656 — 34,024,349 As of June 30, 2019 103,556,730 3,279,265 — 106,835,995 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing activities ​ ​ ​ ​ Consideration ​ Convertible ​ ​ ​ Borrowings for acquisitions notes Total As of June 30, 2019 103,556,730 3,279,265 ​ — 106,835,995 Proceeds 93,273,502 — ​ 42,075,000 135,348,502 Decrease bank overdraft and other short-term borrowings ​ (2,331,974) ​ — ​ — ​ (2,331,974) Payments (76,846,934) (2,937,500) ​ — (79,784,434) Interest payment (21,533,187) — ​ — (21,533,187) Exchange differences, currency translation differences and other financial results 8,830,208 110,889 ​ 954,834 9,895,931 As of June 30, 2020 104,948,345 452,654 ​ 43,029,834 148,430,833 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing activities ​ ​ ​ ​ Consideration ​ Convertible ​ ​ ​ Borrowings for acquisition notes Total As of June 30, 2020 ​ 104,948,345 ​ 452,654 ​ 43,029,834 ​ 148,430,833 Proceeds 143,499,367 — — 143,499,367 Decrease bank overdraft and other short-term borrowings (3,442,491) — — (3,442,491) Payments (113,100,032) — — (113,100,032) Financing for assets acquisitions — 11,214,929 — 11,214,929 Debt incorporated by business combination 5,928,748 — — 5,928,748 Interest payment (12,923,745) — — (12,923,745) Exchange differences, currency translation differences and other financial results (135,867) 122,950 5,634,178 5,621,261 As of June 30, 2021 124,774,325 11,790,533 48,664,012 185,228,870 ​

JOINT VENTURES AND ASSOCIATES

JOINT VENTURES AND ASSOCIATES	12 Months Ended
	Jun. 30, 2021
JOINT VENTURES AND ASSOCIATES
JOINT VENTURES AND ASSOCIATES	13. JOINT VENTURES AND ASSOCIATES ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Assets ​ ​ ​ ​ ​ ​ Synertech Industrias S.A. 27,572,597 24,619,773 25,297,376 Indrasa Biotecnología S.A. 54,957 33,019 23,652 Alfalfa Technologies S.R.L. ​ 97,920 ​ — ​ — Moolec Science Limited (Note 6) ​ 2,931,699 ​ — ​ — ​ 30,657,173 24,652,792 25,321,028 ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Liabilities Trigall Genetics S.A. 1,278,250 1,548,829 1,970,903 ​ 1,278,250 1,548,829 1,970,903 ​ Changes in joint ventures investments and affiliates: ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 As of the beginning of the year 23,103,963 23,350,125 ​ 17,059,757 Adjustment of opening net book amount for the application of IAS 29 — — ​ 8,328,794 Monetary contributions 101,883 — ​ 129,340 Non-monetary contributions (Note 6) 2,931,699 250,000 ​ 94,355 Parent company investment — — ​ 294,041 Loss of control of Indrasa Biotecnología S.A. — — ​ 10,591 Acquisition of control of Semya S.A. — — ​ (3,684,585) Revaluation of property, plant and equipment (413,618) 521,406 ​ 94,009 Foreign currency translation 2,657,567 ​ (3,494,761) ​ 11,337 Share of profit or loss 997,429 ​ 2,477,193 ​ 1,012,486 As of the end of the year 29,378,923 ​ 23,103,963 ​ 23,350,125 ​ Share of profit or loss of joint ventures and affiliates: ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Trigall Genetics S.A. 270,579 ​ 171,502 ​ (2,647) Bioceres Crops S.A. — ​ — ​ (22,895) Synertech Industrias S.A. 708,550 ​ 2,294,332 ​ 1,034,818 Indrasa Biotecnología S.A. 18,300 ​ 11,359 ​ 3,210 ​ 997,429 ​ 2,477,193 ​ 1,012,486 ​ There are no significant restrictions on the ability of the joint ventures and affiliates to transfer funds to the Group for cash dividends, or to repay loans or advances made by the Group, except for the legal obligation to establish a legal reserve for 5% of the profit for the year until reaching 20% of the capital. Summarized financial information prepared in accordance with International Financial Reporting Standards ("IFRS") in relation to the joint ventures is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trigall Genetics Summarised balance sheet 06/30/2021 06/30/2020 06/30/2019 Current assets ​ ​ ​ ​ ​ ​ Cash and cash equivalents 13,798 1,331 13,114 Other current assets 1,949,590 1,024,793 323,265 Total current assets 1,963,388 1,026,124 336,379 Non-current assets ​ ​ ​ Intangible assests 13,335,653 11,776,705 10,214,575 Total non-current assets 13,335,653 11,776,705 10,214,575 Current liabilities ​ ​ ​ Financial liabilities — — 9,476,272 Other current liabilities 1,257,070 869,700 1,016,083 Total current liabilities 1,257,070 869,700 10,492,355 Non-current liabilities ​ ​ ​ Financial liabilities ​ 12,184,030 ​ 10,831,048 ​ — Other non- current liabilities 1,000,774 831,685 460,268 Total non-current liabilities 13,184,804 11,662,733 460,268 Net assets 857,167 270,396 (401,669) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trigall Genetics Summarised statements of comprenhensive income 06/30/2021 06/30/2020 06/30/2019 Revenue 1,110,303 799,625 367,646 Finance income 22,470 79,442 54,003 Finance expense (3,586) (1,863) (16,145) Depreciation and amortization ​ — ​ — ​ — Profit (loss) of the year 586,773 172,670 (33,195) Other comprenhensive income — — — Total comprenhensive income (loss) 586,773 172,670 (33,195) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Synertech Summarised balance sheet 06/30/2021 06/30/2020 06/30/2019 Current assets ​ Cash and cash equivalents 540,149 18,251 40,634 Other current assets 17,274,878 17,983,868 5,709,650 Total current assets 17,815,027 18,002,119 5,750,284 Non-current assets ​ ​ ​ Property,plan and equipment 13,422,832 14,168,459 15,046,903 Other non- current assets 39,171 — — Total non-current assets 13,462,003 14,168,459 15,046,903 Current liabilities ​ ​ ​ Financial liabilities 1,346,327 5,484,866 921,703 Other current liabilities 6,807,330 4,719,276 4,595,906 Total current liabilities 8,153,657 10,204,142 5,517,609 Non-current liabilities ​ ​ ​ Financial liabilities 331,306 2,783,951 — Other non- current liabilities 4,119,471 2,554,905 3,974,975 Total non-current liabilities 4,450,777 5,338,856 3,974,975 Net assets 18,672,596 16,627,580 11,304,603 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Synertech Summarised statements of comprenhensive income 06/30/2021 06/30/2020 06/30/2019 Revenue 23,759,744 21,501,725 18,305,953 Finance income 5,584,007 3,805,655 2,434,610 Finance expense (6,283,955) (6,666,508) (6,193,963) Depreciation and amortization (39,171) (1,076,699) (1,074,552) Profit of the year 1,776,244 5,099,852 2,278,859 Other comprenhensive (loss) income (827,236) 1,042,811 334,403 Total comprenhensive income 949,008 6,142,663 2,613,262 ​

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Jun. 30, 2021
SEGMENT INFORMATION
SEGMENT INFORMATION	14. SEGMENT INFORMATION The Group is organized into three main operating segments: - Seed and integrated products The seed and integrated products segment focuses mainly on the development and commercialization of seed technologies and products that increase yield per hectare, with a focus on the provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics, to improve nutritional value and other benefits. The segment focuses on the commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments—in order to increase crop productivity and create value for customers. While each component can increase yield independently, through an integrated technology strategy the segment offers products that complement and integrate with each other to generate higher yields in crops. Currently the segment generates revenue from ordinary activities through the sale of seeds, integrated packs, royalties and licenses charged to third parties, among others. - Crop protection The crop protection segment mainly includes the development, production and marketing of adjuvants, insecticides and fungicides. The adjuvants are used in mixtures to facilitate greater efficiency of the products to be applied (such as fertilizers and agrochemicals). Insecticides and fungicides can significantly reduce disease or insect problems during the germination period. The segment currently generates revenue from ordinary activities through the sale of adjuvants, insecticides, fungicides and baits, among others. - Crop nutrition The crop nutrition segment focuses mainly on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers including biofertilizers and microgranulated fertilizers that optimize the productivity and yield of the crops. Currently the segment generates income from ordinary activities through the sale of inoculants, bio-inductors, biological fertilizers and microgranulated fertilizers, among others. The measurement principles for the Group’s segment reporting structure are based on the IFRS principles adopted in the Consolidated financial statements. Revenue generated by products and services exchanged between segments and entities within the Group are calculated based on market prices. The following tables present information with respect to the Group´s reporting segments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Seed and ​ ​ ​ ​ ​ integrated ​ Crop ​ Crop ​ ​ ​ Year ended June 30, 2021 ​ products ​ protection ​ nutrition ​ Consolidated ​ Revenues from contracts with customers ​ Sale of goods and services 31,398,592 113,508,465 59,767,015 204,674,072 ​ Royalties 2,023,548 — 2,023,548 ​ Others ​ Government grants 2,302 — — 2,302 ​ Initial recognition and changes in the fair value of biological assets 1,394,127 606,269 825,859 2,826,255 ​ Total 34,818,569 114,114,734 60,592,874 209,526,177 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales (12,931,763) (75,138,491) (30,571,549) (118,641,803) ​ Gross margin per segment 21,886,806 38,976,243 30,021,325 90,884,374 ​ % ​ 63 % 34 % 50 % 43 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Seed and ​ ​ ​ ​ integrated Crop Crop ​ ​ ​ Year ended June 30, 2020 products ​ protection ​ nutrition ​ Consolidated ​ Revenues from contracts with customers ​ ​ ​ ​ ​ ​ ​ ​ ​ Sale of goods and services 27,626,542 93,799,477 49,148,890 170,574,909 ​ Royalties 1,775,790 — — 1,775,790 ​ Others ​ ​ ​ ​ ​ ​ ​ ​ ​ Government grants ​ 24,732 ​ — ​ — ​ 24,732 ​ Initial recognition and changes in the fair value of biological assets 41,755 418,712 256,274 716,741 ​ Total 29,468,819 94,218,189 49,405,164 173,092,172 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales (11,581,494) (53,552,327) (28,441,767) (93,575,588) ​ Gross margin per segment 17,887,325 40,665,862 20,963,397 79,516,584 ​ % of Segment Revenue ​ 61 % 43 % 42 % 46 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Seed and ​ ​ ​ ​ integrated Crop Crop ​ ​ ​ Year ended June 30, 2019 products ​ protection ​ nutrition ​ Consolidated ​ Revenues from contracts with customers ​ ​ ​ ​ ​ ​ ​ ​ ​ Sale of goods and services 24,185,292 89,919,460 45,093,764 159,198,516 ​ Royalties 1,110,463 — — 1,110,463 ​ Others ​ ​ ​ ​ ​ Goverment Grants 16,372 — — 16,372 ​ Initial recognition and changes in the fair value of biological assets. ​ — ​ 279,945 ​ — ​ 279,945 ​ Total 25,312,127 90,199,405 45,093,764 160,605,296 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales (9,783,737) (53,979,391) (23,201,753) (86,964,881) ​ Gross margin per segment 15,528,390 36,220,014 21,892,011 73,640,415 ​ % ​ 61 % 40 % 49 % 46 % ​ Revenue by similar group of products or services ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Seed and integrated products 33,422,140 29,402,332 25,295,755 Seeds, royalties & licenses 6,246,689 5,210,616 3,846,991 Packs 27,175,451 24,191,716 21,448,764 ​ ​ ​ ​ ​ ​ ​ Crop protection 113,508,465 93,799,477 89,919,460 Adjuvants 50,062,012 45,372,840 41,854,730 Insecticides & fungicides 18,231,616 15,227,357 12,655,985 Other 45,214,837 33,199,280 35,408,745 ​ ​ ​ ​ ​ ​ ​ Crop nutrition 59,767,015 49,148,890 45,093,764 Inoculants 16,485,064 16,718,571 18,644,673 Fertilizers 43,281,951 32,430,319 26,449,091 ​ ​ ​ ​ ​ ​ ​ Total revenues ​ 206,697,620 ​ 172,350,699 ​ 160,308,979 ​ Geographical information ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Argentina 157,352,242 130,918,908 124,011,642 Bolivia 3,707,107 2,982,953 2,494,216 Brazil 24,591,539 21,188,655 17,338,608 United States of America 2,504,696 1,515,185 2,562,376 Paraguay 5,369,912 4,428,078 2,506,348 South Africa 2,789,322 1,927,333 3,019,474 France 4,269,368 911,140 711,522 Uruguay 5,752,913 6,234,956 4,684,854 Rest of the world 360,521 2,243,491 2,979,939 Total revenues 206,697,620 172,350,699 160,308,979 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Non-current assets ​ ​ ​ ​ ​ ​ Argentina 107,077,660 93,682,114 106,056,232 Cayman Islands ​ 24,837,572 ​ — ​ — United States 7,799,448 7,168,376 6,136,461 Paraguay 742,767 714,011 722,914 Brazil 3,460,634 685,587 305,477 Bolivia 33,090 15,588 27,487 South Africa 3,892 598 7,080 India ​ — — 38 Francia ​ 26,138 ​ 33,556 ​ — Colombia ​ 18,461 ​ 22,313 ​ — Uruguay ​ 48,502 ​ 53,282 ​ — Total non-current assets 144,048,164 ​ 102,375,425 ​ 113,255,689 ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment ​ 47,954,596 ​ 41,515,106 ​ 43,834,548 Intangible assets ​ 67,342,362 ​ 35,333,464 ​ 39,616,426 Goodwill ​ 28,751,206 ​ 25,526,855 ​ 29,804,715 Total reportable assets ​ 144,048,164 ​ 102,375,425 ​ 113,255,689 Total non-reportable assets ​ 250,541,793 ​ 195,185,944 ​ 129,211,608 Total assets ​ 394,589,957 ​ 297,561,369 ​ 242,467,297 ​

FINANCIAL INSTRUMENTS - RISK MA

FINANCIAL INSTRUMENTS - RISK MANAGEMENT	12 Months Ended
	Jun. 30, 2021
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
FINANCIAL INSTRUMENTS - RISK MANAGEMENT	15. FINANCIAL INSTRUMENTS – RISK MANAGEMENT a) Principal financial instruments The principal financial instruments used by the Group, from which financial instrument risk arise, are as follows: - Cash and cash equivalents - US Treasuary bills - Financial assets at fair value through profit or loss - Trade receivables - Other receivables - Trade and other payables - Bank overdrafts - Other loans - Financed payment for the acquisition of business - Convertible notes The Group is exposed to financial risks: market risk (including currency risk, interest rate risk and fair value risk), credit risk, liquidity risk and capital risk management that arises from its activities and from its use of financial instruments. This Note provides information on the Group’s exposure to each of the above risks, the Group’s objectives, policies and processes regarding the measurement and management of each risk. The Group does not use derivative financial instruments to hedge any of the above risks. b) Financial instruments by category The following tables show additional information required under IFRS 7 on the financial assets and liabilities recorded as of June 30, 2021, 2020 and 2019. Financial assets by category ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Mandatorily measured at fair ​ ​ Amortized cost ​ value through profit or loss Financial asset 06/30/2021 06/30/2020 06/30/2019 06/30/2021 06/30/2020 06/30/2019 Cash and cash equivalents 28,327,569 20,176,452 3,450,873 7,718,544 22,346,409 — Other financial assets 1,523,438 4,713,161 4,703,688 10,735,422 9,045,935 356,233 Trade receivables 88,919,911 73,546,633 59,236,377 — — — Other receivables (*) 5,005,283 3,349,901 1,566,732 — — — Total 123,776,201 101,786,147 68,957,670 18,453,966 31,392,344 356,233 ​ (*) Advances expenses and tax balances are not included. Financial liabilities by category ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Mandatorily measured at fair ​ ​ Amortized cost ​ value through profit or loss Financial liability 06/30/2021 06/30/2020 06/30/2019 06/30/2021 06/30/2020 06/30/2019 Trade and other payables 72,091,408 57,289,862 40,578,494 — — — Borrowings 124,774,325 104,948,345 103,556,730 — — — Convertible notes ​ 48,664,012 ​ 43,029,834 ​ — ​ — ​ — ​ — Lease liability ​ 1,140,717 ​ 1,109,812 ​ — ​ — ​ — ​ — Employee benefits and social security 4,680,078 5,044,630 5,357,218 — — — Consideration for acquisition of assets ​ 11,790,533 ​ 452,654 ​ 3,279,265 ​ — ​ — ​ — Warrants — — — — 1,686,643 2,861,511 Total 263,141,073 211,875,137 152,771,707 — 1,686,643 2,861,511 ​ c) Financial instruments measured at fair value Fair value by hierarchy According to the requirements of IFRS 7, the Group classifies each class of financial instrument valued at fair value into three levels, depending on the relevance of the judgment associated to the assumptions used for measuring the fair value. Level 1 comprises financial assets and liabilities with fair values determined by reference to quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 comprises inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); Level 3 comprises financial instruments with inputs for estimating fair value that are not based on observable market data. ​ ​ ​ ​ ​ ​ ​ ​ Measurement at fair value at 06/30/2021 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ Financial assets at fair value ​ ​ ​ ​ ​ ​ Mutual funds ​ 7,718,544 ​ — ​ — US Treasury bills ​ 7,885,937 ​ — ​ — Other investments ​ 2,110,414 ​ 739,071 ​ — ​ ​ ​ ​ ​ ​ ​ Measurement at fair value at 06/30/2020 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ Financial assets at fair value ​ ​ ​ ​ ​ ​ Mutual funds ​ 22,346,409 ​ — ​ — US Treasury bills 7,768,410 — — Other investments ​ 1,176,977 ​ 100,548 ​ — ​ ​ ​ ​ ​ ​ ​ Financial liabilities valued at fair value ​ ​ ​ ​ ​ ​ Private warrants — — 1,686,643 ​ ​ ​ ​ ​ ​ ​ Measurement at fair value at 06/30/2019 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ Financial assets at fair value ​ ​ Other investments 356,233 — — ​ ​ ​ ​ ​ ​ ​ Financial liabilities valued at fair value ​ ​ ​ ​ ​ ​ Private warrants ​ — ​ — ​ 2,861,511 ​ Changes in financial liabilities valued at fair value level 3 for the year ended June 30,2020 are set below: ​ ​ ​ ​ ​ ​ 06/30/2020 As of the beginning of the year ​ 2,861,511 Changes in finance results(1) ​ (1,174,868) As of the end of the year ​ 1,686,643 ​ (1) The amount of the change in fair value for the year ended June 30,2020 is recognized in “Changes in fair value of financial assets or liabilities and other financial results”. See Note 8.5. Estimation of fair value The fair value of marketable securities, mutual funds and US Treasury Bills is calculated using the market approach using quoted prices in active markets for identical assets. The quoted marked price used for financial assets held by the Group is the current bid price. These instruments are included in level 1. The Group’s financial liabilities, which were not traded in an active market, were determined using valuation techniques that maximize the use of available market information, and thus rely as little as possible on specific estimates of the entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instruments are included in level 2. If one or more of the significant inputs is not based on observable market data, the instruments are included in level 3. The Group’s policy is to recognize transfers between different categories of the fair value hierarchy at the time they occur or when there are changes in the circumstances that cause the transfer.There were no transfers between levels of the fair value hierarchy. There were no changes in economic or business circumstances affecting fair value. The model and inputs used to value the Private warrants at its fair value is mentioned in Note 4.13. d) Financial instruments not measured at fair value The financial instruments not measured at fair value include cash and cash equivalents, trade accounts re. The carrying value of financial instruments not measured at fair value does not differ significantly from their fair value, except for borrowings (Note 7.11). Management estimates that the carrying value of the financial instruments measured at amortized cost approximates their fair value. e) General objectives, policies and processes The Board of Directors has overall responsibility for establishing and monitoring the Group’s risk management objectives and policies and, whilst retaining ultimate responsibility for them, it has delegated the function to design and operate processes that ensure the effective implementation of the objectives and policies to the Group’s finance function that periodically reports to the Board of Directors on the evolution of the risk management activities and results. The overall objective of the Board of Directors is to set policies that seek to reduce risk as much as possible without unduly affecting the Group’s competitiveness and flexibility. The Group’s risk management policy is established to identify and analyze the risks facing the Group, to set appropriate risk limits and controls and to monitor risks and adherence to limits. The risks and methods for managing the risks are reviewed regularly in order to reflect changes in market conditions and the Group’s activities. The Group, through training and management standards and procedures, aims to develop a disciplined and constructive control environment in which all the employees understand their roles and obligations. The Group seeks to use suitable means of financing to minimize the Group’s capital costs and to manage and control the Group’s financial risks effectively. There have been no substantive changes in the Group’s exposure to financial instrument risks, its objectives, policies and processes for managing those risks or the methods used to measure them from previous periods unless otherwise stated in this Note. The Group adopted a code of ethics applicable to its principal executive, financial and accounting officers and all persons performing similar functions. The principal risks and uncertainties facing the business, set out below, do not appear in any particular order of potential materiality or probability of occurrence. f) Credit risk Credit risk is the risk of financial loss to the Group if a customer or counterparty fails to meet its contractual obligations, which derives mainly from trade and other receivables, as well as from cash and deposits in financial institutions. The credit risk to which the Group is exposed is mainly defined in the Group’s accounts receivable followed by cash and cash equivalents, with the logical importance of being able to satisfy the Group’s needs in the short term. Trade and other receivables Credit risk is the risk of financial loss to the Group if a customer or counterparty fails to meet its contractual obligations and derives mainly from trade receivables and other receivables generated by services and product sales, as well as from cash and deposits in financial institutions. The Group is also exposed to political and economic risk events, which may cause nonpayment of local and foreign currency obligations to the Group owed by customers, partners, contractors and suppliers. The Group sells seeds and integrated products, crop protection products, crop nutrition products, and other products and services to a diverse base of customers. Customers include multi-national and local agricultural companies, distributors, research and educational institutions and farmers who purchase the Group’s seed products, integrated products, crop protection products and crop nutrition products. Type and class of customers may differ depending on the Group’s business segments. The Group’s finance function determines concentrations of credit risk by periodically monitoring the credit worthiness rating of existing customers and through a monthly review of the trade receivables’ aging analysis. In monitoring the customers’ credit risk, customers are grouped according to their credit characteristics. The Group’s policy is to manage credit exposure to counterparties through a process of credit rating. The Group performs credit evaluations of existing and new customers, and every new customer is examined thoroughly regarding the quality of its credit before offering the customer transaction terms. The examination made by the Group includes outside credit rating information, if available. Additionally, and even if there is no independent outside rating, the Group assesses the credit quality of the customer taking into account its financial position, past experience, bank references and other factors. A credit limit is prescribed for each customer. These limits are examined annually. Customers that do not meet the Group’s criteria for credit quality may do business with the Group on a prepayment basis or by furnishing collateral satisfactory to the Group. The Group may still seek collateral and guarantees as it may consider appropriate regardless the credit profile of any customer. In monitoring customer credit risk, the customers are grouped according to a characterization of their credit, based on geographical location, industry, aging of receivables, maturity, and existence of past financial difficulties. Customers defined as “high risk” are classified into the restricted customer list and are supervised by management. In a case of a doubtful debt, the Group records a provision for the amount of the debt less the value of the collateral provided and acts to realize the collateral. To cover trade receivables related to Rizobacter, its subsidiaries and Bioceres Semillas, the Group has taken out credit insurance from Grupo Insur SRL, which periodically analyzes its customer portfolio and currently covers 50% of the portfolio. The financial statements contain specific provisions for doubtful debts, which properly reflect, in Management’s estimate, the loss embedded in debts, the collection of which is doubtful. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statement of financial position after deducting any impairment allowance On that basis, the loss allowance as of June 30, 2021 was determined as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying ​ ​ ​ ​ ​ ​ amount-trade ​ Expected Loss ​ Loss ​ receivables rate allowance Current 78,286,114 ​ 0.21 % 161,963 More than 15 days past due ​ 2,192,641 ​ 0.21 % 4,536 More than 30 days past due 1,145,112 0.21 % 2,369 More than 60 days past due ​ 2,396,153 ​ 0.24 % 5,796 More than 90 days past due ​ 3,031,050 ​ 0.25 % 7,719 More than 120 days past due ​ 1,174,948 ​ 0.39 % 4,589 More than 180 days past due ​ 756,820 ​ 0.21 % 1,587 More than 365 days past due ​ 5,659,837 ​ 100 % 5,659,837 IAS 29 effect and Currency conversion ​ — ​ ​ ​ 10,107 Total 06/30/2021 94,642,675 ​ ​ 5,858,503 ​ Cash and deposits in banks The Group is exposed to counterparty credit risk on cash and cash equivalent balances. The Group holds cash on deposit with a number of financial institutions. The Group manages its credit risk exposure by limiting individual deposits to clearly defined limits. The Group only deposits with high quality banks and financial institutions. The maximum exposure to credit risk is represented by the carrying amount of cash and cash equivalents in the statement of financial position. g) Liquidity risk Liquidity risk is the risk that the Group will encounter difficulty in meeting its financial obligations when they come due. The Group’s approach to managing its liquidity risk is to manage the profile of debt maturities and funding sources, maintaining sufficient cash, and ensuring the availability of funding from an adequate amount of committed credit facilities. The Group’s ability to fund its existing and prospective debt requirements is managed by maintaining diversified funding sources with adequate committed funding lines from high quality lenders. The liquidity risk of each of the Group entities is managed centrally by the Group’s finance function. The cash flow forecast is determined at both an entity level and Consolidated level. The forecasts are reviewed by the Board of Directors in advance, enabling the Group’s cash requirements to be anticipated. The Group examines the forecasts of its liquidity requirements in order to ascertain that there is sufficient cash for the operating needs, including the amounts required in order to settle financial liabilities. The following table sets out the contractual maturities of financial liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Between one ​ Between ​ ​ ​ ​ Up to 3 ​ 3 to 12 ​ and three ​ three and ​ Subsequent As of June 30, 2021 months months years five years years Trade and other payables 17,379,825 44,023,803 9,266 — — Borrowings ​ 26,399,791 ​ 57,195,372 ​ 53,290,976 ​ — ​ — Convertible notes — — 48,664,012 — — Leasing liabilities 374,642 2,154,835 755,932 — — Total 44,154,258 103,374,010 102,720,186 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Between one Between ​ ​ ​ Up to 3 ​ 3 to 12 ​ and three ​ three and ​ Subsequent As of June 30, 2020 ​ months ​ months ​ years ​ five years ​ years Trade and other payables 28,150,681 29,130,428 463,568 — — Borrowings 35,863,852 34,810,916 43,799,397 — — Convertible notes — — 43,029,834 — — Leasing liabilities ​ 196,717 ​ 625,463 ​ 483,725 ​ — ​ — Total 64,211,250 64,566,807 87,776,524 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Between one Between ​ ​ ​ Up to 3 ​ 3 to 12 ​ and three ​ three and ​ Subsequent As of June 30, 2019 ​ months ​ months ​ years ​ five years ​ years Trade and other payables 12,854,579 28,987,009 476,482 — — Borrowings 29,051,271 40,097,864 38,524,384 — — Financed payment - Acquisition of business — 2,937,500 — — — Total 41,905,850 72,022,373 39,000,866 — — ​ As of June 30, 2021, 2020 and 2019 the Group had no exposure to derivative liabilities. h) Currency risk Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rate. Currency on foreign exchange risk arises when the Group enters into transactions denominated in a currency other than its functional currency. A significant part of our business activities is conducted in Argentine pesos. However, some of our subsidiaries using the Argentine peso as their functional currency also have significant transactions denominated in U.S. dollars, mainly with respect to sales and financing activities. Our policy is, where possible, to allow the Group entities to settle liabilities denominated in U.S. dollars with the cash generated from their own operations in U.S. dollars. We have liabilities denominated in U.S. dollars in entities utilizing the Argentine peso as functional currency, which expose us to foreign currency exchange risks. Such risks are partially mitigated by our revenues, which are also partly denominated in U.S. dollars (mainly exports) or Argentine pesos but adjusted to reflect changes in U.S. Dollars. We do not use foreign exchange derivatives to hedge our foreign exchange rate exposure. We periodically evaluate the use of derivatives and other financial instruments to hedge our foreign exchange rate exposure, but do not have any exchange rate related financial instruments in place. The table below sets forth our net exposure to currency risk as of June 30, 2021, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ Net foreign currency position 06/30/2021 06/30/2020 06/30/2019 Amount expressed in US$ (50,608,592) (52,968,976) (40,513,954) ​ Considering only this net currency exposure at June 30, 2020, if an Argentine peso/US dollar revaluation or depreciation in relation to other foreign currencies with the remaining variables remaining constant, would have a positive or a negative impact on comprehensive income as a result of foreign exchange gains or losses. We estimate that a devaluation or an appreciation of the Argentine peso against the U.S. dollar of 20% during the year ended June 30, 2021 would have resulted in a net pre-tax loss or gain of approximately $9.9 million. i) Interest rate risk The Group’s financing costs may be affected by interest rate volatility. Borrowings under the Group’s interest rate management policy may be fixed or floating rate. The Group maintains adequate committed borrowing facilities and holds most of its financial assets primarily in cash or checks collected from customers that are readily convertible into known amounts of cash. The Group’s interest rate risk arises from long-term borrowings. Borrowings issued at floating rates expose the Group to cash flow interest rate risk. Borrowings issued at fixed rates expose the Group to fair value interest rate risk. The Group has not entered into derivative contracts to hedge this exposure. The Group’s debt composition, consisting of the loans and the payment financed for the acquisition of Rizobacter, is set out below. ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 ​ ​ Carrying ​ Carrying ​ Carrying ​ ​ amount ​ amount ​ amount Fixed-rate instruments Current financial liabilities (73,125,807) (62,490,975) (69,126,607) Non-current financial liabilities (108,236,265) (84,253,034) (37,459,235) ​ ​ ​ ​ ​ ​ ​ Variable-rate instruments ​ ​ ​ Current financial liabilities (3,660,050) (1,230,760) (177,213) Non-current financial liabilities (206,748) (456,064) (72,940) ​ Holding all other variables constant, including levels of our external indebtedness, at June 30, 2021 a one percentage point increase in floating interest rates would increase interest payable by less than US$ 0.1 million. The Company does not use derivative financial instruments to hedge its interest rate risk exposure. j) Capital risk management The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern, in order to provide returns for shareholders and benefits for other stakeholders, and to maintain an optimal capital structure to reduce the cost of capital. The Group manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Group may adjust the amount of any dividends it could pay to shareholders, return capital to shareholders, issue new shares, or sell assets to reduce debt. The current actions that the Group is carrying on for the capital management are detailed in the Note 1.

LEASES

LEASES	12 Months Ended
	Jun. 30, 2021
LEASES
LEASES	16. LEASES As mentioned in Note 3, the Group began applying IFRS 16 and recognized the cumulative initial effect as an adjustment to the opening equity at the date of initial application. The comparative information was not restated. The Group recognized a right-of-use asset and a lease liability. The right-of-use asset was initially measured at the amount of the lease liability plus initial direct costs incurred, adjusted by pre-payments made in relation to the lease. The right-of-use asset was measured at cost less accumulated depreciation and accumulated impairment. The lease liability was initially measured at the present value of the lease payments payable over the lease term, discounted at the rate implicit in the lease if it can be readily determined. If that rate cannot be readily determined, the Group uses its incremental borrowing rate. In applying IFRS 16 for the first time, the Group has used the following practical expedients permitted by the standard: (i) the use of a single discount rate to a portfolio of leases with reasonably similar characteristics, (ii) reliance on previous assessments on whether leases are onerous, (iii) the accounting for operating leases with a remaining lease term of less than 12 months, as at July 1, 2019, as short-term leases, (iv) the exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application, and (v) the use of hindsight in determining the lease term, where the contract contains options to extend or terminate the lease. The information about the right-of-use and liabilities related with lease assets is as follows: ​ ​ ​ ​ ​ ​ Right-of-use leased asset 06/30/2021 06/30/2020 Cost ​ ​ Book value at the beginning of the year 2,369,326 ​ — Additions for initial application of IFRS 16 — ​ 1,523,177 Additions of the year 913,321 ​ 846,149 Exchange differences ​ 405,503 ​ — Book value at the end of the year 3,688,150 ​ 2,369,326 ​ ​ ​ ​ ​ Depreciation 06/30/2021 ​ 06/30/2020 Book value at the beginning of the year ​ 1,254,729 ​ — Additions for initial application of IFRS 16 — ​ 759,045 Exchange differences 278,441 ​ (78,213) Depreciation of the year 827,320 ​ 573,897 Accumulated depreciation at the end of the year 2,360,490 ​ 1,254,729 Total 1,327,660 ​ 1,114,597 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liability 06/30/2021 ​ 06/30/2020 Book value at the beginning of the year 1,109,812 ​ — Additions for initial application of IFRS 16 — ​ 1,523,177 Additions of the year 259,427 ​ 702,826 Interest expenses, exchange differences and inflation effects 500,442 ​ (551,232) Payments of the year (728,964) ​ (564,959) Total 1,140,717 ​ 1,109,812 ​ ​ ​ ​ ​ Lease Liabilities 06/30/2021 ​ 06/30/2020 Non-current 390,409 ​ 444,714 Current 750,308 ​ 665,098 Total 1,140,717 ​ 1,109,812 ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 Machinery and equipment 661,544 ​ 598,561 Vehicles 1,061,184 ​ 264,069 Equipment and computer software 582,101 ​ 407,546 Land and buildings 1,383,321 ​ 1,099,150 ​ 3,688,150 ​ 2,369,326 ​ (1) The incremental borrowing rate used was 7.74% .

SHAREHOLDERS AND OTHER RELATED

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS	12 Months Ended
	Jun. 30, 2021
SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS
SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS	17. SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS During the year ended June 30, 2021, 2020 and 2019, the transactions between the Group and related parties, and the related balances owed by and to them, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of the transactions of the year ended Party Transaction type 06/30/2021 06/30/2020 06/30/2019 Joint ventures and associates Sales and services 9,404,716 6,139,155 4,913,254 Joint ventures and associates Purchases of goods and services (23,395,323) (21,634,936) (17,542,637) Joint ventures and associates Equity contributions 3,033,582 250,000 517,736 Joint ventures and associates Net loans granted — — (6,964,101) Key management personnel Salaries, social security benefits and other benefits (3,376,292) (5,333,469) (3,940,185) Key management personnel Net loans cancelled 664,398 — 599,984 Key management personnel Interest gain 9,782 44,619 20,106 Shareholders and other related parties Sales of goods and services 572,110 1,871,613 640,095 Shareholders and other related parties Purchases of goods and services (3,092,506) (1,881,013) (1,433,127) Shareholders and other related parties In-kind contributions 714,359 476,292 463,511 Parents companies and related parties to Parents (Note 7.5) Interest expenses (1,219,776) (1,861,774) (1,386,288) Parents companies and related parties to Parents (Note 7.5) Net loans cancelled (101,241) — — Parent company Purchases of goods and services — (92) (120,095) Parent company Equity contributions — — (14,558,347) Total (16,786,191) (21,929,605) (38,790,094) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts receivable from related parties Party Transaction type 06/30/2021 06/30/2020 06/30/2019 Parent company ​ Trade debtors ​ — ​ — ​ 440,268 Parents companies and related parties to Parents Other receivables 770,549 102,069 — Shareholders and other related parties Trade debtors — 1,090,004 467,743 Shareholders and other related parties Allowance for impairment — (768) (75,596) Other receivables - Other related parties Other receivables 134,172 83,839 10,971 Joint ventures and associates Trade debtors 221,048 120,992 2,369 Joint ventures and associates Other receivables 2,219,863 1,562,340 250,783 Total ​ ​ 3,345,632 2,958,476 1,096,538 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts payable to related parties Party Transaction type 06/30/2021 06/30/2020 06/30/2019 Parent company ​ Trade creditors ​ (193,718) ​ (2,210,308) ​ (1,568,036) Parents companies and related parties to Parents ​ Net loans payables ​ (9,578,921) ​ (12,389,521) ​ (17,757,907) Key management personnel Salaries, social security benefits and other benefits (2,338,727) (2,084,088) (2,312,253) Shareholders and other related parties Trade and other payables (52,864) (1,031,710) (1,796,932) Joint ventures and associates Trade creditors (17,669,027) (14,409,853) (4,805,149) Total ​ ​ (29,833,257) (32,125,480) (28,240,277) ​

KEY MANAGEMENT PERSONNEL COMPEN

KEY MANAGEMENT PERSONNEL COMPENSATION	12 Months Ended
	Jun. 30, 2021
KEY MANAGEMENT PERSONNEL COMPENSATION
KEY MANAGEMENT PERSONNEL COMPENSATION	18. KEY MANAGEMENT PERSONNEL COMPENSATION Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group. The compensation of directors and other members of key management personnel, including social contributions and other benefits, were as follows for the year ended June 30, 2021, 2020 and 2019. ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Salaries, social security and other benefits 1,721,157 1,905,440 3,940,185 Share-based incentives ​ 1,655,135 ​ 3,428,029 ​ — Total 3,376,292 5,333,469 3,940,185 ​ The Company entered into indemnification agreements with each of its directors and executive officers. These agreements generally provide that the relevant director or officer will be indemnified by the Company to the fullest extent permitted by law against liability and against all expenses reasonably incurred or paid by him or her in connection with any claim, action, suit or proceeding which he or she becomes involved as a party or otherwise by virtue of his or her being or having been such a director or officer of the Company and against amounts paid or incurred by him or her in the settlement thereof. The agreements are subject to certain exceptions, including that no indemnification will be provided to any director or officer against any liability to the Group or its shareholder (i) by reason of intentional fraudulent conduct, dishonesty, willful misconduct, or gross negligence on the part of the director or officer; or (ii) by reason of payment made under an insurance policy or any third party that has no recourse against the indemnitee director or officer. The compensation of key executives is determined by the Board of Directors of Bioceres S.A. based on the performance of individuals and market trends. The Group currently does not pay any compensation to any of its non-employee board members.

SHARE-BASED PAYMENT

SHARE-BASED PAYMENT	12 Months Ended
	Jun. 30, 2021
SHARE-BASED PAYMENT
SHARE-BASED PAYMENT	19. SHARE-BASED PAYMENT a) Share option plan for directors and senior management. This plan granted 1,200,000 stock options with an exercise price of $4.55. They are vested when the beneficiaries have served a period of service since the grant date until each vesting period described below. The beneficiaries must remain in the Company or subsidiary as of the date of exercising the option to exercise it. The stock options expire on October 31, 2029. Options can be exercised for a period of up to three years, with 1/3 twenty The fair value of the stock options at the grant date was estimated using the "Black-Scholes" model considering the terms and conditions under which the options on shares were granted and adjusted to consider the possible dilutive effect of the future exercise of options. ​ ​ ​ ​ Factor Incentive option plan Weighted average fair value of shares $5.42 Exercise price $4.55 Weighted average expected volatility 29.69% Dividend rate 0% Weighted average risk-free interest rate 1.66% Weighted average expected life 9.89 years Weighted average fair value of stock options at measurement date $2.47 ​ There are no market-related performance conditions or non-vesting conditions that should be considered for determining the fair value of options. The Group estimates that 100% of the share options will be exercised, taking into account historical patterns of executives maintaining their jobs and the probability of the exercising the options. This estimate is reviewed at the end of each annual or interim period. The following table shows the weighted average amount and exercise price and the movements of the stock options of executives and directors of the Group during the years ended June 30, 2021, 2020, and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 ​ 06/30/2020 ​ 06/30/2019 ​ Number of ​ Exercise Number of ​ Exercise Number of Exercise ​ ​ options ​ ​ price ​ options ​ ​ price ​ options ​ price At the beginning 1,200,000 $ 4.55 — ​ — — — Granted during the year — ​ — 1,200,000 $ 4.55 — — Annulled during the year — ​ — — ​ — — — Exercised during the year 33,333 $ 15.09 — ​ — — — Expired during the year — ​ — — ​ — — — Effective at year 1,166,667 $ 4.55 — ​ — — — ​ The charge of the plan recognized during the year was $0.7 million and $1.9 for fiscal year 2021 and 2020. b) Share Option Plan for junior management. The Share Option Plan for junior management is for up to 100,000 underlying ordinary shares for certain key employees. The options have an exercise price of $5.55 and may be exercised for a period of up to three years from the grant date, with 1/3 c) Annual compensation - Bonus Bonus in Cash As well as fiscal year ended June 30, 2020, for the Bonus in Cash 2021, all the beneficiaries decided to receive the bonus in ordinary shares. The charge of the plan recognized during the year ended June 30, 2021 and 2020 was $0.4 million and $0.2 million, respectively. Bonus in Kind The charge of the plan recognized during the year ended June 30, 2021 and 2020 was $0.5 million and $0.3 million, respectively. The number of shares that can be awarded under each bonus will be determined by using a 20-day volume weighted average price (“VWAP”) of the Company’s ordinary shares, starting with the day on which the relevant financial and operational objectives are met by the Company and the bonus is granted. 50% of bonus vests immediately if the financial and operational objectives are achieved as of such date, and the remaining 50% vests in the subsequent 12-months, upon meeting of the financial and operational objectives. As of the date of issuance of These financial statements, shares from the 2020 annual compensation plan were already issue for a total of 147,788. d) Bonus in performance This plan is an in-kind incentive awarded in ordinary shares that contains a performance target that is related to the market price of the Company’s shares. Market-based performance conditions were included in the grant-date fair value measurement. The fair value of the shares at the grant date was estimated using the "Black-Scholes" model, considering the terms and conditions under which the bonus in performance were granted. ​ ​ ​ ​ ​ ​ Factor Bonus in performance Stock price at the grant date $5.42 $5.42 Exercise Price $10.5 $21.0 Weighted average expected volatility 24.78% ​ 24.78% Dividend rate 0% ​ 0% Weighted average risk-free interest rate 1.52% ​ 1.52% Weighted average expected life 2.63 years 2.63 years Weighted average fair value of stock at measurement date $0.479 $0.005 ​ The charge of the plan recognized during the year ended June 30, 2020 was $0.3 million. On March 16, 2021, the target was achieved and on May 14, 2021 the company issued 800,000 shares. e) Employee Stock Purchase Plan (ESPP) This is an incentive plan for eligible employees with no stock compensation to purchase ordinary shares of the Company up to a maximum of 15% percent of such employee’s monthly compensation. The number of ordinary shares subject to the ESPP shall be 200,000 ordinary shares. The purchase price will be equal to 85% of the lower of the closing price of the Company’s ordinary shares on the first business day and the last business day of the relevant offering period. As of the date of these financial statements the ESSP is not yet implemented.

CONTINGENCIES, COMMITMENTS AND

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS	12 Months Ended
	Jun. 30, 2021
CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS
CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS	20. CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS Pledged and restricted assets as of June 30, 2021 are as follows: ​ ​ ​ ​ ​ ​ Detail Asset value Type of restriction IT equipment 99,990 Leasing Vehicles 78,833 Leasing Compass Latam & Odisea ​ 16,016,733 ​ Security Collateral and Mortgage (a) Allaria Ledesma & Cía. ​ 9,395,976 ​ US Treasury bills (b) Cohen S.A. 789,458 US Treasury bills (c) Other financial assets ​ 13,032 ​ Argentina Treasury bills Totals 26,394,022 ​ a) In April 2019, the Group issued Private corporate bonds worth $16 million guaranteeing compliance with a first-degree mortgage of real estate assets of equal value and a pledge on the shares representing 10% of the holding of Rasa Holding LLC in the capital of Rizobacter. On July 5, 2021, we paid the last installment of the private bonds. As of the date of issuance of These financial statements, the commitments assumed by the Group were released. b) In order to guarantee the fulfillment of the obligations assumed from the loan signed with Allaria Ledesma & Cia., the subsidiary Rizobacter granted a pledge of American treasury bonds valued of $ 6,7 c) In order to guarantee the fulfillment of the obligations assumed from the loan signed with Cohen S.A., the subsidiary Rizobacter granted a pledge of American treasury bonds valued of $ 0,8 The Convertibles Notes referenced in Note 6.18 are guaranteed by (i) BCS Holding, RASA Holding, Bioceres Semillas S.A., Rizobacter USA LLC and Rizobacter do Brasil LTD; (ii) a Share Pledge Agreement over the 41.3% of the shares held by RASA Holding in the capital stock of Rizobacter; (iii) an Intercompany Loan Pledge Agreement; (iv) Rizobacter do Brazil Fiduciary Assignment Agreement; and (v) Rizobacter do Brazil Account Pledge Agreement. ​ The Group has committed in the Convertible notes to the non-distribution of dividends.

IMPACT OF COVID-19

IMPACT OF COVID-19	12 Months Ended
	Jun. 30, 2021
IMPACT OF COVID-19
IMPACT OF COVID-19	21. IMPACT OF COVID-19 In December 2019, a novel strain of coronavirus (“COVID-19”) was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. COVID-19 has disrupted business activities in Argentina and worldwide. The Group’s operations, which involve agricultural production and commercialization activities, have been mostly exempted from the disruption. Consequently, our financial condition, liquidity position and results of operations have not been materially impacted as we have been allowed to continue with our operations. The eventual scope of the Coronavirus outbreak and its impact on the country's and global economy are unknown, with governments being able to implement stricter containment measures, which are not predictable in this instance. It cannot be reasonably quantified to what extent the Coronavirus will affect the Company's business and the results of its operations in the future if this situation is prolonged. The Board of Directors and senior management are closely monitoring the situation and taking all necessary measures at their disposal to protect human life and the Group’s operations and financial condition.

EVENTS OCCURRING AFTER THE REPO

EVENTS OCCURRING AFTER THE REPORTING PERIOD	12 Months Ended
	Jun. 30, 2021
EVENTS OCCURRING AFTER THE REPORTING PERIOD
EVENTS OCCURRING AFTER THE REPORTING PERIOD	22. EVENTS OCCURRING AFTER THE REPORTING PERIOD As Insuagro is a public company listed in Bolsas y Mercados Argentinos S.A. ("BYMA"), and in accordance with the Capital Markets Law of Argentina, we have made a mandatory public offer for the acquisition of the remaining Class B Shares for the minority shareholders who did not participate in the sale purchase agreement mentioned in Note 6. The total of shares subject to the offer and outstanding was 3,750,348 Class B Shares. The offer price payable for each Class B Share was $ 0.297 per share (average trading value of the last 6 months). This consideration could be adjusted, if applicable, based on the Company's Adjusted EBITDA in the same conditions mentioned in Note 6. On August 2, the mandatory offer was completed, and we bought 2.467.990 As of the date of issuance of these consolidated financial statements, we own 13,489,990 shares of Insuagro, which represent 61.32% of the share capital and 61.22% of the votes. On August 31, Rizobacter completed a $16.1 million public offering of Series VI corporate bonds in the Argentine market. The bonds were be issued in two tranches: (i) Class A: $12.7 million with maturity in March 2023 and an annual nominal interest rate of 3.75%; and (ii) Class B: $3.4 million with maturity in September 2024 and an annual nominal interest rate of 5.25%. Subsequent to June 30, 2021, there have been no other situations or circumstances that may require significant adjustments or further disclosure in these consolidated financial statements that were not mentioned above.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and cash equivalents	4.1. Cash and cash equivalents For the purposes of the statements of financial position and statements of cash flows, cash and cash equivalents include cash on hand and in banks and short-term highly liquid investments. Investments can be readily convertible to known amounts of cash and they are subject to insignificant risk of changes in value. In the consolidated statements of financial position, bank overdrafts are included in borrowings within current liabilities.
Financial assets	4.2. Financial assets The Group measures its financial assets at initial recognition at fair value. The Group classifies its financial assets as financial assets measured at amortized cost (using the effective interest method) on the basis of both: - The Group’s business model for managing the financial assets; and - The contractual cash flows characteristics of the financial asset. The Group has not irrevocably designated a financial asset as measured at fair value through profit or loss to eliminate or significantly reduce a measurement or recognition inconsistency. Financial assets at fair value through profit or loss are measured at fair value through profit and loss due to the business model used in their negotiation and/or the contractual characteristics of their cash flows. Estimates The Group makes estimates of uncollectability of its recorded receivables. Management analyzes trade account receivables in accordance with conventional criteria, adjusting the amount through a charge of an allowance for bad debts upon recognition of the inability of third parties to afford their financial obligations to the Group. Management specifically analyzes the accounts receivable, the historical bad debts, solvency of customers, current economic trends and the changes to the payment conditions of customers to assess the adequate allowance for bad debts. Offsetting of financial assets with financial liabilities Financial assets and liabilities are offset and presented for their net amount in the statements of financial position only when the Group has the right, legally enforceable, to compensate the recognized amounts and has the intention to liquidate for the net amount or to settle the asset and cancel the liability simultaneously.
Inventories	4.3. Inventories Inventories are recognized at cost initially and subsequently at the lower of cost and net realizable value. Cost comprises all costs of purchase and conversion as well as other costs incurred in bringing the inventories to their present location and condition. Weighted average cost is used to determine the cost of ordinarily interchangeable items. Estimates The Group assesses the recoverability of inventories considering their sale price, whether the inventories are damaged and whether they have become obsolete in whole or in part. Net realizable value is the sale price estimated to be attained in the ordinary course of business, less costs of completion and other selling expenses. The Group sets up an allowance for obsolescence or slow-moving inventories in relation to finished and in-process products. The allowance for obsolescence or slow-moving inventories is recognized for finished products and in-process products based on an analysis by Management of the aging of inventory stocks.
Biological Assets	4.4. Biological assets Within current assets, growing crops are included as biological assets, from the moment of sowing until the moment of harvest (approximately 5 to 7 months depending on the crop). At harvest time the biological assets are transformed into agricultural products, including seed varieties for resale, and incorporated into the inventory. Costs are capitalized as biological assets if, and only if, (a) it is probable that future economic benefits will flow to the entity, and (b) the cost can be measured reliably. The Group capitalizes costs such as: planting, harvesting, weeding, seedlings, irrigation, agrochemicals, fertilizers and a systematic allocation of fixed and variable production overheads that are directly attributable to the management of biological assets, among others. Biological assets, both at initial recognition and at each subsequent reporting date, are measured at fair value less costs to sell, except where fair value cannot be reliably measured. Cost approximates fair value when little biological transformation has taken place since the costs were originally incurred or the impact of biological transformation on price is not expected to be material. Gains and losses that arise from measuring biological assets at fair value less costs to sell and measuring agricultural produce at the point of harvest at fair value less costs to sell are recognized in the statement of income in the period in which they arise in the line item “Initial recognition and changes in fair value of biological assets”. From the harvest time, agricultural products are valued at net realizable value because there is a market asset, and the risk of non-sale is non-significant. Generally, the estimation of the fair value of biological assets is based on models or inputs that are not observable in the market and the use of unobservable inputs is significant to the overall valuation of the assets. Unobservable inputs are determined based on the best information available. Key assumptions include future market prices, estimated yields at the point of harvest, estimated production cycle, future cash flows, future costs of harvesting and other costs, and estimated discount rate. Market prices are generally determined by reference to observable data in the principal market for the agricultural produce. Harvesting costs and other costs are estimated based on historical and statistical data. Yields are estimated based on several factors, including the location of the farmland and soil type, environmental conditions, infrastructure and other restrictions and growth at the time of measurement. Yields are subject to a high degree of uncertainty and may be affected by several factors out of the Group’s control including but not limited to extreme or unusual weather conditions, plagues and other crop diseases, among other factors.
Business combinations	4.5. Business combinations The Group applies the acquisition method to account for business combinations. The acquisition cost is measured as the aggregate of the consideration transferred for the acquisition of a subsidiary, which is measured at fair value at the acquisition date, and the amount of any non-controlling interest in such subsidiary. The Group recognizes any non-controlling interest in a subsidiary at the non-controlling interest’s proportionate share of the recognized amounts of subsidiary’s identifiable net assets. The acquisition related costs are expensed as incurred. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. The contingent consideration is classified as an asset or liability that is a financial instrument under IFRS 9 is measured at fair value through profit or loss. Goodwill is initially measured at cost, which is the excess of the aggregate of the consideration transferred and the amount of the non-controlling interest and any previous interest carried over the net identifiable assets acquired, and liabilities assumed. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For impairment testing, goodwill acquired in a business combination is, as of the acquisition date, allocated to each of the cash-generating units of the Group that is expected to benefit from the synergies of the combination, without considering whether other assets or liabilities of the subsidiary are allocated to those units. Any impairment in the carrying value is recognized in the consolidated statement of comprehensive income. In the case of acquisitions in stages, prior to the write-off of the previously held equity interest in the subsidiary, said interest is re-measured at fair value as of the date of acquisition of control over the subsidiary. The result of the re-measurement at fair value is recognized in profit or loss. When a seller in a business combination has contractually agreed to indemnify the Group for the result of a contingency or uncertainty related to the entirety or a portion of an asset or liability, the Group recognizes an indemnification asset. The indemnification asset is measured on the same basis as the indemnification item. At the end of each period, the Group measures the indemnification assets recognized at the acquisition date on the same basis as the indemnified liability, subject to any contractual limitation on the amount and, for an indemnification asset that is not periodically measured at fair value, based on Management’s assessment of the recoverability of the indemnification asset. The Group derecognizes the indemnification asset when it collects or sells it, or when it loses the right over it.
Business combination under common control	4.6. Business combination under common control Common control of business combination is excluded from the scope of IFRS 3. There is no other specific guidance on this topic elsewhere in IFRS. Therefore, management needs to use judgement to develop an accounting policy that provides relevant and reliable information in accordance with IAS 8. Management accounting police choice for business combination under common control is “Predecessor value method”. A Predecessor value method involves accounting for the assets and liabilities of the acquired business using existing carrying values. Differences between the carrying value and the amount payable should be accounted as an equity contribution.
Impairment of non-financial assets (excluding inventories and deferred tax assets)	4.7. Impairment of non-financial assets (excluding inventories and deferred tax assets) Impairment tests on goodwill and intangible assets not yet available for use are undertaken annually at the end of the reporting period. Other non-financial assets are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to sell), the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the smallest group of assets to which it belongs for which there are separately identifiable cash flows (its Cash Generating Unit or CGU). Goodwill is allocated on initial recognition to each of the Group’s CGUs that are expected to benefit from a business combination that gives rise to the goodwill. Impairment charges are included in profit or loss, except to the extent they reverse gains previously recognized in other comprehensive income. An impairment loss recognized for goodwill is not reversed. Estimate Impairment testing of goodwill and intangible assets not yet available for use requires the use of significant assumptions for the estimation of future cash flows and the determination of discount rates. The significant assumptions and the determination of discount rates for the impairment testing of goodwill are further explained in Note 7.9.
Joint arrangements	4.8. Joint arrangements An associate is an entity over which the Group exerts significant influence. Significant influence is the power to participate in financial and operating policy decision-making at such entity, but it does not involve control or joint control over those policies. The Group is a party to a joint arrangement when there is a contractual arrangement that confers joint control over the relevant activities of the arrangement to the Group and at least one other party. Joint control is assessed under the same principles as control over subsidiaries. The Group classifies its interests in joint arrangements as either: - Joint ventures : where the group has rights to only the net assets of the joint arrangement. - Joint operations : where the group has both the rights to the assets and obligations for the liabilities of the joint arrangement. In assessing the classification of interests in joint arrangements, the Group considers: - The structure of the joint arrangement; - The legal form of joint arrangements structured through a separate vehicle; - The contractual terms of the joint arrangement agreement; and - Any other facts and circumstances (including any other contractual arrangements). The Group accounts for its interests in joint ventures using the equity method, where the Group’s share of post-acquisition profits and losses and other comprehensive income is recognized in the Consolidated statement of profit and loss and other comprehensive income. Losses in excess of the Group’s investment in the joint venture are recognized only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the joint venture. Profits and losses arising on transactions between the Group and its joint ventures are recognized only to the extent of unrelated investors’ interests in the joint venture. The Group’s share in a joint venture’s profits and losses resulting from a transaction is eliminated against the carrying amount of investment in the joint venture through the line “share of profit (or loss) of joint ventures” in the Consolidated statements of profit or loss and other comprehensive income. Any premium paid for an investment in a joint venture above the fair value of the Group’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the investment in the joint venture. Where there is objective evidence that the investment in a joint venture has been impaired, the carrying amount of the investment is tested for impairment in the same way as other non-financial assets. When the Group loses significant influence in an associate or joint control over a joint venture, it measures and recognizes any investment held at fair value. Any difference between the carrying amount of the associate or joint venture when losing significant influence or joint control and the fair value of the held investment and sale revenue are recognized in profit or loss. The Group accounts for its interests in joint operations by recognizing its share of assets, liabilities, revenues and expenses in accordance with its contractually conferred rights and obligations. For all joint arrangements structured in separate vehicles the Group must assess the substance of the joint arrangement in determining whether it is classified as a joint venture or joint operation. This assessment requires the Group to consider whether it has rights to the joint arrangement’s net assets (in which case it is classified as a joint venture), or rights to and obligations for specific assets, liabilities, expenses, and revenues (in which case it is classified as a joint operation). Upon consideration of the factors mentioned above, the Group has determined that all of its joint arrangements except the operation with Espartina S.A. (see below) are structured through separate vehicles only give it rights to the net assets and are therefore classified as joint ventures (Note 13). Rizobacter entered into an agreement with Espartina S.A. ("Espartina") to share its business of producing grain crops. The joint operation is classified as a joint agreement as established in IFRS 11, while the parties are entitled to the assets and obligations over the related liabilities. Rizobacter recognizes as a joint operator, in relation to its participation, assets, liabilities, income and expenses. The production obtained is distributed according to the contributions made by each party. See Note 7.6. Estimates There is considerable uncertainty regarding Management’s estimates of the Group’s ability to recover the carrying amounts of the investments in joint ventures, since such estimates depend on the joint ventures’ ability to generate sufficient funds to complete the development projects, the future outcome of the project deregulation process and the amounts and timing of the cash flows from projects, among other future events. Management assesses whether there are impairment indicators and, if any, it performs a recoverability analysis. Management estimates of the recoverability of these investments represent the best estimate based on available evidence, the existing facts and circumstances, using reasonable and provable assumptions in the cash flow projections. Therefore, the consolidated financial statements do not include adjustments that would be required if the Group were unable to recover the carrying amount of the above-mentioned assets by generating sufficient economic benefits in the future. When the Group acquired control of Rizobacter, it also acquired the joint control of Synertech. Therefore, the investment in Synertech was added at the time of initial recognition of the acquisition at fair value. The determination of the fair value of Synertech at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of higher revenue from sales of micro-granulated fertilizers.
Property, plant and equipment	4.9. Property, plant and equipment Property, plant and equipment items are initially recognized at cost. In addition to the purchase price, cost also includes costs directly attributable to such property, plant and equipment items. There are no unavoidable costs with respect to dismantling and removing items. The cost of property, plant and equipment items acquired in a business combination is their fair value at the acquisition date. Depreciation is calculated using the straight-line method to allocate the property, plant or equipment items’ cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows: Research instruments: 3 to 10 years Office equipment: 5 to 10 years Vehicles: 5 years Computer equipment and software: 3 years Fixture and fittings: 10 years Machinery and equipment: 5 to 10 years Buildings: 50 years Useful lives and depreciation methods are reviewed every year as required by IAS 16. Assets under items Land and Buildings, are accounted for at fair value arising from the last revaluation performed, applying the revaluation model indicated by IAS 16. Revaluations are performed on a regular basis, when there are signs that the book value differs significantly from that to be determined using the fair value at the end of the reporting year. To obtain fair values, the existence of an active market is considered for the assets in their current status. For those assets for which an active market in their current status exists, the fair values were determined based on their market values. For the remaining cases, the market values of comparable new assets are analyzed, applying a discount based on the status and wear of each asset and considering the characteristics of each of the revalued assets (for example, improvements made, maintenance status, level of productivity, use, etc. Estimates The Group carries certain classes of property, plant and equipment under the revaluation model under IAS 16. The revaluation model requires that the Group carry property, plant and equipment at revalued amounts, being fair value at the date of revaluation less any subsequent accumulated depreciation and any subsequent accumulated impairment losses. IAS 16 requires that the Group carry out these revaluations with sufficient regularity so that the carrying amounts of its property, plant and equipment do not differ materially from that which would be determined using fair value at the end of a reporting period. The determination of fair value at the date of revaluation requires judgments, estimates and assumptions based on market conditions prevailing at the time of any such revaluation. Changes to any of the Group’s judgments, estimates or assumptions or to the market conditions subsequent to a revaluation will result in changes to the fair value of property, plant and equipment. The Group prepares the corresponding revaluations on a regular basis taking into account the work of independent appraisers. The Group uses different valuation techniques depending on the class of property being valued. Generally, the Group determines the fair value of its industrial buildings and warehouses based on a depreciated replacement cost approach. The Group determines the fair value of its land based on active market prices adjusted, if necessary, for differences in the nature, location or condition of the specific asset. If this information is not available, the Group may use alternative valuation methods, such as recent prices in less active markets. Property valuation is a significant area of estimation uncertainty. Fair values are prepared regularly by Management, taking into account independent valuations. The determination of fair value for the different classes of property, plant and equipment is sensitive to the selection of various significant assumptions and estimates. Changes in those significant assumptions and estimates could materially affect the determination of the revalued amounts of property, plant and equipment. The Group utilizes historical experience, market information and other internal information to determine and/or review the appropriate revalued amounts. The following are the most significant assumptions used in the preparation of the revalued amounts for its classes of property, plant and equipment: a) Land: The Group generally uses the market price of a square meter of land for the same or similar location as the most significant assumption to determine the revalued amount. The Group typically uses comparable land sales in the same location to assess appropriateness of the value of its land. A 10% increase or decrease in the market price of land could have an impact of $ 0.3 million on the revalued amount of its land. b) Industrial buildings and warehouses: The Group generally determines the construction cost of a new asset and then the Group adjusts it for normal wear and tear. Construction prices may include, but are not limited to, construction materials, labor costs, installation and assembly costs, site preparation, professional fees and applicable taxes. Construction costs may differ significantly from year to year and are subject to macroeconomic changes in the economy where the Group operates, such as the impact of inflation and foreign exchange rates. The construction cost of its industrial buildings and warehouses is determined on a US dollar per constructed square meter basis, while the construction cost of its mills, facilities and grain storage facilities is determined by reference to their total capacity measured in tons milled or stored, respectively. A 5% increase or decrease in the construction costs or the estimate of normal wear and tear relating to such assets could have an impact of $ 1.5 million on their revalued amounts. Increases in the carrying amounts arising on revaluation of land and buildings are recognized, net of tax, in other comprehensive income and accumulated in reserves in shareholders’ equity. To the extent that the increase reverses a decrease previously recognized in profit or loss, the increase is first recognized in profit or loss. Decreases that reverse previous increases of the same asset are first recognized in other comprehensive income to the extent of the remaining surplus attributable to the asset; all other decreases are charged to profit or loss.
Leased assets	4.10. Leased assets Until June 30, 2019 the Group classified its leases at the inception as finance or operating leases. Leases were classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases were classified as operating leases and charged to the statements of income in a straight-line basis over the period of the lease. Finance leases were capitalized at the lease’s inception at the lower of the fair value of the leased property and the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, were included as “Borrowings”. As of the effectiveness of IFRS 16, the Group began applying it and recognized the cumulative initial effect as an adjustment to the opening equity at the date of initial application. The comparative information was not restated. On adoption of IFRS 16, the Group recognized lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under the principles of IAS 17 Leases. In applying IFRS 16 for the first time, the Group has used the following practical expedients permitted by the standard: (i) the use of a single discount rate to a portfolio of leases with reasonably similar characteristics, (ii) reliance on previous assessments on whether leases are onerous, (iii) the accounting for operating leases with a remaining lease term of less than 12 months, as at July 1, 2019, as short-term leases, (iv) the exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application, and (v) the use of hindsight in determining the lease term, where the contract contains options to extend or terminate the lease.
Intangible assets	4.11. Intangible assets a) Externally acquired intangible assets Externally acquired intangible assets are initially recognized at acquisition date fair value (which is considered as their cost). After initial recognition, those assets are measured at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired from third parties have an estimated useful life as follows (in years): Software: 3 years Trademarks and patents: 5 years Certification ISO Standards: 3 years Useful lives and amortization methods are reviewed every year as required by IAS 38. Estimates The Group acquired certain intangible assets from Arcadia (Note 6). To value those intangible assets, valuation techniques generally accepted in the market were applied, based mainly on the revenue approach (such as excess earnings, relief from royalty, and with or without), considering the characteristics of the assets to be valued and available information to estimate their acquisition date fair value. Application of these valuation techniques requires the use of several assumptions related to future cash flows and the discount rate. b) Internally generated intangible assets (development costs) Expenditure on internally developed products is capitalized if it can be demonstrated that: - It is technically feasible to develop the product for it to be sold; - Adequate resources are available to complete the development; - There is an intention to complete and sell the product; - The Group is able to sell the product; - Sale of the product will generate future economic benefits; and - Expenditure on the project can be measured reliably. Development expenditure not satisfying the above criteria and expenditure on the research phase of internal projects are recognized in the consolidated statement of profit or loss and other comprehensive income as incurred (Note 8.3). Capitalized development costs are amortized using the straight-line method over the periods the Group expects to benefit from selling the products developed (Note 7.8). Useful lives and amortization methods are reviewed every year as required by IAS 38. The research and development process can be divided into several discrete steps or phases, which generally begin with discovery, validation and development and end with regulatory approval and commercial launch. The process for developing seed traits is relatively similar for both GM and non-GM traits. However, the two differ significantly in later phases of development. For example, obtaining regulatory approval for GM seeds is a far more comprehensive and lengthy process than for non-GM seeds. Although breeding programs and industrial biotechnology solutions may have shorter or simpler phases than those described below, the Group has used the industry consensus for seed-trait development phases to characterize its technology portfolios, which is generally divided into the following six phases: i) Discovery: The first phase in the technology development process is the discovery or identification of candidate genes or genetic systems, metabolites, or microorganisms potentially capable of enhancing specified plant characteristics or enabling an agro-industrial biotech solution. ii) Proof of concept: Upon successful validation of the technologies in model systems ( in vitro in vivo iii) Early development: In this phase, field tests commenced in the proof of concept phase are expanded to evaluate various permutations of a technology in multiple geographies and growing cycles, as well as other characteristics in order to optimize the technology’s performance in the targeted organisms. The goal of the early development phase is to identify the best mode of use of a technology to define its performance concept. iv) Advanced development and deregulation: In this phase, extensive field tests are used to demonstrate the effectiveness of the technology for its intended purpose. In the case of GM traits, the process of obtaining regulatory approvals from government authorities is also initiated during this phase, and tests are performed to evaluate the potential environmental impact of modified plants. For solutions involving microbial fermentation, industrial-scale runs are conducted. v) Pre-launch: This phase involves finalizing the regulatory approval process and preparing for the launch and commercialization of the technology. The range of activities in this phase includes seed increases, pre-commercial production, and product and solution testing with selected customers. Usually, a more detailed marketing strategy and preparation of marketing materials occur during this phase. vi) Product launch: In general, this phase, which is the last milestone of the research and development process, is carried out by the Group, the joint ventures and/or the Group’s technology licensees. When technology is commercialized through the joint ventures or technology licensees, a successful product launch will trigger royalty payments to the Group, which are generally calculated as a percentage of the net sales realized by the technology and captured upon commercialization. Demonstrability of technical feasibility generally occurs when the project reaches the “advanced development and deregulation” phase because at this stage success is considered to be probable. c) Intangible assets acquired in a business combination Intangible assets acquired in a business combination and recognized separately from goodwill are initially recognized at acquisition date fair value (which is considered as their cost). After initial recognition, those assets are measured at cost less accumulated amortization and accumulated impairment losses in the same manner as intangible assets acquired separately. Intangible assets acquired in a business combination have an estimated useful life as follows (in years): Product registration: 5 years Customer loyalty: 14 - 26 years Estimates The Group acquired certain intangible assets from Rizobacter and Insuagro in the business combinations. To value those intangible assets, valuation techniques generally accepted in the market were applied, based mainly on the revenue approach (such as excess earnings, relief from royalty, and with or without), considering the characteristics of the assets to be valued and available information to estimate their acquisition date fair value. Application of these valuation techniques requires the use of several assumptions related to future cash flows and the discount rate.
Financial liabilities	4.12. Financial liabilities The Group measures its financial liabilities at initial recognition at fair value. The Group classifies all its financial liabilities as financial liabilities measured at amortized cost (using the effective interest rate method), except for Private warrants that were measured at fair value. Private warrants did not reach the fixed-for-fixed' condition and were classified as a financial liability and valued at its fair value applying a simulation model of the share price trajectory under the hypothesis of geometric Brownian motion. See Note 7.16. In the case of the private warrants designated as a whole at fair value through profit or loss, the amount of the change in fair value was recognized as a financial result. Estimates The Group designated private warrants as a whole at fair value. Management of the Group periodically evaluated the appropriate valuation techniques and data used in the fair value measurement and estimation of changes in fair value derived from changes in the inputs. In estimating the fair value of those financial liabilities, the Group use observable market inputs as far as possible. Information about the valuation techniques and significant assumptions used is detailed in Note 15.
Warrants	4.13. Warrants As part of the merger, the Group incorporated 11,500,000 public warrants (“Public warrants”), 12,700,000 private warrants (5,200,000 “Founder warrants” and 7,500,000 “Bioceres warrants”) that Union issued to Bioceres LLC in exchange of its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas. The warrants are an equity instrument only if (a) the instrument includes no contractual obligation to deliver cash or another financial asset to another entity and (b) if the instrument will or may be settled in the issuer’s own equity instruments, it is either a non-derivative that includes no contractual obligation for the issuer to deliver a variable number of its own equity instruments or a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments (“fixed-for-fixed’ condition”). Public warrants were classified as an equity instrument as they comply with the ‘fixed-for-fixed’ condition. Founder warrants and Bioceres warrants (as a group, the “Private warrants”) instead were classified as financial liabilities. Estimates The estimate of the fair value of Private warrants required a determination of which factors were most appropriate to the pricing model, including the expected life of the option and the expected volatility of the share price upon the basis of which hypotheses were made. The Group measured the fair value of these instruments by applying a simulation model of the share price trajectory under the hypothesis of Brownian Motion. The hypotheses used for the estimate of the fair value of these instruments are disclosed in Note 7.16.
Convertible notes	4.14. Convertibles notes The Convertible notes were classified as compound instruments, a non-derivative financial instrument that contains both a liability and an equity component. The equity component was measured as the residual amount that results from deducting the fair value of the liability component from the initial carrying amount of the instrument. The fair value of the consideration of the liability component was measured first at the fair value of a similar liability (including any embedded non-equity derivative features, such as an issuer's call option to redeem the bond early) that does not have any associated equity conversion option. The Group's policy choice is to consider if the instrument meets the 'fixed for fixed' condition, as the strike price is pre-determined at inception and only varies over time, and it is therefore classified as equity. As regards to the mandatory conversion feature (Note 7.17), as it is a contingent settlement provision, the Group decided to measure the liability component at initial recognition, based on its best estimate of the present value of the redemption amount and allocated the residual to the equity component.
Employee benefits	4.15. Employee benefits Employee benefits are expected to be settled wholly within 12 months after the end of the reporting period and are presented as current liabilities. The accounting policies related to incentive payments based on shares are detailed in Note 4.22.
Provisions	4.16. Provisions The Group has recognized provisions for liabilities of uncertain timing or amount. The provision is measured at the best estimate of the expenditure required to settle the obligation at the end of the reporting period, discounted at a pre-tax rate reflecting current market assessments of the time value of money and risks specific to the liability.
Parent company investment	4.17. Parent company investment The Group has recognized the contribution made by Bioceres S.A./Bioceres LLC into the combined entity as Parent company investment. See Note 11. The Group’s ordinary shares are classified as equity instruments, except for the puttable shares which are compound financial instruments. Puttable shares are segregated into separate components of equity instruments and puttable instruments, the latter of which is classified as a financial liability in accordance with IAS 32. The shares classified as equity instruments are measured at nominal value.
Revenue recognition	4.18. Revenue recognition Revenue is measured at fair value of consideration received or receivable. Revenue from ordinary activities from contracts with customers is recognized and measured based on a five-step model, namely: ● ● ● ● ● a) Sale of goods Revenue from the sale of goods is recognized when all the following conditions have been satisfied: (i) the Group has transferred to the buyer the significant risks and rewards of ownership of the goods; (ii) the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; (iii) the amount of revenue can be measured reliably; (iv) it is probable that the economic benefits associated with the transaction will flow to the Group; and (v) the costs incurred or to be incurred in respect of the transaction can be measured reliably. In the case of sales made with where delivery is delayed at the buyer’s request but the buyer assumes ownership and accepts the invoice, revenue is recognized when the buyer assumes ownership, provided that: - It must be probable that delivery will take place; - The goods must be on hand, identified and be ready for delivery to the buyer at the time the sale is recognized - The buyer must specifically acknowledge the deferred delivery instructions; and - The usual payment terms must apply. No revenue is recognized when there is only an intention to purchase or produce the goods in time for delivery. b) Rendering of services When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognized by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied: (i) the amount of revenue can be measured reliably; (ii) it is probable that the economic benefits associated with the transaction will flow to the entity; (iii) the stage of completion of the transaction at the end of the reporting period can be measured reliably; and (iv) the costs incurred for the transaction and the costs to complete the transaction can be measured reliably. When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognized only to the extent of the expenses recognized that are recoverable. The stage of completion for research and development services is generally determined on the basis of internal records of execution of the performed tasks of the respective work plan. For practical purposes, when services are performed by an indeterminate number of acts over a specified period of time, revenue is recognized on a straight-line basis over the specified period unless there is evidence that some other method better represents the stage of completion. When a specific act is much more significant than any other acts, the recognition of revenue is postponed until the significant act is executed. c) Licenses and royalties Licenses and royalties are recognized when it is probable that the economic benefits associated with the transaction will flow to the Group; and the amount of revenue can be measured reliably. Fees and royalties paid for the use of the Group’s assets are normally recognized in accordance with the substance of the agreement. When a licensee has the right to use certain technology for a specified period of time, revenue is recognized on a straight-line basis over the life of the agreement. An assignment of rights for a fixed fee or non-refundable guarantee under a non-cancellable contract which permits the licensee to exploit those rights freely and the licensor has no remaining obligations to perform is, in substance, a sale. In such cases, revenue is recognized at the time of sale. In some cases, whether or not a license fee or royalty will be received is contingent on the occurrence of a future event. In such cases, revenue is recognized only when it is probable that the fee or royalty will be received, which is normally when the event has occurred.
Government grants	4.19. Government grants Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as income in equal amounts over the expected useful life of the related asset. Management elected this accounting policy because the Group determined it better shows the financial effect of government grants in the Consolidated financial statements. When the Group receives grants of non-monetary assets, the asset and the grant are recorded at nominal amounts and released to profit or loss over the expected useful life of the asset. The difference between the money obtained under government loans at subsidized rates and the carrying amount of those loans is treated as a government grant, in accordance with IAS 20.
Borrowing costs	4.20. Borrowing costs Borrowing costs, either generic or specific, attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to get ready for their intended use or sale (qualifying assets) are included in the cost of the assets until the moment that they are substantially ready for use or sale. Income earned on the temporary investments of funds generated in specific borrowings still pending use in the qualifying assets, are deducted from the total of financing costs potentially eligible for capitalization. All other loan costs are recognized under financial costs, through profit and loss.
Income tax and minimum presumed income tax	4.21. Income tax and minimum presumed income tax Deferred tax assets and liabilities are recognized where the carrying amount of an asset or liability in the Consolidated statement of financial position differs from its tax base, except for differences arising on: - - Investments in subsidiaries and jointly controlled entities where the Group is able to control the timing of the reversal of the difference and it is probable that the difference will not reverse in the foreseeable future. Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profit will be available against which the difference can be utilized. The amount of the asset or liability is determined using tax rates that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the deferred tax liabilities / (assets) are settled / (recovered). Deferred tax assets and liabilities are offset when the Group has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority on either: - -
Share-based payments	4.22. Share-based payments Certain executives and directors of the Group were granted incentives in the form of shares and options to purchase Bioceres Crop Solutions shares as consideration for services. The cost of these share-based transactions is determined based on their fair value at the date upon which such incentives are granted using a valuation model that is appropriate in the circumstances. This cost is recognized as an expense together with an increase in equity throughout the period in which the service or performance conditions are satisfied (i.e., the vesting period). The accumulated expense recorded in connection with these transactions at the end of each year until the vesting date reflects the time elapsed between the vesting period and Management’s best estimate of the number of equity instruments that will vest. The charge to income/loss for the period represents the variation in the accumulated expense recorded between the beginning and the end of the year. Non-market related service and performance conditions are not taken into account when determining the grant date fair value of the equity instruments, but the probability that the conditions are fulfilled is assessed as part of Management’s best estimate of the number of equity instruments that will vest. Market-related performance conditions are reflected in the grant date fair value. Any other conditions related to equity-settled share-based payment transactions but without a service requirement are considered as non-vesting conditions. Non-vesting conditions are reflected in the fair value of the equity instruments and are charged to income/loss immediately unless there are service and/or performance conditions as well. No amount is recognized for transactions that will not vest because non-market related performance conditions and/or service conditions were not satisfied. When transactions include market-related conditions or non-vesting conditions, the transactions are considered to be vested, irrespective of whether a market-related condition or the non-vesting condition is satisfied, provided that all the other performance and/or service conditions are met. When the terms and conditions of an equity-settled share-based payment transaction are modified, the minimum expense recognized is the grant date fair value, unmodified, provided that the original terms have been complied with. An additional expense, measured at the date of modification, is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee. When the transaction is settled by the Bioceres Crop Solutions or by the counterparty, any remainder of the fair value is charged to income immediately. The dilutive effect of current options is considered in the calculation of the diluted earnings per share. Estimates The estimate of the fair value of equity-settled share-based payment transactions requires a determination to be made of the most adequate option pricing model to apply depending on the terms and conditions of the arrangement. This estimate also requires a determination of those factors most appropriate to the pricing model, including the expected life of the option and the expected volatility of the share price upon the basis of which hypotheses are made. The Group measures the fair value of these transactions at the grant date applying the Black-Scholes formula adjusted to consider the possible dilutive effect of the future exercise of the share options granted on their estimated fair value at grant date, as established in paragraph B41 of IFRS 2. The hypotheses used for the estimate of the fair value of these transactions are disclosed in Note 18 and will not necessarily take place in the future.

ACCOUNTING STANDARDS AND BASI_2

ACCOUNTING STANDARDS AND BASIS OF PREPARATION (Tables)	12 Months Ended
	Jun. 30, 2021
ACCOUNTING STANDARDS AND BASIS OF PREPARATION
Schedule of equity interest in the subsidiaries	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ incorporation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ and principal ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ place of ​ ​ ​ % Equity interest ​ Name Principal activities business Ref 06/30/2021 06/30/2020 ​ 06/30/2019 ​ RASA Holding, LLC Investment in subsidiaries United States a 100.00 % 100.00 % 100.00 % Rizobacter Argentina S.A. Microbiology Business Argentina a 80.00 % 80.00 % 80.00 % Rizobacter do Brasil Ltda. Selling of agricultural inputs Brazil b 79.99 % 79.99 % 79.99 % Rizobacter del Paraguay S.A. Selling of agricultural inputs Paraguay b 79.92 % 79.92 % 79.92 % Rizobacter Uruguay Selling of agricultural inputs Uruguay b 80.00 % 80.00 % 80.00 % Rizobacter South Africa Selling of agricultural inputs South Africa b 76.00 % 76.00 % 76.00 % Comer. Agrop. Rizobacter de Bolivia S.A. Selling of agricultural inputs Bolivia b 79.96 % 79.96 % 79.96 % Rizobacter USA, LLC Selling of agricultural inputs United States b 80.00 % 80.00 % 80.00 % Rizobacter India Private Ltd. Selling of agricultural inputs India b — ​ 80.00 % 80.00 % Rizobacter Colombia SAS Selling of agricultural inputs Colombia b 80.00 % 80.00 % 80.00 % Rizobacter France SAS ​ Research and development ​ France ​ b ​ 80.00 % 80.00 % 80.00 % Bioceres Crops S.A. ​ Research and development ​ Argentina ​ b c ​ 90.00 % 90.00 % 90.00 % BCS Holding LLC ​ Investment in subsidiaries ​ United States ​ a ​ 100.00 % 100.00 % 100.00 % Bioceres Semillas S.A.U. ​ Production and commercialization of seeds ​ Argentina ​ a ​ 100.00 % 100.00 % 100.00 % Verdeca LLC ​ Research and development ​ United States ​ d ​ 100.00 % 50.00 % 50.00 % Insumos Agroquímicos S.A. ​ Selling of agricultural inputs ​ Argentina ​ e ​ 50.1 % — ​ — ​ ​ a) b) c) d) On November 12, 2020 we acquired from Arcadia Biosciences Inc (“Arcadia”) the remaining 50 % ownership interest in Verdeca LLC (“Verdeca”). See Note 6. e) On April 9, 2021 we acquired a controlling interest in Insumos Agroquímicos S.A. (“Insuagro”). See Note 6.

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
	Jun. 30, 2021
ACQUISITIONS
Summary of fair value of the consideration of payment	​ ​ ​ ​ Cash payment 200,000 Financed payment 2,625,335 Contingent payment 951,622 Total consideration 3,776,957
Summary of assets acquired, liabilities assumed, and non-controlling interest recognized	​ ​ ​ ​ Net assets incorporated Cash and cash equivalents 555,804 Other financial assets 2,024,367 Trade receivables 17,536,888 Other receivables 419,877 Income and minimum presumed income taxes recoverable 117,229 Inventory 5,603,068 Deferred tax assets 106,952 Property, plant and equipment 1,662,516 Intangible assets 264,847 Trade and other payables (17,311,906) Borrowings (5,928,748) Employee benefits and social security (201,472) Deferred revenues and advances from customers (301,017) ​ ​ ​ ​ ​ ​ Revaluation of existing assets ​ ​ ​ Property, plant and equipment 289,529 Intangible assets 2,659,050 Deferred tax (884,574) ​ ​ ​ Total net assets identified 6,612,410 ​ ​ ​ Non-controlling interest (3,305,543) ​ ​ ​ Goodwill 470,090 ​ ​ ​ Total consideration 3,776,957

INFORMATION ABOUT COMPONENTS _4

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Tables)	12 Months Ended
	Jun. 30, 2021
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Schedule of cash and cash equivalents	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Cash at bank and on hand ​ 28,327,569 ​ 20,176,452 ​ 3,450,873 Money market funds ​ 7,718,544 ​ 22,346,409 ​ — ​ 36,046,113 42,522,861 3,450,873
Schedule of other financial assets	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ Restricted short-term deposits 425,976 4,390,458 ​ 4,327,275 US Treasury bills ​ 7,885,937 ​ 7,768,410 ​ — Others mutual funds ​ — ​ — ​ 347,718 Other investments 2,849,485 1,277,525 ​ 8,515 ​ 11,161,398 13,436,393 ​ 4,683,508 ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Non-current Shares of Bioceres S.A. 355,251 321,705 374,685 Other investments 742,211 998 1,728 ​ 1,097,462 322,703 376,413
Schedule of trade receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Trade debtors ​ 87,709,287 ​ 53,047,035 ​ 48,910,484 Allowance for impairment of trade debtors (5,858,503) (3,886,832) (3,360,224) Shareholders and other related parties (Note 17) — 1,090,004 467,743 Allowance for impairment of shareholders and other related parties (Note 17) — (768) (75,596) Allowance for credit notes to be issued (2,987,398) (2,285,197) (800,606) Trade debtors - Parent company (Note 17) — — 440,268 Trade debtors - Joint ventures and associates (Note 17) 221,048 120,992 2,369 Deferred checks 9,699,738 25,461,399 13,651,939 ​ 88,784,172 73,546,633 59,236,377 Non-current ​ ​ ​ ​ ​ ​ Trade debtors ​ 135,739 ​ — ​ — ​ ​ 135,739 ​ — ​ —
Schedule of other receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current Taxes 6,048,533 2,205,342 584,641 Other receivables - Other related parties (Note 17) 1,547 2,102 10,971 Other receivables - Parents companies and related parties to Parents (Note 17) 770,549 102,069 — Other receivables - Joint ventures and associates (Note 17) 2,219,863 1,562,340 250,783 Prepayments to suppliers 1,646,614 379,914 496,001 Prepayments to suppliers - Shareholders and other related parties (Note 17) 132,625 81,737 — Reimbursements over exports 10,547 29,077 366,594 Prepaid expenses and other receivables 1,021 128,650 213,597 Loans receivable 230,000 230,000 — Miscellaneous 92,406 49,441 59,242 ​ 11,153,705 4,770,672 1,981,829 ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Non-current Taxes 862,771 328,701 681,168 Reimbursements over exports 1,680,371 1,293,958 878,470 Miscellaneous — 80,914 672 ​ 2,543,142 1,703,573 1,560,310
Schedule of inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Agrochemicals 1,161,025 356,489 22,137 Seeds and grains 22,389,400 1,300,998 207,519 Resale products ​ 20,207,496 ​ 13,486,668 ​ 13,894,018 Manufactured products ​ 10,902,683 ​ 8,079,553 ​ 8,370,583 Goods in transit 1,169,303 1,292,239 751,737 Supplies 6,320,594 5,930,471 4,482,827 Allowance for obsolescence (1,112,950) (1,107,870) (406,818) ​ 61,037,551 29,338,548 27,322,003
Schedule of changes in biological assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean Corn Wheat Barley HB4 Soy HB4 Wheat Total Beginning of the year 105,101 271,754 45,639 34,050 — 509,184 965,728 Initial recognition and changes in the fair value of biological assets 981,551 250,443 284,903 35,847 741,799 531,712 2,826,255 Costs incurred during the year 252,504 417,586 241,610 37,115 17,716,018 7,053,929 25,718,762 Exchange differences (113,718) (153,795) (65,797) (16,876) (2,823,643) (1,153,734) (4,327,563) Decrease due to harvest (1,171,276) (758,342) (484,044) (87,065) (15,634,174) (4,732,443) (22,867,344) Year ended June 30, 2021 54,162 27,646 22,311 3,071 — 2,208,648 2,315,838 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean Corn Wheat Barley HB4 Wheat Total Beginning of the year 237,723 32,856 — — — 270,579 Initial recognition and changes in the fair value of biological assets 198,932 252,056 202,543 63,210 — 716,741 Decrease due to harvest (447,132) (252,372) (227,303) (59,626) — (986,433) Cost incurred during the year 284,951 314,950 87,615 38,033 509,184 1,234,733 Exchange differences (169,373) (75,736) (17,216) (7,567) — (269,892) Year ended June 30, 2020 105,101 271,754 45,639 34,050 509,184 965,728 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean Corn Wheat Barley Total Beginning of the year — — — — — Initial recognition and changes in the fair value of biological assets 241,707 38,238 — — 279,945 Decrease due to harvest (288,791) (45,687) — — (334,478) Cost incurred during the year 339,088 47,986 — — 387,074 Exchange differences (54,281) (7,681) — — (61,962) Year ended June 30, 2019 237,723 32,856 — — 270,579
Schedule of property plant and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Gross carrying amount 63,974,402 54,527,392 57,059,972 Accumulated depreciation (16,019,806) (13,012,286) (13,225,424) Net carrying amount 47,954,596 41,515,106 43,834,548
Schedule of net carrying amount	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net carrying ​ Net carrying ​ Net carrying ​ ​ amount ​ amount ​ amount Class 06/30/2021 06/30/2020 06/30/2019 Office equipment ​ 288,920 ​ 188,280 ​ 213,437 Vehicles ​ 1,835,634 ​ 1,149,455 ​ 1,785,701 Equipment and computer software 67,105 32,448 123,472 Fixtures and fittings 2,967,431 3,679,075 4,737,396 Machinery and equipment 5,125,728 5,449,233 6,336,691 Land and buildings 35,674,513 29,746,076 29,969,237 Buildings in progress 1,995,265 1,270,539 668,614 Total 47,954,596 41,515,106 43,834,548
Schedule of gross carrying amount	. Gross carrying amount as of June 30, 2021 is as follows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ ​ ​ Additions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ ​ ​ from ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ ​ ​ beginning ​ ​ ​ business ​ ​ ​ ​ ​ currency ​ ​ ​ As of the Class of year Additions combination Transfers Disposals translation Revaluation end of year Office equipment ​ 579,882 ​ 66,331 ​ 5,491 ​ — ​ (5,622) ​ 116,743 ​ — ​ 762,825 Vehicles ​ 2,977,542 ​ 987,101 ​ 466,024 ​ — ​ (1,045,656) ​ 127,206 ​ — ​ 3,512,217 Equipment and computer software ​ 465,679 ​ 66,263 ​ 13,952 ​ — ​ — ​ 46,232 ​ — ​ 592,126 Fixtures and fittings 5,480,431 50,976 — 85,490 — 21,046 — 5,637,943 Machinery and equipment 9,054,701 604,307 — — (10,240) 339,043 — 9,987,811 Land and buildings 34,698,618 — 1,466,578 2,517,158 — 4,022,972 (1,219,111) 41,486,215 Buildings in progress 1,270,539 1,030,847 — (438,492) — 132,371 — 1,995,265 Total 54,527,392 2,805,825 1,952,045 2,164,156 (1,061,518) 4,805,613 (1,219,111) 63,974,402 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ As of the ​ ​ ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ ​ ​ beginning ​ ​ ​ ​ ​ ​ ​ currency ​ ​ ​ As of the Class of year Additions Reclassifications Disposals translation Revaluation end of year Office equipment ​ 629,119 ​ 42,658 ​ — ​ — ​ (91,895) ​ — ​ 579,882 Vehicles ​ 3,604,537 ​ 248,800 ​ (264,069) ​ (139,369) ​ (472,357) ​ — ​ 2,977,542 Equipment and computer software ​ 955,657 ​ 27,961 ​ (375,242) ​ — ​ (142,697) ​ — ​ 465,679 Fixtures and fittings ​ 6,438,430 ​ 14,985 ​ 20,801 ​ — ​ (993,785) ​ — ​ 5,480,431 Machinery and equipment 10,233,501 556,693 (598,561) — (1,136,932) — 9,054,701 Land and buildings 34,530,114 3,261 36,487 — (4,772,065) 4,900,821 34,698,618 Buildings in progress 668,614 752,339 (57,288) — (93,126) — 1,270,539 Total 57,059,972 1,646,697 (1,237,872) (139,369) (7,702,857) 4,900,821 54,527,392 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of opening ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ net book ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ amount for ​ ​ ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ ​ ​ beginning ​ application ​ ​ ​ ​ ​ ​ ​ currency ​ ​ ​ As of the Class of year of IAS 29 Additions Transfers Disposals translation Revaluation end of year Office equipment ​ 243,948 ​ 333,904 ​ 30,621 ​ — ​ (8,493) ​ 29,139 ​ — ​ 629,119 Vehicles ​ 1,660,294 ​ 1,054,631 ​ 1,093,749 ​ — ​ (297,269) ​ 93,132 ​ — ​ 3,604,537 Equipment and computer software ​ 419,638 ​ 416,274 ​ 75,152 ​ — ​ (1,685) ​ 46,278 ​ — ​ 955,657 Fixtures and fittings ​ 3,826,665 ​ 1,909,115 ​ 7,518 ​ 213,333 ​ — ​ 481,799 ​ — ​ 6,438,430 Machinery and equipment 5,404,029 3,976,720 98,034 7,863 (31,407) 778,262 — 10,233,501 Land and buildings 33,026,981 1,438,728 125,930 — — 1,994,906 (2,056,431) 34,530,114 Buildings in progress 182,839 75,405 613,098 (221,196) — 18,468 — 668,614 Total 44,764,394 9,204,777 2,044,102 — (338,854) 3,441,984 (2,056,431) 57,059,972
Schedule of accumulated depreciation	Accumulated depreciation as of June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of the ​ ​ ​ ​ ​ Foreign ​ ​ ​ Accumulated ​ ​ beginning of ​ ​ ​ ​ ​ currency ​ ​ ​ as of the end Class year Disposals Of the year translation Revaluation of year Office equipment 391,602 (3,265) 45,174 40,394 — 473,905 Vehicles 1,828,087 (974,102) 689,273 133,325 — 1,676,583 Equipment and computer software 433,231 — 50,949 40,841 — 525,021 Fixtures and fittings 1,801,356 — 683,537 185,619 — 2,670,512 Machinery and equipment 3,605,468 (10,239) 898,522 368,332 — 4,862,083 Land and buildings 4,952,542 — 681,084 517,991 (339,915) 5,811,702 Total 13,012,286 (987,606) 3,048,539 1,286,502 (339,915) 16,019,806 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of the ​ ​ ​ ​ ​ Foreign ​ ​ ​ Accumulated ​ ​ beginning of ​ Disposals/ ​ ​ ​ currency ​ ​ ​ as of the end of Class year Reclassifications Of the year translation Revaluation year Office equipment ​ 415,682 ​ — ​ 35,879 ​ (59,959) ​ — ​ 391,602 Vehicles ​ 1,818,836 ​ (173,482) ​ 426,623 ​ (243,890) ​ — ​ 1,828,087 Equipment and computer software ​ 832,185 ​ (307,816) ​ 28,170 ​ (119,308) ​ — ​ 433,231 Fixtures and fittings ​ 1,701,034 ​ — ​ 338,092 ​ (237,770) ​ — ​ 1,801,356 Machinery and equipment 3,896,810 (279,322) 553,399 (565,419) — 3,605,468 Land and buildings 4,560,877 — 627,973 (604,216) 367,908 4,952,542 Total 13,225,424 (760,620) 2,010,136 (1,830,562) 367,908 13,012,286 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ ​ ​ Adjustments of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ opening net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of the ​ book amount ​ ​ ​ ​ ​ Foreign ​ ​ ​ Accumulated ​ ​ beginning of ​ for application ​ ​ ​ Of the ​ currency ​ ​ ​ as of the end of Class year of IAS 29 Disposals year translation Revaluation year Office equipment ​ 49,129 ​ 309,339 ​ (4,007) ​ 39,997 ​ 21,224 ​ — ​ 415,682 Vehicles ​ 560,691 ​ 750,195 ​ (205,618) ​ 621,974 ​ 91,594 ​ — ​ 1,818,836 Equipment and computer software ​ 207,402 ​ 486,143 ​ (769) ​ 99,350 ​ 40,059 ​ — ​ 832,185 Fixtures and fittings 318,582 ​ 912,404 ​ — ​ 397,989 ​ 72,059 ​ — ​ 1,701,034 Machinery and equipment 937,736 2,121,816 (16,807) 673,784 ​ 180,281 — 3,896,810 Land and buildings 2,513,708 1,343,500 — 617,162 ​ 221,428 (134,921) 4,560,877 Total 4,587,248 5,923,397 (227,201) 2,450,256 ​ 626,645 (134,921) 13,225,424
Schedule of carrying amounts if recognized under cost model	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Value at cost Class of property 06/30/2021 06/30/2020 06/30/2019 Land and buildings 17,937,729 12,549,876 14,330,892
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Gross carrying amount 78,019,203 42,832,837 45,848,737 Accumulated amortization (10,676,841) (7,499,373) (6,232,311) Net carrying amount 67,342,362 35,333,464 39,616,426
Schedule of net carrying amount of each class of intangibles	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net carrying ​ Net carrying ​ Net carrying ​ ​ amount ​ amount ​ amount Class 06/30/2021 06/30/2020 06/30/2019 Seed and integrated products HB4 soy and breeding program 27,611,142 7,345,923 6,120,336 Integrated seed products 2,558,220 2,296,955 2,627,946 Crop nutrition ​ ​ ​ Microbiological products 3,996,657 2,503,631 2,208,117 Other intangible assets ​ ​ Trademarks and patents 6,923,256 6,374,782 8,063,648 Software 1,849,041 686,965 994,723 Customer loyalty 19,404,046 16,125,208 19,601,656 RG/RS/OX Wheat ​ 5,000,000 ​ — ​ — Total 67,342,362 35,333,464 39,616,426
Schedule of gross carrying amounts of intangibles	Gross carrying amount as of June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ ​ ​ Additions ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ ​ ​ from ​ ​ ​ Foreign ​ ​ ​ ​ beginning of ​ ​ ​ business ​ Transfers / ​ currency ​ As of the Class year Additions combination Disposals translation end of year Seed and integrated products ​ ​ ​ ​ ​ ​ HB4 soy and breeding program (1) ​ 7,345,923 ​ 20,471,002 ​ — ​ (205,783) ​ — ​ 27,611,142 Integrated seed products ​ 2,296,955 ​ — ​ — ​ — ​ 261,265 ​ 2,558,220 Crop nutrition Microbiological products 3,867,593 1,791,008 — (51,716) 430,795 6,037,680 Other intangible assets Trademarks and patents 8,432,746 4,834 499,329 — 887,262 9,824,171 Software 2,088,929 2,205,796 — (711,441) 201,309 3,784,593 Customer loyalty 18,800,691 — 2,424,568 — 1,978,138 23,203,397 GLA/ARA safflower (Note 6) — 2,931,699 — (2,931,699) — — RG/RS/OX Wheat (Note 6) — 5,000,000 — — — 5,000,000 Total 42,832,837 32,404,339 2,923,897 (3,900,639) 3,758,769 78,019,203 ​ (1) Of the total additions, $18.4 million are associated with Arcadia’s transaction mentioned in Note 6. ​ op ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ beginning of ​ ​ ​ ​ ​ currency ​ As of the Class year Additions Disposals translation end of year Seed and integrated products ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HB4 soy and breeding program ​ 6,120,336 ​ 1,225,587 ​ — ​ — ​ 7,345,923 Integrated seed products ​ 2,627,946 ​ 38,143 ​ — ​ (369,134) ​ 2,296,955 Crop nutrition ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Microbiological products 3,267,200 1,358,315 (286,496) (471,426) 3,867,593 Other intangible assets ​ ​ ​ ​ ​ Trademarks and patents 9,810,822 — — (1,378,076) 8,432,746 Software 2,149,340 233,434 — (293,845) 2,088,929 Customer loyalty 21,873,093 — — (3,072,402) 18,800,691 Total 45,848,737 2,855,479 (286,496) (5,584,883) 42,832,837 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying amount ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of opening ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ net book ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of the ​ amount for ​ ​ ​ ​ ​ Foreign ​ ​ ​ ​ beginning of ​ application ​ ​ ​ ​ ​ currency ​ As of the Class year of IAS 29 Additions Disposals translation end of year Seed and integrated products ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Soybean HB4 ​ 4,927,853 ​ — ​ 1,192,483 ​ — ​ — ​ 6,120,336 Integrated seed products ​ — ​ — ​ 2,627,946 ​ — ​ — ​ 2,627,946 Crop nutrition ​ ​ ​ ​ ​ ​ Microbiology products 2,505,864 841,753 41,485 (318,949) 197,047 3,267,200 Other intangible assets Trademarks and patents 6,278,706 2,986,739 — — 545,377 9,810,822 Software 1,444,603 438,703 200,600 (40,359) 105,793 2,149,340 Customer loyalty 13,998,289 6,658,894 — — 1,215,910 21,873,093 Total 29,155,315 10,926,089 4,062,514 (359,308) 2,064,127 45,848,737
Schedule of accumulated amortization of intangibles	Accumulated amortization as of June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ beginning of ​ ​ ​ Transfers / ​ Foreign currency ​ as of the end Class year Of the year Disposals translation of year Crop nutrition ​ ​ ​ ​ ​ Microbiological products ​ 1,363,962 ​ 523,992 ​ — ​ 153,069 ​ 2,041,023 Other intangible assets ​ ​ ​ ​ ​ Trademarks and patents 2,057,964 626,420 — 216,531 2,900,915 Software 1,401,964 396,207 — 137,381 1,935,552 Customer loyalty 2,675,483 842,363 — 281,505 3,799,351 Total 7,499,373 2,388,982 — 788,486 10,676,841 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ ​ ​ ​ ​ Foreign ​ Accumulated ​ ​ beginning of ​ ​ ​ ​ ​ currency ​ as of the end of Class year Of the period Disposals translation year Crop nutrition ​ ​ ​ ​ ​ Microbiological products ​ 1,059,083 ​ 471,135 ​ (17,495) ​ (148,761) ​ 1,363,962 Other intangible assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trademarks and patents ​ 1,747,174 ​ 556,206 ​ — ​ (245,416) ​ 2,057,964 Software 1,154,617 399,090 — (151,743) 1,401,964 Customer loyalty 2,271,437 723,103 — (319,057) 2,675,483 Total 6,232,311 2,149,534 (17,495) (864,977) 7,499,373 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of opening ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ net book ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ amount for ​ ​ ​ ​ ​ Foreign ​ Accumulated ​ ​ beginning of ​ application ​ ​ ​ ​ ​ currency ​ as of the end of Class year of IAS 29 Disposals Of the year translation year Crop nutrition ​ ​ ​ ​ ​ Microbiology products 383,380 ​ 202,791 ​ (20,887) ​ 459,287 ​ 34,512 ​ 1,059,083 Other intangible assets ​ ​ ​ ​ ​ Trademarks and patents 704,024 ​ 334,919 ​ — ​ 647,101 ​ 61,130 ​ 1,747,174 Software 495,293 227,264 (40,359) 429,258 43,161 1,154,617 Customer loyalty 915,273 435,389 — 841,273 79,502 2,271,437 Total 2,497,970 1,200,363 (61,246) 2,376,919 218,305 6,232,311
Schedule of carrying amount of goodwill	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Rizobacter Argentina S.A. 22,277,336 20,094,633 23,484,761 Bioceres Crops S.A. 6,003,780 5,432,222 6,319,954 Insumos Agroquímicos S.A. ​ 470,090 ​ — ​ — ​ 28,751,206 25,526,855 29,804,715
Schedule of key assumptions for goodwill	​ Key assumption Management’s approach Discount rate ​ The discount rate used ranges was 15.55% for Rizobacter and Bioceres Crops and 22% for Insuagro. The weighted average cost of capital ("WACC") rate has been estimated based on the market capital structure. For the cost of debt, the indebtedness cost of the CGUs was used. For the cost of equity, the discount rate is estimated based on the Capital Asset Pricing Model (CAPM). The value assigned is consistent with external sources of information. Budgeted market share of joint ventures and other customers ​ The projected revenue from the products and services of the CGUs has been estimated by the management based on market penetration data for comparable products and technologies and on future expectations of foreseen economic and market conditions. The value assigned is consistent with external sources of information. Budgeted product prices ​ The prices estimated in the revenue projections are based on current and projected market prices for the products and services of the CGUs The value assigned is consistent with external sources of information. Growth rate used to extrapolate future cash flow projections to terminal period ​ The growth rate used to extrapolate the future cash flow projections to terminal period is 2%. The value assigned is consistent with external sources of information.
Schedule of trade and other payable	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Trade creditors 51,389,515 37,139,351 30,489,072 Shareholders and other related parties (Note 17) 52,864 1,031,710 1,796,932 Trade creditors - Parent company (Note 17) 193,718 2,210,308 1,568,036 Trade creditors - Joint ventures and associates (Note 17) 17,669,027 14,409,853 4,805,149 Taxes 2,556,945 2,163,552 1,475,410 Miscellaneous 229,339 335,088 443,895 ​ 72,091,408 57,289,862 40,578,494
Schedule of borrowings	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Bank overdrafts 32,838 73,362 — Bank borrowings 33,684,287 47,646,912 52,274,611 Corporate bonds 24,742,752 12,611,940 8,416,768 Trust debt securities 3,470,448 — — Net loans payables-Parents companies and related parties to Parents (Note 17) 3,578,921 3,389,521 5,399,883 Subordinated loan ​ 11,276,611 ​ — ​ — Finance lease — — 385,947 ​ 76,785,857 63,721,735 66,477,209 Non-current ​ ​ ​ Subordinated loan ​ — ​ 10,364,045 ​ — Bank borrowings 4,161,827 3,497,671 16,239,743 Corporate bonds 37,826,641 18,364,894 8,018,884 Net loans payables-Parents companies and related parties to Parents (Note 17) 6,000,000 9,000,000 12,358,024 Finance lease — — 462,870 ​ 47,988,468 41,226,610 37,079,521
Schedule of carrying value of borrowings	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 ​ 06/30/2020 ​ 06/30/2019 ​ ​ Amortized ​ ​ ​ Amortized ​ ​ ​ Amortized ​ ​ ​ cost Fair value cost Fair value cost Fair value Current ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bank borrowings 33,684,287 32,770,615 47,646,912 43,046,111 52,274,611 52,088,002 Corporate bonds 24,742,752 24,085,087 12,611,940 11,997,981 8,416,768 7,632,806 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-current Bank borrowings 4,161,827 3,864,666 3,497,671 3,072,395 16,239,743 14,274.55 Corporate bonds 37,826,641 32,656,097 18,364,894 16,135,876 8,018,884 6,972,332
Schedule of financial instruments that are offset	As of June 30, 2021 and 2020, there was no offsets of financial assets and liabilities of the Parents. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross amounts set off Net amounts presented ​ ​ ​ ​ in the Statement of ​ in the Statement of Parents companies and related parties to Parents ​ Gross amounts ​ Financial Position ​ Financial Position Current other receivables 15,827,847 (15,827,847) — Total current assets 15,827,847 (15,827,847) — Current borrowings (21,227,730) 15,827,847 (5,399,883) Total current liabilities (21,227,730) 15,827,847 (5,399,883) Non-current borrowings ​ (12,358,024) ​ — ​ (12,358,024) Total non-current liabilities ​ (12,358,024) ​ — ​ (12,358,024)
Schedule of employee benefits and social security	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current ​ ​ ​ ​ ​ ​ Salaries, accrued incentives, vacations and social security 2,341,351 2,960,542 3,044,965 Key management personnel (Note 17) 2,338,727 1,550,050 2,312,253 ​ 4,680,078 4,510,592 5,357,218 ​ ​ ​ ​ ​ ​ ​ Non-current ​ ​ ​ ​ ​ ​ Key management personnel (Note 17) ​ — ​ 534,038 ​ — ​ ​ — ​ 534,038 ​ —
Schedule of deferred revenue and advances from customers	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Advances from customers 6,277,313 2,865,437 1,074,463 ​ 6,277,313 2,865,437 1,074,463
Schedule of government grants rollforward	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 At of the beginning of the year 3,605 10,208 33,227 Adjustment of opening net book amount for application of IAS 29 — — (27,794) Received during the year 4,749 32,073 31,785 Currency conversion difference (5,268) (13,944) (10,638) Released to the statement of profit or loss (2,302) (24,732) (16,372) At the end of the year 784 3,605 10,208
Schedule of provisions	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Provisions for contingencies 449,847 417,396 439,740 ​ 449,847 417,396 439,740
Schedule of private placements	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Private warrants — 1,686,643 2,861,511 ​ — 1,686,643 2,861,511
Schedule of changes in allowances and provisions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additions ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ ​ ​ from business ​ Uses and ​ conversion ​ ​ Item 06/30/2020 Additions combination reversals difference 06/30/2021 DEDUCTED FROM ASSETS ​ Allowance for impairment of trade debtors (3,886,832) (698,741) (852,926) 284,727 (704,731) (5,858,503) Allowance for impairment of related parties (768) — ​ 565 203 — Allowance for obsolescence (1,107,870) (643,530) (8,850) 474,945 172,355 (1,112,950) ​ ​ ​ ​ ​ ​ ​ Total deducted from assets (4,995,470) (1,342,271) (861,776) 760,237 (532,173) (6,971,453) ​ ​ ​ ​ ​ ​ ​ INCLUDED IN LIABILITIES ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provisions for contingencies (417,396) (162,321) — 3,503 126,367 (449,847) ​ ​ ​ ​ ​ ​ ​ Total included in liabilities (417,396) (162,321) — 3,503 126,367 (449,847) ​ ​ ​ ​ ​ ​ ​ Total (5,412,866) (1,504,592) (861,776) 763,740 (405,806) (7,421,300) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ ​ ​ Uses and ​ conversion ​ ​ Item 06/30/2019 Additions reversals difference 06/30/2020 DEDUCTED FROM ASSETS ​ Allowance for impairment of trade debtors (3,360,224) (1,520,928) 2,115 992,205 (3,886,832) Allowance for impairment of related parties (75,596) (879) 45,516 30,191 (768) Allowance for obsolescence (406,818) (984,207) 6,390 276,765 (1,107,870) ​ ​ ​ ​ ​ ​ Total deducted from assets (3,842,638) (2,506,014) 54,021 1,299,161 (4,995,470) ​ ​ ​ ​ ​ ​ INCLUDED IN LIABILITIES ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provisions for contingencies (439,740) (208,377) 7,852 222,869 (417,396) ​ ​ ​ ​ ​ ​ Total included in liabilities (439,740) (208,377) 7,852 222,869 (417,396) ​ ​ ​ ​ ​ ​ Total (4,282,378) (2,714,391) 61,873 1,522,030 (5,412,866) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ ​ ​ Uses and ​ ​ ​ conversion ​ ​ Item 06/30/2018 Additions reversals IAS 29 difference 06/30/2019 DEDUCTED FROM ASSETS ​ Allowance for impairment of trade debtors (3,212,170) (654,991) 87,916 1,220,652 (801,631) (3,360,224) Allowance for impairment of related parties (23,126) (80,913) 12,408 17,396 (1,361) (75,596) Allowance for obsolescence (770,742) (736,372) 615,467 273,252 211,577 (406,818) ​ ​ ​ ​ ​ ​ ​ Total deducted from assets (4,006,038) (1,472,276) 715,791 1,511,300 (591,415) (3,842,638) ​ ​ ​ ​ ​ ​ ​ INCLUDED IN LIABILITIES ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provisions for contingencies (845,486) (74,109) 320,941 353,257 (194,343) (439,740) ​ ​ ​ ​ ​ ​ ​ Total included in liabilities (845,486) (74,109) 320,941 353,257 (194,343) (439,740) ​ ​ ​ ​ ​ ​ ​ Total (4,851,524) (1,546,385) 1,036,732 1,864,557 (785,758) (4,282,378)

INFORMATION ABOUT COMPONENTS _5

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Tables)	12 Months Ended
	Jun. 30, 2021
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Schedule of revenue from contracts with customers	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Sale of goods and services 204,674,072 170,574,909 159,198,516 Royalties 2,023,548 1,775,790 1,110,463 ​ 206,697,620 172,350,699 160,308,979
Schedule of cost of sales	​ ​ ​ ​ ​ ​ ​ ​ Item 06/30/2021 06/30/2020 06/30/2019 Inventories as of the beginning of the year 29,338,548 27,322,003 19,366,001 Adjustment of opening net book amount for the application of IAS 29 — — 4,273,416 Business combination ​ 5,611,918 ​ — ​ — Purchases of the year 112,084,246 88,195,797 88,380,452 Production costs 11,169,890 10,998,165 11,558,513 Foreign currency translation (509,874) (3,601,829) (9,291,498) Subtotal 157,694,728 122,914,136 114,286,884 Inventories as of the end of the year (*) (39,052,925) (29,338,548) (27,322,003) Cost of sales 118,641,803 93,575,588 86,964,881 ​ (*) Net of agricultural products from HB4 program.
Schedule of R&D classified by nature	​ ​ ​ ​ ​ ​ ​ ​ ​ Research Research Research ​ ​ and ​ and ​ and ​ development development development ​ expenses expenses expenses Item 06/30/2021 06/30/2020 06/30/2019 Amortization of intangible assets 1,138,720 1,027,340 1,106,390 Import and export expenses 5,220 17,303 16,360 Depreciation of property, plant and equipment 454,575 97,171 220,849 Freight and haulage ​ 2,335 ​ — ​ — Employee benefits and social securities 1,430,277 787,931 541,025 Maintenance 54,551 59,219 56,395 Energy and fuel 44,518 52,614 52,919 Supplies and materials 1,401,869 871,930 1,175,184 Mobility and travel 29,783 70,138 48,308 Professional fees and outsourced services 235,443 94,286 69,110 Professional fees related parties ​ 691,723 ​ 821,809 ​ 378,273 Office supplies 5,170 9,801 3,796 Information technology expenses ​ 14,531 ​ — ​ — Insurance 24,439 5,353 8,593 Depreciation of leased assets ​ 23,286 ​ 7,079 ​ — Impairment of R&D projects ​ 51,716 ​ 269,001 ​ — Miscellaneous 9,499 4,295 12,189 Total 5,617,655 4,195,270 3,689,391
Schedule of expenses classified by nature and function	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Selling, general ​ ​ ​ ​ ​ and ​ ​ ​ ​ ​ ​ administrative ​ Total Item ​ Production costs ​ expenses ​ 06/30/2021 Amortization of intangible assets — 1,250,262 1,250,262 Analysis and storage 23,417 123,168 146,585 Commissions and royalties 971,932 996,636 1,968,568 Import and export expenses 70,783 720,888 791,671 Depreciation of property, plant and equipment 1,274,206 1,319,758 2,593,964 Depreciation of leased assets 159,325 644,709 804,034 Impairment of receivables — 560,931 560,931 Freight and haulage 488,683 3,894,696 4,383,379 Employee benefits and social securities 4,974,759 14,979,262 19,954,021 Maintenance 632,406 586,614 1,219,020 Energy and fuel 336,812 52,710 389,522 Supplies and materials 516,431 203,250 719,681 Mobility and travel 11,225 940,619 951,844 Publicity and advertising — 2,518,286 2,518,286 Contingencies — 158,818 158,818 Share-based incentives — 1,655,135 1,655,135 Professional fees and outsourced services 787,462 7,668,043 8,455,505 Professional fees related parties — 157,714 157,714 Office supplies 217,146 463,790 680,936 Insurance 79,272 993,738 1,073,010 Information technology expenses 441 1,347,374 1,347,815 Obsolescence 579,832 — 579,832 Taxes 44,228 6,001,292 6,045,520 Miscellaneous 1,530 364,208 365,738 Total 11,169,890 47,601,901 58,771,791 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Selling, ​ ​ ​ general and ​ ​ ​ Production administrative ​ Total Item ​ costs expenses ​ 06/30/2020 Amortization of intangible assets — 1,122,194 1,122,194 Analysis and storage 46,620 23,851 70,471 Commissions and royalties 1,268,670 553,518 1,822,188 Import and export expenses 190,226 1,321,256 1,511,482 Depreciation of property, plant and equipment 1,170,624 742,341 1,912,965 Depreciation of leased assets 248,948 317,870 566,818 Impairment of receivables — 1,499,298 1,499,298 Freight and haulage 541,019 3,458,525 3,999,544 Employee benefits and social securities 4,744,240 12,505,277 17,249,517 Maintenance 400,162 530,758 930,920 Energy and fuel ​ 397,253 ​ 111,141 ​ 508,394 Supplies and materials ​ 321,962 ​ 260,126 ​ 582,088 Mobility and travel 12,980 1,358,857 1,371,837 Publicity and advertising — 1,718,572 1,718,572 Contingencies — 200,525 200,525 Share-based incentives — 3,428,029 3,428,029 Professional fees and outsourced services 575,566 2,752,852 3,328,418 Professional fees related parties — 32,816 32,816 Office supplies 2,093 356,906 358,999 Insurance 64,019 295,206 359,225 Information technology expenses ​ — ​ 917,230 ​ 917,230 Obsolescence 977,817 — 977,817 Taxes 28,724 4,656,318 4,685,042 Miscellaneous 7,242 181,562 188,804 Total 10,998,165 38,345,028 49,343,193 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Selling, ​ ​ ​ general and ​ ​ ​ Production administrative ​ Total Item ​ costs expenses ​ 06/30/2019 Amortization of intangible assets — 1,270,529 1,270,529 Analysis and storage 5,811 905 6,716 Commissions and royalties 751,972 489,301 1,241,273 Bank expenses and commissions — 30,784 30,784 Import and export expenses 95,111 1,396,636 1,491,747 Depreciation of property, plant and equipment 1,164,810 1,064,597 2,229,407 Impairment of receivables — 686,985 686,985 Freight and haulage 1,433,867 2,662,715 4,096,582 Employee benefits and social securities 5,313,211 12,969,653 18,282,864 Maintenance 501,699 532,648 1,034,347 Energy and fuel 568,848 195,449 764,297 Supplies and materials 275,378 214,513 489,891 Mobility and travel 12,097 1,306,067 1,318,164 Publicity and advertising — 1,709,552 1,709,552 Contingencies — 67,417 67,417 Professional fees and outsourced services 681,790 7,346,607 8,028,397 Professional fees related parties — 401,005 401,005 Office supplies 31,394 352,167 383,561 Insurance 105,302 802,352 907,654 Information technology expenses ​ — ​ 709,539 ​ 709,539 Obsolescence 564,873 — 564,873 Taxes 37,388 4,821,136 4,858,524 Miscellaneous 14,962 213,243 228,205 Total 11,558,513 39,243,800 50,802,313 ​
Schedule of financial results	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial costs 06/30/2021 06/30/2020 06/30/2019 Interest expenses with the Parents (Note 17) (1,219,776) ​ (1,861,774) ​ (1,386,288) Interest expenses (17,702,770) ​ (17,535,324) ​ (20,450,254) Financial commissions (2,317,690) ​ (1,483,428) ​ (1,578,292) ​ (21,240,236) ​ (20,880,526) ​ (23,414,834) ​ ​ ​ ​ ​ ​ ​ Other financial results ​ ​ ​ Exchange differences generated by assets 22,161,855 ​ 30,194,601 ​ 48,355,784 Exchange differences generated by liabilities (35,541,048) ​ (50,815,215) ​ (66,200,973) Changes in fair value of financial assets or liabilities and other financial results (5,057,589) ​ (418,186) ​ (540,589) Gain from cancellation of purchase option ​ — ​ — ​ 6,582,849 Share-based payment cost of listing shares ​ — ​ — ​ (20,893,789) Net gain of inflation effect on monetary items ​ 11,824,678 ​ 9,216,684 ​ 14,653,335 ​ ​ (6,612,104) ​ (11,822,116) ​ (18,043,383) ​ ​ ​ ​ ​ ​ ​ Total net financial results (27,852,340) ​ (32,702,642) ​ (41,458,217)

TAXATION (Tables)

TAXATION (Tables)	12 Months Ended
	Jun. 30, 2021
Income tax and minimum presumed income tax
Schedule of income tax and minimum presumed income tax recoverable and payable	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current assets Income tax 990,881 112,220 1,263,795 ​ 990,881 112,220 1,263,795 Non-current assets Income tax 10,105 2,653 — Minimum presumed income tax 2,484 3,376 1,184 ​ 12,589 6,029 1,184 ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Liabilities Income tax 7,452,891 1,556,715 142,028 ​ 7,452,891 1,556,715 142,028 ​
Schedule of deferred tax assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets 06/30/2021 06/30/2020 06/30/2019 Tax Loss-Carry Forward ​ 3,226,305 ​ 2,362,657 ​ 2,663,813 Changes in fair value of financial assets or liabilities ​ 89,574 ​ 41,183 ​ 32,062 Trade receivables ​ 609,913 ​ 1,068,054 ​ 374,425 Royalties ​ 485,426 ​ 245,140 ​ — Right-of-use leased asset ​ — ​ 5,424 ​ — Government grants ​ — ​ — ​ 2,649 Others ​ 1,552,370 ​ 813,294 ​ 670,760 Total deferred tax assets ​ 5,963,588 ​ 4,535,752 ​ 3,743,709 ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities ​ 06/30/2021 06/30/2020 06/30/2019 Intangible assets ​ (10,624,621) ​ (6,839,112) ​ (9,458,239) Property, plant and equipment depreciation (12,632,296) (9,365,882) ​ (9,618,648) Borrowings — (7,930) ​ (13,170) Inflation tax adjustment ​ (2,682,172) ​ (2,032,078) ​ (1,706,092) Allowances ​ (78,076) ​ (209,490) ​ (152,159) Inventories ​ (1,821,524) ​ (237,258) ​ (153,563) Biological assets ​ (229,296) ​ — ​ — Government grants ​ (3,179) ​ (3,939) ​ — Others financial assets ​ (276,800) ​ — ​ — Right-of-use leased asset ​ (32,651) ​ — ​ — Others (4,098) (4,993) ​ — Total deferred tax liabilities (28,384,713) (18,700,682) ​ (21,101,871) ​ ​ ​ ​ ​ ​ ​ Net deferred tax (22,421,125) (14,164,930) ​ (17,358,162) ​ The roll forward of deferred tax assets and liabilities as of June 30, 2021, 2020 and 2019 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ from ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income ​ deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ Additions for ​ tax ​ tax ​ Charge ​ Conversion ​ Balance Deferred tax assets ​ 06/30/2020 ​ business combination ​ provision ​ liabilities ​ to OCI ​ difference ​ 06/30/2021 Tax Loss-Carry Forward 2,362,657 — 982,329 — — (118,681) 3,226,305 Changes in fair value of financial assets or liabilities 41,183 — 51,037 — — (2,646) 89,574 Trade receivables 1,068,054 — 138,438 — — (596,579) 609,913 Royalties 245,140 — 214,493 — — 25,793 485,426 Right-of-use leased asset 5,424 — (38,793) 32,651 — 718 — Others 813,294 370,556 (427,433) — — 795,953 1,552,370 Total deferred tax assets 4,535,752 370,556 920,071 32,651 — 104,558 5,963,588 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ Additions ​ Income ​ from ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ for business ​ tax ​ deferred tax ​ Charge to ​ Conversion ​ Balance Deferred tax liabilities ​ 06/30/2020 ​ combination ​ provision ​ assets ​ OCI ​ difference ​ 06/30/2021 Intangible assets (6,839,112) (882,434) (2,188,663) — — (714,412) (10,624,621) Property, plant and equipment depreciation (9,365,882) (537,922) (357,614) — (1,388,022) (982,856) (12,632,296) Borrowings (7,930) — 8,797 — — (867) — Inflation tax adjustment (2,032,078) 73,755 (527,654) — — (196,195) (2,682,172) Allowances (209,490) 201,969 (46,622) — — (23,933) (78,076) Inventories (237,258) (3,546) (1,561,687) — — (19,033) (1,821,524) Biological assets — — (229,296) — — — (229,296) Government grants (3,939) — 1,174 — — (414) (3,179) Others financial assets — — (277,841) — — 1,041 (276,800) Right-of-use leased asset — — — (32,651) — — (32,651) Others (4,993) — 1,423 — — (528) (4,098) Total deferred tax liabilities (18,700,682) (1,148,178) (5,177,983) (32,651) (1,388,022) (1,937,197) (28,384,713) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax (14,164,930) (777,622) (4,257,912) — (1,388,022) (1,832,639) (22,421,125) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ from ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income ​ deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ tax ​ tax ​ Charge ​ Conversion ​ Balance Deferred tax assets 06/30/2019 provision liabilities to OCI difference 06/30/2020 Tax Loss-Carry Forward 2,663,813 (133,346) — — (167,810) 2,362,657 Changes in fair value of financial assets or liabilities 32,062 20,222 — — (11,101) 41,183 Trade receivables 374,425 764,707 — — (71,078) 1,068,054 Goverment grants 2,649 (6,216) 3,939 — (372) — Royalties ​ — ​ 245,140 ​ — ​ — ​ — ​ 245,140 Right-of-use leased asset ​ — ​ 5,676 ​ — ​ — ​ (252) ​ 5,424 Others 670,760 263,407 — — (120,873) 813,294 Total deferred tax assets 3,743,709 1,159,590 3,939 — (371,486) 4,535,752 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ from ​ ​ ​ ​ ​ ​ Income deferred ​ ​ ​ ​ ​ ​ ​ Balance tax ​ tax Charge ​ Conversion ​ Balance Deferred tax liabilities 06/30/2019 provision assets to OCI difference 06/30/2020 Intangible assets (9,458,239) 1,469,311 — — 1,149,816 (6,839,112) Property, plant and equipment depreciation (9,618,648) 45,028 — (1,133,228) 1,340,966 (9,365,882) Borrowings (13,170) 3,548 — — 1,692 (7,930) Inflation tax adjustment (1,706,092) (589,811) — — 263,825 (2,032,078) Allowances ​ (152,159) ​ (84,515) ​ — ​ — ​ 27,184 ​ (209,490) Inventories ​ (153,563) ​ (110,152) ​ — ​ — ​ 26,457 ​ (237,258) Goverment grants ​ — ​ — ​ (3,939) ​ — ​ — ​ (3,939) Others — (4,993) — — — (4,993) Total deferred tax liabilities (21,101,871) 728,416 (3,939) (1,133,228) 2,809,940 (18,700,682) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax (17,358,162) 1,888,006 — (1,133,228) 2,438,454 (14,164,930) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition ​ ​ ​ from ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ of control ​ Income ​ deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ of Semya ​ tax ​ tax ​ Charge ​ Conversion ​ Balance Deferred tax assets 06/30/2018 S.A. provision liabilities to OCI difference 06/30/2019 Tax Loss-Carry Forward 3,638,269 113,289 (1,306,198) — — 218,453 2,663,813 Changes in fair value of financial assets or liabilities 35,944 25,868 (33,200) — — 3,450 32,062 Trade receivables 462,756 — (114,765) — — 26,434 374,425 Allowances 370,930 — (555,679) 152,159 — 32,590 — Inventories 710,391 — (119,316) 153,563 — (744,638) — Intangible assets 15,098 (482,387) (22,467) 476,174 — 13,582 — Goverment grants 9,360 — (7,262) — — 551 2,649 Others 359,073 — 290,552 — — 21,135 670,760 Total deferred tax assets 5,601,821 (343,230) (1,868,335) 781,896 — (428,443) 3,743,709 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer ​ ​ ​ ​ ​ ​ ​ ​ ​ Adquisition ​ from ​ ​ ​ ​ ​ ​ of control Income deferred ​ ​ ​ ​ ​ ​ ​ ​ Balance of Semya ​ tax tax ​ Charge ​ Conversion ​ Balance Deferred tax liabilities 06/30/2018 S.A. provision assets to OCI difference 06/30/2019 Intangible assets (5,071,808) — (937,962) (476,174) — (2,972,295) (9,458,239) Property, plant and equipment depreciation (8,497,756) — (335,077) — 576,453 (1,362,268) (9,618,648) Borrowings (19,372) — 7,342 — — (1,140) (13,170) Contingencies (2,709) — 2,869 — — (160) — Inflation tax adjustment — — (1,706,092) — — — (1,706,092) Allowances ​ — ​ — ​ — ​ (152,159) ​ — ​ — ​ (152,159) Inventories ​ — ​ — ​ — ​ (153,563) ​ — ​ — ​ (153,563) Others (297) — 314 — — (17) — Total deferred tax liabilities (13,591,942) — (2,968,606) (781,896) 576,453 (4,335,880) (21,101,871) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax ​ (7,990,121) ​ (343,230) ​ (4,836,941) ​ — ​ 576,453 ​ (4,764,323) ​ (17,358,162) ​
Schedule of reconciliation of the statutory tax rate to the effective tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Loss before income tax-rate 0% (17,127,991) (205,022) ​ (21,669,882) Earnings before income tax-rate 21% ​ (2,046,392) ​ 828,074 ​ 1,264 Earnings before income tax-rate 30% ​ 29,704,931 ​ 5,820,286 ​ 12,296,011 Earnings (Loss) before income tax-rate ​ 10,530,548 ​ 6,443,338 ​ (9,372,607) Income tax expense by applying tax rate to profit (loss) before tax (8,481,737) (1,919,981) ​ (3,689,069) Share of profit or loss of subsidiaries, joint ventures and associates 274,877 847,512 ​ (44,721) Stock options charge (58,248) (298,222) ​ 78,681 Rate change adjustment (1,780,962) (144,660) ​ (54,735) Non-deductible expenses (365,350) (84,128) ​ (254,201) Untaxed gains ​ 557,911 ​ — ​ — Representation expenses — (36,691) ​ (136,614) Foreign investment coverage 390,170 551,968 ​ 233,634 Tax provision adjustments ​ 476,890 ​ 307,944 ​ — Tax inflation adjustment ​ (2,182,988) ​ (1,174,964) ​ (941,734) Result of inflation effect on monetary items and other finance results ​ (3,181,733) ​ (255,488) ​ (2,177,525) Income tax expenses (14,351,170) (2,206,710) ​ (6,986,284)
Schedule of Principal statutory taxes rates	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax rate Tax jurisdiction 2021 2020 2019 Argentina 25% - 35 % 30 % 30 % Cayman Island 0 % 0 % 0 % Paraguay ​ 10 % 10 % 10 % Uruguay ​ 25 % 25 % 25 % France ​ 28 % 28 % 28 % Brazil ​ 34 % 34 % 34 % United State of America 21 % 21 % 21 %
Schedule of income tax	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Current tax expense (10,093,258) (4,094,716) (2,149,343) Deferred tax (4,257,912) 1,888,006 (4,836,941) Total (14,351,170) (2,206,710) (6,986,284)
Schedule of carry forward tax losses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fiscal year Tax-Loss Carry forward Tax-Loss Carry forward Prescription Tax jurisdiction 2017 186,545 55,261 2022 Argentina 2018 168,888 49,976 2023 Argentina 2019 206,082 51,520 2024 Argentina 2019 4,258,576 894,301 2039 United States of America 2020 ​ 1,094,530 ​ 273,633 ​ 2025 ​ Argentina 2020 2,845,571 597,570 2040 United States of America 2021 2,961,583 826,643 2026 Argentina 2021 2,161,267 453,866 2041 United States of America Total 13,883,042 3,202,770
Argentina
Income tax and minimum presumed income tax
Schedule of carry forward tax losses	​ ​ ​ ​ ​ ​ Fiscal year Amount Prescription 2014 474 2024 2015 1,003 2025 2016 1,007 2026 Total 2,484

EARNING PER SHARE (Tables)

EARNING PER SHARE (Tables)	12 Months Ended
	Jun. 30, 2021
EARNING PER SHARE
Schedule of earning per share	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Numerator (Loss) profit for the year (basic EPS) (6,870,163) ​ 3,359,175 ​ (18,369,045) (Loss) profit for the year (diluted EPS) (6,870,163) ​ 3,359,175 ​ (18,369,045) Denominator Weighted average number of shares (basic EPS) 39,218,632 ​ 36,120,447 ​ 30,478,390 Weighted average number of shares (diluted EPS) 39,218,632 ​ 36,416,988 ​ 30,478,390 ​ ​ ​ ​ ​ ​ ​ Basic (loss) gain attributable to ordinary equity holders of the parent ​ (0.1752) ​ 0.0930 ​ (0.6027) Diluted (loss) gain attributable to ordinary equity holders of the parent (0.1752) ​ 0.0922 ​ (0.6027)

INFORMATION ABOUT COMPONENTS _6

INFORMATION ABOUT COMPONENTS OF EQUITY (Tables)	12 Months Ended
	Jun. 30, 2021
Disclosure of subsidiaries
Summary of subsidiaries whose non-controlling interest are significant	​ ​ ​ ​ ​ ​ ​ ​ ​ Name 06/30/2021 06/30/2020 06/30/2019 ​ Rizobacter Argentina S.A. ​ 20 % 20 % 20 % Insumos Agroquimicos S.A. ​ 49.9 % — ​ — ​
Rizobacter Argentina
Disclosure of subsidiaries
Summarized financial information	​ ​ ​ ​ ​ ​ ​ ​ Summary financial statements: 06/30/2021 06/30/2020 06/30/2019 Current assets 175,827,504 148,256,827 115,546,951 Non-current assets 59,868,513 49,843,457 47,418,450 Total assets 235,696,017 198,100,284 162,965,401 ​ ​ ​ ​ ​ ​ ​ Current liabilities 119,966,445 129,838,941 100,590,919 Non-current liabilities 57,480,984 32,935,399 34,788,705 Total liabilities 177,447,429 162,774,340 135,379,624 ​ ​ ​ ​ ​ ​ ​ Equity attributable to controlling interest 58,246,057 35,324,227 27,584,666 Equity attributable to non-controlling interest 2,531 1,717 1,111 Total equity 58,248,588 35,325,944 27,585,777 ​ ​ ​ ​ ​ ​ ​ Total liabilities and equity 235,696,017 198,100,284 162,965,401 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Summary statements of comprehensive income or loss 06/30/2021 06/30/2021 06/30/2019 Revenues 189,749,478 ​ 162,404,866 ​ 156,741,933 Initial recognition and changes in the fair value of biological assets 1,552,746 ​ 716,741 ​ — Cost of sales ​ (106,636,141) ​ (86,533,561) ​ (85,287,771) Gross margin 84,666,083 ​ 76,588,046 ​ 71,454,162 ​ ​ ​ ​ ​ ​ ​ Research and development expenses (3,208,904) ​ (2,689,468) ​ (2,367,727) Selling, general and administrative expenses (37,500,952) ​ (36,103,289) ​ (31,316,843) Share of profit or loss of joint ventures and associates 481,442 ​ 1,960,549 ​ 1,071,297 Other income 507,246 ​ (380,871) ​ 286,626 Operating profit 44,944,915 ​ 39,374,967 ​ 39,127,515 ​ ​ ​ ​ ​ ​ ​ Financial results (11,032,748) ​ (30,014,131) ​ (24,650,359) Profit before taxes 33,912,167 ​ 9,360,836 ​ 14,477,156 ​ ​ ​ ​ ​ ​ ​ Income tax expense (14,141,515) ​ (3,830,106) ​ (7,729,300) Result for the year 19,770,652 ​ 5,530,730 ​ 6,747,856 ​ ​ ​ ​ ​ ​ ​ Exchange differences on translation of foreign operations 1,704,590 ​ 1,281,974 ​ 17,197 Revaluation of property, plant and equipment, net of tax (2,682,457) ​ 3,921,091 ​ (1,347,124) Total comprehensive result 18,792,785 ​ 10,733,795 ​ 5,417,929
Insumos Agroquimicos S.A.
Disclosure of subsidiaries
Summarized financial information	​ ​ ​ ​ Summary statements of comprehensive income or loss (1) ​ ​ 06/30/2021 Revenues 7,600,041 Cost of sales (5,886,326) Gross margin 1,713,715 ​ ​ ​ Selling, general and administrative expenses (1,065,147) Other income or expenses, net 18,305 Operating profit 666,873 ​ ​ ​ Financial results (961,635) Loss before tax (294,762) Income tax 127,876 Loss for the period (166,886) ​ ​ ​ Exchange differences on translation of foreign operations 180,519 Total comprehensive result 13,633 ​ (1) Results from 9th April 2021, the date of the acquisition of Insuagro. See note 6.

CASH FLOW INFORMATION (Tables)

CASH FLOW INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2021
CASH FLOW INFORMATION
Schedule of significant non-cash transactions related to investing and financing activities	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Investment activities ​ ​ ​ ​ ​ ​ Settlement of liability with loan to joint venture (1) ​ — ​ — ​ 6,964,101 Net assets acquisition by business combination (2) (Note 6) ​ 6,612,410 ​ — ​ — Settlement of receivables through PPE contribution ​ 2,164,156 ​ — ​ — Investment in-kind in other related parties (Note 17) 714,359 ​ 476,292 ​ 463,511 Arcadia asset acquisition financed by debt (Note 6) ​ 7,637,972 ​ — ​ — Arcadia asset acquisition through issuance of capital (Note 6) ​ 15,000,000 ​ — ​ — Non-monetary contributions in joint ventures and associates (Note 13) ​ 2,931,699 ​ 250,000 ​ 94,355 ​ 35,060,596 ​ 726,292 ​ 7,521,967 ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Financing activities Purchase option paid by a parent loan — — (1,265,000) Consideration for acquisition ​ (2,625,335) ​ — ​ — Parent company investment — — (14,558,347) Capitalization of financial debt — — 13,720,000 Reverse recapitalization — — (3,688,963) Net assets incorporated of Semya (3) ​ — ​ — ​ 7,369,168 Acquisition of control of Semya — — (3,684,585) ​ (2,625,335) — (2,107,727) ​ (1) (2) ​ ​ ​ ​ Balance sheet as of March 31, 2021 Total Current assets Cash and equivalents 555,804 Other current assets 24,981,656 Non-current assets Deferred tax 106,952 Other financial assets 719,772 Intangibles 2,923,897 Property, plant and equipment 1,952,045 Total assets 31,240,126 ​ ​ ​ Current liabilities Trade payables and other payables 17,814,395 Borrowings 5,749,928 Deferred tax 884,574 Non-current liabilities Borrowings 178,820 Total liabilities 24,627,717 ​ ​ ​ Total equity 6,612,409 ​ (3) As a result of the Share purchase agreement between Bioceres Crop Solutions and Bioceres S.A. (see Note 6), the Group incorporated the following assets and liabilities: ​ ​ ​ ​ Balance sheet as of May 31, 2019 Total Current assets 67,924 Non-current assets Tax credits 253,655 Intangibles 2,147,199 Goodwill 5,836,268 Total assets 8,305,046 ​ ​ ​ Current liabilities Trade payables 273,442 Borrowings 114,568 Non-current liabilities Deferred tax 547,868 Total liabilities 935,878 ​ ​ ​ Total equity 7,369,168 ​
Schedule of assets and liabilities incorporated as a result of the Share purchase agreement between Bioceres Crop Solutions and Bioceres S.A.	​ ​ ​ ​ Balance sheet as of May 31, 2019 Total Current assets 67,924 Non-current assets Tax credits 253,655 Intangibles 2,147,199 Goodwill 5,836,268 Total assets 8,305,046 ​ ​ ​ Current liabilities Trade payables 273,442 Borrowings 114,568 Non-current liabilities Deferred tax 547,868 Total liabilities 935,878 ​ ​ ​ Total equity 7,369,168
Schedule of changes in liabilities arising from financing activities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing activities ​ ​ Consideration Convertible ​ ​ ​ Borrowings ​ for acquisitions ​ notes ​ Total As of June 30, 2018 91,017,133 22,874,609 — 113,891,742 Proceeds from borrowings 88,693,632 — — 88,693,632 Decrease bank overdraft and other short-term borrowings (4,968,813) — — (4,968,813) Payments (83,777,814) (7,140,000) — (90,917,814) Capitalization of financial debt — (13,720,000) — (13,720,000) Interest payment (20,167,101) — — (20,167,101) Exchange differences and currency translation differences 32,759,693 1,264,656 — 34,024,349 As of June 30, 2019 103,556,730 3,279,265 — 106,835,995 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing activities ​ ​ ​ ​ Consideration ​ Convertible ​ ​ ​ Borrowings for acquisitions notes Total As of June 30, 2019 103,556,730 3,279,265 ​ — 106,835,995 Proceeds 93,273,502 — ​ 42,075,000 135,348,502 Decrease bank overdraft and other short-term borrowings ​ (2,331,974) ​ — ​ — ​ (2,331,974) Payments (76,846,934) (2,937,500) ​ — (79,784,434) Interest payment (21,533,187) — ​ — (21,533,187) Exchange differences, currency translation differences and other financial results 8,830,208 110,889 ​ 954,834 9,895,931 As of June 30, 2020 104,948,345 452,654 ​ 43,029,834 148,430,833 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing activities ​ ​ ​ ​ Consideration ​ Convertible ​ ​ ​ Borrowings for acquisition notes Total As of June 30, 2020 ​ 104,948,345 ​ 452,654 ​ 43,029,834 ​ 148,430,833 Proceeds 143,499,367 — — 143,499,367 Decrease bank overdraft and other short-term borrowings (3,442,491) — — (3,442,491) Payments (113,100,032) — — (113,100,032) Financing for assets acquisitions — 11,214,929 — 11,214,929 Debt incorporated by business combination 5,928,748 — — 5,928,748 Interest payment (12,923,745) — — (12,923,745) Exchange differences, currency translation differences and other financial results (135,867) 122,950 5,634,178 5,621,261 As of June 30, 2021 124,774,325 11,790,533 48,664,012 185,228,870

JOINT VENTURES AND ASSOCIATES (

JOINT VENTURES AND ASSOCIATES (Tables)	12 Months Ended
	Jun. 30, 2021
JOINT VENTURES AND ASSOCIATES
Schedule of investments in joint ventures and affiliates	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Assets ​ ​ ​ ​ ​ ​ Synertech Industrias S.A. 27,572,597 24,619,773 25,297,376 Indrasa Biotecnología S.A. 54,957 33,019 23,652 Alfalfa Technologies S.R.L. ​ 97,920 ​ — ​ — Moolec Science Limited (Note 6) ​ 2,931,699 ​ — ​ — ​ 30,657,173 24,652,792 25,321,028 ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Liabilities Trigall Genetics S.A. 1,278,250 1,548,829 1,970,903 ​ 1,278,250 1,548,829 1,970,903
Schedule of changes in joint ventures investments and affiliates	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 As of the beginning of the year 23,103,963 23,350,125 ​ 17,059,757 Adjustment of opening net book amount for the application of IAS 29 — — ​ 8,328,794 Monetary contributions 101,883 — ​ 129,340 Non-monetary contributions (Note 6) 2,931,699 250,000 ​ 94,355 Parent company investment — — ​ 294,041 Loss of control of Indrasa Biotecnología S.A. — — ​ 10,591 Acquisition of control of Semya S.A. — — ​ (3,684,585) Revaluation of property, plant and equipment (413,618) 521,406 ​ 94,009 Foreign currency translation 2,657,567 ​ (3,494,761) ​ 11,337 Share of profit or loss 997,429 ​ 2,477,193 ​ 1,012,486 As of the end of the year 29,378,923 ​ 23,103,963 ​ 23,350,125
Schedule of share of profit or loss of joint ventures and affiliates	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Trigall Genetics S.A. 270,579 ​ 171,502 ​ (2,647) Bioceres Crops S.A. — ​ — ​ (22,895) Synertech Industrias S.A. 708,550 ​ 2,294,332 ​ 1,034,818 Indrasa Biotecnología S.A. 18,300 ​ 11,359 ​ 3,210 ​ 997,429 ​ 2,477,193 ​ 1,012,486
Schedule of summarized balance sheet of joint venture prepared in accordance with International Financial Reporting Standards ("IFRS")	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trigall Genetics Summarised balance sheet 06/30/2021 06/30/2020 06/30/2019 Current assets ​ ​ ​ ​ ​ ​ Cash and cash equivalents 13,798 1,331 13,114 Other current assets 1,949,590 1,024,793 323,265 Total current assets 1,963,388 1,026,124 336,379 Non-current assets ​ ​ ​ Intangible assests 13,335,653 11,776,705 10,214,575 Total non-current assets 13,335,653 11,776,705 10,214,575 Current liabilities ​ ​ ​ Financial liabilities — — 9,476,272 Other current liabilities 1,257,070 869,700 1,016,083 Total current liabilities 1,257,070 869,700 10,492,355 Non-current liabilities ​ ​ ​ Financial liabilities ​ 12,184,030 ​ 10,831,048 ​ — Other non- current liabilities 1,000,774 831,685 460,268 Total non-current liabilities 13,184,804 11,662,733 460,268 Net assets 857,167 270,396 (401,669) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Synertech Summarised balance sheet 06/30/2021 06/30/2020 06/30/2019 Current assets ​ Cash and cash equivalents 540,149 18,251 40,634 Other current assets 17,274,878 17,983,868 5,709,650 Total current assets 17,815,027 18,002,119 5,750,284 Non-current assets ​ ​ ​ Property,plan and equipment 13,422,832 14,168,459 15,046,903 Other non- current assets 39,171 — — Total non-current assets 13,462,003 14,168,459 15,046,903 Current liabilities ​ ​ ​ Financial liabilities 1,346,327 5,484,866 921,703 Other current liabilities 6,807,330 4,719,276 4,595,906 Total current liabilities 8,153,657 10,204,142 5,517,609 Non-current liabilities ​ ​ ​ Financial liabilities 331,306 2,783,951 — Other non- current liabilities 4,119,471 2,554,905 3,974,975 Total non-current liabilities 4,450,777 5,338,856 3,974,975 Net assets 18,672,596 16,627,580 11,304,603
Schedule of summarized statements of comprehensive income of joint venture prepared in accordance with International Financial Reporting Standards ("IFRS")	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trigall Genetics Summarised statements of comprenhensive income 06/30/2021 06/30/2020 06/30/2019 Revenue 1,110,303 799,625 367,646 Finance income 22,470 79,442 54,003 Finance expense (3,586) (1,863) (16,145) Depreciation and amortization ​ — ​ — ​ — Profit (loss) of the year 586,773 172,670 (33,195) Other comprenhensive income — — — Total comprenhensive income (loss) 586,773 172,670 (33,195) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Synertech Summarised statements of comprenhensive income 06/30/2021 06/30/2020 06/30/2019 Revenue 23,759,744 21,501,725 18,305,953 Finance income 5,584,007 3,805,655 2,434,610 Finance expense (6,283,955) (6,666,508) (6,193,963) Depreciation and amortization (39,171) (1,076,699) (1,074,552) Profit of the year 1,776,244 5,099,852 2,278,859 Other comprenhensive (loss) income (827,236) 1,042,811 334,403 Total comprenhensive income 949,008 6,142,663 2,613,262

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2021
SEGMENT INFORMATION
Schedule of operating results of the Group's reporting segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Seed and ​ ​ ​ ​ ​ integrated ​ Crop ​ Crop ​ ​ ​ Year ended June 30, 2021 ​ products ​ protection ​ nutrition ​ Consolidated ​ Revenues from contracts with customers ​ Sale of goods and services 31,398,592 113,508,465 59,767,015 204,674,072 ​ Royalties 2,023,548 — 2,023,548 ​ Others ​ Government grants 2,302 — — 2,302 ​ Initial recognition and changes in the fair value of biological assets 1,394,127 606,269 825,859 2,826,255 ​ Total 34,818,569 114,114,734 60,592,874 209,526,177 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales (12,931,763) (75,138,491) (30,571,549) (118,641,803) ​ Gross margin per segment 21,886,806 38,976,243 30,021,325 90,884,374 ​ % ​ 63 % 34 % 50 % 43 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Seed and ​ ​ ​ ​ integrated Crop Crop ​ ​ ​ Year ended June 30, 2020 products ​ protection ​ nutrition ​ Consolidated ​ Revenues from contracts with customers ​ ​ ​ ​ ​ ​ ​ ​ ​ Sale of goods and services 27,626,542 93,799,477 49,148,890 170,574,909 ​ Royalties 1,775,790 — — 1,775,790 ​ Others ​ ​ ​ ​ ​ ​ ​ ​ ​ Government grants ​ 24,732 ​ — ​ — ​ 24,732 ​ Initial recognition and changes in the fair value of biological assets 41,755 418,712 256,274 716,741 ​ Total 29,468,819 94,218,189 49,405,164 173,092,172 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales (11,581,494) (53,552,327) (28,441,767) (93,575,588) ​ Gross margin per segment 17,887,325 40,665,862 20,963,397 79,516,584 ​ % of Segment Revenue ​ 61 % 43 % 42 % 46 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Seed and ​ ​ ​ ​ integrated Crop Crop ​ ​ ​ Year ended June 30, 2019 products ​ protection ​ nutrition ​ Consolidated ​ Revenues from contracts with customers ​ ​ ​ ​ ​ ​ ​ ​ ​ Sale of goods and services 24,185,292 89,919,460 45,093,764 159,198,516 ​ Royalties 1,110,463 — — 1,110,463 ​ Others ​ ​ ​ ​ ​ Goverment Grants 16,372 — — 16,372 ​ Initial recognition and changes in the fair value of biological assets. ​ — ​ 279,945 ​ — ​ 279,945 ​ Total 25,312,127 90,199,405 45,093,764 160,605,296 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales (9,783,737) (53,979,391) (23,201,753) (86,964,881) ​ Gross margin per segment 15,528,390 36,220,014 21,892,011 73,640,415 ​ % ​ 61 % 40 % 49 % 46 %
Schedule of revenue by similar group of products or services	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Seed and integrated products 33,422,140 29,402,332 25,295,755 Seeds, royalties & licenses 6,246,689 5,210,616 3,846,991 Packs 27,175,451 24,191,716 21,448,764 ​ ​ ​ ​ ​ ​ ​ Crop protection 113,508,465 93,799,477 89,919,460 Adjuvants 50,062,012 45,372,840 41,854,730 Insecticides & fungicides 18,231,616 15,227,357 12,655,985 Other 45,214,837 33,199,280 35,408,745 ​ ​ ​ ​ ​ ​ ​ Crop nutrition 59,767,015 49,148,890 45,093,764 Inoculants 16,485,064 16,718,571 18,644,673 Fertilizers 43,281,951 32,430,319 26,449,091 ​ ​ ​ ​ ​ ​ ​ Total revenues ​ 206,697,620 ​ 172,350,699 ​ 160,308,979
Schedule of geographical information	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Argentina 157,352,242 130,918,908 124,011,642 Bolivia 3,707,107 2,982,953 2,494,216 Brazil 24,591,539 21,188,655 17,338,608 United States of America 2,504,696 1,515,185 2,562,376 Paraguay 5,369,912 4,428,078 2,506,348 South Africa 2,789,322 1,927,333 3,019,474 France 4,269,368 911,140 711,522 Uruguay 5,752,913 6,234,956 4,684,854 Rest of the world 360,521 2,243,491 2,979,939 Total revenues 206,697,620 172,350,699 160,308,979 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Non-current assets ​ ​ ​ ​ ​ ​ Argentina 107,077,660 93,682,114 106,056,232 Cayman Islands ​ 24,837,572 ​ — ​ — United States 7,799,448 7,168,376 6,136,461 Paraguay 742,767 714,011 722,914 Brazil 3,460,634 685,587 305,477 Bolivia 33,090 15,588 27,487 South Africa 3,892 598 7,080 India ​ — — 38 Francia ​ 26,138 ​ 33,556 ​ — Colombia ​ 18,461 ​ 22,313 ​ — Uruguay ​ 48,502 ​ 53,282 ​ — Total non-current assets 144,048,164 ​ 102,375,425 ​ 113,255,689 ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment ​ 47,954,596 ​ 41,515,106 ​ 43,834,548 Intangible assets ​ 67,342,362 ​ 35,333,464 ​ 39,616,426 Goodwill ​ 28,751,206 ​ 25,526,855 ​ 29,804,715 Total reportable assets ​ 144,048,164 ​ 102,375,425 ​ 113,255,689 Total non-reportable assets ​ 250,541,793 ​ 195,185,944 ​ 129,211,608 Total assets ​ 394,589,957 ​ 297,561,369 ​ 242,467,297

FINANCIAL INSTRUMENTS - RISK _2

FINANCIAL INSTRUMENTS - RISK MANAGEMENT (Tables)	12 Months Ended
	Jun. 30, 2021
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of financial assets by category	Financial assets by category ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Mandatorily measured at fair ​ ​ Amortized cost ​ value through profit or loss Financial asset 06/30/2021 06/30/2020 06/30/2019 06/30/2021 06/30/2020 06/30/2019 Cash and cash equivalents 28,327,569 20,176,452 3,450,873 7,718,544 22,346,409 — Other financial assets 1,523,438 4,713,161 4,703,688 10,735,422 9,045,935 356,233 Trade receivables 88,919,911 73,546,633 59,236,377 — — — Other receivables (*) 5,005,283 3,349,901 1,566,732 — — — Total 123,776,201 101,786,147 68,957,670 18,453,966 31,392,344 356,233 ​ (*) Advances expenses and tax balances are not included.
Schedule financial liabilities by category	Financial liabilities by category ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Mandatorily measured at fair ​ ​ Amortized cost ​ value through profit or loss Financial liability 06/30/2021 06/30/2020 06/30/2019 06/30/2021 06/30/2020 06/30/2019 Trade and other payables 72,091,408 57,289,862 40,578,494 — — — Borrowings 124,774,325 104,948,345 103,556,730 — — — Convertible notes ​ 48,664,012 ​ 43,029,834 ​ — ​ — ​ — ​ — Lease liability ​ 1,140,717 ​ 1,109,812 ​ — ​ — ​ — ​ — Employee benefits and social security 4,680,078 5,044,630 5,357,218 — — — Consideration for acquisition of assets ​ 11,790,533 ​ 452,654 ​ 3,279,265 ​ — ​ — ​ — Warrants — — — — 1,686,643 2,861,511 Total 263,141,073 211,875,137 152,771,707 — 1,686,643 2,861,511
Schedule of fair value by hierarchy	​ ​ ​ ​ ​ ​ ​ ​ Measurement at fair value at 06/30/2021 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ Financial assets at fair value ​ ​ ​ ​ ​ ​ Mutual funds ​ 7,718,544 ​ — ​ — US Treasury bills ​ 7,885,937 ​ — ​ — Other investments ​ 2,110,414 ​ 739,071 ​ — ​ ​ ​ ​ ​ ​ ​ Measurement at fair value at 06/30/2020 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ Financial assets at fair value ​ ​ ​ ​ ​ ​ Mutual funds ​ 22,346,409 ​ — ​ — US Treasury bills 7,768,410 — — Other investments ​ 1,176,977 ​ 100,548 ​ — ​ ​ ​ ​ ​ ​ ​ Financial liabilities valued at fair value ​ ​ ​ ​ ​ ​ Private warrants — — 1,686,643 ​ ​ ​ ​ ​ ​ ​ Measurement at fair value at 06/30/2019 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ Financial assets at fair value ​ ​ Other investments 356,233 — — ​ ​ ​ ​ ​ ​ ​ Financial liabilities valued at fair value ​ ​ ​ ​ ​ ​ Private warrants ​ — ​ — ​ 2,861,511
Schedule of changes in financial liabilities valued at fair value level 3	​ ​ ​ ​ ​ ​ 06/30/2020 As of the beginning of the year ​ 2,861,511 Changes in finance results(1) ​ (1,174,868) As of the end of the year ​ 1,686,643 ​ (1) The amount of the change in fair value for the year ended June 30,2020 is recognized in “Changes in fair value of financial assets or liabilities and other financial results”. See Note 8.5.
Schedule of contractual maturities of financial liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Between one ​ Between ​ ​ ​ ​ Up to 3 ​ 3 to 12 ​ and three ​ three and ​ Subsequent As of June 30, 2021 months months years five years years Trade and other payables 17,379,825 44,023,803 9,266 — — Borrowings ​ 26,399,791 ​ 57,195,372 ​ 53,290,976 ​ — ​ — Convertible notes — — 48,664,012 — — Leasing liabilities 374,642 2,154,835 755,932 — — Total 44,154,258 103,374,010 102,720,186 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Between one Between ​ ​ ​ Up to 3 ​ 3 to 12 ​ and three ​ three and ​ Subsequent As of June 30, 2020 ​ months ​ months ​ years ​ five years ​ years Trade and other payables 28,150,681 29,130,428 463,568 — — Borrowings 35,863,852 34,810,916 43,799,397 — — Convertible notes — — 43,029,834 — — Leasing liabilities ​ 196,717 ​ 625,463 ​ 483,725 ​ — ​ — Total 64,211,250 64,566,807 87,776,524 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Between one Between ​ ​ ​ Up to 3 ​ 3 to 12 ​ and three ​ three and ​ Subsequent As of June 30, 2019 ​ months ​ months ​ years ​ five years ​ years Trade and other payables 12,854,579 28,987,009 476,482 — — Borrowings 29,051,271 40,097,864 38,524,384 — — Financed payment - Acquisition of business — 2,937,500 — — — Total 41,905,850 72,022,373 39,000,866 — —
Credit risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of loss allowances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross carrying ​ ​ ​ ​ ​ ​ amount-trade ​ Expected Loss ​ Loss ​ receivables rate allowance Current 78,286,114 ​ 0.21 % 161,963 More than 15 days past due ​ 2,192,641 ​ 0.21 % 4,536 More than 30 days past due 1,145,112 0.21 % 2,369 More than 60 days past due ​ 2,396,153 ​ 0.24 % 5,796 More than 90 days past due ​ 3,031,050 ​ 0.25 % 7,719 More than 120 days past due ​ 1,174,948 ​ 0.39 % 4,589 More than 180 days past due ​ 756,820 ​ 0.21 % 1,587 More than 365 days past due ​ 5,659,837 ​ 100 % 5,659,837 IAS 29 effect and Currency conversion ​ — ​ ​ ​ 10,107 Total 06/30/2021 94,642,675 ​ ​ 5,858,503
Currency Risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of net exposure	​ ​ ​ ​ ​ ​ ​ ​ Net foreign currency position 06/30/2021 06/30/2020 06/30/2019 Amount expressed in US$ (50,608,592) (52,968,976) (40,513,954)
Interest Rate Risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of net exposure	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 ​ ​ Carrying ​ Carrying ​ Carrying ​ ​ amount ​ amount ​ amount Fixed-rate instruments Current financial liabilities (73,125,807) (62,490,975) (69,126,607) Non-current financial liabilities (108,236,265) (84,253,034) (37,459,235) ​ ​ ​ ​ ​ ​ ​ Variable-rate instruments ​ ​ ​ Current financial liabilities (3,660,050) (1,230,760) (177,213) Non-current financial liabilities (206,748) (456,064) (72,940)

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Jun. 30, 2021
LEASES
Reconciliation of right of use leased assets and lease liability from beginning of year to end of year	​ ​ ​ ​ ​ ​ Right-of-use leased asset 06/30/2021 06/30/2020 Cost ​ ​ Book value at the beginning of the year 2,369,326 ​ — Additions for initial application of IFRS 16 — ​ 1,523,177 Additions of the year 913,321 ​ 846,149 Exchange differences ​ 405,503 ​ — Book value at the end of the year 3,688,150 ​ 2,369,326 ​ ​ ​ ​ ​ Depreciation 06/30/2021 ​ 06/30/2020 Book value at the beginning of the year ​ 1,254,729 ​ — Additions for initial application of IFRS 16 — ​ 759,045 Exchange differences 278,441 ​ (78,213) Depreciation of the year 827,320 ​ 573,897 Accumulated depreciation at the end of the year 2,360,490 ​ 1,254,729 Total 1,327,660 ​ 1,114,597 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liability 06/30/2021 ​ 06/30/2020 Book value at the beginning of the year 1,109,812 ​ — Additions for initial application of IFRS 16 — ​ 1,523,177 Additions of the year 259,427 ​ 702,826 Interest expenses, exchange differences and inflation effects 500,442 ​ (551,232) Payments of the year (728,964) ​ (564,959) Total 1,140,717 ​ 1,109,812 ​ ​ ​ ​ ​ Lease Liabilities 06/30/2021 ​ 06/30/2020 Non-current 390,409 ​ 444,714 Current 750,308 ​ 665,098 Total 1,140,717 ​ 1,109,812
Schedule of right-of-use leased assets	​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 Machinery and equipment 661,544 ​ 598,561 Vehicles 1,061,184 ​ 264,069 Equipment and computer software 582,101 ​ 407,546 Land and buildings 1,383,321 ​ 1,099,150 ​ 3,688,150 ​ 2,369,326

SHAREHOLDERS AND OTHER RELATE_2

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Jun. 30, 2021
SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS
Schedule of transactions between the group and related parties, and the related balances owed	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of the transactions of the year ended Party Transaction type 06/30/2021 06/30/2020 06/30/2019 Joint ventures and associates Sales and services 9,404,716 6,139,155 4,913,254 Joint ventures and associates Purchases of goods and services (23,395,323) (21,634,936) (17,542,637) Joint ventures and associates Equity contributions 3,033,582 250,000 517,736 Joint ventures and associates Net loans granted — — (6,964,101) Key management personnel Salaries, social security benefits and other benefits (3,376,292) (5,333,469) (3,940,185) Key management personnel Net loans cancelled 664,398 — 599,984 Key management personnel Interest gain 9,782 44,619 20,106 Shareholders and other related parties Sales of goods and services 572,110 1,871,613 640,095 Shareholders and other related parties Purchases of goods and services (3,092,506) (1,881,013) (1,433,127) Shareholders and other related parties In-kind contributions 714,359 476,292 463,511 Parents companies and related parties to Parents (Note 7.5) Interest expenses (1,219,776) (1,861,774) (1,386,288) Parents companies and related parties to Parents (Note 7.5) Net loans cancelled (101,241) — — Parent company Purchases of goods and services — (92) (120,095) Parent company Equity contributions — — (14,558,347) Total (16,786,191) (21,929,605) (38,790,094) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts receivable from related parties Party Transaction type 06/30/2021 06/30/2020 06/30/2019 Parent company ​ Trade debtors ​ — ​ — ​ 440,268 Parents companies and related parties to Parents Other receivables 770,549 102,069 — Shareholders and other related parties Trade debtors — 1,090,004 467,743 Shareholders and other related parties Allowance for impairment — (768) (75,596) Other receivables - Other related parties Other receivables 134,172 83,839 10,971 Joint ventures and associates Trade debtors 221,048 120,992 2,369 Joint ventures and associates Other receivables 2,219,863 1,562,340 250,783 Total ​ ​ 3,345,632 2,958,476 1,096,538 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts payable to related parties Party Transaction type 06/30/2021 06/30/2020 06/30/2019 Parent company ​ Trade creditors ​ (193,718) ​ (2,210,308) ​ (1,568,036) Parents companies and related parties to Parents ​ Net loans payables ​ (9,578,921) ​ (12,389,521) ​ (17,757,907) Key management personnel Salaries, social security benefits and other benefits (2,338,727) (2,084,088) (2,312,253) Shareholders and other related parties Trade and other payables (52,864) (1,031,710) (1,796,932) Joint ventures and associates Trade creditors (17,669,027) (14,409,853) (4,805,149) Total ​ ​ (29,833,257) (32,125,480) (28,240,277)

KEY MANAGEMENT PERSONNEL COMP_2

KEY MANAGEMENT PERSONNEL COMPENSATION (Tables)	12 Months Ended
	Jun. 30, 2021
KEY MANAGEMENT PERSONNEL COMPENSATION
Schedule of compensation of directors and other members of key management personnel	​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 06/30/2020 06/30/2019 Salaries, social security and other benefits 1,721,157 1,905,440 3,940,185 Share-based incentives ​ 1,655,135 ​ 3,428,029 ​ — Total 3,376,292 5,333,469 3,940,185

SHARE-BASED PAYMENT (Tables)

SHARE-BASED PAYMENT (Tables)	12 Months Ended
	Jun. 30, 2021
SHARE-BASED PAYMENT
Schedule of assumptions in the estimated fair value of stock options	​ ​ ​ ​ Factor Incentive option plan Weighted average fair value of shares $5.42 Exercise price $4.55 Weighted average expected volatility 29.69% Dividend rate 0% Weighted average risk-free interest rate 1.66% Weighted average expected life 9.89 years Weighted average fair value of stock options at measurement date $2.47
Schedule of weighted average amount and exercise price and the movements of the stock options of executives and directors	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 06/30/2021 ​ 06/30/2020 ​ 06/30/2019 ​ Number of ​ Exercise Number of ​ Exercise Number of Exercise ​ ​ options ​ ​ price ​ options ​ ​ price ​ options ​ price At the beginning 1,200,000 $ 4.55 — ​ — — — Granted during the year — ​ — 1,200,000 $ 4.55 — — Annulled during the year — ​ — — ​ — — — Exercised during the year 33,333 $ 15.09 — ​ — — — Expired during the year — ​ — — ​ — — — Effective at year 1,166,667 $ 4.55 — ​ — — —
Schedule of assumptions in the estimated fair value of bonus performance shares granted	​ ​ ​ ​ ​ ​ Factor Bonus in performance Stock price at the grant date $5.42 $5.42 Exercise Price $10.5 $21.0 Weighted average expected volatility 24.78% ​ 24.78% Dividend rate 0% ​ 0% Weighted average risk-free interest rate 1.52% ​ 1.52% Weighted average expected life 2.63 years 2.63 years Weighted average fair value of stock at measurement date $0.479 $0.005

CONTINGENCIES, COMMITMENTS AN_2

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS (Tables)	12 Months Ended
	Jun. 30, 2021
CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS
Schedule of pledged and restricted assets	​ ​ ​ ​ ​ ​ Detail Asset value Type of restriction IT equipment 99,990 Leasing Vehicles 78,833 Leasing Compass Latam & Odisea ​ 16,016,733 ​ Security Collateral and Mortgage (a) Allaria Ledesma & Cía. ​ 9,395,976 ​ US Treasury bills (b) Cohen S.A. 789,458 US Treasury bills (c) Other financial assets ​ 13,032 ​ Argentina Treasury bills Totals 26,394,022 ​ a) In April 2019, the Group issued Private corporate bonds worth $16 million guaranteeing compliance with a first-degree mortgage of real estate assets of equal value and a pledge on the shares representing 10% of the holding of Rasa Holding LLC in the capital of Rizobacter. On July 5, 2021, we paid the last installment of the private bonds. As of the date of issuance of These financial statements, the commitments assumed by the Group were released. b) In order to guarantee the fulfillment of the obligations assumed from the loan signed with Allaria Ledesma & Cia., the subsidiary Rizobacter granted a pledge of American treasury bonds valued of $ 6,7 c) In order to guarantee the fulfillment of the obligations assumed from the loan signed with Cohen S.A., the subsidiary Rizobacter granted a pledge of American treasury bonds valued of $ 0,8

GENERAL INFORMATION (Details)

GENERAL INFORMATION (Details)	Mar. 14, 2019	Oct. 22, 2018shares	Jun. 30, 2021country	Feb. 13, 2019
Disclosure of detailed information about business combination
Number of countries with agricultural inputs | country			30
Rizobacter Argentina
Disclosure of detailed information about business combination
Number of shares to be acquired in option agreement | shares		11,916,000
Voting interest to be acquired in option agreement		29.99%
BCS Holding Inc | Rizobacter Argentina
Disclosure of detailed information about business combination
Percentage of ownership interests	80.00%
Bioceres LLC | BCS Holding Inc
Disclosure of detailed information about business combination
Percentage of voting equity interests acquired				100.00%

ACCOUNTING STANDARDS AND BASI_3

ACCOUNTING STANDARDS AND BASIS OF PREPARATION - Functional currency (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Fair value of the consideration of payment
Argentine price indexes	483.6049	321.9738	225.5730

ACCOUNTING STANDARDS AND BASI_4

ACCOUNTING STANDARDS AND BASIS OF PREPARATION - Subsidiaries (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Nov. 12, 2020
Bioceres Crops S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Percentage of voting equity interests acquired			50.00%
RASA Holding, LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	100.00%	100.00%	100.00%
Rizobacter Argentina S.A
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	80.00%	80.00%	80.00%
Rizobacter do Brasil Ltda.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	79.99%	79.99%	79.99%
Rizobacter del Paraguay S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	79.92%	79.92%	79.92%
Rizobacter Uruguay
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	80.00%	80.00%	80.00%
Rizobacter South Africa
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	76.00%	76.00%	76.00%
Comer Agrop Rizobacter de Bolivia S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	79.96%	79.96%	79.96%
Rizobacter USA, LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	80.00%	80.00%	80.00%
Rizobacter India Private Ltd.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary		80.00%	80.00%
Rizobacter Colombia SAS
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	80.00%	80.00%	80.00%
Rizobacter France SAS
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	80.00%	80.00%	80.00%
Bioceres Crops S.A
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	90.00%	90.00%	90.00%
Percentage of voting equity interests acquired			50.00%
BCS Holding LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	100.00%	100.00%	100.00%
Bioceres Semillas S.A.U.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	100.00%	100.00%	100.00%
Verdeca LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	100.00%	50.00%	50.00%
Percentage of voting equity interests acquired				50.00%
Insumos Agroqumicos S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	50.10%
Indirect ownership through Rizobacter
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Percentage of voting equity interests acquired	80.00%

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business combinations (Details) - shares	Oct. 22, 2018	Jun. 30, 2021
Minimum
Business combinations:
Period from moment of sowing until the moment of harvest		5 months
Maximum
Business combinations:
Period from moment of sowing until the moment of harvest		7 months
Rizobacter Argentina
Business combinations:
Voting interest to be acquired in option agreement	29.99%
Number of shares to be acquired in option agreement	11,916,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, plant and equipment (Details) $ in Millions	12 Months Ended
	Jun. 30, 2021USD ($)
Property, plant and equipment
Revalued amount of land	$ 0.3
Impact on revaluation amount	$ 1.5
Land
Property, plant and equipment
Change in market price change that impacts valuation (as a percent)	10.00%
Research instruments | Minimum
Property, plant and equipment
Useful lives (in years)	3 years
Research instruments | Maximum
Property, plant and equipment
Useful lives (in years)	10 years
Office equipment | Minimum
Property, plant and equipment
Useful lives (in years)	5 years
Office equipment | Maximum
Property, plant and equipment
Useful lives (in years)	10 years
Vehicles
Property, plant and equipment
Useful lives (in years)	5 years
Equipment and computer software
Property, plant and equipment
Useful lives (in years)	3 years
Fixture and fittings
Property, plant and equipment
Useful lives (in years)	10 years
Machinery and equipment | Minimum
Property, plant and equipment
Useful lives (in years)	5 years
Machinery and equipment | Maximum
Property, plant and equipment
Useful lives (in years)	10 years
Buildings
Property, plant and equipment
Useful lives (in years)	50 years
Change in construction costs that impacts valuation (as a percent)	5.00%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible assets (Details)	12 Months Ended
	Jun. 30, 2021
Product registration
Intangible assets
Useful life (in years)	5 years
Customer loyalty | Minimum
Intangible assets
Useful life (in years)	14 years
Customer loyalty | Maximum
Intangible assets
Useful life (in years)	26 years
Externally acquired | Software
Intangible assets
Useful life (in years)	3 years
Externally acquired | Trademarks and patents
Intangible assets
Useful life (in years)	5 years
Externally acquired | Certification ISO Standards
Intangible assets
Useful life (in years)	3 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Warrants (Details)	Mar. 14, 2019USD ($)
Public warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	11,500,000
Founder warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	5,200,000
Bioceres warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	7,500,000
Private warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	12,700,000

ACQUISITIONS - Bioceres Crops S

ACQUISITIONS - Bioceres Crops S.A (Details) $ in Millions	12 Months Ended
	Jun. 30, 2019USD ($)
Bioceres Crops S.A.
Disclosure of detailed information about business combination
Ownership interest acquired	50.00%
Consideration as percentage of royalties	50.00%
Royalties	$ 0.7
Bioceres S.A. | Bioceres Crops S.A.
Disclosure of detailed information about business combination
Proportion of ownership interest in joint operation	50.00%

ACQUISITIONS - Verdeca and othe

ACQUISITIONS - Verdeca and other intangibles assets (Details)	Nov. 12, 2020USD ($)item	Jun. 30, 2021USD ($)
Disclosure of detailed information about business combination
Consideration for acquisition		$ 2,625,335
Verdeca
Disclosure of detailed information about business combination
Percentage of less gluten in wheat varieties	65.00%
Number of times the dietary fiber content of conventional wheat flours | item	10
Cash payment	$ 5,000,000
Consideration in equity	$ 15,000,000
Shares issued in exchange for the acquisition of assets	1,875,000
Soybean HB4 | Verdeca
Disclosure of detailed information about business combination
Amount to be paid for obtaining Chinese import clearance for HB4 Soy or achieving penetration of this technology in a minimum number of planted hectares	$ 2,000,000
Consideration for acquisition	$ 1,000,000
Percentage of royalty payments	6.00%
Royalty payments	$ 10,000,000
Net wheat technology | Verdeca
Disclosure of detailed information about business combination
Percentage of royalty payments	25.00%

ACQUISITIONS - Moolec Science L

ACQUISITIONS - Moolec Science Ltd (Details) - Moolec Science Ltd	Mar. 16, 2021shares
Disclosure of detailed information about business combination
Ownership interest acquired	6.00%
Number of shares acquired	2,919,715

ACQUISITIONS - Insuagro (Detail

ACQUISITIONS - Insuagro (Details) - Insumos Agroquimicos S.A.	Apr. 09, 2021USD ($)directorVoteinstallment$ / sharesshares	Aug. 31, 2024USD ($)	Aug. 31, 2023USD ($)	Aug. 31, 2022USD ($)	Apr. 09, 2021$ / shares
Disclosure of detailed information about business combination
Number of shares acquired | shares	11,022,000
Percentage of equity interest acquired	50.10%
Percentage of voting interest acquired	55.05%
Number of directors resigned | director	2
Total number of directors | director	3
Number of directors replaced | director	2
Number of SPEs on whom we acquired control	2
Consideration per share | $ / shares	$ 0.282
Total consideration, fixed price	$ 3,100,000
Cash payment	$ 200,000
Number of installments | installment	3
Installment amount		$ 1,200,000	$ 900,000	$ 900,000
Interest rate on consideration payable	5.50%
Percentage of increase on Adjusted EBITDA for consideration payable	3.50%
Class A ordinary shares
Disclosure of detailed information about business combination
Number of shares acquired | shares	2,749,390
Nominal value per share | $ / shares					$ 0.10
Number of votes per share | Vote	5
Class B ordinary shares
Disclosure of detailed information about business combination
Number of shares acquired | shares	8,272,610
Nominal value per share | $ / shares					$ 0.10
Number of votes per share | Vote	1

ACQUISITIONS - Fair Value (Deta

ACQUISITIONS - Fair Value (Details) - USD ($)	Jun. 30, 2021	Apr. 09, 2021
Fair value of the consideration of payment
Financed payment	$ 2,625,335
Insumos Agroquimicos S.A.
Fair value of the consideration of payment
Cash payment		$ 200,000
Financed payment		2,625,335
Contingent payment		951,622
Total consideration		$ 3,776,957

ACQUISITIONS - Assets acquired,

ACQUISITIONS - Assets acquired, liabilities assumed (Details) - Insumos Agroquimicos S.A.	Apr. 09, 2021USD ($)
Net assets incorporated
Cash and cash equivalents	$ 555,804
Other financial assets	2,024,367
Trade receivables	17,536,888
Other receivables	419,877
Income and minimum presumed income taxes recoverable	117,229
Inventory	5,603,068
Deferred tax assets	106,952
Property, plant and equipment	1,662,516
Intangible assets	264,847
Trade and other payables	(17,311,906)
Borrowings	5,928,748
Employee benefits and social security	(201,472)
Deferred revenues and advances from customers	301,017
Revaluation of existing assets
Property, plant and equipment	289,529
Intangible assets	2,659,050
Deferred tax	(884,574)
Total net assets identified	6,612,410
Non-controlling interest	3,305,543
Goodwill	470,090
Total consideration	$ 3,776,957

ACQUISITIONS (Details)

ACQUISITIONS (Details) - Insumos Agroquimicos S.A. $ in Millions	3 Months Ended
	Jun. 30, 2021USD ($)
Disclosure of detailed information about business combination
Revenue of the acquiree since the acquisition date	$ 7.6
Profit or loss of the acquiree since the acquisition date	0.2
Revenue of the combined entity for the current reporting period as though the acquisition date for the business combination had been as of the beginning of the annual reporting period	233.3
Profit or loss of the combined entity for the current reporting period as though the acquisition date for the business combination had been as of the beginning of the annual reporting period	$ 4.6

INFORMATION ABOUT COMPONENTS _7

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Cash and cash equivalents (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Cash at bank and on hand	$ 28,327,569	$ 20,176,452	$ 3,450,873
Mutual funds	7,718,544	22,346,409
Total cash and cash equivalents	$ 36,046,113	$ 42,522,861	$ 3,450,873

INFORMATION ABOUT COMPONENTS _8

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Other financial assets (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current
Restricted short-term deposit	$ 425,976	$ 4,390,458	$ 4,327,275
US Treasury bills	7,885,937	7,768,410
Others mutual funds			347,718
Other investments	2,849,485	1,277,525	8,515
Other financial assets	11,161,398	13,436,393	4,683,508
Non-current assets
Shares of Bioceres S.A.	355,251	321,705	374,685
Other investments	742,211	998	1,728
Other financial assets	$ 1,097,462	$ 322,703	$ 376,413

INFORMATION ABOUT COMPONENTS _9

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Trade receivables (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Components of Consolidated Statement of Financial Position
Receivables	$ 88,784,172	$ 73,546,633	$ 59,236,377
Total trade and other non-current receivables	135,739
Trade receivables
Components of Consolidated Statement of Financial Position
Trade debtors	87,709,287	53,047,035	48,910,484
Allowance for impairment of trade debtors	(5,858,503)	(3,886,832)	(3,360,224)
Allowance for credit notes to be issued	(2,987,398)	(2,285,197)	(800,606)
Deferred checks	9,699,738	25,461,399	13,651,939
Receivables	88,784,172	73,546,633	59,236,377
Trade debtors	135,739
Total trade and other non-current receivables	135,739
Shareholders and other related parties
Components of Consolidated Statement of Financial Position
Allowance for impairment of related parties		(768)	(75,596)
Shareholders and other related parties | Trade receivables
Components of Consolidated Statement of Financial Position
Trade debtors		1,090,004	467,743
Allowance for impairment of related parties		(768)	(75,596)
Parent company | Trade receivables
Components of Consolidated Statement of Financial Position
Trade debtors			440,268
Joint ventures and associates | Trade receivables
Components of Consolidated Statement of Financial Position
Trade debtors	$ 221,048	$ 120,992	$ 2,369

INFORMATION ABOUT COMPONENTS_10

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Other receivables (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current
Other receivables	$ 11,153,705	$ 4,770,672	$ 1,981,829
Non-current assets
Other receivables	2,543,142	1,703,573	1,560,310
Other receivables
Current
Taxes	6,048,533	2,205,342	584,641
Other receivables	11,153,705	4,770,672	1,981,829
Prepayments to suppliers	1,646,614	379,914	496,001
Reimbursements over exports	10,547	29,077	366,594
Prepaid expenses and other receivables	1,021	128,650	213,597
Loans receivable	230,000	230,000
Miscellaneous	92,406	49,441	59,242
Non-current assets
Taxes	862,771	328,701	681,168
Reimbursements over exports	1,680,371	1,293,958	878,470
Miscellaneous		80,914	672
Other receivables	2,543,142	1,703,573	1,560,310
Shareholders and other related parties | Other receivables
Current
Other receivables	1,547	2,102	10,971
Prepayments to suppliers	132,625	81,737
Parent company | Other receivables
Current
Other receivables	770,549	102,069
Joint ventures and associates | Other receivables
Current
Other receivables	$ 2,219,863	$ 1,562,340	$ 250,783

INFORMATION ABOUT COMPONENTS_11

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Inventories (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Inventory
Inventories	$ 61,037,551	$ 29,338,548	$ 27,322,003
Goods in transit	1,169,303	1,292,239	751,737
Supplies	6,320,594	5,930,471	4,482,827
Inventory recognized as expense	102,369,869	86,179,252	80,424,450
Agrochemicals
Inventory
Inventories	1,161,025	356,489	22,137
Seeds and Grains
Inventory
Inventories	22,389,400	1,300,998	207,519
Resale products
Inventory
Inventories	20,207,496	13,486,668	13,894,018
Manufactured products
Inventory
Inventories	10,902,683	8,079,553	8,370,583
Allowance for obsolescence
Inventory
Inventories	$ (1,112,950)	$ (1,107,870)	$ (406,818)

INFORMATION ABOUT COMPONENTS_12

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Biological assets (Details)	12 Months Ended
	Jun. 30, 2021USD ($)ha	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Biological assets
Biological assets at beginning of the year	$ 965,728	$ 270,579	$ 0
Initial recognition and changes in the fair value of biological assets	2,826,255	716,741	279,945
Decrease due to harvest / disposals	(22,867,344)	(986,433)	(334,478)
Cost incurred during the year	25,718,762	1,234,733	387,074
Exchange differences	(4,327,563)	(269,892)	(61,962)
Biological assets at year ended June 30	$ 2,315,838	965,728	270,579
Increase in estimated yields (as a percent)	20.00%
Increase in the fair value if estimated yield were to increase	$ 400,000
Soybean
Biological assets
Biological assets at beginning of the year	105,101	237,723	0
Initial recognition and changes in the fair value of biological assets	981,551	198,932	241,707
Decrease due to harvest / disposals	(1,171,276)	(447,132)	(288,791)
Cost incurred during the year	252,504	284,951	339,088
Exchange differences	(113,718)	(169,373)	(54,281)
Biological assets at year ended June 30	54,162	105,101	237,723
Corn
Biological assets
Biological assets at beginning of the year	271,754	32,856	0
Initial recognition and changes in the fair value of biological assets	250,443	252,056	38,238
Decrease due to harvest / disposals	(758,342)	(252,372)	(45,687)
Cost incurred during the year	417,586	314,950	47,986
Exchange differences	(153,795)	(75,736)	(7,681)
Biological assets at year ended June 30	27,646	271,754	32,856
Wheat
Biological assets
Biological assets at beginning of the year	45,639	0	0
Initial recognition and changes in the fair value of biological assets	284,903	202,543	0
Decrease due to harvest / disposals	(484,044)	(227,303)	0
Cost incurred during the year	241,610	87,615	0
Exchange differences	(65,797)	(17,216)	0
Biological assets at year ended June 30	22,311	45,639	0
Barley
Biological assets
Biological assets at beginning of the year	34,050	0	0
Initial recognition and changes in the fair value of biological assets	35,847	63,210	0
Decrease due to harvest / disposals	(87,065)	(59,626)	0
Cost incurred during the year	37,115	38,033	0
Exchange differences	(16,876)	(7,567)	0
Biological assets at year ended June 30	3,071	34,050	0
HB4 Soy
Biological assets
Initial recognition and changes in the fair value of biological assets	741,799
Decrease due to harvest / disposals	(15,634,174)
Cost incurred during the year	17,716,018
Exchange differences	(2,823,643)
HB4 Wheat
Biological assets
Biological assets at beginning of the year	509,184	0
Initial recognition and changes in the fair value of biological assets	531,712	0
Decrease due to harvest / disposals	(4,732,443)	0
Cost incurred during the year	7,053,929	509,184
Exchange differences	(1,153,734)	0
Biological assets at year ended June 30	2,208,648	$ 509,184	$ 0
Hb4 Program
Biological assets
Contributed goods	$ 8,300,000
Contributed goods weighted average gross margin (as a percent)	43.00%
Number of Hectares for Contributed Goods | ha	80,000
Joint operation in producing grain crops | Rizobacte Argentina and Espartina
Biological assets
In-kind contributions	$ 700,000

INFORMATION ABOUT COMPONENTS_13

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment - gross carrying amounts (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Property, plant and equipment
As of the beginning of period	$ 41,515,106	$ 43,834,548
Transfers	(2,164,156)
As of the end of period	47,954,596	41,515,106	$ 43,834,548
Office equipment
Property, plant and equipment
As of the beginning of period	188,280	213,437
As of the end of period	288,920	188,280	213,437
Vehicles
Property, plant and equipment
As of the beginning of period	1,149,455	1,785,701
As of the end of period	1,835,634	1,149,455	1,785,701
Equipment and computer software
Property, plant and equipment
As of the beginning of period	32,448	123,472
As of the end of period	67,105	32,448	123,472
Fixture and fittings
Property, plant and equipment
As of the beginning of period	3,679,075	4,737,396
As of the end of period	2,967,431	3,679,075	4,737,396
Machinery and equipment
Property, plant and equipment
As of the beginning of period	5,449,233	6,336,691
As of the end of period	5,125,728	5,449,233	6,336,691
Land and buildings
Property, plant and equipment
As of the beginning of period	29,746,076	29,969,237
As of the end of period	35,674,513	29,746,076	29,969,237
Buildings in progress
Property, plant and equipment
As of the beginning of period	1,270,539	668,614
As of the end of period	1,995,265	1,270,539	668,614
Gross carrying amount
Property, plant and equipment
As of the beginning of period	54,527,392	57,059,972	44,764,394
Adjustment of opening net book amount for application of IAS 29			9,204,777
Additions	2,805,825	1,646,697	2,044,102
Reclassifications		(1,237,872)
Additions from business combinations	1,952,045
Transfers	2,164,156
Disposals	(1,061,518)	(139,369)	(338,854)
Foreign currency translation	4,805,613	(7,702,857)	3,441,984
Revaluation	(1,219,111)	4,900,821	(2,056,431)
As of the end of period	63,974,402	54,527,392	57,059,972
Gross carrying amount | Office equipment
Property, plant and equipment
As of the beginning of period	579,882	629,119	243,948
Adjustment of opening net book amount for application of IAS 29			333,904
Additions	66,331	42,658	30,621
Additions from business combinations	5,491
Disposals	(5,622)		(8,493)
Foreign currency translation	116,743	(91,895)	29,139
As of the end of period	762,825	579,882	629,119
Gross carrying amount | Vehicles
Property, plant and equipment
As of the beginning of period	2,977,542	3,604,537	1,660,294
Adjustment of opening net book amount for application of IAS 29			1,054,631
Additions	987,101	248,800	1,093,749
Reclassifications		(264,069)
Additions from business combinations	466,024
Disposals	(1,045,656)	(139,369)	(297,269)
Foreign currency translation	127,206	(472,357)	93,132
As of the end of period	3,512,217	2,977,542	3,604,537
Gross carrying amount | Equipment and computer software
Property, plant and equipment
As of the beginning of period	465,679	955,657	419,638
Adjustment of opening net book amount for application of IAS 29			416,274
Additions	66,263	27,961	75,152
Reclassifications		(375,242)
Additions from business combinations	13,952
Disposals			(1,685)
Foreign currency translation	46,232	(142,697)	46,278
As of the end of period	592,126	465,679	955,657
Gross carrying amount | Fixture and fittings
Property, plant and equipment
As of the beginning of period	5,480,431	6,438,430	3,826,665
Adjustment of opening net book amount for application of IAS 29			1,909,115
Additions	50,976	14,985	7,518
Reclassifications		20,801
Transfers	85,490		213,333
Foreign currency translation	21,046	(993,785)	481,799
As of the end of period	5,637,943	5,480,431	6,438,430
Gross carrying amount | Machinery and equipment
Property, plant and equipment
As of the beginning of period	9,054,701	10,233,501	5,404,029
Adjustment of opening net book amount for application of IAS 29			3,976,720
Additions	604,307	556,693	98,034
Reclassifications		(598,561)
Transfers			7,863
Disposals	(10,240)		(31,407)
Foreign currency translation	339,043	(1,136,932)	778,262
As of the end of period	9,987,811	9,054,701	10,233,501
Gross carrying amount | Land and buildings
Property, plant and equipment
As of the beginning of period	34,698,618	34,530,114	33,026,981
Adjustment of opening net book amount for application of IAS 29			1,438,728
Additions		3,261	125,930
Reclassifications		36,487
Additions from business combinations	1,466,578
Transfers	2,517,158
Foreign currency translation	4,022,972	(4,772,065)	1,994,906
Revaluation	(1,219,111)	4,900,821	(2,056,431)
As of the end of period	41,486,215	34,698,618	34,530,114
Gross carrying amount | Buildings in progress
Property, plant and equipment
As of the beginning of period	1,270,539	668,614	182,839
Adjustment of opening net book amount for application of IAS 29			75,405
Additions	1,030,847	752,339	613,098
Reclassifications		(57,288)
Transfers	(438,492)		(221,196)
Foreign currency translation	132,371	(93,126)	18,468
As of the end of period	$ 1,995,265	$ 1,270,539	$ 668,614

INFORMATION ABOUT COMPONENTS_14

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment - accumulated depreciation (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Property, plant and equipment
As of the beginning of period	$ (41,515,106)	$ (43,834,548)
As of the end of period	(47,954,596)	(41,515,106)	$ (43,834,548)
Office equipment
Property, plant and equipment
As of the beginning of period	(188,280)	(213,437)
As of the end of period	(288,920)	(188,280)	(213,437)
Vehicles
Property, plant and equipment
As of the beginning of period	(1,149,455)	(1,785,701)
As of the end of period	(1,835,634)	(1,149,455)	(1,785,701)
Equipment and computer software
Property, plant and equipment
As of the beginning of period	(32,448)	(123,472)
As of the end of period	(67,105)	(32,448)	(123,472)
Fixture and fittings
Property, plant and equipment
As of the beginning of period	(3,679,075)	(4,737,396)
As of the end of period	(2,967,431)	(3,679,075)	(4,737,396)
Machinery and equipment
Property, plant and equipment
As of the beginning of period	(5,449,233)	(6,336,691)
As of the end of period	(5,125,728)	(5,449,233)	(6,336,691)
Land and buildings
Property, plant and equipment
As of the beginning of period	(29,746,076)	(29,969,237)
As of the end of period	(35,674,513)	(29,746,076)	(29,969,237)
Buildings in progress
Property, plant and equipment
As of the beginning of period	(1,270,539)	(668,614)
As of the end of period	(1,995,265)	(1,270,539)	(668,614)
Property, plant and equipment depreciation
Property, plant and equipment
As of the beginning of period	13,012,286	13,225,424	4,587,248
Adjustment of opening net book amount for application of IAS 29	3,048,539		5,923,397
Additions		2,010,136	2,450,256
Disposals	(987,606)	(760,620)	(227,201)
Foreign currency translation	1,286,502	1,830,562	(626,645)
Revaluation	(339,915)	367,908	(134,921)
As of the end of period	16,019,806	13,012,286	13,225,424
Property, plant and equipment depreciation | Office equipment
Property, plant and equipment
As of the beginning of period	391,602	415,682	49,129
Adjustment of opening net book amount for application of IAS 29	45,174		309,339
Additions		35,879	39,997
Disposals	(3,265)		(4,007)
Foreign currency translation	40,394	59,959	(21,224)
As of the end of period	473,905	391,602	415,682
Property, plant and equipment depreciation | Vehicles
Property, plant and equipment
As of the beginning of period	1,828,087	1,818,836	560,691
Adjustment of opening net book amount for application of IAS 29	689,273		750,195
Additions		426,623	621,974
Disposals	(974,102)	(173,482)	(205,618)
Foreign currency translation	133,325	243,890	(91,594)
As of the end of period	1,676,583	1,828,087	1,818,836
Property, plant and equipment depreciation | Equipment and computer software
Property, plant and equipment
As of the beginning of period	433,231	832,185	207,402
Adjustment of opening net book amount for application of IAS 29	50,949		486,143
Additions		28,170	99,350
Disposals		(307,816)	(769)
Foreign currency translation	40,841	119,308	(40,059)
As of the end of period	525,021	433,231	832,185
Property, plant and equipment depreciation | Fixture and fittings
Property, plant and equipment
As of the beginning of period	1,801,356	1,701,034	318,582
Adjustment of opening net book amount for application of IAS 29	683,537		912,404
Additions		338,092	397,989
Foreign currency translation	185,619	237,770	(72,059)
As of the end of period	2,670,512	1,801,356	1,701,034
Property, plant and equipment depreciation | Machinery and equipment
Property, plant and equipment
As of the beginning of period	3,605,468	3,896,810	937,736
Adjustment of opening net book amount for application of IAS 29	898,522		2,121,816
Additions		553,399	673,784
Disposals	(10,239)	(279,322)	(16,807)
Foreign currency translation	368,332	565,419	(180,281)
As of the end of period	4,862,083	3,605,468	3,896,810
Property, plant and equipment depreciation | Land and buildings
Property, plant and equipment
As of the beginning of period	4,952,542	4,560,877	2,513,708
Adjustment of opening net book amount for application of IAS 29	681,084		1,343,500
Additions		627,973	617,162
Foreign currency translation	517,991	604,216	(221,428)
Revaluation	(339,915)	367,908	(134,921)
As of the end of period	$ 5,811,702	$ 4,952,542	$ 4,560,877

INFORMATION ABOUT COMPONENTS_15

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment- revaluation (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Land and buildings
Property, plant and equipment
Carrying amount of land and buildings recognized if under cost model	$ 17,937,729	$ 12,549,876	$ 14,330,892

INFORMATION ABOUT COMPONENTS_16

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Intangible assets
Intangible assets other than goodwill	$ 67,342,362	$ 35,333,464	$ 39,616,426
Gross carrying amount
Intangible assets
Intangible assets other than goodwill	78,019,203	42,832,837	45,848,737	$ 29,155,315
Property, plant and equipment depreciation
Intangible assets
Intangible assets other than goodwill	$ (10,676,841)	$ (7,499,373)	$ (6,232,311)	$ (2,497,970)

INFORMATION ABOUT COMPONENTS_17

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets, net carrying amount (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Intangible assets
Intangible assets	$ 67,342,362	$ 35,333,464	$ 39,616,426
Soybean HB4
Intangible assets
Intangible assets	27,611,142	7,345,923	6,120,336
Ecoseed integrated products
Intangible assets
Intangible assets	2,558,220	2,296,955	2,627,946
Microbiology products
Intangible assets
Intangible assets	3,996,657	2,503,631	2,208,117
Trademarks and patents
Intangible assets
Intangible assets	6,923,256	6,374,782	8,063,648
Software
Intangible assets
Intangible assets	1,849,041	686,965	994,723
Customer loyalty
Intangible assets
Intangible assets	19,404,046	$ 16,125,208	$ 19,601,656
RG/RS/OX Wheat
Intangible assets
Intangible assets	$ 5,000,000

INFORMATION ABOUT COMPONENTS_18

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets, gross carrying amount (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Intangible assets
Balance at beginning of the year	$ 35,333,464	$ 39,616,426
Balance at end of the year	67,342,362	35,333,464	$ 39,616,426
Gross carrying amount
Intangible assets
Balance at beginning of the year	42,832,837	45,848,737	29,155,315
Additions	32,404,339	2,855,479	4,062,514
Additions from business combination	2,923,897
Disposals	(3,900,639)	(286,496)	(359,308)
Foreign currency translation	3,758,769	(5,584,883)	2,064,127
Balance at end of the year	78,019,203	42,832,837	45,848,737
Soybean HB4
Intangible assets
Balance at beginning of the year	7,345,923	6,120,336
Balance at end of the year	27,611,142	7,345,923	6,120,336
Soybean HB4 | Gross carrying amount
Intangible assets
Balance at beginning of the year	7,345,923	6,120,336	4,927,853
Additions	20,471,002	1,225,587	1,192,483
Disposals	(205,783)
Balance at end of the year	27,611,142	7,345,923	6,120,336
Ecoseed integrated products
Intangible assets
Balance at beginning of the year	2,296,955	2,627,946
Balance at end of the year	2,558,220	2,296,955	2,627,946
Ecoseed integrated products | Gross carrying amount
Intangible assets
Balance at beginning of the year	2,296,955	2,627,946
Additions		38,143	2,627,946
Foreign currency translation	261,265	(369,134)
Balance at end of the year	2,558,220	2,296,955	2,627,946
Microbiology products
Intangible assets
Balance at beginning of the year	2,503,631	2,208,117
Balance at end of the year	3,996,657	2,503,631	2,208,117
Microbiology products | Gross carrying amount
Intangible assets
Balance at beginning of the year	3,867,593	3,267,200	2,505,864
Additions	1,791,008	1,358,315	41,485
Disposals	(51,716)	(286,496)	(318,949)
Foreign currency translation	430,795	(471,426)	197,047
Balance at end of the year	6,037,680	3,867,593	3,267,200
Trademarks and patents
Intangible assets
Balance at beginning of the year	6,374,782	8,063,648
Balance at end of the year	6,923,256	6,374,782	8,063,648
Trademarks and patents | Gross carrying amount
Intangible assets
Balance at beginning of the year	8,432,746	9,810,822	6,278,706
Additions	4,834
Additions from business combination	499,329
Foreign currency translation	887,262	(1,378,076)	545,377
Balance at end of the year	9,824,171	8,432,746	9,810,822
Software
Intangible assets
Balance at beginning of the year	686,965	994,723
Balance at end of the year	1,849,041	686,965	994,723
Software | Gross carrying amount
Intangible assets
Balance at beginning of the year	2,088,929	2,149,340	1,444,603
Additions	2,205,796	233,434	200,600
Disposals	(711,441)		(40,359)
Foreign currency translation	201,309	(293,845)	105,793
Balance at end of the year	3,784,593	2,088,929	2,149,340
Customer loyalty
Intangible assets
Balance at beginning of the year	16,125,208	19,601,656
Balance at end of the year	19,404,046	16,125,208	19,601,656
Customer loyalty | Gross carrying amount
Intangible assets
Balance at beginning of the year	18,800,691	21,873,093	13,998,289
Additions from business combination	2,424,568
Foreign currency translation	1,978,138	(3,072,402)	1,215,910
Balance at end of the year	23,203,397	$ 18,800,691	$ 21,873,093
GLA/ARA safflower (Note 6) | Gross carrying amount
Intangible assets
Additions	2,931,699
Disposals	(2,931,699)
RG/RS/OX Wheat
Intangible assets
Balance at end of the year	5,000,000
RG/RS/OX Wheat | Gross carrying amount
Intangible assets
Additions	5,000,000
Balance at end of the year	5,000,000
Verdeca
Intangible assets
Additions from business combination	$ 18,400,000

INFORMATION ABOUT COMPONENTS_19

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets, accumulated amortization (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Intangible assets
Balance at beginning of the year	$ (35,333,464)	$ (39,616,426)
Adjustment of opening net book amount for application of IAS 29			$ 1,200,363
Balance at end of the year	(67,342,362)	(35,333,464)	(39,616,426)
Gross carrying amount
Intangible assets
Balance at beginning of the year	(42,832,837)	(45,848,737)	(29,155,315)
Adjustment of opening net book amount for application of IAS 29			10,926,089
Of the year	32,404,339	2,855,479	4,062,514
Disposals	3,900,639	286,496	359,308
Foreign currency translation	3,758,769	(5,584,883)	2,064,127
Balance at end of the year	(78,019,203)	(42,832,837)	(45,848,737)
Property, plant and equipment depreciation
Intangible assets
Balance at beginning of the year	7,499,373	6,232,311	2,497,970
Adjustment of opening net book amount for application of IAS 29	2,388,982
Of the year		2,149,534	(2,376,919)
Disposals		(17,495)	(61,246)
Foreign currency translation	788,486	864,977	(218,305)
Balance at end of the year	10,676,841	7,499,373	6,232,311
Microbiology products
Intangible assets
Balance at beginning of the year	(2,503,631)	(2,208,117)
Adjustment of opening net book amount for application of IAS 29			202,791
Balance at end of the year	(3,996,657)	(2,503,631)	(2,208,117)
Microbiology products | Gross carrying amount
Intangible assets
Balance at beginning of the year	(3,867,593)	(3,267,200)	(2,505,864)
Adjustment of opening net book amount for application of IAS 29			841,753
Of the year	1,791,008	1,358,315	41,485
Disposals	51,716	286,496	318,949
Foreign currency translation	430,795	(471,426)	197,047
Balance at end of the year	(6,037,680)	(3,867,593)	(3,267,200)
Microbiology products | Property, plant and equipment depreciation
Intangible assets
Balance at beginning of the year	1,363,962	1,059,083	383,380
Of the year	523,992	471,135	(459,287)
Disposals		(17,495)	(20,887)
Foreign currency translation	153,069	148,761	(34,512)
Balance at end of the year	2,041,023	1,363,962	1,059,083
Trademarks and patents
Intangible assets
Balance at beginning of the year	(6,374,782)	(8,063,648)
Adjustment of opening net book amount for application of IAS 29			334,919
Balance at end of the year	(6,923,256)	(6,374,782)	(8,063,648)
Trademarks and patents | Gross carrying amount
Intangible assets
Balance at beginning of the year	(8,432,746)	(9,810,822)	(6,278,706)
Adjustment of opening net book amount for application of IAS 29			2,986,739
Of the year	4,834
Foreign currency translation	887,262	(1,378,076)	545,377
Balance at end of the year	(9,824,171)	(8,432,746)	(9,810,822)
Trademarks and patents | Property, plant and equipment depreciation
Intangible assets
Balance at beginning of the year	2,057,964	1,747,174	704,024
Of the year	626,420	556,206	(647,101)
Foreign currency translation	216,531	245,416	(61,130)
Balance at end of the year	2,900,915	2,057,964	1,747,174
Software
Intangible assets
Balance at beginning of the year	(686,965)	(994,723)
Adjustment of opening net book amount for application of IAS 29			227,264
Balance at end of the year	(1,849,041)	(686,965)	(994,723)
Software | Gross carrying amount
Intangible assets
Balance at beginning of the year	(2,088,929)	(2,149,340)	(1,444,603)
Adjustment of opening net book amount for application of IAS 29			438,703
Of the year	2,205,796	233,434	200,600
Disposals	711,441		40,359
Foreign currency translation	201,309	(293,845)	105,793
Balance at end of the year	(3,784,593)	(2,088,929)	(2,149,340)
Software | Property, plant and equipment depreciation
Intangible assets
Balance at beginning of the year	1,401,964	1,154,617	495,293
Of the year	396,207	399,090	(429,258)
Disposals			(40,359)
Foreign currency translation	137,381	151,743	(43,161)
Balance at end of the year	1,935,552	1,401,964	1,154,617
Customer loyalty
Intangible assets
Balance at beginning of the year	(16,125,208)	(19,601,656)
Adjustment of opening net book amount for application of IAS 29			435,389
Balance at end of the year	(19,404,046)	(16,125,208)	(19,601,656)
Customer loyalty | Gross carrying amount
Intangible assets
Balance at beginning of the year	(18,800,691)	(21,873,093)	(13,998,289)
Adjustment of opening net book amount for application of IAS 29			6,658,894
Foreign currency translation	1,978,138	(3,072,402)	1,215,910
Balance at end of the year	(23,203,397)	(18,800,691)	(21,873,093)
Customer loyalty | Property, plant and equipment depreciation
Intangible assets
Balance at beginning of the year	2,675,483	2,271,437	915,273
Of the year	842,363	723,103	(841,273)
Foreign currency translation	281,505	319,057	(79,502)
Balance at end of the year	$ 3,799,351	$ 2,675,483	$ 2,271,437

INFORMATION ABOUT COMPONENTS_20

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Goodwill (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Goodwill
Goodwill	$ 28,751,206	$ 25,526,855	$ 29,804,715
Rizobacter Argentina
Goodwill
Goodwill	22,277,336	20,094,633	23,484,761
Bioceres Crops S.A.
Goodwill
Goodwill	6,003,780	$ 5,432,222	$ 6,319,954
Insumos Agroquimicos S.A.
Goodwill
Goodwill	$ 470,090

INFORMATION ABOUT COMPONENTS_21

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Goodwill, key assumptions (Details)	Jun. 30, 2021
Disclosure of reconciliation of changes in goodwill [line items]
Growth rate	2.00%
Rizobacter
Disclosure of reconciliation of changes in goodwill [line items]
Discount rate	15.55%
Insumos Agroquimicos S.A.
Disclosure of reconciliation of changes in goodwill [line items]
Discount rate	22.00%

INFORMATION ABOUT COMPONENTS_22

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Trade and other payable (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current
Trade creditors	$ 51,389,515	$ 37,139,351	$ 30,489,072
Taxes	2,556,945	2,163,552	1,475,410
Miscellaneous	229,339	335,088	443,895
Trade and other payable	72,091,408	57,289,862	40,578,494
Shareholders and other related parties
Current
Trade payable, related party	52,864	1,031,710	1,796,932
Parent company
Current
Trade payable, related party	193,718	2,210,308	1,568,036
Joint ventures and associates
Current
Trade payable, related party	$ 17,669,027	$ 14,409,853	$ 4,805,149

INFORMATION ABOUT COMPONENTS_23

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current liabilities
Corporate bonds	$ 24,742,752	$ 12,611,940	$ 8,416,768
Borrowings	76,785,857	63,721,735	66,477,209
Non-current
Corporate bonds	37,826,641	18,364,894	8,018,884
Borrowings	47,988,468	41,226,610	37,079,521
Bank overdraft
Current liabilities
Borrowings	32,838	73,362
Bank borrowings
Current liabilities
Borrowings	33,684,287	47,646,912	52,274,611
Non-current
Borrowings	4,161,827	3,497,671	16,239,743
Trust debt securities
Current liabilities
Borrowings	3,470,448
Subordinated loan
Current liabilities
Borrowings	11,276,611
Non-current
Borrowings		10,364,045
Finance lease
Current liabilities
Borrowings			385,947
Non-current
Borrowings			462,870
Parents companies and related parties
Current liabilities
Borrowings	3,578,921	3,389,521	5,399,883
Non-current
Borrowings	$ 6,000,000	$ 9,000,000	$ 12,358,024

INFORMATION ABOUT COMPONENTS_24

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, carrying amount (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current liabilities
Borrowings	$ 76,785,857	$ 63,721,735	$ 66,477,209
Corporate bonds	24,742,752	12,611,940	8,416,768
Non-current
Corporate bonds	37,826,641	18,364,894	8,018,884
Borrowings	47,988,468	41,226,610	37,079,521
Amortized cost
Current liabilities
Corporate bonds	24,742,752	12,611,940	8,416,768
Non-current
Corporate bonds	37,826,641	18,364,894	8,018,884
Fair value
Current liabilities
Corporate bonds	24,085,087	11,997,981	7,632,806
Non-current
Corporate bonds	32,656,097	16,135,876	6,972,332
Bank borrowings
Current liabilities
Borrowings	33,684,287	47,646,912	52,274,611
Non-current
Borrowings	4,161,827	3,497,671	16,239,743
Bank borrowings | Amortized cost
Current liabilities
Borrowings	33,684,287	47,646,912	52,274,611
Non-current
Borrowings	4,161,827	3,497,671	16,239,743
Bank borrowings | Fair value
Current liabilities
Borrowings	32,770,615	43,046,111	52,088,002
Non-current
Borrowings	$ 3,864,666	$ 3,072,395	$ 14,274.55

INFORMATION ABOUT COMPONENTS_25

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, parent company loans (Details)	Jun. 30, 2019USD ($)
Current borrowings
Borrowings:
Gross amounts	$ (21,227,730)
Gross amounts set off in the Statement of Financial Position	15,827,847
Net amounts presented in the Statement of Financial Position	(5,399,883)
Total current liabilities
Borrowings:
Gross amounts	(21,227,730)
Gross amounts set off in the Statement of Financial Position	15,827,847
Net amounts presented in the Statement of Financial Position	(5,399,883)
Non-current borrowings
Borrowings:
Gross amounts	(12,358,024)
Net amounts presented in the Statement of Financial Position	(12,358,024)
Total non-current liabilities
Borrowings:
Gross amounts	(12,358,024)
Net amounts presented in the Statement of Financial Position	(12,358,024)
Current other receivables
Borrowings:
Gross amounts	15,827,847
Gross amounts set off in the Statement of Financial Position	(15,827,847)
Total current assets
Borrowings:
Gross amounts	15,827,847
Gross amounts set off in the Statement of Financial Position	$ (15,827,847)

INFORMATION ABOUT COMPONENTS_26

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, corporate bonds (Details) - USD ($) $ in Millions	Jun. 30, 2021	Apr. 04, 2019
Issuance of public corporate bonds
Borrowings:
Amount approved for issuance	$ 80
Outstanding amount	$ 22.6
Issuance of private corporate bonds
Borrowings:
Notional amount		$ 16

INFORMATION ABOUT COMPONENTS_27

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, syndicated loan (Details) $ in Millions	Jun. 30, 2017USD ($)
Rizobacter | Syndicated loan
Borrowings:
Notional amount	$ 45

INFORMATION ABOUT COMPONENTS_28

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Employee benefits and social security (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Salaries, accrued incentives, vacations and social security	$ 2,341,351	$ 2,960,542	$ 3,044,965
Key management personnel	2,338,727	1,550,050	2,312,253
Employee benefits and social security	$ 4,680,078	4,510,592	$ 5,357,218
Key management personnel		534,038
Employee benefits and social security, Non-current		$ 534,038

INFORMATION ABOUT COMPONENTS_29

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Deferred revenue and advances from customers (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Advances from customers	$ 6,277,313	$ 2,865,437	$ 1,074,463
Deferred revenue and advances from customers	$ 6,277,313	$ 2,865,437	$ 1,074,463

INFORMATION ABOUT COMPONENTS_30

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Government grants, rollforward (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
At the beginning of the year	$ 3,605	$ 10,208	$ 33,227
Adjustment of opening net book amount for application of IAS 29			(27,794)
Received during the year	4,749	32,073	31,785
Currency conversion differences	(5,268)	(13,944)	(10,638)
Released to the statement of profit or loss	(2,302)	(24,732)	(16,372)
At the end of year	$ 784	$ 3,605	$ 10,208

INFORMATION ABOUT COMPONENTS_31

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Provisions (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Provisions
Provision	$ 7,421,300	$ 5,412,866	$ 4,282,378	$ 4,851,524
Total included in liabilities
Provisions
Provision	449,847	417,396	439,740	845,486
Provisions for contingencies
Provisions
Provision	$ 449,847	$ 417,396	$ 439,740	$ 845,486

INFORMATION ABOUT COMPONENTS_32

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Private Warrants (Details)	Aug. 24, 2020USD ($)$ / sharesshares	Jul. 24, 2020	Mar. 14, 2019USD ($)$ / shares	Mar. 02, 2018shares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)$ / shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Private Warrants, Non-Current					$ 1,686,643	$ 2,861,511
Aggregate Number Of Shares Issued Upon Exchange Of Warrants | shares	2,601,954
Payments For Redemption Of Warrants	$ 915,796
Exchange of warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of outstanding warrants exchanged | shares	24,200,000
Number Of Shares Issued Upon Exchange Of Each Warrant | shares	0.12
Cash Consideration For Exchange Of Each Warrant | $ / shares	$ 0.45
Percentage Of Cash Consideration Provided For Premium To Closing Trading Price Of Warrants		321.00%
Percentage Of Implied Value Of Exchange Shares Provided For Premium To Closing Trading Price Of Warrants		482.00%
Number Of Warrants Validly Tendered But Not Properly Withdrawn | shares	21,938,774
Aggregate Cash Consideration For Exchange Of Warrants	$ 115,062
Aggregate Number Of Shares Issued Upon Exchange Of Warrants | shares	2,601,954
Number Of Warrants Redeemed | shares	2,261,226
Warrants Redeemed, Offering Price Per Warrant | $ / shares	$ 0.405
Private warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrant exercise period			5 years
Warrants incorporate in the reverse capitalization as reduction of equity			$ 1,589,548
Number of instruments or interests issued or issuable			12,700,000
Financial liabilities, at fair value			$ 3,400,000		1,700,000	2,800,000
Gain recognized from change in fair value	$ 6,200,000				$ 1,200,000	$ 600,000
Private warrants | Volatility
INFORMATION ABOUT COMPONENTS OF EQUITY
Assumption used in estimating fair value			32
Private warrants | Share price
INFORMATION ABOUT COMPONENTS OF EQUITY
Assumption used in estimating fair value | $ / shares			5.35		6.06	5.30
Private warrants | Risk-free rate
INFORMATION ABOUT COMPONENTS OF EQUITY
Assumption used in estimating fair value			2.43		0.29	1.7631
Private warrants, strike price $15.00
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants strike price			15
Number of instruments or interests issued or issuable			2,500,000
Private warrants, strike price $18.00
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants strike price			18
Number of instruments or interests issued or issuable			2,500,000
Founder warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants incorporate in the reverse capitalization as reduction of equity			$ 1,843,175
Number of instruments or interests issued or issuable			5,200,000
Bioceres warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable			7,500,000
UAC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of warrants issued in IPO | shares				5,200,000
Warrants strike price				11.50
Warrant exercise period				5 years
UAC | Private warrants, strike price $11.50
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants strike price			11.50
Number of instruments or interests issued or issuable			2,500,000
Share price at which warrants become exercisable | $ / shares			$ 15
Number of trading days of shares at $15.00 for the warrants to vest			20
Continuous trading period at the warrant strike price for the warrants to vest			30 days

INFORMATION ABOUT COMPONENTS_33

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Convertible Notes (Details)	Mar. 06, 2020USD ($)multiple$ / shares	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Convertible Notes [Abstract]
Convertible notes | $		$ 48,664,012	$ 43,029,834
Convertible Notes
Convertible Notes [Abstract]
Notional amount | $	$ 42,500,000
Conversion price (in USD per share) | $ / shares	$ 8
Amount of free float over which the notes can be mandatorily converted to ordinary shares | $	$ 100,000,000
Period of amount of free float over which the notes can be mandatorily converted to ordinary shares	10 days
Borrowings, interest rate	11.50%
EBITDA to interest ratio	2
Convertible Notes | Fair value | Discount rate
Convertible Notes [Abstract]
Significant unobservable input, liabilities	12.66
Convertible Notes | Year 2020
Convertible Notes [Abstract]
Net Debt to EBITDA ratio must be less than	3.5
Convertible Notes | Year 2022
Convertible Notes [Abstract]
Net Debt to EBITDA ratio must be less than	3.25
Convertible Notes | Year 2023
Convertible Notes [Abstract]
Net Debt to EBITDA ratio must be less than	3

INFORMATION ABOUT COMPONENTS_34

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Changes in allowance and provisions (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Changes in allowances and provisions
Beginning	$ (5,412,866)	$ (4,282,378)	$ (4,851,524)
Additions	(1,504,592)	(2,714,391)	(1,546,385)
Additions for business combination	(861,776)
Uses and reversals	763,740	61,873	1,036,732
IAS 29			(1,864,557)
Currency conversion difference	(405,806)	1,522,030	(785,758)
Ending	(7,421,300)	(5,412,866)	(4,282,378)
Allowance deducted from assets
Changes in allowances and provisions
Beginning	(4,995,470)	(3,842,638)	(4,006,038)
Additions	(1,342,271)	(2,506,014)	(1,472,276)
Additions for business combination	(861,776)
Uses and reversals	760,237	54,021	715,791
IAS 29			(1,511,300)
Currency conversion difference	(532,173)	1,299,161	(591,415)
Ending	(6,971,453)	(4,995,470)	(3,842,638)
Allowance for impairment of trade debtors
Changes in allowances and provisions
Beginning	(3,886,832)	(3,360,224)	(3,212,170)
Additions	(698,741)	(1,520,928)	(654,991)
Additions for business combination	(852,926)
Uses and reversals	284,727	2,115	87,916
IAS 29			(1,220,652)
Currency conversion difference	(704,731)	992,205	(801,631)
Ending	(5,858,503)	(3,886,832)	(3,360,224)
Allowance for impairment of related parties
Changes in allowances and provisions
Beginning	(768)	(75,596)	(23,126)
Additions		(879)	(80,913)
Uses and reversals	565	45,516	12,408
IAS 29			(17,396)
Currency conversion difference	203	30,191	(1,361)
Ending		(768)	(75,596)
Allowance for obsolescence
Changes in allowances and provisions
Beginning	(1,107,870)	(406,818)	(770,742)
Additions	(643,530)	(984,207)	(736,372)
Additions for business combination	(8,850)
Uses and reversals	474,945	6,390	615,467
IAS 29			(273,252)
Currency conversion difference	172,355	276,765	211,577
Ending	(1,112,950)	(1,107,870)	(406,818)
Total included in liabilities
Changes in allowances and provisions
Beginning	(417,396)	(439,740)	(845,486)
Additions	(162,321)	(208,377)	(74,109)
Uses and reversals	3,503	7,852	320,941
IAS 29			(353,257)
Currency conversion difference	126,367	222,869	(194,343)
Ending	(449,847)	(417,396)	(439,740)
Provisions for contingencies
Changes in allowances and provisions
Beginning	(417,396)	(439,740)	(845,486)
Additions	(162,321)	(208,377)	(74,109)
Uses and reversals	3,503	7,852	320,941
IAS 29			(353,257)
Currency conversion difference	126,367	222,869	(194,343)
Ending	$ (449,847)	$ (417,396)	$ (439,740)

INFORMATION ABOUT COMPONENTS_35

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Acquisition of business (Details) - USD ($)	Mar. 14, 2019	Jun. 30, 2019
Business combinations:
Gain for cancellation of purchase option		$ 6,582,849
Acquisition of 9.99% Ownership of Rizobacter Argentina
Business combinations:
Cash transferred	$ 1,265,000
Number of instruments or interests issued or issuable	1,334,047
Rizobacter Argentina | BCS Holding Inc
Business combinations:
Proportion of ownership interest in subsidiary	80.00%

INFORMATION ABOUT COMPONENTS_36

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Revenue (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Revenue
Royalties	$ 2,023,548	$ 1,775,790	$ 1,110,463
Revenues from contracts with customers	206,697,620	172,350,699	160,308,979
Sale of goods and services
Revenue
Revenues from contracts with customers	$ 204,674,072	$ 170,574,909	$ 159,198,516

INFORMATION ABOUT COMPONENTS_37

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Cost of Sales (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Inventories as of the beginning of the year	$ 29,338,548	$ 27,322,003	$ 19,366,001
Adjustment of opening net book amount for the application of IAS 29			4,273,416
Business combination	5,611,918
Purchases of the year	112,084,246	88,195,797	88,380,452
Production costs	11,169,890	10,998,165	11,558,513
Foreign currency translation	(509,874)	(3,601,829)	(9,291,498)
Subtotal	157,694,728	122,914,136	114,286,884
Inventories as of the end of the year	39,052,925	29,338,548	27,322,003
Cost of sales	$ 118,641,803	$ 93,575,588	$ 86,964,881

INFORMATION ABOUT COMPONENTS_38

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - R&D classified by nature (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
R&D classified by nature
Amortization of intangible assets	$ 1,250,262	$ 1,122,194	$ 1,270,529
Import and export expenses	791,671	1,511,482	1,491,747
Depreciation of property, plant and equipment	2,593,964	1,912,965	2,229,407
Employee benefits and social securities	19,954,021	17,249,517	18,282,864
Maintenance	1,219,020	930,920	1,034,347
Energy and fuel	389,522	508,394	764,297
Supplies and materials	719,681	582,088	489,891
Mobility and travel	951,844	1,371,837	1,318,164
Professional fees and outsourced services	8,455,505	3,328,418	8,028,397
Professional fees related parties	157,714	32,816	401,005
Office supplies	680,936	358,999	383,561
Insurance	1,073,010	359,225	907,654
Depreciation of leased assets	827,320	573,897
Miscellaneous	365,738	188,804	228,205
Research and development expenses	5,617,655	4,195,270	3,689,391
Research and development expenses
R&D classified by nature
Amortization of intangible assets	1,138,720	1,027,340	1,106,390
Import and export expenses	5,220	17,303	16,360
Depreciation of property, plant and equipment	454,575	97,171	220,849
Freight and haulage	2,335
Employee benefits and social securities	1,430,277	787,931	541,025
Maintenance	54,551	59,219	56,395
Energy and fuel	44,518	52,614	52,919
Supplies and materials	1,401,869	871,930	1,175,184
Mobility and travel	29,783	70,138	48,308
Professional fees and outsourced services	235,443	94,286	69,110
Professional fees related parties	691,723	821,809	378,273
Office supplies	5,170	9,801	3,796
Information technology expenses	14,531
Insurance	24,439	5,353	8,593
Depreciation of leased assets	23,286	7,079
Impairment of R&D projects	51,716	269,001
Miscellaneous	9,499	4,295	12,189
Research and development expenses	$ 5,617,655	$ 4,195,270	$ 3,689,391

INFORMATION ABOUT COMPONENTS_39

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Expenses Classified by Nature and Function (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Production costs
Analysis and storage	$ 23,417	$ 46,620	$ 5,811
Commissions and royalties	971,932	1,268,670	751,972
Import and export expenses	70,783	190,226	95,111
Depreciation property, plant and equipment	1,274,206	1,170,624	1,164,810
Depreciation of leased assets	159,325	248,948
Freight and haulage	488,683	541,019	1,433,867
Employee benefits and social securities	4,974,759	4,744,240	5,313,211
Maintenance	632,406	400,162	501,699
Energy and fuel	336,812	397,253	568,848
Supplies and materials	516,431	321,962	275,378
Mobility and travel	11,225	12,980	12,097
Professional fees and outsourced services	787,462	575,566	681,790
Office supplies	217,146	2,093	31,394
Insurance	79,272	64,019	105,302
Information technology expenses	441
Obsolescence	579,832	977,817	564,873
Taxes	44,228	28,724	37,388
Miscellaneous	1,530	7,242	14,962
Production costs	11,169,890	10,998,165	11,558,513
Selling, general and administrative expenses
Amortization intangible assets	1,250,262	1,122,194	1,270,529
Analysis and storage	123,168	23,851	905
Commissions and royalties	996,636	553,518	489,301
Bank expenses and commissions			30,784
Import and export expenses	720,888	1,321,256	1,396,636
Depreciation of property, plant and equipment	1,319,758	742,341	1,064,597
Depreciation of leased assets	644,709	317,870
Impairment of receivables	560,931	1,499,298	686,985
Freight and haulage	3,894,696	3,458,525	2,662,715
Employee benefits and social securities	14,979,262	12,505,277	12,969,653
Maintenance	586,614	530,758	532,648
Energy and fuel	52,710	111,141	195,449
Supplies and materials	203,250	260,126	214,513
Mobility and travel	940,619	1,358,857	1,306,067
Publicity and advertising	2,518,286	1,718,572	1,709,552
Contingencies	158,818	200,525	67,417
Share-based incentives	1,655,135	3,428,029
Professional fees and outsourced services	7,668,043	2,752,852	7,346,607
Professional fees related parties	157,714	32,816	401,005
Office supplies	463,790	356,906	352,167
Insurance	993,738	295,206	802,352
Information technology expenses	1,347,374	917,230	709,539
Taxes	6,001,292	4,656,318	4,821,136
Miscellaneous	364,208	181,562	213,243
Total selling, general and administrative expense	47,601,901	38,345,028	39,243,800
Production costs and selling, general and administrative expenses
Amortization of intangible assets	1,250,262	1,122,194	1,270,529
Analysis and storage	146,585	70,471	6,716
Commissions and royalties	1,968,568	1,822,188	1,241,273
Bank expenses and commissions			30,784
Import and export expenses	791,671	1,511,482	1,491,747
Depreciation of property, plant and equipment	2,593,964	1,912,965	2,229,407
Depreciation of leased assets	804,034	566,818
Impairment of receivables	560,931	1,499,298	686,985
Freight and haulage	4,383,379	3,999,544	4,096,582
Employee benefits and social securities	19,954,021	17,249,517	18,282,864
Maintenance	1,219,020	930,920	1,034,347
Information technology expenses	1,347,815	917,230	709,539
Energy and fuel	389,522	508,394	764,297
Supplies and materials	719,681	582,088	489,891
Mobility and travel	951,844	1,371,837	1,318,164
Publicity and advertising	2,518,286	1,718,572	1,709,552
Contingencies	158,818	200,525	67,417
Share-based incentives	1,655,135	3,428,029
Professional fees and outsourced services	8,455,505	3,328,418	8,028,397
Professional fees related parties	157,714	32,816	401,005
Office supplies	680,936	358,999	383,561
Insurance	1,073,010	359,225	907,654
Obsolescence	579,832	977,817	564,873
Taxes	6,045,520	4,685,042	4,858,524
Miscellaneous	365,738	188,804	228,205
Total	$ 58,771,791	$ 49,343,193	$ 50,802,313

INFORMATION ABOUT COMPONENTS_40

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Finance results (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Finance Costs
Interest expenses with the Parents	$ (1,219,776)	$ (1,861,774)	$ (1,386,288)
Interest expenses	(17,702,770)	(17,535,324)	(20,450,254)
Financial commissions	(2,317,690)	(1,483,428)	(1,578,292)
Finance Costs	(21,240,236)	(20,880,526)	(23,414,834)
Other finance results
Exchange differences generated by assets	22,161,855	30,194,601	48,355,784
Exchange differences generated by liabilities	(35,541,048)	(50,815,215)	(66,200,973)
Changes in fair value of financial assets or liabilities and other financial results	(5,057,589)	(418,186)	(540,589)
Gain from cancellation of purchase option			6,582,849
Share-based payment cost of listing shares			(20,893,789)
Net gain of inflation effect on monetary items	11,824,678	9,216,684	14,653,335
Other finance results	(6,612,104)	(11,822,116)	(18,043,383)
Total net finance results	(27,852,340)	(32,702,642)	(41,458,217)
Profit from translation effects	10,076,208	(10,108,444)	5,240,151
Rizobacter Argentina S.A
Other finance results
Profit from translation effects	$ 6,700,000	$ 3,600,000	$ 1,200,000

TAXATION - Adiitional informati

TAXATION - Adiitional information (Details) - ARS ($) $ in Millions	1 Months Ended			6 Months Ended	12 Months Ended	36 Months Ended
	Jun. 30, 2021	Dec. 31, 2019	Dec. 31, 2017	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021
Income Taxes [Line Items]
Applicable tax rate	25.00%	30.00%	35.00%			30.00%
Dividends tax (as a percent)				7.00%
Accumulated net taxable income with 25%					$ 5
Accumulated net taxable income with 35%					50
Maximum
Income Taxes [Line Items]
Accumulated net taxable income with 30%					50
Minimum
Income Taxes [Line Items]
Accumulated net taxable income with 30%					$ 5

TAXATION - Tax recoverable and

TAXATION - Tax recoverable and payable (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current assets
Income tax	$ 990,881	$ 112,220	$ 1,263,795
Non-current assets
Income tax	10,105	2,653
Minimum presumed income tax	2,484	3,376	1,184
Total	12,589	6,029	1,184
Liabilities
Income tax	$ 7,452,891	$ 1,556,715	$ 142,028

TAXATION - Deferred tax assets

TAXATION - Deferred tax assets and liabilities (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Deferred tax assets and liabilities
Net deferred tax	$ (22,421,125)	$ (14,164,930)	$ (17,358,162)	$ (7,990,121)
Deferred tax asset
Deferred tax assets and liabilities
Total deferred tax assets	5,963,588	4,535,752	3,743,709	5,601,821
Tax Loss-Carry Forward
Deferred tax assets and liabilities
Total deferred tax assets	3,226,305	2,362,657	2,663,813	3,638,269
Changes in fair value of financial assets or liabilities
Deferred tax assets and liabilities
Total deferred tax assets	89,574	41,183	32,062	35,944
Trade receivables
Deferred tax assets and liabilities
Total deferred tax assets	609,913	1,068,054	374,425	462,756
Royalties
Deferred tax assets and liabilities
Total deferred tax assets	485,426	245,140
Right-of-use leased assets
Deferred tax assets and liabilities
Total deferred tax assets		5,424
Government grants
Deferred tax assets and liabilities
Total deferred tax assets			2,649	9,360
Others
Deferred tax assets and liabilities
Total deferred tax assets	1,552,370	813,294	670,760	359,073
Deferred tax liability
Deferred tax assets and liabilities
Total deferred tax liabilities	(28,384,713)	(18,700,682)	(21,101,871)	(13,591,942)
Intangibles assets
Deferred tax assets and liabilities
Total deferred tax liabilities	(10,624,621)	(6,839,112)	(9,458,239)	(5,071,808)
Property, plant and equipment depreciation
Deferred tax assets and liabilities
Total deferred tax liabilities	(12,632,296)	(9,365,882)	(9,618,648)	(8,497,756)
Borrowings
Deferred tax assets and liabilities
Total deferred tax liabilities		(7,930)	(13,170)	(19,372)
Inflation tax adjustment
Deferred tax assets and liabilities
Total deferred tax liabilities	(2,682,172)	(2,032,078)	(1,706,092)
Allowances
Deferred tax assets and liabilities
Total deferred tax liabilities	(78,076)	(209,490)	(152,159)
Inventories
Deferred tax assets and liabilities
Total deferred tax liabilities	(1,821,524)	(237,258)	$ (153,563)
Biological assets
Deferred tax assets and liabilities
Total deferred tax liabilities	(229,296)
Government grants
Deferred tax assets and liabilities
Total deferred tax liabilities	(3,179)	(3,939)
Others financial assets
Deferred tax assets and liabilities
Total deferred tax liabilities	(276,800)
Right-of-use leased asset
Deferred tax assets and liabilities
Total deferred tax liabilities	(32,651)
Others
Deferred tax assets and liabilities
Total deferred tax liabilities	$ (4,098)	$ (4,993)		$ (297)

TAXATION - Deferred tax asset_2

TAXATION - Deferred tax assets and liabilities rollforward (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Deferred tax assets and liabilities
Balance	$ 14,164,930	$ 17,358,162	$ 7,990,121
Additions for business combination	(777,622)		(343,230)
Income tax provision	(4,257,912)	1,888,006	(4,836,941)
Charge to OCI	(1,388,022)	(1,133,228)	576,453
Conversion difference	(1,832,639)	2,438,454	(4,764,323)
Balance	22,421,125	14,164,930	17,358,162
Deferred tax asset
Deferred tax assets and liabilities
Balance	4,535,752	3,743,709	5,601,821
Additions for business combination	370,556		(343,230)
Income tax provision	920,071	1,159,590	(1,868,335)
Transfer from deferred tax assets /liabilities	32,651	3,939	781,896
Conversion difference	104,558	(371,486)	(428,443)
Balance	5,963,588	4,535,752	3,743,709
Tax Loss-Carry Forward
Deferred tax assets and liabilities
Balance	2,362,657	2,663,813	3,638,269
Additions for business combination			113,289
Income tax provision	982,329	(133,346)	(1,306,198)
Conversion difference	(118,681)	(167,810)	218,453
Balance	3,226,305	2,362,657	2,663,813
Changes in fair value of financial assets or liabilities
Deferred tax assets and liabilities
Balance	41,183	32,062	35,944
Additions for business combination			25,868
Income tax provision	51,037	20,222	(33,200)
Conversion difference	(2,646)	(11,101)	3,450
Balance	89,574	41,183	32,062
Trade receivables
Deferred tax assets and liabilities
Balance	1,068,054	374,425	462,756
Income tax provision	138,438	764,707	(114,765)
Conversion difference	(596,579)	(71,078)	26,434
Balance	609,913	1,068,054	374,425
Royalties
Deferred tax assets and liabilities
Balance	245,140
Income tax provision	214,493	245,140
Conversion difference	25,793
Balance	485,426	245,140
Right-of-use leased asset
Deferred tax assets and liabilities
Balance	5,424
Income tax provision	(38,793)	5,676
Transfer from deferred tax assets /liabilities	32,651
Conversion difference	718	(252)
Balance		5,424
Allowances
Deferred tax assets and liabilities
Balance			370,930
Income tax provision			(555,679)
Transfer from deferred tax assets /liabilities			152,159
Conversion difference			32,590
Inventories
Deferred tax assets and liabilities
Balance			710,391
Income tax provision			(119,316)
Transfer from deferred tax assets /liabilities			153,563
Conversion difference			(744,638)
Intangible assets
Deferred tax assets and liabilities
Balance			15,098
Additions for business combination			(482,387)
Income tax provision			(22,467)
Transfer from deferred tax assets /liabilities			476,174
Conversion difference			13,582
Government grants
Deferred tax assets and liabilities
Balance		2,649	9,360
Income tax provision		(6,216)	(7,262)
Transfer from deferred tax assets /liabilities		3,939
Conversion difference		(372)	551
Balance			2,649
Others
Deferred tax assets and liabilities
Balance	813,294	670,760	359,073
Additions for business combination	370,556
Income tax provision	(427,433)	263,407	290,552
Conversion difference	795,953	(120,873)	21,135
Balance	1,552,370	813,294	670,760
Deferred tax liability
Deferred tax assets and liabilities
Balance	(18,700,682)	(21,101,871)	(13,591,942)
Additions for business combination	(1,148,178)
Income tax provision	(5,177,983)	728,416	(2,968,606)
Transfer from deferred tax assets /liabilities	(32,651)	(3,939)	(781,896)
Charge to OCI	(1,388,022)	(1,133,228)	576,453
Conversion difference	(1,937,197)	2,809,940	(4,335,880)
Balance	(28,384,713)	(18,700,682)	(21,101,871)
Intangibles assets
Deferred tax assets and liabilities
Balance	(6,839,112)	(9,458,239)	(5,071,808)
Additions for business combination	(882,434)
Income tax provision	(2,188,663)	1,469,311	(937,962)
Transfer from deferred tax assets /liabilities			(476,174)
Conversion difference	(714,412)	1,149,816	(2,972,295)
Balance	(10,624,621)	(6,839,112)	(9,458,239)
Property, plant and equipment depreciation
Deferred tax assets and liabilities
Balance	(9,365,882)	(9,618,648)	(8,497,756)
Additions for business combination	(537,922)
Income tax provision	(357,614)	45,028	(335,077)
Charge to OCI	(1,388,022)	(1,133,228)	576,453
Conversion difference	(982,856)	1,340,966	(1,362,268)
Balance	(12,632,296)	(9,365,882)	(9,618,648)
Borrowings
Deferred tax assets and liabilities
Balance	(7,930)	(13,170)	(19,372)
Income tax provision	8,797	3,548	7,342
Conversion difference	(867)	1,692	(1,140)
Balance		(7,930)	(13,170)
Contingencies
Deferred tax assets and liabilities
Balance			(2,709)
Income tax provision			2,869
Conversion difference			(160)
Inflation tax adjustment
Deferred tax assets and liabilities
Balance	(2,032,078)	(1,706,092)
Additions for business combination	73,755
Income tax provision	(527,654)	(589,811)	(1,706,092)
Conversion difference	(196,195)	263,825
Balance	(2,682,172)	(2,032,078)	(1,706,092)
Allowances
Deferred tax assets and liabilities
Balance	(209,490)	(152,159)
Additions for business combination	201,969
Income tax provision	(46,622)	(84,515)
Transfer from deferred tax assets /liabilities			(152,159)
Conversion difference	(23,933)	27,184
Balance	(78,076)	(209,490)	(152,159)
Inventories
Deferred tax assets and liabilities
Balance	(237,258)	(153,563)
Additions for business combination	(3,546)
Income tax provision	(1,561,687)	(110,152)
Transfer from deferred tax assets /liabilities			(153,563)
Conversion difference	(19,033)	26,457
Balance	(1,821,524)	(237,258)	(153,563)
Biological assets
Deferred tax assets and liabilities
Income tax provision	(229,296)
Balance	(229,296)
Government grants
Deferred tax assets and liabilities
Balance	(3,939)
Income tax provision	1,174
Transfer from deferred tax assets /liabilities		(3,939)
Conversion difference	(414)
Balance	(3,179)	(3,939)
Others financial assets
Deferred tax assets and liabilities
Income tax provision	(277,841)
Conversion difference	1,041
Balance	(276,800)
Right-of-use leased asset
Deferred tax assets and liabilities
Transfer from deferred tax assets /liabilities	(32,651)
Balance	(32,651)
Others
Deferred tax assets and liabilities
Balance	(4,993)		(297)
Income tax provision	1,423	(4,993)	314
Conversion difference	(528)		$ (17)
Balance	$ (4,098)	$ (4,993)

TAXATION - Reconciliation of th

TAXATION - Reconciliation of the statutory tax rate (Details) - USD ($)	1 Months Ended			12 Months Ended			36 Months Ended
	Jun. 30, 2021	Dec. 31, 2019	Dec. 31, 2017	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2021
TAXATION
Tax rate applied to loss (as a percent)					0.00%	0.00%
Tax rate applied to first level of earnings (as a percent)					21.00%	21.00%
Income tax rate (as a percent)	25.00%	30.00%	35.00%				30.00%
Loss before income tax-rate 0%				$ (17,127,991)	$ (205,022)	$ (21,669,882)
Earning before income tax-rate 21%				(2,046,392)	828,074	1,264
Earnings before income tax-rate 30%				29,704,931	5,820,286	12,296,011
Earnings (Loss) before income tax-rate				10,530,548	6,443,338	(9,372,607)
Income tax expense by applying tax rate to profit (loss) before tax				(8,481,737)	(1,919,981)	(3,689,069)
Share of profit or loss of subsidiaries, joint ventures and associates				274,877	847,512	(44,721)
Stock options charge				(58,248)	(298,222)	78,681
Rate change adjustment				(1,780,962)	(144,660)	(54,735)
Non-deductible expenses				(365,350)	(84,128)	(254,201)
Untaxed gains				557,911
Representation expenses					(36,691)	(136,614)
Foreign investment coverage				390,170	551,968	233,634
Tax provision adjustments				476,890	307,944
Tax inflation adjustment				(2,182,988)	(1,174,964)	(941,734)
Result of inflation effect on monetary items and other finance results				(3,181,733)	(255,488)	(2,177,525)
Income tax expenses				(14,351,170)	(2,206,710)	(6,986,284)
Deferred income tax liabilities not recognized	$ 2,497,033			$ 2,497,033	$ 1,052,022	$ 44,721	$ 2,497,033

TAXATION - Schedule of Principa

TAXATION - Schedule of Principal statutory taxes rates and current tax (Details) - USD ($)	1 Months Ended			12 Months Ended			36 Months Ended
	Jun. 30, 2021	Dec. 31, 2019	Dec. 31, 2017	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2021
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate	25.00%	30.00%	35.00%				30.00%
Current tax expense				$ (10,093,258)	$ (4,094,716)	$ (2,149,343)
Deferred tax				(4,257,912)	1,888,006	(4,836,941)
Income tax expenses				$ (14,351,170)	$ (2,206,710)	$ (6,986,284)
Argentina
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate					30.00%	30.00%
Cayman Island
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				0.00%	0.00%	0.00%
Paraguay
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				10.00%	10.00%	10.00%
Uruguay
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				25.00%	25.00%	25.00%
France
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				28.00%	28.00%	28.00%
Brazil
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				34.00%	34.00%	34.00%
United States of America
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				21.00%	21.00%	21.00%
Maximum | Argentina
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				35.00%
Minimum | Argentina
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				25.00%

TAXATION - Tax loss carryforwar

TAXATION - Tax loss carryforward (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Tax loss carryforward
Deferred tax assets	$ 3,278,370	$ 2,693,195	$ 3,743,709
Argentina
Tax loss carryforward
Minimum amount of presumed income tax		2,484
Argentina | 2014
Tax loss carryforward
Minimum amount of presumed income tax		474
Argentina | 2015
Tax loss carryforward
Minimum amount of presumed income tax		1,003
Argentina | 2016
Tax loss carryforward
Minimum amount of presumed income tax		$ 1,007
Tax Loss-Carry Forward
Tax loss carryforward
Tax-Loss Carry forward	13,883,042
Deferred tax assets	3,202,770
Tax Loss-Carry Forward | 2017
Tax loss carryforward
Tax-Loss Carry forward	186,545
Deferred tax assets	55,261
Tax Loss-Carry Forward | 2018
Tax loss carryforward
Tax-Loss Carry forward	168,888
Deferred tax assets	49,976
Tax Loss-Carry Forward | 2019
Tax loss carryforward
Tax-Loss Carry forward	206,082
Deferred tax assets	51,520
Tax Loss-Carry Forward | 2019
Tax loss carryforward
Tax-Loss Carry forward	4,258,576
Deferred tax assets	894,301
Tax Loss-Carry Forward | 2020
Tax loss carryforward
Tax-Loss Carry forward	1,094,530
Deferred tax assets	273,633
Tax Loss-Carry Forward | 2020
Tax loss carryforward
Tax-Loss Carry forward	2,845,571
Deferred tax assets	597,570
Tax Loss-Carry Forward | 2021
Tax loss carryforward
Tax-Loss Carry forward	2,961,583
Deferred tax assets	826,643
Tax Loss-Carry Forward | 2021
Tax loss carryforward
Tax-Loss Carry forward	2,161,267
Deferred tax assets	$ 453,866

EARNING PER SHARE (Details)

EARNING PER SHARE (Details) - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Numerator
(Loss) profit for the year (basic EPS)		$ (6,870,163)	$ 3,359,175	$ (18,369,045)
(Loss) profit for the year (diluted EPS)		$ (6,870,163)	$ 3,359,175	$ (18,369,045)
Denominator
Weighted average number of shares (basic EPS)	[1]	39,218,632	36,120,447	30,478,390
Weighted average number of shares - (diluted EPS)		39,218,632	36,416,988	30,478,390
Basic (loss) gain attributable to ordinary equity holders of the parent		$ (0.1752)	$ 0.0930	$ (0.6027)
Diluted (loss) gain attributable to ordinary equity holders of the parent		$ (0.1752)	$ 0.0922	$ (0.6027)
[1]	For the years ended June 30, 2021 and 2019 diluted EPS was the same as basic EPS as the effect of potential ordinary shares would be antidilutive.

EARNING PER SHARE - Capital iss

EARNING PER SHARE - Capital issued (Details) - shares	Aug. 24, 2020	Jun. 30, 2021	Jun. 30, 2019	Jun. 30, 2018
Disclosure of detailed information about business combination
Shares issued in exchange of warrants	2,601,954
Exchange of warrants
Disclosure of detailed information about business combination
Warrants exchanged to issue shares of common stock	24,200,000
Shares issued in exchange of warrants	2,601,954
Original founders of Union | Founder Shares | Bioceres LLC
Disclosure of detailed information about business combination
Number of shares issued in the merger and acquisition included		27,116,174		862,500
Original founders of Union | Founder Shares | Bioceres Semillas S.A.U.
Disclosure of detailed information about business combination
Number of shares issued in the merger and acquisition included			119,443

INFORMATION ABOUT COMPONENTS_41

INFORMATION ABOUT COMPONENTS OF EQUITY - Reverse recapitalization (Details) - USD ($)	Mar. 14, 2019	Feb. 27, 2019	Oct. 19, 2016
INFORMATION ABOUT COMPONENTS OF EQUITY
Excess of fair value of equity instruments over the net monetary assets acquired	$ 20,900,000
Trust account proceeds incorporated to the Group		$ 1,083,840
Bioceres LLC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable	27,116,174
Number of instruments or interests issued or issuable	27,116,174
Acquisition of 9.99% Ownership of Rizobacter Argentina
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable	1,334,047
Percentage of voting equity interests acquired			9.99%
Cash transferred	$ 1,265,000
Number of instruments or interests issued or issuable	1,334,047
Acquisition of 20% Ownership of Rizobacter Argentina
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable	3,402,688
Percentage of voting equity interests acquired	20.00%
Number of instruments or interests issued or issuable	3,402,688
UAC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of rights converted to ordinary shares		11,500,000
Number of shares issued for the 11,500,000 rights		1,150,000
Number ordinary share redeemed		11,376,836
Redemption payment		$ 117,005,196
Share price		$ 5.35
Original founders of Union | Founder Shares | Bioceres LLC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable	862,500
Number of instruments or interests issued or issuable	862,500
BCS Holding Inc | Rizobacter Argentina
INFORMATION ABOUT COMPONENTS OF EQUITY
Proportion of ownership interest in subsidiary	80.00%

INFORMATION ABOUT COMPONENTS_42

INFORMATION ABOUT COMPONENTS OF EQUITY - Capital issued (Details)	Jun. 30, 2021USD ($)Vote$ / sharesshares	Aug. 24, 2020shares	Jun. 30, 2021USD ($)Vote$ / sharesshares	Nov. 12, 2020USD ($)	Mar. 14, 2019USD ($)
Capital issued
Shares issued in exchange of warrants | shares		2,601,954
Shares in reference to the share-based incentives			971,072
Number of own shares repurchased | shares	464,455
Principal amount of convertible notes	$ 49,100,000		$ 49,100,000
Bioceres LLC
Capital issued
Number of instruments or interests issued or issuable					27,116,174
Shares issued in exchange for the acquisition of assets					27,116,174
Bioceres Semillas S.A.U.
Capital issued
Number of instruments or interests issued or issuable					119,443
Shares issued in exchange for the acquisition of assets					119,443
Verdeca
Capital issued
Number of instruments or interests issued or issuable				1,875,000
Shares issued in exchange for the acquisition of assets				1,875,000
Equity Compensation Plan
Capital issued
Stock options granted under share option agreements	2,032,092		2,032,092
Ordinary shares
Capital issued
Number of shares authorised | shares	100,000,000		100,000,000
Par value per share | $ / shares	$ 0.0001		$ 0.0001
Number of shares issued | shares	41,104,087		41,104,087
Number of shares outstanding | shares	41,104,087		41,104,087
Vote per share | Vote	1		1
Preference shares
Capital issued
Number of shares authorised | shares	1,000,000		1,000,000
Par value per share | $ / shares	$ 0.0001		$ 0.0001
Number of shares issued | shares	0		0
Number of shares outstanding | shares	0		0
Original founders of Union | Founder Shares | Bioceres LLC
Capital issued
Number of instruments or interests issued or issuable					862,500
Shares issued in exchange for the acquisition of assets					862,500

INFORMATION ABOUT COMPONENTS_43

INFORMATION ABOUT COMPONENTS OF EQUITY - Rizobacter Argentina and Insuagro (Details) - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Financial position
Current assets		$ 211,489,658	$ 164,693,055	$ 98,208,964
Non-current assets		183,100,299	132,868,314	144,258,333
Total assets		394,589,957	297,561,369	242,467,297
Current liabilities		168,037,855	130,610,709	116,458,133
Non-current liabilities		136,261,798	106,201,178	63,914,298
Total liabilities		304,299,653	236,811,887	180,372,431
Equity attributable to controlling interest		67,743,242	46,179,395	47,301,863
Equity attributable to non-controlling interest		22,547,062	14,570,087	14,793,003
Total equity		90,290,304	60,749,482	62,094,866	$ 33,133,656
Total liabilities and equity		394,589,957	297,561,369	242,467,297
Summary statements of comprehensive income or loss
Revenues		209,526,177	173,092,172	160,605,296
Initial recognition and changes in the fair value of biological assets		2,826,255	716,741	279,945
Cost of sales		(118,641,803)	(93,575,588)	(86,964,881)
Gross margin		90,884,374	79,516,584	73,640,415
Research and development expenses		(5,617,655)	(4,195,270)	(3,689,391)
Selling, general and administrative expenses		(47,601,901)	(38,345,028)	(39,243,800)
Share of profit or loss of joint ventures and associates		997,429	2,477,193	1,012,486
Other income		(279,359)	(307,499)	365,900
Operating profit		38,382,888	39,145,980	32,085,610
Financial results		(27,852,340)	(32,702,642)	(41,458,217)
Profit (loss) before income tax		10,530,548	6,443,338	(9,372,607)
Income tax expense		(14,351,170)	(2,206,710)	(6,986,284)
Result for the year		(3,820,622)	4,236,628	(16,358,891)
Exchange differences on translation of foreign operations		10,076,208	(10,108,444)	5,240,151
Revaluation of property, plant and equipment, net of tax	[1]	(2,268,839)	3,399,683	(1,441,132)
Total comprehensive profit (loss)		$ 6,230,696	$ (5,445,488)	$ (12,454,526)
Rizobacter Argentina
Summarized financial information
Proportion of ownership interests held by non-controlling interests		20.00%	20.00%	20.00%
Financial position
Current assets		$ 175,827,504	$ 148,256,827	$ 115,546,951
Non-current assets		59,868,513	49,843,457	47,418,450
Total assets		235,696,017	198,100,284	162,965,401
Current liabilities		119,966,445	129,838,941	100,590,919
Non-current liabilities		57,480,984	32,935,399	34,788,705
Total liabilities		177,447,429	162,774,340	135,379,624
Equity attributable to controlling interest		58,246,057	35,324,227	27,584,666
Equity attributable to non-controlling interest		2,531	1,717	1,111
Total equity		58,248,588	35,325,944	27,585,777
Total liabilities and equity		235,696,017	198,100,284	162,965,401
Summary statements of comprehensive income or loss
Revenues		189,749,478	162,404,866	156,741,933
Initial recognition and changes in the fair value of biological assets		1,552,746	716,741
Cost of sales		(106,636,141)	(86,533,561)	(85,287,771)
Gross margin		84,666,083	76,588,046	71,454,162
Research and development expenses		(3,208,904)	(2,689,468)	(2,367,727)
Selling, general and administrative expenses		(37,500,952)	(36,103,289)	(31,316,843)
Share of profit or loss of joint ventures and associates		481,442	1,960,549	1,071,297
Other income		507,246	(380,871)	286,626
Operating profit		44,944,915	39,374,967	39,127,515
Financial results		(11,032,748)	(30,014,131)	(24,650,359)
Profit (loss) before income tax		33,912,167	9,360,836	14,477,156
Income tax expense		(14,141,515)	(3,830,106)	(7,729,300)
Result for the year		19,770,652	5,530,730	6,747,856
Exchange differences on translation of foreign operations		1,704,590	1,281,974	17,197
Revaluation of property, plant and equipment, net of tax		(2,682,457)	3,921,091	(1,347,124)
Total comprehensive profit (loss)		$ 18,792,785	$ 10,733,795	$ 5,417,929
Insumos Agroquimicos S.A.
Summarized financial information
Proportion of ownership interests held by non-controlling interests		49.90%
Summary statements of comprehensive income or loss
Revenues		$ 7,600,041
Cost of sales		(5,886,326)
Gross margin		1,713,715
Selling, general and administrative expenses		(1,065,147)
Other income		18,305
Operating profit		666,873
Financial results		(961,635)
Profit (loss) before income tax		(294,762)
Income tax expense		127,876
Result for the year		(166,886)
Exchange differences on translation of foreign operations		180,519
Total comprehensive profit (loss)		$ 13,633
[1]	The tax effect of the revaluation of property, plant and equipment was ($1,389,643), ($1,133,230) and $480,378 for the years ended June 30, 2021, 2020 and 2019, respectively.

CASH FLOW INFORMATION (Details)

CASH FLOW INFORMATION (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Apr. 09, 2021	Jun. 30, 2018
Investment activities
Settlement of liability with loan to joint venture			$ 6,964,101
Net assets acquisition by business combination	$ 6,612,410
Settlement of receivables through PPE contribution	2,164,156
Investment in kind in other related parties	714,359	$ 476,292	463,511
Arcadia asset acquisition financed by debt	7,637,972
Arcadia asset acquisition through issuance of capital	15,000,000
Non-monetary contributions in joint ventures	2,931,699	250,000	94,355
Investing activities	35,060,596	726,292	7,521,967
Financing Activities
Purchase option paid by a parent loan			(1,265,000)
Consideration for acquisition	(2,625,335)
Parent company investment			(14,558,347)
Capitalization of financial debt			13,720,000
Reverse recapitalization			(3,688,963)
Net assets incorporated of Semya			7,369,168
Acquisition of control of Semya S.A.			(3,684,585)
Total of Financing Activities	(2,625,335)		(2,107,727)
Non-current assets
Other financial assets	1,097,462	322,703	376,413
Intangible assets	67,342,362	35,333,464	39,616,426
Property, plant and equipment	47,954,596	41,515,106	43,834,548
Assets	394,589,957	297,561,369	242,467,297
Current liabilities
Borrowings	76,785,857	63,721,735	66,477,209
NON-CURRENT LIABILITIES
Borrowings	47,988,468	41,226,610	37,079,521
Total liabilities	304,299,653	236,811,887	180,372,431
Total equity	$ 90,290,304	$ 60,749,482	$ 62,094,866		$ 33,133,656
Insumos Agroquimicos S.A.
Financing Activities
Consideration for acquisition				$ (2,625,335)
Current assets
Cash and equivalents				555,804
Other current assets				24,981,656
Non-current assets
Deferred tax				106,952
Other financial assets				719,772
Intangible assets				2,923,897
Property, plant and equipment				1,952,045
Assets				31,240,126
Current liabilities
Trade and other payables				17,814,395
Borrowings				5,749,928
Deferred tax				(884,574)
NON-CURRENT LIABILITIES
Borrowings				178,820
Total liabilities				24,627,717
Total equity				$ 6,612,409

CASH FLOW INFORMATION - Busines

CASH FLOW INFORMATION - Business combination of assets and liabilities (Details) - Semya S.A.	May 31, 2019USD ($)
Business Combination Assets And Liabilities
Current assets	$ 67,924
Non-current assets
Deferred tax	253,655
Intangibles	2,147,199
Goodwill	5,836,268
Total assets	8,305,046
Current liabilities
Trade payables	273,442
Borrowings	114,568
Non-current liabilities
Deferred tax	547,868
Total liabilities	935,878
Total equity	$ 7,369,168

CASH FLOW INFORMATION - Changes

CASH FLOW INFORMATION - Changes in liabilities arising from financing activities (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Changes in liabilities arising from financing activities
As of June 30, 2019	$ 148,430,833	$ 106,835,995	$ 113,891,742
Proceeds	143,499,367	135,348,502	88,693,632
Decrease bank overdraft and other short-term borrowings	(3,442,491)	(2,331,974)	(4,968,813)
Payments	(113,100,032)	(79,784,434)	(90,917,814)
Financing for assets acquisitions	11,214,929
Debt incorporated by business combination	5,928,748
Capitalization and compensation of financial debt			(13,720,000)
Interest payment	(12,923,745)	(21,533,187)	(20,167,101)
Exchange differences, currency translation differences and other financial results	5,621,261	9,895,931	34,024,349
As of June 30, 2020	185,228,870	148,430,833	106,835,995
Convertible notes
Changes in liabilities arising from financing activities
As of June 30, 2019	43,029,834
Proceeds		42,075,000
Exchange differences, currency translation differences and other financial results	5,634,178	954,834
As of June 30, 2020	48,664,012	43,029,834
Borrowings
Changes in liabilities arising from financing activities
As of June 30, 2019	104,948,345	103,556,730	91,017,133
Proceeds	143,499,367	93,273,502	88,693,632
Decrease bank overdraft and other short-term borrowings	(3,442,491)	(2,331,974)	(4,968,813)
Payments	(113,100,032)	(76,846,934)	(83,777,814)
Debt incorporated by business combination	5,928,748
Interest payment	(12,923,745)	(21,533,187)	(20,167,101)
Exchange differences, currency translation differences and other financial results	(135,867)	8,830,208	32,759,693
As of June 30, 2020	124,774,325	104,948,345	103,556,730
Financed payment - Acquisition of business
Changes in liabilities arising from financing activities
As of June 30, 2019	452,654	3,279,265	22,874,609
Payments		(2,937,500)	(7,140,000)
Financing for assets acquisitions	11,214,929
Capitalization and compensation of financial debt			(13,720,000)
Exchange differences, currency translation differences and other financial results	122,950	110,889	1,264,656
As of June 30, 2020	$ 11,790,533	$ 452,654	$ 3,279,265

JOINT VENTURES AND ASSOCIATES -

JOINT VENTURES AND ASSOCIATES - Investment in Joint Venture and affiliates (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	$ 30,657,173	$ 24,652,792	$ 25,321,028
Investments in joint ventures and affiliates, Liabilities	1,278,250	1,548,829	1,970,903
Synertech Industrias S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	27,572,597	24,619,773	25,297,376
Indrasa Biotecnologia S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	54,957	33,019	23,652
Alfalfa Technologies S.R.L.
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	97,920
Moolec Science Limited
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	2,931,699
Trigall Genetics S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Liabilities	$ 1,278,250	$ 1,548,829	$ 1,970,903

JOINT VENTURES AND ASSOCIATES_2

JOINT VENTURES AND ASSOCIATES - Changes in joint ventures investments and affiliates (Details) - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
JOINT VENTURES AND ASSOCIATES
As of the beginning of the year		$ 23,103,963	$ 23,350,125	$ 17,059,757
Adjustment of opening net book amount for the application of IAS 29				8,328,794
Monetary contributions		101,883		129,340
Non-monetary contributions		2,931,699	250,000	94,355
Parent company investment				294,041
Loss of control of Indrasa Biotecnologa S.A.				10,591
Acquisition of control of Semya S.A.				(3,684,585)
Revaluation of property, plant and equipment	[1]	(413,618)	521,406	94,009
Foreign currency translation		2,657,567	(3,494,761)	11,337
Share of profit or loss		997,429	2,477,193	1,012,486
As of the end of the year		$ 29,378,923	$ 23,103,963	$ 23,350,125
[1]	The tax effect of the revaluation of property, plant and equipment of joint ventures and associates was ($222,717), ($173,802) and ($47,005) for the years ended June 30, 2021, 2020 and 2019, respectively.

JOINT VENTURES AND ASSOCIATES_3

JOINT VENTURES AND ASSOCIATES - Share of profit or loss of joint ventures and affiliates (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	$ 997,429	$ 2,477,193	$ 1,012,486
Trigall Genetics S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	270,579	171,502	(2,647)
Bioceres Crops S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates			(22,895)
Synertech Industrias S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	708,550	2,294,332	1,034,818
Indrasa Biotecnologia S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	$ 18,300	$ 11,359	$ 3,210

JOINT VENTURES AND ASSOCIATES_4

JOINT VENTURES AND ASSOCIATES - Summarized balance sheet (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Summarised balance sheet
Cash and cash equivalents	$ 36,046,113	$ 42,522,861	$ 3,450,873
Total current assets	211,489,658	164,693,055	98,208,964
Intangible assets	67,342,362	35,333,464	39,616,426
Property, plant and equipment	47,954,596	41,515,106	43,834,548
Total non-current assets	183,100,299	132,868,314	144,258,333
Total current liabilities	168,037,855	130,610,709	116,458,133
Total non-current liabilities	136,261,798	106,201,178	63,914,298
Trigall Genetics S.A.
Summarised balance sheet
Cash and cash equivalents	13,798	1,331	13,114
Other current assets	1,949,590	1,024,793	323,265
Total current assets	1,963,388	1,026,124	336,379
Intangible assets	13,335,653	11,776,705	10,214,575
Total non-current assets	13,335,653	11,776,705	10,214,575
Financial liabilities			9,476,272
Other current liabilities	1,257,070	869,700	1,016,083
Total current liabilities	1,257,070	869,700	10,492,355
Financial liabilities	12,184,030	10,831,048
Other non- current liabilities	1,000,774	831,685	460,268
Total non-current liabilities	13,184,804	11,662,733	460,268
Net assets	857,167	270,396	(401,669)
Synertech Industrias S.A.
Summarised balance sheet
Cash and cash equivalents	540,149	18,251	40,634
Other current assets	17,274,878	17,983,868	5,709,650
Total current assets	17,815,027	18,002,119	5,750,284
Property, plant and equipment	13,422,832	14,168,459	15,046,903
Other non- current assets	39,171
Total non-current assets	13,462,003	14,168,459	15,046,903
Financial liabilities	1,346,327	5,484,866	921,703
Other current liabilities	6,807,330	4,719,276	4,595,906
Total current liabilities	8,153,657	10,204,142	5,517,609
Financial liabilities	331,306	2,783,951
Other non- current liabilities	4,119,471	2,554,905	3,974,975
Total non-current liabilities	4,450,777	5,338,856	3,974,975
Net assets	$ 18,672,596	$ 16,627,580	$ 11,304,603

JOINT VENTURES AND ASSOCIATES_5

JOINT VENTURES AND ASSOCIATES - Summarized statements of comprehensive income (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Summarised statements of comprehensive income
Revenue	$ 206,697,620	$ 172,350,699	$ 160,308,979
Profit (loss) of the year	(3,820,622)	4,236,628	(16,358,891)
Other comprehensive income	10,051,318	(9,682,116)	3,904,365
Total comprehensive profit (loss)	6,230,696	(5,445,488)	(12,454,526)
Trigall Genetics S.A.
Summarised statements of comprehensive income
Revenue	1,110,303	799,625	367,646
Finance income	22,470	79,442	54,003
Finance expense	(3,586)	(1,863)	(16,145)
Profit (loss) of the year	586,773	172,670	(33,195)
Total comprehensive profit (loss)	586,773	172,670	(33,195)
Synertech Industrias S.A.
Summarised statements of comprehensive income
Revenue	23,759,744	21,501,725	18,305,953
Finance income	5,584,007	3,805,655	2,434,610
Finance expense	(6,283,955)	(6,666,508)	(6,193,963)
Depreciation and amortization	(39,171)	(1,076,699)	(1,074,552)
Profit (loss) of the year	1,776,244	5,099,852	2,278,859
Other comprehensive income	(827,236)	1,042,811	334,403
Total comprehensive profit (loss)	$ 949,008	$ 6,142,663	$ 2,613,262

JOINT VENTURES AND ASSOCIATES_6

JOINT VENTURES AND ASSOCIATES - Additional Information (Details)	12 Months Ended
	Jun. 30, 2021
JOINT VENTURES AND ASSOCIATES
Percentage of profit	5.00%
Maximum percentage of capital	20.00%

SEGMENT INFORMATION - Number of

SEGMENT INFORMATION - Number of segments (Details)	Jun. 30, 2021USD ($)
SEGMENT INFORMATION
Number of main operating segments	3
Number of complementary components	3

SEGMENT INFORMATION - Group's r

SEGMENT INFORMATION - Group's reporting segments (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Revenues
Revenue	$ 206,697,620	$ 172,350,699	$ 160,308,979
Royalties	2,023,548	1,775,790	1,110,463
Initial recognition and changes in the fair value of biological assets	2,826,255	716,741	279,945
Government grants	2,302	24,732	16,372
Total	209,526,177	173,092,172	160,605,296
Cost of sales	(118,641,803)	(93,575,588)	(86,964,881)
Gross margin per segment	$ 90,884,374	$ 79,516,584	$ 73,640,415
% of Segment Revenue	43.00%	46.00%	46.00%
Seed and integrated products
Revenues
Revenue	$ 33,422,140	$ 29,402,332	$ 25,295,755
Royalties	2,023,548	1,775,790	1,110,463
Initial recognition and changes in the fair value of biological assets	1,394,127	41,755
Government grants	2,302	24,732	16,372
Total	34,818,569	29,468,819	25,312,127
Cost of sales	(12,931,763)	(11,581,494)	(9,783,737)
Gross margin per segment	$ 21,886,806	$ 17,887,325	$ 15,528,390
% of Segment Revenue	63.00%	61.00%	61.00%
Crop protection
Revenues
Revenue	$ 113,508,465	$ 93,799,477	$ 89,919,460
Initial recognition and changes in the fair value of biological assets	606,269	418,712	279,945
Total	114,114,734	94,218,189	90,199,405
Cost of sales	(75,138,491)	(53,552,327)	(53,979,391)
Gross margin per segment	$ 38,976,243	$ 40,665,862	$ 36,220,014
% of Segment Revenue	34.00%	43.00%	40.00%
Crop nutrition
Revenues
Revenue	$ 59,767,015	$ 49,148,890	$ 45,093,764
Initial recognition and changes in the fair value of biological assets	825,859	256,274
Total	60,592,874	49,405,164	45,093,764
Cost of sales	(30,571,549)	(28,441,767)	(23,201,753)
Gross margin per segment	$ 30,021,325	$ 20,963,397	$ 21,892,011
% of Segment Revenue	50.00%	42.00%	49.00%
Sale of goods and services
Revenues
Revenue	$ 204,674,072	$ 170,574,909	$ 159,198,516
Sale of goods and services | Seed and integrated products
Revenues
Revenue	31,398,592	27,626,542	24,185,292
Sale of goods and services | Crop protection
Revenues
Revenue	113,508,465	93,799,477	89,919,460
Sale of goods and services | Crop nutrition
Revenues
Revenue	$ 59,767,015	$ 49,148,890	$ 45,093,764

SEGMENT INFORMATION - Revenue b

SEGMENT INFORMATION - Revenue by similar group of products or services (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
SEGMENT INFORMATION
Revenue	$ 206,697,620	$ 172,350,699	$ 160,308,979
Seed and integrated products
SEGMENT INFORMATION
Revenue	33,422,140	29,402,332	25,295,755
Crop protection
SEGMENT INFORMATION
Revenue	113,508,465	93,799,477	89,919,460
Crop nutrition
SEGMENT INFORMATION
Revenue	59,767,015	49,148,890	45,093,764
Seeds, royalties & licenses | Seed and integrated products
SEGMENT INFORMATION
Revenue	6,246,689	5,210,616	3,846,991
Packs | Seed and integrated products
SEGMENT INFORMATION
Revenue	27,175,451	24,191,716	21,448,764
Adjuvants | Crop protection
SEGMENT INFORMATION
Revenue	50,062,012	45,372,840	41,854,730
Insecticides & fungicides | Crop protection
SEGMENT INFORMATION
Revenue	18,231,616	15,227,357	12,655,985
Other | Crop protection
SEGMENT INFORMATION
Revenue	45,214,837	33,199,280	35,408,745
Inoculants | Crop nutrition
SEGMENT INFORMATION
Revenue	16,485,064	16,718,571	18,644,673
Fertilizers | Crop nutrition
SEGMENT INFORMATION
Revenue	$ 43,281,951	$ 32,430,319	$ 26,449,091

SEGMENT INFORMATION - Geographi

SEGMENT INFORMATION - Geographical information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
SEGMENT INFORMATION
Revenues from contracts with customers	$ 206,697,620	$ 172,350,699	$ 160,308,979
Total non current assets	144,048,164	102,375,425	113,255,689
Property, plant and equipment	47,954,596	41,515,106	43,834,548
Intangible assets	67,342,362	35,333,464	39,616,426
Goodwill	28,751,206	25,526,855	29,804,715
Total non reportable assets	250,541,793	195,185,944	129,211,608
Total assets	394,589,957	297,561,369	242,467,297
Argentina
SEGMENT INFORMATION
Revenues from contracts with customers	157,352,242	130,918,908	124,011,642
Total non current assets	107,077,660	93,682,114	106,056,232
Cayman Island
SEGMENT INFORMATION
Total non current assets	24,837,572
Bolivia
SEGMENT INFORMATION
Revenues from contracts with customers	3,707,107	2,982,953	2,494,216
Total non current assets	33,090	15,588	27,487
Brazil
SEGMENT INFORMATION
Revenues from contracts with customers	24,591,539	21,188,655	17,338,608
Total non current assets	3,460,634	685,587	305,477
United States of America
SEGMENT INFORMATION
Revenues from contracts with customers	2,504,696	1,515,185	2,562,376
Total non current assets	7,799,448	7,168,376	6,136,461
Paraguay
SEGMENT INFORMATION
Revenues from contracts with customers	5,369,912	4,428,078	2,506,348
Total non current assets	742,767	714,011	722,914
South Africa
SEGMENT INFORMATION
Revenues from contracts with customers	2,789,322	1,927,333	3,019,474
Total non current assets	3,892	598	7,080
France
SEGMENT INFORMATION
Revenues from contracts with customers	4,269,368	911,140	711,522
Total non current assets	26,138	33,556
Colombia
SEGMENT INFORMATION
Total non current assets	18,461	22,313
Uruguay
SEGMENT INFORMATION
Revenues from contracts with customers	5,752,913	6,234,956	4,684,854
Total non current assets	48,502	53,282
India
SEGMENT INFORMATION
Total non current assets			38
Rest of the world
SEGMENT INFORMATION
Revenues from contracts with customers	$ 360,521	$ 2,243,491	$ 2,979,939

FINANCIAL INSTRUMENTS - RISK _3

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Financial assets by category (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Amortized cost
Financial assets by category
Financial assets.	$ 123,776,201	$ 101,786,147	$ 68,957,670
Fair value
Financial assets by category
Financial assets.	18,453,966	31,392,344	356,233
Cash and cash equivalents | Amortized cost
Financial assets by category
Financial assets.	28,327,569	20,176,452	3,450,873
Cash and cash equivalents | Fair value
Financial assets by category
Financial assets.	7,718,544	22,346,409
Other financial assets | Amortized cost
Financial assets by category
Financial assets.	1,523,438	4,713,161	4,703,688
Other financial assets | Fair value
Financial assets by category
Financial assets.	10,735,422	9,045,935	356,233
Trade receivables | Amortized cost
Financial assets by category
Financial assets.	88,919,911	73,546,633	59,236,377
Other receivables | Amortized cost
Financial assets by category
Financial assets.	$ 5,005,283	$ 3,349,901	$ 1,566,732

FINANCIAL INSTRUMENTS - RISK _4

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Financial liabilities by category (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Amortized cost
Financial liabilities by category
Financial liabilities	$ 263,141,073	$ 211,875,137	$ 152,771,707
Fair value
Financial liabilities by category
Financial liabilities		1,686,643	2,861,511
Trade and other payables | Amortized cost
Financial liabilities by category
Financial liabilities	72,091,408	57,289,862	40,578,494
Borrowings | Amortized cost
Financial liabilities by category
Financial liabilities	124,774,325	104,948,345	103,556,730
Employee benefits and social security | Amortized cost
Financial liabilities by category
Financial liabilities	4,680,078	5,044,630	5,357,218
Consideration for acquisition of assets | Amortized cost
Financial liabilities by category
Financial liabilities	11,790,533	452,654	3,279,265
Private warrants | Fair value
Financial liabilities by category
Financial liabilities		1,686,643	$ 2,861,511
Convertible notes | Amortized cost
Financial liabilities by category
Financial liabilities	48,664,012	43,029,834
Lease liability | Amortized cost
Financial liabilities by category
Financial liabilities	$ 1,140,717	$ 1,109,812

FINANCIAL INSTRUMENTS - RISK _5

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Fair value by hierarchy (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Private warrants | Level 3
Fair value by hierarchy
Financial liabilities, at fair value		$ 1,686,643	$ 2,861,511
Mutual funds | Level 1
Fair value by hierarchy
Financial assets, at fair value	$ 7,718,544	22,346,409
Other investments | Level 1
Fair value by hierarchy
Financial assets, at fair value	2,110,414	1,176,977	$ 356,233
Other investments | Level 2
Fair value by hierarchy
Financial assets, at fair value	739,071	100,548
US Treasury bills | Level 1
Fair value by hierarchy
Financial assets, at fair value	$ 7,885,937	$ 7,768,410

FINANCIAL INSTRUMENTS - RISK _6

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Changes in financial liabilities values at fair value level 3 (Details) - Level 3 - Private warrants	12 Months Ended
	Jun. 30, 2020USD ($)
Fair value
As of the beginning of the year	$ 2,861,511
Changes in finance results	(1,174,868)
As of the end of the year	$ 1,686,643

FINANCIAL INSTRUMENTS - RISK _7

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Credit risk (Details)	12 Months Ended
	Jun. 30, 2021USD ($)
Trade and other receivables
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Gross carrying amount-trade receivables	$ 94,642,675
Loss allowance	5,858,503
Loss allowance of IAS 29 effect and Currency conversion	$ 10,107
Trade and other receivables | Current
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.21%
Gross carrying amount-trade receivables	$ 78,286,114
Loss allowance	$ 161,963
Trade and other receivables | More Than 15 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.21%
Gross carrying amount-trade receivables	$ 2,192,641
Loss allowance	$ 4,536
Trade and other receivables | More Than 30 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.21%
Gross carrying amount-trade receivables	$ 1,145,112
Loss allowance	$ 2,369
Trade and other receivables | More Than 60 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.24%
Gross carrying amount-trade receivables	$ 2,396,153
Loss allowance	$ 5,796
Trade and other receivables | More Than 90 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.25%
Gross carrying amount-trade receivables	$ 3,031,050
Loss allowance	$ 7,719
Trade and other receivables | More Than 120 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.39%
Gross carrying amount-trade receivables	$ 1,174,948
Loss allowance	$ 4,589
Trade and other receivables | More Than 180 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.21%
Gross carrying amount-trade receivables	$ 756,820
Loss allowance	$ 1,587
Trade and other receivables | More Than 365 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	100.00%
Gross carrying amount-trade receivables	$ 5,659,837
Loss allowance	$ 5,659,837
Credit risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Customer portfolio insurance coverage (as a percent)	50.00%

FINANCIAL INSTRUMENTS - RISK _8

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Liquidity risk (Details) - Liquidity risk - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	$ 44,154,258	$ 64,211,250	$ 41,905,850
3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	103,374,010	64,566,807	72,022,373
Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	102,720,186	87,776,524	39,000,866
Trade and other payables | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	17,379,825	28,150,681	12,854,579
Trade and other payables | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	44,023,803	29,130,428	28,987,009
Trade and other payables | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	9,266	463,568	476,482
Borrowings | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	26,399,791	35,863,852	29,051,271
Borrowings | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	57,195,372	34,810,916	40,097,864
Borrowings | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	53,290,976	43,799,397	38,524,384
Financed payment - Acquisition of business | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities			$ 2,937,500
Convertible notes | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	48,664,012	43,029,834
Lease liability | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	374,642	196,717
Lease liability | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	2,154,835	625,463
Lease liability | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	$ 755,932	$ 483,725

FINANCIAL INSTRUMENTS - RISK _9

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Currency risk (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Risk exposure associated with instruments sharing characteristic	$ (50,608,592)	$ (52,968,976)	$ (40,513,954)
Currency Risk | Amount expressed in USD
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Estimate of devaluation of Argentine peso (as a percent)	20.00%
Result in pre-tax gain	$ 9,900,000

FINANCIAL INSTRUMENTS - RISK_10

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Interest rate risk (Details) - Interest Rate Risk - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Debt composition
Percentage point increase in interest point	1.00%
Maximum
Debt composition
Increase in interest payable	$ 100,000
Fixed-rate instruments
Debt composition
Current financial liabilities	(73,125,807)	$ (62,490,975)	$ (69,126,607)
Non-current financial liabilities	(108,236,265)	(84,253,034)	(37,459,235)
Variable-rate instruments
Debt composition
Current financial liabilities	(3,660,050)	(1,230,760)	(177,213)
Non-current financial liabilities	$ (206,748)	$ (456,064)	$ (72,940)

LEASES - Right-of-use lease ass

LEASES - Right-of-use lease asset and Liabilities rollforward (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Right-of-use lease asset and Liabilities
Beginning of the year	$ 1,114,597
Depreciation of the year	827,320	$ 573,897
End of the year	1,327,660	1,114,597
Gross carrying amount
Right-of-use lease asset and Liabilities
Beginning of the year	2,369,326
Additions for initial application of IFRS 16		1,523,177
Additions of the year	913,321	846,149
Exchange differences	405,503
End of the year	3,688,150	2,369,326
Property, plant and equipment depreciation
Right-of-use lease asset and Liabilities
Beginning of the year	(1,254,729)
Additions for initial application of IFRS 16		759,045
Exchange differences	278,441	(78,213)
Depreciation of the year	827,320	573,897
End of the year	$ (2,360,490)	$ (1,254,729)

LEASES - Liabilities (Details)

LEASES - Liabilities (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Lease liability
Book value at the beginning of the year	$ 1,109,812
Additions for initial application of IFRS 16		$ 1,523,177
Additions of the year	259,427	702,826
Interest expenses, exchange differences and inflation effects	500,442	(551,232)
Payments of the year	(728,964)	(564,959)
Total	1,140,717	1,109,812
Lease liabilities	390,409	444,714
Lease liabilities	750,308	665,098
Total	$ 1,140,717	$ 1,109,812

LEASES - Right-of-use lease a_2

LEASES - Right-of-use lease asset by type (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Disclosure of quantitative information about right-of-use assets
Right-of-use assets	$ 1,327,660	$ 1,114,597
Incremental borrowing rate (as a percent)	7.74%
Gross carrying amount
Disclosure of quantitative information about right-of-use assets
Right-of-use assets	$ 3,688,150	2,369,326
Gross carrying amount | Machinery and equipment
Disclosure of quantitative information about right-of-use assets
Right-of-use assets	661,544	598,561
Gross carrying amount | Vehicles
Disclosure of quantitative information about right-of-use assets
Right-of-use assets	1,061,184	264,069
Gross carrying amount | Equipment and computer software
Disclosure of quantitative information about right-of-use assets
Right-of-use assets	582,101	407,546
Gross carrying amount | Land and buildings
Disclosure of quantitative information about right-of-use assets
Right-of-use assets	$ 1,383,321	$ 1,099,150

SHAREHOLDERS AND OTHER RELATE_3

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS - Transactions (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Trade and other payable
In-kind contributions	$ 714,359	$ 476,292	$ 463,511
Total	(16,786,191)	(21,929,605)	(38,790,094)
Joint ventures
Trade and other payable
Sales of goods and services	9,404,716	6,139,155	4,913,254
Purchases of goods and services	23,395,323	21,634,936	17,542,637
Equity contributions	3,033,582	250,000	517,736
Net loans granted / (cancelled)			(6,964,101)
Key management personnel
Trade and other payable
Salaries, social security benefits and other benefits	3,376,292	5,333,469	3,940,185
Loans granted	664,398		599,984
Interest gain	9,782	44,619	20,106
Shareholders and other related parties
Trade and other payable
Sales of goods and services	572,110	1,871,613	640,095
Purchases of goods and services	3,092,506	1,881,013	1,433,127
Interest gain	714,359	476,292	463,511
In-kind contributions	(1,219,776)	(1,861,774)	(1,386,288)
Parents companies and related parties to Parents
Trade and other payable
Interest gain/(lost)	$ (101,241)
Parent company
Trade and other payable
Purchases of goods and services		$ 92	120,095
Equity contributions			$ (14,558,347)

SHAREHOLDERS AND OTHER RELATE_4

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS - Receivable (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Trade and other payable
Other receivables	$ 11,153,705	$ 4,770,672	$ 1,981,829
Amounts receivable from related parties	3,345,632	2,958,476	1,096,538
Parent company
Trade and other payable
Trade receivables			440,268
Parents companies and related parties to Parents
Trade and other payable
Other receivables	770,549	102,069
Shareholders and other related parties
Trade and other payable
Trade receivables		1,090,004	467,743
Allowance for impairment		(768)	(75,596)
Other receivables - Other related parties
Trade and other payable
Other receivables	134,172	83,839	10,971
Joint ventures
Trade and other payable
Trade receivables	221,048	120,992	2,369
Other receivables	$ 2,219,863	$ 1,562,340	$ 250,783

SHAREHOLDERS AND OTHER RELATE_5

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS - Payables (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Trade and other payable
Borrowings	$ (76,785,857)	$ (63,721,735)	$ (66,477,209)
Amounts payable to related parties	(29,833,257)	(32,125,480)	(28,240,277)
Parent company
Trade and other payable
Trade payables	(193,718)	(2,210,308)	(1,568,036)
Parents companies and related parties to Parents
Trade and other payable
Loans payables	(9,578,921)	(12,389,521)	(17,757,907)
Key management personnel
Trade and other payable
Salaries, social security benefits and other benefits	(2,338,727)	(2,084,088)	(2,312,253)
Shareholders and other related parties
Trade and other payable
Trade payables	(52,864)	(1,031,710)	(1,796,932)
Joint ventures
Trade and other payable
Trade payables	$ (17,669,027)	$ (14,409,853)	$ (4,805,149)

KEY MANAGEMENT PERSONNEL COMP_3

KEY MANAGEMENT PERSONNEL COMPENSATION - Summary of compensation of directors and other members (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
KEY MANAGEMENT PERSONNEL COMPENSATION
Salaries, social security and other benefits	$ 1,721,157	$ 1,905,440	$ 3,940,185
Share-based incentives	1,655,135	3,428,029
Total	$ 3,376,292	$ 5,333,469	$ 3,940,185

SHARE-BASED PAYMENT - Options (

SHARE-BASED PAYMENT - Options (Details)	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2020USD ($)
SHARE-BASED PAYMENTS
Shares in reference to the share-based incentives | $		971,072
Exercise price | $ / shares			$ 4.55
Options incentive Plan
SHARE-BASED PAYMENTS
Shares in reference to the share-based incentives | $			1,200,000	1,200,000
Exercise price | $ / shares			$ 4.55
Vesting period	3 years
Options that vest every 12 months (as a percent)	0.33%
Period of weighted average price ("VWAP") of the ordinary shares for cashless basis exercise	20 days

SHARE-BASED PAYMENT - Fair valu

SHARE-BASED PAYMENT - Fair value of share options (Details)	12 Months Ended
	Jun. 30, 2021USD ($)$ / shares
SHARE-BASED PAYMENTS
Exercise price	$ 4.55
Estimates of options that will be exercised (as a percent)	100.00%
Options incentive Plan
SHARE-BASED PAYMENTS
Weighted average fair value of shares	$ 5.42
Exercise price	$ 4.55
Weighted average expected volatility	29.69%
Dividend rate	0.00%
Weighted average risk-free interest rate	1.66%
Weighted average expected life of stock options | $	9.89
Weighted average fair value at measurement date (per option) | $	$ 2.47

SHARE-BASED PAYMENT - Option ac

SHARE-BASED PAYMENT - Option activity (Details)	3 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)
SHARE-BASED PAYMENTS
Number of options, granted during the year	971,072
Charges accounted				$ 20,893,789
Options incentive Plan
SHARE-BASED PAYMENTS
Number of options, at the beginning		1,200,000
Number of options, granted during the year		1,200,000	1,200,000
Number of options, exercised during the year		33,333
Number of options, effective at year	1,166,667	1,166,667	1,200,000
Weighted average exercise price, at the beginning | $ / shares		$ 4.55
Weighted average exercise price, granted during the year | $ / shares			$ 4.55
Weighted average exercise price, exercised during the year | $ / shares		15.09
Weighted average exercise price, effective at year | $ / shares	$ 4.55	$ 4.55	$ 4.55
Charges accounted		$ 700,000	$ 1,900,000

SHARE-BASED PAYMENT - Share opt

SHARE-BASED PAYMENT - Share option plan for junior management (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 4.55
Charges accounted		$ 20,893,789
Share Option Plan for junior management
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares authorized	100,000
Exercise price	$ 5.55
Exercisable term	3 years
Options that vest every 12 months (as a percent)	0.33%
Charges accounted	$ 0

SHARE-BASED PAYMENT - Annual co

SHARE-BASED PAYMENT - Annual compensation - Bonus (Details)	Mar. 16, 2021USD ($)	Jun. 30, 2021USD ($)item	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Multiple of monthly salary for cash bonus paid in ordinary shares | item		5
Incremental value of bonus in cash payable		$ 30,000
Charges accounted				$ 20,893,789
Number of days of VWAP considered for bonus payment		20 days
Bonus in Kind
Disclosure of terms and conditions of share-based payment arrangement [line items]
Charges accounted		$ 500,000	$ 300,000
Shares already in issue		147,788
Bonus in Kind | Vests immediately
Disclosure of terms and conditions of share-based payment arrangement [line items]
Bonus vesting percentage		50.00%
Bonus in Kind | Vests in the subsequent 12-months
Disclosure of terms and conditions of share-based payment arrangement [line items]
Bonus vesting percentage		50.00%
Bonus in performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Charges accounted			300,000
Number of shares issued	800,000
Bonus In Cash
Disclosure of terms and conditions of share-based payment arrangement [line items]
Charges accounted		$ 400,000	$ 200,000
Chief Executive Officer | Bonus in Kind
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized bonus amount		315,000
Chief Financial Officer | Bonus in Kind
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized bonus amount		165,000
Chief Technology Officer | Bonus in Kind
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized bonus amount		$ 100,000

SHARE-BASED PAYMENT - Fair va_2

SHARE-BASED PAYMENT - Fair value assumptions of Bonus in performance (Details)	12 Months Ended
	Jun. 30, 2021USD ($)$ / shares
Bonus in performance on achieving 100% of the objectives
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at the grant date	$ 5.42
Exercise Price	$ 10.5
Weighted average expected volatility	24.78%
Dividend rate	0.00%
Weighted average risk-free interest rate	1.52%
Weighted average expected life	2 years 7 months 17 days
Weighted average fair value of stock at measurement date | $	$ 0.479
Bonus in performance on achieving 200% of the objectives
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at the grant date	$ 5.42
Exercise Price	$ 21
Weighted average expected volatility	24.78%
Dividend rate	0.00%
Weighted average risk-free interest rate	1.52%
Weighted average expected life	2 years 7 months 17 days
Weighted average fair value of stock at measurement date | $	$ 0.005

SHARE-BASED PAYMENT - Employee

SHARE-BASED PAYMENT - Employee stock purchase plan (Details) - Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2021shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maximum percentage of employee's monthly compensation	15.00%
Number of ordinary shares subject to the ESPP	200,000
Percentage of closing price of the Company's ordinary shares on the first business day and the last business day to determine purchase price	85.00%

CONTINGENCIES, COMMITMENTS AN_3

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS - Summary of Pledged and restricted assets (Details)	Jun. 30, 2021USD ($)
Pledged and restricted assets
Pledged and restricted assets	$ 26,394,022
Other financial assets
Pledged and restricted assets
Pledged and restricted assets	13,032
Compass Latam & Odisea
Pledged and restricted assets
Pledged and restricted assets	16,016,733
Allaria Ledesma & Cia.
Pledged and restricted assets
Pledged and restricted assets	9,395,976
Cohen S.A.
Pledged and restricted assets
Pledged and restricted assets	789,458
IT equipment
Pledged and restricted assets
Pledged and restricted assets	99,990
Vehicles
Pledged and restricted assets
Pledged and restricted assets	$ 78,833

CONTINGENCIES, COMMITMENTS AN_4

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS - Additional Information (Details) - USD ($)	1 Months Ended
	Apr. 30, 2019	Jun. 30, 2021
Pledged and restricted assets
Pledged and restricted assets		$ 26,394,022
Compass Latam & Odisea
Pledged and restricted assets
Amount of negotiable instruments issued	$ 16,000,000
Percentage of shares pledged	10.00%
Pledged and restricted assets		16,016,733
Allaria Ledesma & Cia.
Pledged and restricted assets
Pledged and restricted assets		9,395,976
Cohen S.A.
Pledged and restricted assets
Pledged and restricted assets		789,458
Other financial assets
Pledged and restricted assets
Pledged and restricted assets		13,032
Rizobacter | Allaria Ledesma & Cia.
Pledged and restricted assets
Pledged and restricted assets		6,700,000
Rizobacter | Cohen S.A.
Pledged and restricted assets
Pledged and restricted assets		$ 800,000
RASA Holding, LLC | Rizobacter
Pledged and restricted assets
Percentage of shares pledged		41.30%

EVENTS OCCURRING AFTER THE RE_2

EVENTS OCCURRING AFTER THE REPORTING PERIOD (Details) - Insumos Agroquimicos S.A. - USD ($)	Oct. 21, 2021	Aug. 02, 2021	Apr. 09, 2021
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Number of shares acquired			11,022,000
Consideration of payment			$ 3,776,957
Percentage of equity interest acquired			50.10%
Class B ordinary shares
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Number of shares acquired			8,272,610
Acquisition of the remaining Class B Shares | Class B ordinary shares
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Total shares subject to the offer			3,750,348
Offer price per share			$ 0.297
Number of shares acquired		2,467,990
Consideration of payment		$ 700,000
Number of shares owned	13,489,990
Percentage of equity interest acquired	61.32%
Percentage of voting interest acquired	61.22%

EVENTS OCCURRING AFTER THE RE_3

EVENTS OCCURRING AFTER THE REPORTING PERIOD - Additional Information (Details) - Rizobacter Argentina - Public offering of Series VI corporate bonds	1 Months Ended
	Aug. 31, 2020USD ($)
Series VI corporate bonds
Disclosure of non-adjusting events after reporting period [line items]
Nominal value	$ 16,100,000
Number of tranches for issuance of bonds	2
Class A
Disclosure of non-adjusting events after reporting period [line items]
Nominal value	$ 12,700,000
Nominal interest rate (as a percent)	3.75%
Class B
Disclosure of non-adjusting events after reporting period [line items]
Nominal value	$ 3,400,000
Nominal interest rate (as a percent)	5.25%